"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT03340727","Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial","MoCHA","Recruiting","No Results Available","Apnea of Prematurity","Drug: Caffeine Citrate|Drug: Placebo","Number of days of hospitalization|The number of days to physiologic maturity after randomization|PMA at discharge|The number of all-cause hospital re-admissions|The number of all-cause sick visits|Death|Weight|Elevated Heart Rate|High Blood Pressure|Periods of NPO|Reflux|Significant Apnea|Significant Bradycardia|Arrhythmia|Seizures","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","29 Weeks to 33 Weeks   (Child)","Phase 3","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0056|UG1HD034216|UG1HD027904|UG1HD021364|UG1HD027853|UG1HD040689|UG1HD040492|UG1HD027851|UG1HD087229|UG1HD053109|UG1HD068278|UG1HD068244|UG1HD068263|UG1HD027880|UG1HD053089|UG1HD087226|U10HD036790","February 27, 2019","October 2022","October 2022","November 13, 2017","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03340727"
2,"NCT02951130","Milrinone in Congenital Diaphragmatic Hernia",,"Recruiting","No Results Available","Congenital Diaphragmatic Hernia|Persistent Pulmonary Hypertension of the Newborn|Hypoxemic Respiratory Failure|Pulmonary Hypoplasia","Drug: Milrinone|Drug: Placebo (5% Dextrose)","Oxygenation Response|Oxygenation Response at 48 and 72 h|Changes in estimated systolic pulmonary arterial pressure on echocardiogram|Vasoactive Inotrope Score and Systemic Blood Pressure|Area Under the Curve for Inspired Oxygen|Oxygenation Response to Additional Inotropes or Pulmonary Vasodilators|Supplemental Continuous Oxygen|Survival to discharge without ECMO|Clinical status (Pulmonary and Nutritional)|Feasibility and sample size calculation to Perform a Definitive Trial (primary outcome - improvement in survival without ECMO|Feasibility to perform a definitive trial (incidence of systemic hypotension)|Feasibility to perform a definitive trial (incidence of intracranial bleeding)|Feasibility to perform a definitive trial (incidence of arrhythmias)|Adjusted Oxygen Response","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 168 Hours   (Child)","Phase 2","66","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0057|UG1HD034216|UG1HD027904|UG1HD021364|UG1HD027853|UG1HD040689|UG1HD040492|UG1HD027851|UG1HD087229|UG1HD053109|UG1HD068278|UG1HD068244|UG1HD068263|UG1HD027880|UG1HD053089|UG1HD087226|U10HD036790","August 22, 2017","February 2020","February 2021","November 1, 2016","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02951130"
3,"NCT02160002","Incubator Weaning of Moderately Preterm Infants",,"Completed","Has Results","Infant, Newborn|Infant, Moderate Preterm","Procedure: Weaning from an incubator at a lower weight (1600 grams)|Procedure: Weaning from an incubator at a higher weight (1800 grams)","Length of Hospital Stay (LOS) From Birth to Discharge (up to 120 Days)|Length of Stay (LOS) Following Weaning From Incubator to Crib to Hospital Discharge (up to 120 Days)|Failure Rate of Weaning to Crib (Number of Infants With Axillary Temperature < 36.3°C After 2 Weaning Attempts)|Growth Velocity (Weight in Grams/kg/Day) From Start of Weaning From Incubator (Following Random Assignment) to 36 Weeks Postmenstrual Age (PMA)|Growth Parameters: Weight at Status|Growth Parameters: Length at Status|Growth Parameters: Head Circumference at Status|Postmenstrual Age (PMA) at Discharge|Readmission to the Hospital Within 1 Week of Discharge|Death Among Enrolled Infants|Transferred to a Non-Network Hospital|Length of Stay (LOS) Following Randomization to Hospital Discharge","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","29 Weeks to 34 Weeks   (Child)","Not Applicable","366","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0054","February 2015","July 2016","June 2017","June 10, 2014","December 21, 2017","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02160002"
4,"NCT01793129","Preemie Hypothermia for Neonatal Encephalopathy",,"Recruiting","No Results Available","Infant, Newborn|Hypoxia, Brain|Hypoxia-Ischemia, Brain|Encephalopathy, Hypoxic-Ischemic|Hypoxic-Ischemic Encephalopathy|Ischemic-Hypoxic Encephalopathy","Device: Hypothermia|Procedure: Normothermic Control","Death or moderate or severe disability|Number of deaths in the NICU and following discharge|Differences in MRI findings after cessation of cooling/control obtained|Number of infants with moderate and severe disability|Causes of Death|Neurological injury by cranial ultrasound within 24 hours of enrollment","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","33 Weeks to 35 Weeks   (Child)","Phase 2|Phase 3","168","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0051|U10HD021364|U10HD040689|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027904|U10HD027880|U10HD034216|U10HD021373|U10HD040492|U10HD053109|U10HD040461|U10HD068244|U10HD068263|U10HD068270|U10HD068278|U10HD068284|U10HD036790|UG1HD087226","May 2015","August 2020","October 2022","February 15, 2013","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01793129"
5,"NCT01793116","Generic Database of Moderate Preterm Infants",,"Completed","No Results Available","Infant, Newborn|Infant, Moderate Preterm","","Number of infants born moderately preterm","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","29 Weeks to 33 Weeks   (Child)","","7057","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0049|U10HD021364|U10HD040689|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027904|U10HD027880|U10HD034216|U10HD021373|U10HD040492|U10HD053109|U10HD040461|U10HD068244|U10HD068263|U10HD068270|U10HD068278|U10HD068284|U10HD036790","March 2012","October 2013","February 2014","February 15, 2013","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01793116"
6,"NCT01534481","Donor Milk vs. Formula in Extremely Low Birth Weight (ELBW) Infants",,"Recruiting","No Results Available","Infant, Newborn|Infant, Small for Gestational Age|Infant, Extremely Low Birth Weight","Biological: Donor Milk|Dietary Supplement: Preterm Formula","Neurodevelopmental Outcome|In Hospital Morbidities|Growth outcomes|Follow-up Outcomes","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 21 Days   (Child)","Phase 3","670","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0047|U10HD021364|U10HD040689|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027904|U10HD027880|U10HD034216|U10HD021373|U10HD040492|U10HD053109|U10HD040461|U10HD068244|U10HD068263|U10HD068278|U10HD068284|U10HD036790","August 2012","June 2019","June 2020","February 16, 2012","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01534481"
7,"NCT00598429","Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure","IPGE1","Withdrawn","No Results Available","Infant, Newborn|Respiratory Insufficiency|Pulmonary Hypertension|Respiratory Distress Syndrome, Newborn|Streptococcal Infections","Drug: Inhaled Prostaglandin E1","The ability to recruit an adequate number of patients (n = 50) in a 6-9 month period without excessive (>20%) protocol violations.|Progression to an OI greater than 25|Improvement in partial pressure of oxygen (PaO2) in the blood gas|Change in OI|Death|Need for inhaled nitric oxide or ECMO|Length of hospitalization|Duration of mechanical ventilation|Number of days of oxygen used and need for supplemental oxygen at 28 days of life|Occurrence of grade III-IV intracranial hemorrhage and cystic leukomalacia","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 7 Days   (Child)","Phase 2","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0037|U10HD036790|U10HD021364|U10HD021385|U10HD027880|U10HD034216|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124","May 2008","September 2008","September 2008","January 21, 2008","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00598429"
8,"NCT02410486","Early-Onset Sepsis an NICHD/CDC Surveillance Study","EOSII","Completed","No Results Available","Infant, Newborn, Diseases|Early Onset Neonatal Sepsis|Early-Onset Meningitis","","To determine current hospital-based rates of early-onset neonatal infection|To determine the antimicrobial susceptibility patterns of organisms associated with EOS and EOM|To identify risk factors associated with EOS/EOM due to Gram-negative pathogens (case control comparison)|To determine the clinical signs/symptoms and laboratory abnormalities associated with EOS/EOM|To identify risk factors for EOS/EOM in infants born to mothers with chorioamnionitis (case control comparison)|To determine if term infants with EOS, identified because of maternal chorioamnionitis, can be asymptomatic at birth|To determine sepsis-associated mortality rates (total, GA-specific and BW-specific, pathogen-specific) for infants with EOS/EOM|To review changes over time in overall rates of EOS and EOM, pathogens associated with infection, risk factors for infection, clinical and laboratory abnormalities, and sepsis-associated mortality","NICHD Neonatal Research Network|Centers for Disease Control and Prevention|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","","570","Other|U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0055|UG1HD034216|UG1HD027904|UG1HD021364|UG1HD027853|UG1HD040689|UG1HD040492|UG1HD027851|UG1HD087229|UG1HD027856|UG1HD053109|UG1HD068284|UG1HD068278|UG1HD068244|UG1HD068263|UG1HD027880|UG1HD068270|UG1HD053089|UG1HD087226|U10HD036790","April 2015","December 2017","December 2017","April 7, 2015","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02410486"
9,"NCT01954082","Inositol to Reduce Retinopathy of Prematurity","INS-3","Terminated","Has Results","Retinopathy of Prematurity (ROP)","Drug: myo-Inositol 5% Injection|Drug: Placebo","Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status|Number of Participants With Bronchopulmonary Dysplasia (BPD)|Number of Participants With Bronchopulmonary Dysplasia (BPD) or Death From BPD|Number of Participants With All Cause Death Before Retinopathy of Prematurity (ROP) Endpoint|Number of Participants With Any Retinopathy of Prematurity (ROP)|Number of Participants With Type 2 or More Severe Retinopathy of Prematurity (ROP)|Number of Participants With Severe Intraventricular Hemorrhage (IVH)","NICHD Neonatal Research Network|National Eye Institute (NEI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","Phase 3","638","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0053|U10HD021364|U10HD040689|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027904|U10HD027880|U10HD034216|U10HD021373|U10HD040492|U10HD053109|U10HD053089|U10HD068244|U10HD068263|U10HD068270|U10HD068278|U10HD068284|U10HD036790","April 17, 2014","December 31, 2016","December 31, 2016","October 1, 2013","September 26, 2018","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01954082"
10,"NCT01702805","Transfusion of Prematures Trial","TOP","Active, not recruiting","No Results Available","Infant, Newborn, Diseases|Infant, Extremely Low Birth Weight|Infant, Small for Gestational Age|Bronchopulmonary Dysplasia (BPD)|Anemia","Procedure: Liberal Cell Transfusion|Procedure: Restricted red cell transfusion","Death or significant neurodevelopmental impairment|Grade 3 or 4 IVH, cystic PVL, or ventriculomegaly|Moderate or severe cerebral palsy|Episodes of necrotizing enterocolitis|Time to full feeds|Length of hospital stay|Number of transfusions|Age at final tracheal extubation|Age at final caffeine dose|Growth|Survival to discharge without severe morbidity|Respiratory disease|Hydrocephalus shunt, microcephaly, or seizure disorder|Economic cost-benefit analysis","NICHD Neonatal Research Network|National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 48 Hours   (Child)","Phase 3","1824","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0050|U01HL112776|U01HL112748","December 2012","October 2019","December 2019","October 8, 2012","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01702805"
11,"NCT01467076","Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)",,"Terminated","Has Results","Prematurity|Respiratory Insufficiency|Pulmonary Hypertension|Respiratory Distress Syndrome, Newborn","Drug: Aerosolized Normal Saline|Drug: Inhaled PGE1","Feasibility Assessed as the Number of Participants Who Were Enrolled in the Study|Improvement in Partial Pressure of Oxygen in the Blood (PaO2)|Improvement in Oxygenation Index (OI)|Need for Inhaled Nitric Oxide (INO) 72 Hours After INO|Duration of iNO Therapy|Death|Need for Extracorporeal Membrane Oxygenation (ECMO)|Duration of Mechanical Ventilation|Number of Days of Supplemental Oxygen (O2) Used|Length of Hospital Stay","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 7 Days   (Child)","Phase 2","7","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0046|U10HD040689|U10HD021385|U10HD027904|U10HD027880|U10HD034216|U10HD040492|U10HD053109|U10HD040461|U10HD068263|U10HD068270|U10HD068278|U10HD036790","November 2011","May 2012","June 2012","November 8, 2011","December 30, 2016","March 28, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01467076"
12,"NCT01223287","Physiologic Definition of Bronchopulmonary Dysplasia","PhysiologicDef","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia (BPD)","","Bronchopulmonary dysplasia","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","36 Weeks to 37 Weeks   (Child)","","410","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0032|U10HD027904|U10HD021364|M01RR000080|U10HD027853|M01RR008084|U10HD040492|M01RR000030|U10HD027851|M01RR000039|UL1RR025008|U10HD027856|M01RR000750|UL1RR025761|U10HD027880|M01RR000070|UL1RR025744|U10HD053119|M01RR000054|U10HD034216|M01RR000032|U10HD040461|U10HD053109|M01RR000059|UL1RR024979|U10HD021397|M01RR016587|U10HD053089|M01RR000997|U10HD040521|M01RR000044|UL1RR024160|U10HD053124|M01RR000064|UL1RR025764|U10HD040689|M01RR000633|U10HD021373|U10HD040498|M01RR007122|U10HD021385|U10HD027871|UL1RR024139","May 2005","May 2008","September 2008","October 18, 2010","null","September 26, 2017","University of Alabama, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01223287"
13,"NCT01193270","Vitamin E for Extremely Preterm Infants",,"Completed","No Results Available","Infant, Newborn|Infant, Small for Gestational Age|Infant, Very Low Birth Weight|Infant, Premature|Intracranial Hemorrhages","Drug: Vitamin E|Drug: Placebo","Serum tocopherol levels","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 4 Hours   (Child)","Phase 1","93","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0044|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR024979|UL1RR025744|UL1RR025008|UL1RR025761|UL1RR025764","October 2010","August 2011","August 2011","September 1, 2010","null","November 11, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01193270"
14,"NCT01192776","Optimizing (Longer, Deeper) Cooling for Neonatal Hypoxic-Ischemic Encephalopathy(HIE)",,"Terminated","Has Results","Infant, Newborn|Hypoxia, Brain|Hypoxia-Ischemia, Brain|Encephalopathy, Hypoxic-Ischemic|Hypoxic-Ischemic Encephalopathy|Ischemic-Hypoxic Encephalopathy","Procedure: Whole-body Cooling","Death or Moderate to Severe Disability|Death|Level of Disability Among Survivors|Withdrawal of Care|Clinical Neonatal Seizures|Bayley Cognitive Score|Cerebral Palsy|Level of Disability Among Survivors, by Level of HIE|Visual Impairment|Hearing Impairment|Multiple Disabilities|Multiorgan Dysfunction","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Hours   (Child)","Phase 3","364","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0043|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR024979|UL1RR025008|UL1RR025744|UL1RR025747|UL1RR025761|UL1RR025764|U10HD068284|U10HD068278|U10HD068270|U10HD068263|U10HD068244","September 2010","March 2016","March 2016","September 1, 2010","August 15, 2017","April 9, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01192776"
15,"NCT01029353","Laparotomy vs. Drainage for Infants With Necrotizing Enterocolitis","NEST","Active, not recruiting","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Enterocolitis, Necrotizing|Intestinal Perforation","Procedure: Laparotomy|Procedure: Drainage","Death or neurodevelopmental impairment|Surgical complications|Number of surgical procedures|Sepsis episodes|Duration of parenteral nutrition|Parenteral nutrition associated cholestasis|Length of hospital stay|Rehospitalizations","NICHD Neonatal Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)","All","up to 8 Weeks   (Child)","Not Applicable","310","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0039|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|UL1RR025764|UL1RR025777|M01RR008084|UL1RR024979|U10HD068284|U10HD068278|U10HD068270|U10HD068263|U10HD068244|UG1HD087226","January 2010","May 2019","May 2019","December 10, 2009","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01029353"
16,"NCT00882284","Hypotension in Neonates",,"Completed","No Results Available","Infant, Newborn|Hypotension|Blood Pressure","","Prevalence of Hypotension in infants|Management of hypotension in infants|Short-term outcomes, including: vasopressor/inotrope exposure, death, time to full nipple feedings, duration of ventilation, and length of NICU stay","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","","820","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0040|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|M01RR008084","April 2009","December 2009","December 2009","April 16, 2009","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00882284"
17,"NCT00874393","Early Blood Pressure Management in Extremely Premature Infants","ELGAN BP","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Hypotension|Blood Pressure","Drug: Dopamine|Drug: Hydrocortisone|Drug: Infusion Placebo|Drug: Syringe Placebo","Enrollment and completion of 60 infants|Death|Duration of antihypotensive therapy|Receipt and timing of medical and/or surgical therapy for a PDA|Use of open-label antihypotensive therapies (inotropes, corticosteroids, blood and plasma volume expanders) for persistently low BP with biochemical evidence of poor perfusion|Spontaneous gastrointestinal perforation|In-hospital complications (grade III or IV intraventricular hemorrhage, cystic periventricular leukomalacia, necrotizing enterocolitis requiring surgical intervention, retinopathy of prematurity requiring laser surgery, or bronchopulmonary dysplasia)","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 24 Hours   (Child)","Phase 1","10","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0041|U10HD021364|U10HD027880|U10HD034216|U10HD036790|U10HD040492|U10HD053089|U10HD053124|UL1RR025744|UL1RR025764|UL1RR025777|U10HD027904|U10HD027853|U10HD040689|U10HD027851|UL1RR025008|U10HD021373|U10HD027856|U10HD053109|UL1RR024979|U10HD053119|UL1RR025747|U10HD021385|U10HD027871|UL1RR024139","July 2009","December 2010","December 2011","April 2, 2009","null","May 25, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00874393"
18,"NCT00873847","Cerebral Function Monitoring in Premature Infants",,"Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Electroencephalography","","First aEEG within 72 hours of age|Time required by research personnel to conduct study activities|Serious adverse events|Agreement between aEEG recordings and clinical events including: seizures, cardiopulmonary resuscitation, surfactant administration, suctioning, and intubation|Weekly aEEG until infant is 36 weeks post menstrual age","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","","102","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0042|U10HD021373|U10HD021385|U10HD027851|U10HD027880|U10HD027904|U10HD040492|U10HD040689|UL1RR025744","July 2009","June 2010","August 2012","April 2, 2009","null","September 26, 2017","Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Wayne State University, Detroit, Michigan, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00873847"
19,"NCT00614744","Late Hypothermia for Hypoxic-Ischemic Encephalopathy",,"Completed","Has Results","Infant, Newborn|Hypoxia, Brain|Hypoxia-Ischemia, Brain|Encephalopathy, Hypoxic-Ischemic|Hypoxic-Ischemic Encephalopathy|Ischemic-Hypoxic Encephalopathy","Procedure: Hypothermia|Procedure: Normothermic Control","Death or Moderate or Severe Disability|Number of Deaths in the NICU and Following Discharge|Number of Infants With Moderate and Severe Disability|Number of Infants With Mild, Moderate and Severe Disability|Number of Infants With Any Disability Based on Level of Encephalopathy at Randomization|Number of Infants With Non-CNS Organ System Dysfunction|Number of Infants With a DNR Order|Number of Infants With a DNR Order and Support is Withdrawn|Number of Infants With a DNR Order That Died|Number of Infants With Neonatal Seizures, With and Without EEG Abnormalities","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 24 Hours   (Child)","Phase 2|Phase 3","168","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0038|U10HD036790|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|UL1RR024979|U10HD068244|1U10HD068263-01|U10HD068270|U10HD068278|U10HD068284","April 2008","June 2016","June 2016","February 13, 2008","August 7, 2017","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00614744"
20,"NCT00273325","Immunogenicity of PCV-7 Vaccine in VLBW Infants","PCV-7","Completed","No Results Available","Pneumococcal Infections|Streptococcus Pneumoniae|Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","","Serotype 6B pneumococcal capsular polysaccharide antibody >=0.15 μg/ml|Pneumococcal capsular polysaccharide antibody >=0.15 μg/ml for the other six vaccine serotypes|Pneumococcal capsular polysaccharide antibodies >=1.0 μg/ml for all seven vaccine serotypes|Geometric mean titers of pneumococcal capsular polysaccharide antibody to the seven vaccine serotypes|Pneumococcal capsular polysaccharide antibodies >=0.15 μg/ml and >=1.0 μg/ml, and geometric mean titers of antibody, to the seven vaccine serotypes in children completing the primary series, regardless of postnatal age|Opsonization of 6B pneumococcal capsular polysaccharide plus 1 low immunogenicity, high prevalence serotype (e.g., 23F) among infants in the lowest quartile of antibody response|Effect of possible mediating variables on the achievement of levels of serotype 6B pneumococcal capsular polysaccharide antibody >=0.15 μg/ml|Effect of pneumococcal conjugate immunization status (complete & timely v. complete v. incomplete) on outcome (survival, serious infection, neurodevelopmental outcome) at 18-22 months corrected age in infants <=1000g|Levels of antibody >=0.15 μg/ml and >=1.0 μg/ml to Hib polyribosylribitol|Avidity of antibody to Hib-PRP among infants in the lowest quartile of antibody response,regardless of postnatal or gestational age","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 3 Months   (Child)","","368","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0031|UL1RR024128|UL1RR024160|UL1RR024982|UL1RR025008|UL1RR025744|UL1RR025777|M01RR016587|M01RR000030|M01RR000032|M01RR000039|M01RR000044|M01RR000633|M01RR000070|M01RR007122|U01HD036790|U10HD021385|U10HD021397|U10HD027851|U10HD027880|U10HD034216|U10HD040492|U10HD040498|U10HD040521|U10HD040689","July 2004","July 2007","March 2009","January 9, 2006","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Wayne State University, Detroit, Michigan, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00273325"
21,"NCT00109525","Early Diagnosis of Candidiasis in Premature Infants","Candida","Completed","No Results Available","Infection|Candida|Candidiasis|Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","","Probability of invasive candidiasis based on new assay results|Determine test performance of clinical predictive model|Determine test performance (sensitivity and specificity) of polymerase chain reaction (PCR) testing|Determine test performance of Beta-glucan assay|Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of blood samples|Determine test performance of Gas Chromatography Mass Spectrometry for D-arabinitol of urine samples|Determine test performance of the blood culture|Determine test performance of the lumbar puncture (cell count, protein, glucose, and culture)|Determine test performance of tracheal aspirates|Determine test performance of urine cultures|Compare clinical predictive model performance to neonatologist clinical judgment|Determine incidence of end-organ damage in neonates with candidemia|Determine resistance patterns of organisms isolated|Determine molecular epidemiology of candidemia|Determine genetic expression of organism virulence factors|Neurodevelopmental outcome","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 120 Days   (Child)","","1500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0030|UL1RR024139|UL1RR024160|M01RR016587|M01RR000030|M01RR000032|M01RR000039|M01RR000044|M01RR000054|M01RR000059|M01RR006022|M01RR000633|M01RR000070|M01RR007122|M01RR000750|M01RR000080|M01RR008084|M01RR000997|U10HD036790|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD040461|U10HD040492|U10HD040498|U10HD040521|U10HD040689|U10HD053089|U10HD053109|U10HD053119","March 2004","July 2007","December 2009","April 29, 2005","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00109525"
22,"NCT01353313","Hydrocortisone for BPD",,"Active, not recruiting","No Results Available","Infant, Newborn|Infant, Small for Gestational Age|Infant, Very Low Birth Weight|Infant, Premature|Bronchopulmonary Dysplasia","Drug: Hydrocortisone|Drug: Placebo","Efficacy|Safety|Morbidity and Growth|Successful Extubation|Use of open-label dexamethasone|Respiratory status at 40 weeks","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)","All","up to 30 Weeks   (Child)","Phase 3","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NICHD-NRN-0045|U10HD034216|U10HD027904|U10HD021364|U10HD027853|U10HD040689|U10HD040492|U10HD027851|U10HD021373|U10HD027856|U10HD053109|U10HD036790|U10HD027880|U10HD053089|U10HD021385|U10HD068244|U10HD068263|U10HD068270|U10HD068278|U10HD068284|U24HL137729|1UG3HL137872","September 2011","January 2020","January 2025","May 13, 2011","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01353313"
23,"NCT00063063","Generic Database of Very Low Birth Weight Infants","GDB","Recruiting","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","","To maintain a registry of baseline and outcome data for VLBW infants with data collected in a uniform manner|To examine the relationship between baseline characteristics and outcome|To monitor trends in incidence of various disease entities|To monitor changes in VLBW and early gestational age survival|To provide data for hypothesis formulation and sample size calculation for Network multi-center studies","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 14 Days   (Child)","","80000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0001|U01HD019897|U01HD021466|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD021415|U01HD021438|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027881|U10HD027904|U10HD034167|U10HD034216|U10HD036790|U10HD040461|U10HD040492|U10HD040498|U10HD040521|U10HD040689|U10HD042638|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|M01RR000032|M01RR000039|M01RR000044|M01RR000054|M01RR000059|M01RR000064|M01RR000070|M01RR000080|M01RR000633|M01RR000750|M01RR000997|M01RR008084|M01RR001032|M01RR002172|M01RR002635|M01RR007122|M01RR016587|U10HD068244|U10HD068263|U10HD068270|U10HD068278|U10HD068284|UG1HD034216|UG1HD027904|UG1HD021364|UG1HD027853|UG1HD040689|UG1HD040492|UG1HD027851|UG1HD087229|UG1HD027856|UG1HD053109|UG1HD068284|UG1HD068278|UG1HD068244|UG1HD068263|UG1HD027880|UG1HD068270|UG1HD053089|UG1HD087226","January 1987","March 2021","March 2021","June 20, 2003","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Harvard University, Cambridge, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Vermont, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT00063063"
24,"NCT01030575","Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)","INS-2","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Retinopathy of Prematurity|Bronchopulmonary Dysplasia (BPD)","Drug: Inositol lower volume|Drug: Inositol mid-level volume|Drug: Inositol high volume|Drug: Placebo low volume","Population pharmacokinetics|Adverse events during and following infusion, using a neonatal toxicity classification","NICHD Neonatal Research Network|National Eye Institute (NEI)|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","Phase 2","125","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0036-2|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|UL1RR024979|M01RR008084","January 2010","May 2011","September 2013","December 11, 2009","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01030575"
25,"NCT00009633","Follow-up Visit of High Risk Infants","FU","Recruiting","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","","To maintain a registry of baseline and outcome data for VLBW infants with data collected in a uniform manner|To examine the relationship between baseline characteristics and outcome|To provide data for hypothesis formulation and sample size calculation for Network multi-center studies","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Months to 26 Months   (Child)","","68000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0007|U01HD019897|U01HD021466|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD021415|U01HD021438|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027881|U10HD027904|U10HD034167|U10HD034216|U10HD036790|U10HD040461|U10HD040492|U10HD040498|U10HD040521|U10HD040689|U10HD042638|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|M01RR000633|M01RR000750|M01RR000997|M01RR008084|M01RR001032|M01RR002172|M01RR002635|M01RR007122|M01RR016587|UG1HD087226","January 1993","March 2021","March 2021","February 5, 2001","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Harvard University, Cambridge, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00009633"
26,"NCT00874367","Early-Onset Sepsis Surveillance Study","EOS","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Sepsis|Gram-Negative Bacterial Infections|Gram-Positive Bacterial Infections","","Early onset sepsis infections|Group B streptococcal (GBS) infections|Symptomatic early onset sepsis infections|Death with early gram-negative or early gram-positive infections|Prolonged exposure to maternal intrapartum antibiotics (>24 hours)|Placental examinations to confirm clinical diagnosis of chorioamnionitis","NICHD Neonatal Research Network|Centers for Disease Control and Prevention|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","","615","Other|U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0035|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040492|U10HD040498|U10HD040521|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|UL1RR025764|UL1RR025777|M01RR000030|M01RR000032|M01RR000039|M01RR000044|M01RR000054|M01RR000059|M01RR000064|M01RR000070|M01RR000080|M01RR000633|M01RR000750|M01RR000997|M01RR008084|M01RR006022|M01RR007122","February 2006","December 2009","May 2011","April 2, 2009","null","September 25, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00874367"
27,"NCT00349726","Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants","INS-1","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Retinopathy of Prematurity|Bronchopulmonary Dysplasia (BPD)","Drug: Inositol lower volume|Drug: Inositol higher volume|Drug: Placebo lower volume|Drug: Placebo higher volume","Population pharmacokinetics|Adverse events during and following infusion, using a neonatal toxicity classification","NICHD Neonatal Research Network|National Eye Institute (NEI)|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Days   (Child)","Phase 2","74","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0036-1|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024139|UL1RR025744|UL1RR024979","June 2006","December 2007","December 2007","July 10, 2006","null","June 20, 2017","Yale University, New Haven, Connecticut, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00349726"
28,"NCT00233324","Surfactant Positive Airway Pressure and Pulse Oximetry Trial","SUPPORT","Completed","Has Results","Infant, Newborn, Diseases|Other Preterm Infants|Infant, Small for Gestational Age|Premature Birth|Bronchopulmonary Dysplasia|Retinopathy of Prematurity","Drug: Surfactant|Device: Continuous Positive Airway Pressure (CPAP)|Drug: Supplemental oxygen with target saturation of 85 to 89%|Drug: Supplemental oxygen with target saturation of 91 to 95%","Survival Without Bronchopulmonary Dysplasia (BPD)|Survival Without Severe Retinopathy of Prematurity (ROP) (Threshold Disease or the Need for Surgery)|Death or Neurodevelopmental Impairment|Duration of Mechanical Ventilation|Survival Without Ventilation|Received Surfactant Treatment|Incidence of Air Leaks|Bronchopulmonary Disease (Using the Physiologic Definition of BPD)|Death|Severe Intraventricular Hemorrhage (IVH)|Periventricular Leukomalacia (PVL)|Threshold ROP Requiring Surgery|Endotracheal Intubation|Duration of Oxygen Supplementation|Pulse Oximetry Values > 90%|Blindness in at Least One Eye|Received Postnatal Steroids|Necrotizing Enterocolitis (NEC)|Cerebral Palsy","NICHD Neonatal Research Network|National Heart, Lung, and Blood Institute (NHLBI)|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","24 Weeks to 27 Weeks   (Child)","Phase 3","1316","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0033|U10HD021364|U10HD021373|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD036790|U10HD040461|U10HD040492|U10HD040689|U10HD053089|U10HD053109|U10HD053119|U10HD053124|UL1RR024128|UL1RR024139|UL1RR024979|UL1RR024982|UL1RR024989|UL1RR025008|M01RR000633|M01RR000750|M01RR008084|U10HD021397|U10HD040521|U10HD040498","February 2005","February 2009","August 2016","October 5, 2005","December 5, 2014","October 25, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Tufts Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00233324"
29,"NCT03456336","Management of the PDA Trial","PDA","Recruiting","No Results Available","Infant, Premature|Patent Ductus Arteriosus|Infant, Newborn, Diseases|Patent Ductus Arteriosus After Premature Birth","Other: Active Treatment|Other: Expectant Management","Death or Bronchopulmonary Dysplasia (BPD) at 36 weeks PMA|Mortality at 36 weeks PMA|Mortality before discharge|Bronchopulmonary dysplasia - Physiological Test|Bronchopulmonary dysplasia - NIH Consensus Definition|Necrotizing Enterocolitis (NEC) at 36 weeks PMA|Retinopathy of Prematurity at 36 weeks PMA|Receipt of therapies designed to close the PDA|Weight at 36 weeks PMA|Height at 36 weeks PMA|Head Circumference at 36 weeks PMA","NICHD Neonatal Research Network","All","up to 21 Days   (Child)","Phase 3","1116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0059","December 3, 2018","May 30, 2022","July 31, 2024","March 7, 2018","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University - Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03456336"
30,"NCT03169881","Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants","Darbe","Recruiting","No Results Available","Neurocognitive|Neuroprotective|Neonatal|Neurodevelopmental Impairment","Drug: Darbepoetin|Drug: Placebo","Composite cognitive score on Bayley Scale of Infant Development III|Death|Cerebral Palsy|Length of Hospital Stay|Number of transfusions|Hematocrit|Red cell mass|Volume of transfusions|Neurodevelopmental impairment (NDI)|Seizures|Thromboses|Hypertension|Intra-cranial Hemorrhage (ICH)|Necrotizing Enterocolitis (NEC) requiring surgery|Bronchopulmonary dysplasia (BPD)|Retinopathy of prematurity (ROP) requiring intervention|Culture positive sepsis","NICHD Neonatal Research Network|National Heart, Lung, and Blood Institute (NHLBI)","All","23 Weeks to 28 Weeks   (Child)","Phase 3","650","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0058","September 20, 2017","September 2022","September 2023","May 30, 2017","null","March 11, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|University of Iowa, Iowa City, Iowa, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Brown University - Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT03169881"
31,"NCT01223274","Delivery Room CPAP in Extremely Low Birth Weight Infants","DR-CPAP","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia|Continuous Positive Airway Pressure","Device: CPAP/PEEP|Device: Standard management practices","Compliance with the study protocol|Extent of resuscitation needed|Five minute Apgar|Total duration of mechanical ventilation|Proportion of infants requiring surfactant|Bronchopulmonary dysplasia (BPD)|Number and duration of intubation attempts|Infants who required positive pressure ventilation for resuscitation in the DR/resuscitation room","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 10 Minutes   (Child)","Phase 1|Phase 2","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0028|U10HD021364|M01RR000080|U10HD034216|U10HD027853|M01RR008084|U10HD021397|M01RR016587|U10HD040461|U10HD036790","July 2002","January 2003","January 2003","October 18, 2010","null","September 26, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California at San Diego, San Diego, California, United States|University of Miami, Miami, Florida, United States|RTI International, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01223274"
32,"NCT01223261","Observational Study of Surgical Treatment of Necrotizing Enterocolotis","NEC Surgery","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Enterocolitis, Necrotizing|Intestinal Perforation","","Feasibility of conducting a randomized trial|Document variation in current surgical practices|Prevalence of infants who would qualify for the study|Frequency of postoperative complications|Neurodevelopmental impairment","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 6 Weeks   (Child)","","156","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0027|U10HD034216|U10HD027904|U10HD021364|M01RR000080|U10HD027853|M01RR008084|U10HD027851|M01RR000039|U10HD021397|M01RR016587|U10HD027856|M01RR000750|U10HD027880|M01RR000070|U10HD040689|M01RR000633|U10HD021373|U10HD021385|U10HD027871|M01RR006022|U10HD040492|M01RR000030|U10HD040498|M01RR007122|U10HD040521|M01RR000044|U10HD040461|U10HD036790","March 2001","September 2002","March 2004","October 18, 2010","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01223261"
33,"NCT01222364","Delayed Cord Clamping in VLBW Infants",,"Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","Procedure: Standard Cord Clamping|Procedure: Delayed Cord Clamping","Infants enrolled|Intention to treat|Hematocrit level|Arterial blood pressure|Use of volume expansion or pressor therapy|Blood transfusions","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 1 Minute   (Child)","Phase 1|Phase 2","54","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0023|U10HD021364|U01HD021438|U10HD027853|U10HD027904|M01RR000080|M01RR008084","June 2000","December 2000","December 2000","October 18, 2010","null","September 26, 2017","University of Alabama, Birmingham, Alabama, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01222364"
34,"NCT01203514","The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants","EPO","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Anemia, Neonatal","Drug: Erythropoietin|Other: Sham Comparator","Erythrocyte transfusions in infants 401-1,000g birthweight|Blood transfusions","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 96 Days   (Child)","Phase 2|Phase 3","318","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0017|U10HD027853|M01RR008084|U10HD027851|M01RR000039|U10HD034167|M01RR002635|M01RR002172|M01RR001032|U10HD027856|M01RR000750|U10HD027881|M01RR000997|U10HD021415|U10HD021385|U10HD027871|M01RR006022","August 1997","August 1998","August 2000","September 16, 2010","null","September 26, 2017","Yale University, New Haven, Connecticut, United States|George Washington University, Washington, D.C., District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Harvard University, Cambridge, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|University of Tennessee, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01203514"
35,"NCT01203501","In Utero Magnesium Sulfate Exposure: Effects on Extremely-Low-Birth-Weight Infants","MgSO4","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Intracranial Hemorrhages|Leukomalacia, Periventricular|Cerebral Palsy","","Incidence of Intraventricular Hemorrhage|Incidence of cerebral palsy","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 14 Days   (Child)","","1339","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0016|U10HD034216|U10HD027904|U10HD021364|M01RR000080|U10HD027853|M01RR008084|U10HD027851|M01RR000039|U10HD034167|M01RR001032|M01RR002635|U10HD027856|M01RR000750|U10HD021397|U10HD027881|M01RR000997|U10HD027880|M01RR000070|U10HD021415|U10HD021373|M01RR000633|U10HD021385|U10HD027871|M01RR006022","July 1996","June 1998","June 2000","September 16, 2010","null","September 26, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, D.C., District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Harvard University, Cambridge, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203501"
36,"NCT01203488","Vitamin A Supplementation for Extremely-Low-Birth-Weight Infants","Vitamin A","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia|Respiration, Artificial|Respiratory Distress Syndrome, Newborn|Sepsis","Drug: Vitamin A|Other: Sham Procedure","Chronic lung disease or death|Sepsis","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 96 Hours   (Child)","Phase 1|Phase 2","807","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0015|U10HD021373|U10HD027904|U01HD019897|U10HD027871|M01RR006022|U10HD027851|U10HD027856|M01RR000750|U10HD027880|M01RR000070|U10HD021397|U10HD021415|U10HD021364|U10HD027853|M01RR008084|U10HD034216|U10HD021385|U10HD034167|U10HD027881|M01RR000997","January 1996","July 1997","July 1999","September 16, 2010","null","September 26, 2017","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, D.C., District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203488"
37,"NCT01203475","Growth Observational Study","Growth","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","","","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 24 Hours   (Child)","","1660","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0013|U10HD021364|U10HD027853|M01RR008084|U10HD027851|U01HD019897|U10HD027856|M01RR000750|U10HD021397|U10HD027881|M01RR000997|U10HD027880|M01RR000070|U10HD021415|U10HD021373|U10HD021385|U10HD027904|U10HD027871|M01RR006022","August 1994","August 1995","August 1995","September 16, 2010","null","June 8, 2015","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203475"
38,"NCT01203449","Development of Standards for the New Ballard Maturation Score","Ballard","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Pregnancy","","","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 48 Hours   (Child)","","1090","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0012|U10HD027853|U10HD027871|U10HD021385|U10HD027880|U01HD019897|U10HD021364|U10HD021415|U10HD027851|U10HD021373|U10HD027856|U10HD027881|M01RR008084|M01RR006022|M01RR000750|M01RR000070|M01RR000997|U10HD021397","June 1994","March 1996","March 1996","September 16, 2010","null","June 8, 2015","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203449"
39,"NCT01203436","Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity","STOP-ROP","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Retinopathy of Prematurity|Blindness","Procedure: Supplemental Oxygen Management|Procedure: Conventional Oxygen Management","Progression from moderate to severe ROP (prethreshold) to threshold ROP requiring peripheral ablative surgery","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|National Eye Institute (NEI)|National Institute of Nursing Research (NINR)|Delta Gamma Sorority|Rhea and Raymond White|Research to Prevent Blindness","All","up to 48 Hours   (Child)","Phase 2|Phase 3","649","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0010|U10HD027904|U10HD027851|U10HD027856|U10HD027880|U10HD027853|U10HD021415|U10HD040689|U10HD021385|U10HD027871|M01RR000054|M01RR000070","February 1994","March 1999","March 1999","September 16, 2010","null","June 8, 2015","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203436"
40,"NCT01203423","Persistent Pulmonary Hypertension of the Newborn (PPHN) Observational Study","PPHN","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Persistent Fetal Circulation Syndrome|Persistent Pulmonary Hypertension of Newborn","","Death","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 7 Days   (Child)","","385","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0009|U10HD027881|U10HD021373|U10HD027851|U10HD027853|U10HD021397|U01HD019897|U10HD021415|U10HD027856|U10HD021364|U10HD027880|U10HD027904|U10HD027871|U10HD021385|M01RR000997|M01RR008084|M01RR000750|M01RR000070|M01RR006022","October 1993","December 1994","December 1994","September 16, 2010","null","March 22, 2019","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203423"
41,"NCT01203410","Prediction of Jaundice in Term Infants",,"Completed","No Results Available","Infant, Newborn|Jaundice","","End-tidal carbon End-tidal carbon monoxide levels corrected for ambient air (ETCOc)","NICHD Neonatal Research Network","All","up to 8 Hours   (Child)","","535","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0004|U10HD021364|U10HD027853|U10HD027851|U01HD019897|U10HD027856|U10HD027881|U10HD027880|U10HD021415|U10HD021373|U10HD021385|U10HD027904|U10HD027871","November 1991","November 1992","November 1992","September 16, 2010","null","March 22, 2019","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT01203410"
42,"NCT01203358","Exosurf Neonatal and Survanta for Treatment of Respiratory Distress Syndrome","Surfactant 1","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia","Drug: Exosurf|Drug: Survanta","Death or bronchopulmonary dysplasia|Average fraction of inspired oxygen (FIO2)|Mean airway pressure (MAP)","NICHD Neonatal Research Network","All","up to 6 Hours   (Child)","Phase 2|Phase 3","617","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0003|U01HD019897|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD021415|U10HD027856|U10HD027853|U10HD027871|U10HD027851|U10HD027880|U10HD027881","January 1991","January 1992","January 1992","September 16, 2010","null","March 22, 2019","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Vermont, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT01203358"
43,"NCT01203345","Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection","IVIG","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Sepsis","Drug: IVIG|Drug: Placebo","Incidence of nosocomial infection|Death|Morbidity|Local infections|Necrotizing enterocolitis|Specific complications of immune globulin or placebo infusion","NICHD Neonatal Research Network","All","up to 72 Hours   (Child)","Phase 2|Phase 3","2416","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0002|U10HD021364|U10HD021415|U01HD019897|U10HD021385|U10HD021397|U10HD021373","January 1988","March 1991","March 1991","September 16, 2010","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Wayne State University, Detroit, Michigan, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Vermont, Burlington, Vermont, United States","","https://ClinicalTrials.gov/show/NCT01203345"
44,"NCT01035697","Inflammatory Cytokines Associated With Perinatal Brain Injury","Cytokines","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Cerebral Palsy","","Pro-cytokines increased and anti-inflammatory cytokines decreased|Type and severity of CP and other neurodevelopmental handicaps, the appearance of PVL, and neonatal mortality|Abnormal pro-inflammatory and anti-inflammatory cytokines at birth are associated with prenatal insults (e.g., chorioamnionitis, occult intrauterine infection, early-onset neonatal sepsis, perinatal asphyxia, early death)|Abnormal postnatal cytokine levels associated with postnatal insults (e.g., postnatal intraventricular hemorrhage, late-onset neonatal sepsis, bronchopulmonary dysplasia, chronic lung disease, and/or necrotizing enterocolitis)|Pro-inflammatory cytokine elevations at the time of a workup for possible sepsis occur in infants with a positive bacterial blood culture and those with negative blood cultures who are treated with a full course of antibiotics","NICHD Neonatal Research Network|Centers for Disease Control and Prevention|National Center for Research Resources (NCRR)","All","up to 72 Hours   (Child)","","1067","Other|U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0022|U10HD027853|M01RR008084|U10HD040492|M01RR000030|U10HD027851|M01RR000039|U10HD027856|M01RR000750|U10HD021364|M01RR000080|U01HD036790|U10HD027880|M01RR000070|U10HD034216|M01RR000032|U10HD040461|U10HD021397|M01RR016587|U10HD027881|M01RR000997|U10HD021415|U10HD040689|M01RR000633|U10HD021373|U10HD040498|M01RR007122|U10HD021385|U10HD027904|U10HD027871|M01RR006022","July 1999","July 2002","May 2004","December 21, 2009","null","March 22, 2019","University of Alabama, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01035697"
45,"NCT00114543","Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight","Phototherapy","Completed","No Results Available","Hyperbilirubinemia, Neonatal|Jaundice, Neonatal|Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","Procedure: Aggressive Phototherapy 501-750g|Procedure: Aggressive Phototherapy 751-1000g|Procedure: Conservative Phototherapy 501-750g|Procedure: Conservative Phototherapy 751-1000g","Death or neurodevelopmental impairment (MDI <70; PDI <70; cerebral palsy; blindness; or severe hearing loss)|Patent ductus arteriosus requiring drug or surgical treatment|Retinopathy of prematurity|Bronchopulmonary dysplasia (BPD)|Ventilator settings and FiO2 at 36 weeks|Necrotizing enterocolitis (NEC)|Intraventricular hemorrhage (IVH) by grade|Periventricular leukomalacia|Sepsis|Hearing assessments","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 36 Hours   (Child)","Phase 3","1974","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0029|M01RR016587|M01RR000030|M01RR000032|M01RR000039|M01RR000044|M01RR006022|M01RR000633|M01RR000070|M01RR007122|M01RR000750|M01RR000080|M01RR008084|U01HD036790|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD040461|U10HD040492|U10HD040498|U10HD040521|U10HD040689","September 2002","April 2005","November 2007","June 16, 2005","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00114543"
46,"NCT00067613","Benchmarking Initiative to Reduce Bronchopulmonary Dysplasia","Benchmarking","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia (BPD)","Other: Benchmarking Management Practices|Other: Standard Management Practices","Survival without BPD|Bronchopulmonary Dysplasia","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 36 Weeks   (Child)","Not Applicable","4095","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NICHD-NRN-0025|U10HD034216|U10HD021364|U10HD027853|U10HD027851|U01HD036790|U10HD027856|U10HD021397|U10HD027881|U10HD027880|U10HD021415|U10HD021373|U10HD021385|U10HD027871|U10HD034167|U10HD027904|M01RR008084|M01RR000750|M01RR000997|M01RR000070|M01RR006022|M01RR002635|M01RR002172|M01RR001032","March 2001","May 2004","May 2004","August 26, 2003","null","June 8, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00067613"
47,"NCT00016523","Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure","Preemie iNO","Terminated","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Respiratory Distress Syndrome (RDS)|Sepsis|Pneumonia|Hypertension, Pulmonary","Drug: Inhaled nitric oxide|Drug: Placebo","Death or Bronchopulmonary Dysplasia|Intraventricular Hemorrhage Grade III and IV|Days on assisted ventilation|Length of hospitalization|Retinopathy of prematurity|Air leaks|Days on oxygen|Supplemental oxygen|Neurodevelopmental outcome","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 120 Hours   (Child)","Phase 3","420","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0026|U10HD034216|M01RR000032|U10HD027904|U10HD027853|M01RR008084|U10HD027856|M01RR000750|U10HD021397|M01RR016587|U10HD027880|M01RR000070|U10HD040689|M01RR000633|U10HD021373|U10HD021385|U10HD027871|M01RR006022|U10HD040498|M01RR007122|U10HD040461|U10HD040521|M01RR000044","January 2001","September 2003","May 2006","May 16, 2001","null","September 26, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of Rochester, Rochester, New York, United States|Wake Forest University, Charlotte, North Carolina, United States|RTI International, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00016523"
48,"NCT00011362","Dexamethasone Therapy in VLBW Infants at Risk of CLD","Dexamethasone","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Bronchopulmonary Dysplasia","Drug: Dexamethasone Early|Drug: Dexamethasone Late","Number of days from randomization to ventilator independence, defined as extubation not requiring reintubation, or extubation followed by elective reintubation for seven days or less so that the infant could undergo a surgical procedure|Death before discharge from the hospital|Duration of assisted ventilation|Duration of supplemental oxygen therapy|Duration of hospital stay|Incidence of chronic lung disease|Morbidity and mortality from respiratory causes during the first year","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 15 Days   (Child)","Phase 3","371","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NICHD-NRN-0005|U10HD027881|U10HD021373|U10HD027851|U10HD027853|U10HD021397|U01HD019897|U10HD021415|U10HD027856|U10HD021364|U10HD027880|U10HD027904|U10HD027871|U10HD021385|M01RR000997|M01RR008084|M01RR000750|M01RR000070|M01RR006022","September 1992","January 1994","April 1994","February 19, 2001","null","March 22, 2019","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00011362"
49,"NCT00009646","Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)","TIPP","Completed","No Results Available","Infant, Very Low Birth Weight|Infant, Premature|Ductus Arteriosus, Patent","Drug: indomethacin|Drug: Indomethacin|Drug: Placebo","Death or Neurodevelopment Impairment|Patent ductus arteriosus|Bronchopulmonary Dysplasia (BPD)|Necrotizing enterocolitis (NEC)|Intracranial abnormalities|Retinopathy of Prematurity (ROP)|Pulmonary hemorrhage","NICHD Neonatal Research Network|Medical Research Council of Canada|National Center for Research Resources (NCRR)","All","up to 6 Hours   (Child)","Phase 3","1202","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD-NRN-0011|U10HD034216|U10HD027904|U10HD021364|U10HD027851|U10HD021397|U10HD027881|U10HD027880|U10HD021373|U10HD021385|MT-13288|M01RR000997|M01RR000070","November 1993","March 1999","March 2001","February 5, 2001","null","June 8, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00009646"
50,"NCT00005777","Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)","SAVE","Terminated","No Results Available","Bronchopulmonary Dysplasia|Respiratory Distress Syndrome|Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature","Procedure: Minimal mechanical ventilation management|Procedure: Routine mechanical ventilation management|Drug: Dexamethasone|Drug: Placebo","Death or moderate to severe bronchopulmonary dysplasia|Death|Mechanical ventilation|Pulmonary interstitial emphysema|Pneumothorax|Open-label steroids|Reintubation|Intracranial hemorrhage (IVH) III or IV|Periventricular leukomalacia|Necrotizing enterocolitis|Duration of oxygen supplementation|Duration of ventilation|Length of hospitalization|Death or neurodevelopmental impairment|Neurodevelopmental impairment|Cerebral palsy|Bilateral blindness|Deafness|Bayley Scales of Infant Development-Revised II Psychomotor Developmental Index (PDI)|Rehospitalizations","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 10 Days   (Child)","Phase 3","220","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0018|U10HD034216|U10HD034167|U10HD021397|U10HD027853|U10HD027871|U10HD021415|U10HD027904|U10HD027881|U10HD021385|U10HD027851|U10HD027880|U10HD021373|U01HD036790|M01RR008084|M01RR006022|M01RR000750|M01RR000997|M01RR000070|M01RR001032","February 1998","September 1998","September 2002","June 2, 2000","null","June 8, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00005777"
51,"NCT00005776","Inhaled Nitric Oxide Study for Respiratory Failure in Newborns","NINOS","Terminated","No Results Available","Infant, Newborn|Hypertension, Pulmonary|Persistent Fetal Circulation Syndrome|Pneumonia, Aspiration|Respiratory Distress Syndrome, Newborn|Respiratory Insufficiency","Drug: Inhaled nitric oxide|Drug: Placebo","Death or initiation of ECMO|PaO2 levels, oxygenation index, and alveolar-arterial oxygen gradient|Neurodevelopmental outcome|Duration of hospital stay|Duration of assisted ventilation, air leaks, or chronic lung disease|Transfers for ECMO|Meeting ECMO criteria","NICHD Neonatal Research Network|Medical Research Council of Canada|National Center for Research Resources (NCRR)","All","up to 14 Days   (Child)","Phase 3","235","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0014|U01HD019897|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD021415|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027881|U10HD027904|U10HD034167|U10HD034216|M01RR000070|M01RR000750|M01RR000997|M01RR001032|M01RR006022|M01RR008084","October 1995","May 1996","May 1998","June 2, 2000","null","September 26, 2017","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, D.C., District of Columbia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Foothills Hospital, Calgary, Alberta, Canada|Royal Alexandra Hospital, Edmonton, Alberta, Canada|British Columbia Children's Hospital, Vancouver, British Columbia, Canada|Health Sciences Center, Winnipeg, Manitoba, Canada|McMaster University, Hamilton, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Montreal Children's Hospital, Montreal, Quebec, Canada|Université de Sherbrooke,, Sherbrooke,, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT00005776"
52,"NCT00005775","Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants","Glutamine","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Sepsis","Drug: Glutamine|Drug: Placebo","Death or late-onset sepsis|Tolerance of enteral feeding (number of days to reach full enteral feeds) and decrease number of episodes of feeding intolerance|Necrotizing Enterocolitis|Episodes of late-onset sepsis|Growth (days to reach 1500 grams)|Number of days on parenteral nutrition|Length of stay in NICU|Neurodevelopmental outcome|Levels of pro-inflammatory cytokines","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 72 Hours   (Child)","Phase 3","1433","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0020|U10HD027856|U10HD021364|U10HD034216|U10HD034167|U10HD021397|U10HD027853|U10HD027871|U10HD021415|U10HD027904|U10HD027881|U10HD021385|U10HD027851|U10HD027880|U10HD021373|U01HD036790|M01RR008084|M01RR006022|M01RR000750|M01RR000997|M01RR000070|M01RR001032","July 1999","December 2000","August 2001","June 2, 2000","null","June 8, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|University of California at San Diego, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00005775"
53,"NCT00005774","Early Surfactant to Reduce Use of Mechanical Breathing in Low Birth Weight Infants","Surfactant 2","Terminated","No Results Available","Infant, Newborn|Respiratory Distress Syndrome|Respiratory Insufficiency","Drug: Early surfactant|Drug: Standard practice","Need for mechanical ventilation following randomization|Mean duration of mechanical ventilation|Risk morbidities associated with mechanical ventilation and/or early surfactant administration","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 12 Hours   (Child)","Phase 3","61","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0024|U10HD027856|U10HD021364|U10HD034216|U10HD034167|U10HD021397|U10HD027853|U10HD027871|U10HD021415|U10HD027904|U10HD027881|U10HD021385|U10HD027851|U10HD027880|U01HD036790|M01RR008084|M01RR006022|M01RR000750|M01RR000997|M01RR000070|M01RR001032","May 2000","July 2002","July 2002","June 2, 2000","null","June 8, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00005774"
54,"NCT00005773","Early Inhaled Nitric Oxide for Respiratory Failure in Newborns","Early iNO","Terminated","No Results Available","Infant, Newborn|Hypertension, Pulmonary|Persistent Fetal Circulation Syndrome|Pneumonia, Aspiration|Respiratory Distress Syndrome, Newborn|Respiratory Insufficiency","Drug: Inhaled Nitric Oxide|Drug: Standard iNO therapy","Death or use of extracorporeal membrane oxygenation (ECMO)|Use of iNO therapy based on the standard recommended threshold|Progression to severe respiratory failure (OI>40)|Neurodevelopmental impairment","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Canadian Institutes of Health Research (CIHR)|Mallinckrodt","All","up to 14 Days   (Child)","Phase 3","302","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0019|U01HD019897|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD021415|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027881|U10HD027904|U10HD034167|U10HD034216|U10HD040689|M01RR000070|M01RR000633|M01RR000750|M01RR000997|M01RR001032|M01RR006022|M01RR008084|M01RR016587","August 1998","May 2001","August 2003","June 2, 2000","null","September 26, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|St. Joseph's Hospital, Phoenix, Arizona, United States|Stanford University, Palo Alto, California, United States|San Diego Children's Hospital, San Diego, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Washington School of Medicine, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00005773"
55,"NCT00005772","Whole-Body Cooling for Birth Asphyxia in Term Infants",,"Completed","No Results Available","Infant, Newborn|Hypoxia-Ischemia, Brain","Device: Induced hypothermia|Device: Control","Death or moderate or severe disability|Length of hospital stay|Frequency of multi-organ dysfunction|Withdrawal of support|Post-neonatal deaths|Multiple disability|Seizure disorders|Rehospitalizations","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","All","up to 6 Hours   (Child)","Phase 3","208","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-NRN-0021|U10HD021364|U10HD021373|U10HD021385|U10HD021397|U10HD027851|U10HD027853|U10HD027856|U10HD027871|U10HD027880|U10HD027904|U10HD034216|U10HD040461|U10HD040492|U10HD040498|U10HD040521|U10HD040689|M01RR000030|M01RR000039|M01RR000044|M01RR000070|M01RR000080|M01RR000633|M01RR000750|M01RR006022|M01RR007122|M01RR008084|M01RR016587","October 1999","May 2003","July 2010","June 2, 2000","null","March 22, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Harvard University, Cambridge, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|RTI International, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00005772"
56,"NCT01084109","First Bites: Complementary Feeding - A Global Network Cluster Randomized Controlled Trial","First Bites","Completed","No Results Available","Complementary Feeding|Infant Growth","Other: Lyophilized meat|Other: Cereal","Linear growth velocity|Infant Zinc and Ferritin levels|Bayleys II|Incidence of diarrhea, lower respiratory infection, and malaria","NICHD Global Network for Women's and Children's Health|Kinshasa School of Public Health|University of Zambia|INCAP, Chiimaltenango, Guatemala|Aga Khan University|University of Colorado, Denver|University of North Carolina, Chapel Hill|University of Alabama at Birmingham|Drexel University|RTI International","All","3 Months to 4 Months   (Child)","Phase 3","1236","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","GN CF","July 2008","April 2010","July 2010","March 10, 2010","null","November 25, 2013","Kinshasa School of Public Health, Karawa, Congo|Institute for Nutrition of Central America and Panama (INCAP), Chiimaltenango, Guatemala|Agha Khan University, Karachi, Pakistan|University of Zambia, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT01084109"
57,"NCT00640055","Verbal Autopsy to Assess Early Neonatal Death and Stillbirth","VA","Completed","No Results Available","Perinatal Mortality|Cause of Neonatal Death|Cause of Stilbirth","Other: Coordinator|Other: Physician-assigned cause of death","Cause of death as assigned by a Community Coordinator compared to the cause of death assigned by the physician panel|The COD for stillbirth as assigned by the Community Coordinator compared to the COD for stillbirth as assigned by the Physician Panel|The agreement between mothers' and birth attendants' responses on selected items on the VA questionnaire (considering the mothers' response as the reference standard).","NICHD Global Network for Women's and Children's Health","All","up to 7 Days   (Child)","Phase 4","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Diagnostic","CP03|U01HD040636","July 2007","May 2008","July 2008","March 20, 2008","null","July 31, 2014","Kinshasa School of Public Health, Kinshasa, Congo|San Carlos University, Guatemala City, Guatemala|Aga Khan University, Karachi, Pakistan|University of Zambia, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00640055"
58,"NCT00639184","BRAIN - Home Intervention Trial","BRAIN-HIT","Completed","No Results Available","Asphyxia","Other: Early intervention counseling|Other: Health education counseling","neurodevelopmental outcome|The improvements in cognitive, social, and motor development will be larger in the infants who have had birth asphyxia compared to those without birth asphyxia.|The effects of EI in infants with and without birth asphyxia will be moderated by child and family characteristics.","NICHD Global Network for Women's and Children's Health","All","up to 28 Days   (Child)","Phase 4","240","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","CP04|HD 40636","June 2007","May 2010","June 2010","March 20, 2008","null","July 31, 2014","JN Medical College, Belgaum, India|Aga Khan University, Karachi, Pakistan|University of Zambia, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00639184"
59,"NCT00518609","Prevention of Infection in Indian Neonates - Phase I Observational Study",,"Completed","No Results Available","Sepsis","","","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|All India Institute of Medical Sciences, New Delhi|TN Medical College, Mumbai|Department of Health and Family Welfare, Orissa|SCB Medical College, Cuttack|Capital Hospital, Bhubaneswar|Ispat General Hospital, Rourkela|Kalinga Hospital, Bhubaneswar|University of Maryland","All","up to 60 Days   (Child)","","1326","Other|NIH","Observational","Time Perspective: Prospective","GN 07 Phase I|U01HD040574","July 2003","null","July 2006","August 21, 2007","null","July 31, 2014","Capital Hospital, Bhubaneswar, Orissa, India|Kalinga Hospital, Bhubaneswar, Orissa, India|Ispat General Hospital, Rourkela, Orissa, India","","https://ClinicalTrials.gov/show/NCT00518609"
60,"NCT00518596","Prevention of Infection in Indian Neonates - Phase II Probiotics Study",,"Completed","No Results Available","Sepsis","Dietary Supplement: Probiotic supplementation (Lactobacillus plantarum)","Colonizing ability of L. plantarum in Indian neonates after 5-7 days of administration.|Clinical safety (including sepsis and death) and tolerance of a daily administration of oral L. plantarum probiotic supplement when used in healthy full-term neonates.|Changes in stool microfloral patterns with 5-7 day administration of L. plantarum supplement.|Feasibility of the future community study (consent and retention rates, completeness of stool sampling, ability to complete the study in the home for infants discharged early).","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|All India Institute of Medical Sciences, New Delhi|TN Medical College, Mumbai|Department of Health and Family Welfare, Orissa|SCB Medical College, Cuttack|Capital Hospital, Bhubaneswar|Ispat General Hospital, Rourkela|Kalinga Hospital, Bhubaneswar|University of Maryland","All","up to 72 Hours   (Child)","Phase 2","284","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","GN 07 Phase II|U01HD040574|R01HD053719","July 2005","null","August 2006","August 21, 2007","null","June 15, 2017","Capital Hospital, Bhubaneswar, Orissa, India|Kalinga Hospital, Bhubaneswar, Orissa, India|Ispat General Hospital, Rourkela, Orissa, India","","https://ClinicalTrials.gov/show/NCT00518596"
61,"NCT00097149","Systematic Pediatric Care for Oral Clefts - South America",,"Completed","No Results Available","Cleft Lip|Cleft Palate|Congenital Defects","Procedure: Systematic pediatric care","SUBPROJECT A: Neonatal mortality|SUBPROJECT B: Neurodevelopmental outcome|Weight|SUBPROJECT A: Hospitalizations, Weight|SUBPROJECT B: Height, Speech, Hearing, Mortality, Cleft surgery, Rate of weight gain, Financial burden, Syndromic classification, Emotional and social family development","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|National Institute of Dental and Craniofacial Research (NIDCR)|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Cancer Institute (NCI)|RTI International|University of Iowa|Latin-American Collaborative Study of Congenital Malformations (ECLAMC)","All","up to 2 Years   (Child)","Not Applicable","696","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GN 04 Aim II|U01HD040561","May 2003","null","May 2006","November 18, 2004","null","December 17, 2013","Latin-American Collaborative Study of Congenital Malformations (ECLAMC), Rio de Janeiro, Brazil","","https://ClinicalTrials.gov/show/NCT00097149"
62,"NCT02728141","Healthy Infant Development Project - Sucrose Component",,"Completed","No Results Available","Iron Deficiency","Other: Water|Other: Sucrose","Infant behavior (emotion regulation)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 5 Days   (Child)","Not Applicable","424","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","1R01HD052069","November 2009","June 2014","June 2014","April 5, 2016","null","April 5, 2016","Peking University First Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT02728141"
63,"NCT02654262","Soft Tissue and Bone Development in Young Girls","STAR","Unknown status","No Results Available","Bone Development","","Bone development","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","9 Years to 12 Years   (Child)","","450","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HD74565","January 2013","December 2017","December 2017","January 13, 2016","null","September 26, 2016","University of Arizona, Nutritional Sciences Department, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT02654262"
64,"NCT01444261","Prevention of Iron Deficiency in Breastfed Infants",,"Completed","No Results Available","Iron Deficiency|Anemia","Dietary Supplement: Fer-in-Sol|Other: control","Iron deficiency anemia will be prevented in all infants before 5.5 mo of age|Determine the number of infants with iron deficiency between 5.5 and 9 mo of age","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Iowa","All","up to 9 Months   (Child)","Phase 4","219","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BFe10D","December 2010","April 2014","April 2014","September 30, 2011","null","March 31, 2017","University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT01444261"
65,"NCT01322204","Codeine in Mechanically Ventilated Neonates",,"Completed","No Results Available","Mechanically Ventilated Neonates|Painful Procedures in Newborns","Drug: Codeine","The rate and extent of absorption of oral codeine, the ratios of the observed concentration of each metabolite to the observed concentration of parent drug and the formation and clearances of the metabolites.|Secondary outcomes include the additional PK parameters elimination half life, area under the curve and mean residence time.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 30 Days   (Child)","Phase 1","6","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10922","August 2008","March 6, 2013","March 6, 2013","March 24, 2011","null","August 27, 2018","State University of New York Downstate, Brooklyn, New York, United States","","https://ClinicalTrials.gov/show/NCT01322204"
66,"NCT01193374","The Healthy Families Project","HF","Completed","No Results Available","Childhood Obesity","Behavioral: Clinician enhanced screening and counseling prompts|Behavioral: Tailored education and motivational materials|Behavioral: basic educational brochure","BMI z score|Parental readiness to initiate change","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 10 Years   (Child)","Not Applicable","149","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R21HD050996","February 2007","March 2008","August 2009","September 1, 2010","null","May 24, 2011","Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Dartmouth Medical School, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01193374"
67,"NCT01166451","The Anemia Control Program: High or Low Iron Supplementation",,"Completed","No Results Available","Iron Deficiency Anemia|Cognitive Development|Motor Development","Dietary Supplement: Low-iron formula|Dietary Supplement: High-iron formula","Iron deficiency anemia|Longitudinal child behavior and development","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 6 Months   (Child)","Not Applicable","835","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R01HD033487","September 1991","August 1994","March 2004","July 21, 2010","null","October 18, 2011","Instituto de Nutriticion y Tecnologia de los Alimentos, Santiago, Chile","","https://ClinicalTrials.gov/show/NCT01166451"
68,"NCT01166425","Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.","Lithium2","Completed","No Results Available","Bipolar Disorder","Drug: Lithium Carbonate|Drug: Placebo","YMRS score|Clinical Global Impressions Scale- Severity and Improvement|Children Depression Rating Scale-Revised","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 17 Years   (Child)","Phase 2|Phase 3","81","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-2005-07-2","June 2010","April 2013","April 2013","July 21, 2010","null","October 9, 2013","Childrens National Medical Center, Washington, District of Columbia, United States|University of Illinois at Chicago, South Chicago Heights, Illinois, United States|University of Kansas School of Medicine, Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, Kansas, United States|University of Massachusetts Medical School, Biotech One Suite 100, 365 Plantation, Worcester, Massachusetts, United States|The Zucker Hillside Hospital, Glen Oaks, New York, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Department of Psychiatry, CB 7160, Chapel Hill, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|University of Cincinnati, Cincinnati, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Seattle Childrens Hospital Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01166425"
69,"NCT00999778","Optimizing Social and Communication Outcomes for Toddlers With Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Caregiver-Mediated Intervention|Behavioral: Caregiver-Education Intervention","Cognitive Assessment - Mullen Scales of Early Learning (MSEL)|Language Assessment - Reynell Developmental Language Scales|Language Sample - The Caregiver Child Interaction will be coded at each timepoint to obtain a 10 minute sample of the child's language transcription will yield a measure of lexical density, type-token ration and mean length of utterances|Early Social-Communication Scales; frequencies of initiating and responses of joint attention behaviors to toys and l interaction - sessions will be video taped|MacArthur Communicative Development Inventories|Parent Expectancy/Belief in the Intervention - assesses caregiver beliefs that the intervention is appropriate and working for the child|ADOS - The Autism Diagnostic Observation Schedule - semi-structured, standardized assessment of communication, social interaction, play and imaginative use of materials|Generalization of skills to classroom - Observational measure to determine whether child show generalization of skill to the classroom,and in interaction with teachers & peers|Coding of child behaviors in classroom - using time sampling procedure, four different contexts; direct instruction, structure play, circle-time, unstructured play|Caregiver-child interaction - A 10-minute interaction between parent and child|ADI-R Clinical diagnostic instrument for assessing autism in children|Parenting Stress - The Parenting Stress Index (PSI) measuring parents reported stress associated with the care of autistic child","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Autism Speaks","All","18 Months to 36 Months   (Child)","Not Applicable","86","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","1P50HD055784","July 2008","July 2012","August 2012","October 22, 2009","null","August 16, 2012","University of California Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00999778"
70,"NCT00998998","The Anemia Control Program: Early Intervention",,"Completed","No Results Available","Iron Deficiency Anemia","Behavioral: Home stimulation|Behavioral: Surveillance|Dietary Supplement: Iron","Infant behavior and development|Iron-deficiency anemia","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 12 Months   (Child)","Not Applicable","277","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD014122","April 1992","July 1996","July 1996","October 21, 2009","null","July 21, 2010","Instituto de Nutrición y Tecnología de los Alimentos (INTA), Santiago, Chile","","https://ClinicalTrials.gov/show/NCT00998998"
71,"NCT00891891","Psychosocial Adjustment of Adolescents With Spina Bifida","CHATS","Active, not recruiting","No Results Available","Spina Bifida","","Social functioning/peer relationships|Psychosocial adjustment|Transition to adult healthcare","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|March of Dimes|National Institute of Nursing Research (NINR)","All","8 Years to 15 Years   (Child)","","140","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD R01 HD048629","September 2005","June 2021","June 2021","May 1, 2009","null","April 18, 2017","Loyola University Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00891891"
72,"NCT00853814","Increasing Youth Physical Activity: Neighborhood Environment Influences",,"Unknown status","No Results Available","Obesity|Overweight","Behavioral: Access to sedentary behaviors","Physical activity|Physical activity in parks|Dietary intake|BMI percentile","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 16 Years   (Child)","Not Applicable","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","R01HD055270|5R01HD055270-02|5R01HD055270-03","September 2007","September 2010","September 2011","March 2, 2009","null","March 2, 2009","University at Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00853814"
73,"NCT00810108","Lopinavir/Ritonavir (Kaletra) PK in Children",,"Completed","Has Results","HIV/AIDS Treatment|HIV Infections","Drug: lopinavir/ritonavir (Kaletra®) tablets","Lopinavir Area Under the Curve (AUC)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Association of Colleges of Pharmacy","Female","6 Years to 17 Years   (Child)","Phase 4","12","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10894","June 2006","May 2009","May 2009","December 17, 2008","July 6, 2012","July 6, 2012","University of California, San Diego - Skaggs School of Pharmacy and School of Medicine, San Diego, California, United States|Children's National Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00810108"
74,"NCT00760279","An Open Label Evaluation of the Pharmacokinetics and Safety of Single Dose Intravenous Azithromycin in Preterm Neonates",,"Completed","No Results Available","Ureaplasma|Bacterial Infection","Drug: Azithromycin","Safety: Patients will be monitored for clinical adverse events and have standard hematology labs drawn within 72 hours of study entry. Liver function tests, renal function tests and standard chemistries will be drawn prior to and at the end of the study.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Pediatric Pharmacology Research Units Network|Children's Hospital of Michigan","All","up to 30 Days   (Child)","Phase 1","16","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPRU10820","September 2005","null","null","September 26, 2008","null","September 26, 2008","Wayne State, Detroit, Michigan, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00760279"
75,"NCT00729378","Jump-In: Building Better Bones",,"Completed","Has Results","Adolescent Development","Other: Skeletal loading","Baseline Total Volumetric Bone Density at the Femur 4% Site|Baseline Volumetric Bone Density of Trabecular Bone at the Femur 4% Site|Baseline Volumetric Bone Density of Cortical Bone at the Femur 4% Site|Baseline Trabecular Bone Area at the Femur 4% Site|Baseline Cortical Bone Area at the Femur 4% Site|Baseline Periosteal Circumference at the Femur 4% Site|Baseline Bone Strength Index at the Femur 4% Site|Baseline Total Volumetric Bone Density at the Femur 20% Site|Baseline Volumetric Bone Density of Trabecular Bone at the Femur 20% Site|Baseline Volumetric Bone Density of Cortical Bone at the Femur 20% Site|Baseline Periosteal Circumference at the Femur 20% Site|Baseline Cortical Thickness at the Femur 20% Site|Baseline Stress-Strain Index at the Femur 20% Site|Baseline Volumetric Bone Density of Trabecular Bone at the Tibia 4% Site|Baseline Total Volumetric Bone Density at the Tibia 4% Site|Baseline Volumetric Bone Density of Cortical Bone at the Tibia 4% Site|Baseline Trabecular Bone Area at the Tibia 4% Site|Baseline Cortical Bone Area at the Tibia 4% Site|Baseline Periosteal Circumference at the Tibia 4% Site|Baseline Bone Strength Index at the Tibia 4% Site|Baseline Total Volumetric Bone Density at the Tibia 50% Site|Baseline Volumetric Bone Density of Trabecular Bone at the Tibia 50% Site|Baseline Volumetric Bone Density of Cortical Bone at the Tibia 50% Site|Baseline Periosteal Circumference at the Tibia 50% Site|Baseline Cortical Thickness at the Tibia 50% Site|Baseline Stress-Strain Index at the Tibia 50% Site|Baseline Total Volumetric Bone Density at the Tibia 66% Site|Baseline Volumetric Bone Density of Trabecular Bone at the Tibia 66% Site|Baseline Volumetric Bone Density of Cortical Bone at the Tibia 66% Site|Baseline Periosteal Circumference at the Tibia 66% Site|Baseline Cortical Thickness at the Tibia 66% Site|Baseline Stress-Strain Index at the Tibia 66% Site|12-month Change in Total Volumetric Bone Density the Femur 4% Site|12-month Change in Volumetric Bone Density of Trabecular Bone at the Femur 4% Site|12-month Change in Volumetric Bone Density of Cortical Bone at the Femur 4% Site|12-month Change in Trabecular Bone Area at the Femur 4% Site|12-month Change in Cortical Bone Area at the Femur 4% Site|12-month Change in Periosteal Circumference at the Femur 4% Site|12-month Change in Bone Strength Index at the Femur 4% Site|12-month Change in Total Volumetric Bone Density at the Femur 20% Site|12-month Change in Volumetric Bone Density of Trabecular Bone at the Femur 20% Site|12-month Change in Volumetric Bone Density of Cortical Bone at the Femur 20% Site|12-month Change in Thickness of Cortical Bone at the Femur 20% Site|12-month Change in Periosteal Circumference at the Femur 20% Site|12-month Change in Stress-Strain Index at the Femur 20% Site|12-month Change in Total Volumetric Bone Density at the Tibia 4% Site|12-month Change in Volumetric Bone Density of Trabecular Bone at the Tibia 4% Site|12-month Change in Volumetric Bone Density of Cortical Bone at the Tibia 4% Site|12-month Change in Trabecular Bone Area at the Tibia 4% Site|12-month Change in Cortical Bone Area at the Tibia 4% Site|12-month Change in Periosteal Circumference at the Tibia 4% Site|12-month Change in Bone Strength Index at the Tibia 4% Site|12-month Change in Total Volumetric Bone Density at the Tibia 50% Site|12-month Change in Volumetric Bone Density of Trabecular Bone at the Tibia 50% Site|12-month Change in Volumetric Bone Density of Cortical Bone at the Tibia 50% Site|12-month Change in Periosteal Circumference at the Tibia 50% Site|12-month Change in Cortical Thickness at the Tibia 50% Site|12-month Change in Stress-Strain Index at the Tibia 50% Site|12-month Change in Total Volumetric Bone Density at the Tibia 66% Site|12-month Change in Volumetric Bone Density of Trabecular Bone at the Tibia 66% Site|12-month Change in Volumetric Bone Density of Cortical Bone at the Tibia 66% Site|12-month Change in Periosteal Circumference at the Tibia 66% Site|12-month Change in Cortical Thickness at the Tibia 66% Site|12-month Change in Stress-Strain Index at the Tibia 66% Site|24-month in Change in Total Volumetric Bone Density the Femur 4% Site|24-month in Change in Volumetric Bone Density of Trabecular Bone at the Femur 4% Site|24-month in Change in Volumetric Bone Density of Cortical Bone at the Femur 4% Site|24-month Change in Trabecular Bone Area at the Femur 4% Site|24-month Change in Cortical Bone Area at the Femur 4% Site|24-month Change in Periosteal Circumference at the Femur 4% Site|24-month Change in Bone Strength Index at the Femur 4% Site|24-month Change in Total Volumetric Bone Density at the Femur 20% Site|24-month Change in Volumetric Bone Density of Trabecular Bone at the Femur 20% Site|24-month Change in Volumetric Bone Density of Cortical Bone at the Femur 20% Site|24-month Change in Thickness of Cortical Bone at the Femur 20% Site|24-month Change in Periosteal Circumference at the Femur 20% Site|24-month Change in Stress-Strain Index at the Femur 20% Site|24-month Change in Total Volumetric Bone Density at the Tibia 4% Site|24-month Change in Volumetric Bone Density of Trabecular Bone at the Tibia 4% Site|24-month Change in Volumetric Bone Density of Cortical Bone at the Tibia 4% Site|24-month Change in Trabecular Bone Area at the Tibia 4% Site|24-month Change in Cortical Bone Area at the Tibia 4% Site|24-month Change in Periosteal Circumference at the Tibia 4% Site|24-month Change in Bone Strength Index at the Tibia 4% Site|24-month Change in Total Volumetric Bone Density at the Tibia 50% Site|24-month Change in Volumetric Bone Density of Trabecular Bone at the Tibia 50% Site|24-month Change in Volumetric Bone Density of Cortical Bone at the Tibia 50% Site|24-month Change in Periosteal Circumference at the Tibia 50% Site|24-month Change in Cortical Thickness at the Tibia 50% Site|24-month Change in Stress-Strain Index at the Tibia 50% Site|24-month Change in Total Volumetric Bone Density at the Tibia 66% Site|24-month Change in Volumetric Bone Density of Trabecular Bone at the Tibia 66% Site|24-month Change in Volumetric Bone Density of Cortical Bone at the Tibia 66% Site|24-month Change in Periosteal Circumference at the Tibia 66% Site|24-month Change in Cortical Thickness at the Tibia 66% Site|24-month Change in Stress-Strain Index at the Tibia 66% Site","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","9 Years to 12 Years   (Child)","Not Applicable","509","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HD050775","April 2007","April 2012","April 2013","August 7, 2008","December 8, 2017","December 8, 2017","University of Arizona-Ina Gittings Bldg. #93, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT00729378"
76,"NCT00642863","Brain and Behavior Depending on Timing of Iron Deficiency in Human Infants",,"Completed","No Results Available","Iron Deficiency|Iron Deficiency Anemia","Dietary Supplement: Ferrous Sulfate (liquid) + vitamins A and D|Dietary Supplement: vitamins A and D|Dietary Supplement: Ferrous sulfate (liquid)","Infant behavior and development|Low or marginal birth iron|Infant anemia","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 5 Days   (Child)","Not Applicable","1614","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","2P01HD039386-06A1","April 2008","June 2014","June 2014","March 25, 2008","null","October 29, 2014","Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China","","https://ClinicalTrials.gov/show/NCT00642863"
77,"NCT00621816","Sodium Nitroprusside for Blood Pressure Reduction in the ICU (SNP2)",,"Completed","No Results Available","Hypertension","Drug: nitroprusside|Drug: placebo infusion","The primary endpoint is the change in MAP during the Blinded Study Drug Administration Phase in the absence of other stimuli.|1. To compare the proportion of patients randomized to receive either sodium nitroprusside or placebo who experience offset during the 30-minute blinded study drug period.|2. To compare the proportion of patients randomized to receive either sodium nitroprusside or placebo who experience rebound hypertension during blinded study drug period|3. To compare the proportion of patients randomized to receive either sodium nitroprusside or placebo who experience a serious adverse event during the 30-minute blinded study drug period|4. To compare the distribution of patients randomized to receive either sodium nitroprusside or placebo who experience a treatment-emergent and related adverse event, by maximum severity grade, during the 30-minute blinded study drug period.|5. To compare the changes in vital signs (systolic blood pressure, diastolic blood pressure, MAP, and heart rate) between patients randomized to receive either sodium nitroprusside or placebo|6. To compare the changes in individual laboratory parameters between patients randomized to receive either sodium nitroprusside or placebo.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 17 Years   (Child)","Phase 2","45","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","N01-HD-4-3386|NICHD-2003-09-DR","January 2009","January 2011","January 2011","February 22, 2008","null","December 6, 2011","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Stanford University School of Medicine, Stanford, California, United States|Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States|University of Michigan - Mott Children's Hospital, Ann Arbor, Michigan, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|West Virginia University, Morgantown, West Virginia, United States","","https://ClinicalTrials.gov/show/NCT00621816"
78,"NCT00621192","Pharmacokinetic (PK) and Safety Study of Meropenem in Young Infants With Intra-abdominal Infections",,"Completed","Has Results","Necrotizing Enterocolitis|Intra-abdominal Infection","Drug: meropenem","Efficacy Success (Alive at Efficacy Visit,Last Culture (if Obtained) From Sterile Body Fluid is Negative for Bacteria (Except Staphylococcus Species) From Start of Study Drug Until Efficacy Visit,Presumptive Clinical Cure Score(PCCS) >7 at Efficacy Visit)|Deaths|Meropenem Clearance|Key Safety Endpoints","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation","All","up to 90 Days   (Child)","Phase 1|Phase 2","200","NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HHSN267200700051C","June 2008","October 2009","October 2009","February 22, 2008","November 29, 2011","April 17, 2015","University of Alabama, Birmingham, Alabama, United States|Children's Hospital of Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|University of California Medical Center, San Diego, California, United States|Sharp-Mary Birch Hospital for Women, San Diego, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Children's National Medical Center, Washington DC, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Evanston Northwestern Healthcare, Evanston, Illinois, United States|Indiana University - Riley Hospital for Children, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Kansas City Children's Mercy Hospital, Kansas City, Missouri, United States|Albany Medical Center, Albany, New York, United States|Suny Downstate Medical Center, Brooklyn, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Case Western Reserve, RB&C, UHCMC, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburg, Pennsylvania, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|University of Utah medical Center, Salt lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00621192"
79,"NCT00613717","Healthy Infant Development Project",,"Completed","No Results Available","Iron Deficiency Anemia|Iron Deficiency","Dietary Supplement: folic acid + iron prenatally, vits A & D + iron postnatally|Dietary Supplement: folic acid + iron prenatally, vitamins A & D postnatally|Dietary Supplement: folic acid prenatally, vitamins A & D + iron postnatally|Dietary Supplement: folic acid prenatally, vitamins A & D postnatally","Infant behavior and development|Infant anemia","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Centers for Disease Control and Prevention","All","up to 5 Days   (Child)","Not Applicable","2371","NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1R01HD052069-01A2","November 2009","June 2014","June 2014","February 13, 2008","null","October 29, 2014","Peking University First Hospital, Beijing, China","","https://ClinicalTrials.gov/show/NCT00613717"
80,"NCT00607542","Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity","Best PK/PD","Completed","No Results Available","Spasticity|Cerebral Palsy","Drug: baclofen","Determine pharmacokinetic parameters of oral baclofen in children with spasticity associated with cerebral palsy (CP).|Describe the relationship between plasma concentrations of oral baclofen and clinical measures of spasticity.|Determine optimal dosing range and interval for administration of oral baclofen for use in a randomized clinical trial of safety and efficacy.|Describe the relationship between plasma concentrations of oral baclofen and measures of strength, function, ease of care, pain/comfort and health related quality of life.|Describe the safety and tolerability of oral baclofen in children with spasticity associated with CP.|Investigate preliminarily whether oral baclofen improves dystonia","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 16 Years   (Child)","Phase 1|Phase 2","61","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-2005-13-2|267200603421","November 2008","January 2011","January 2011","February 5, 2008","null","December 6, 2011","Rehabilitation Institute of Chicago, Chicago, Illinois, United States|Children's Hospital of Lousiana, New Orleans, Louisiana, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Gillette Children's Speciality Healthcare, St. Paul, Minnesota, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Washington Univeristy - St. Louis Children's hospital, St. Louis, Missouri, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States|Kluge Children's Rehabilitation Center - University of Virginia, Charlottesville, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00607542"
81,"NCT00565357","Silicone Earplugs for VLBW Newborns in Intensive Care",,"Completed","No Results Available","Postnatal Growth","Device: Silicone Earplugs|Other: Control","Weight|Length of stay in neonatal intensive care|Time on mechanical ventilator|Length|Frontal-occipital circumference|Bayley Mental Developmental Index|Bayley Psychomotor Developmental Index|ABR Hearing Screen","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 7 Days   (Child)","Not Applicable","34","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","R01HD042639-01A3","June 2002","null","August 2005","November 29, 2007","null","November 29, 2007","","","https://ClinicalTrials.gov/show/NCT00565357"
82,"NCT00560222","Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children",,"Completed","No Results Available","Diarrhea|Malnutrition","Dietary Supplement: bovine lactoferrin|Dietary Supplement: placebo [maltodextrin]","Determination of the effect of bovine lactoferrin supplementation on prevention of diarrhea,measured by the number of episodes of diarrhea during a 6 month trial in previously weaned Peruvian children enrolled at 12 to 18 months of age.|Determination of the effect of bovine lactoferrin supplementation on growth.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Months to 18 Months   (Child)","Phase 3","555","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1R01HD051716-01A2","February 2008","May 2011","October 2011","November 19, 2007","null","November 1, 2011","Universidad Peruana Cayetana Heredia, Lima, Peru","","https://ClinicalTrials.gov/show/NCT00560222"
83,"NCT00559390","Research Study for Children With a Mother or Sister With Polycystic Ovary Syndrome","PCOS","Completed","No Results Available","Precursors to PCOS","","It is believed that PCOS is inherited. We are trying to look for clinical, blood and/or genetic markers of PCOS in the sisters and daughters of women with PCOS","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Northwestern Memorial Hospital|Ann & Robert H Lurie Children's Hospital of Chicago","Female","8 Years to 12 Years   (Child)","","136","NIH|Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","0956-023|R01DK040605|DK73411","July 2006","October 2012","October 2012","November 16, 2007","null","April 5, 2013","Northwestern University, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00559390"
84,"NCT00545727","Blood Glucose Response to Meals of Varying Glycemic Index in Youth With Type 1 & 2 Diabetes",,"Completed","No Results Available","Type 1 Diabetes|Type 2 Diabetes|Impaired Glucose Metabolism","Behavioral: Diet|Other: Standard diet","Blood glucose level","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 16 Years   (Child)","Not Applicable","36","NIH","Interventional","Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","06-CH-N182","July 2006","null","August 2006","October 17, 2007","null","October 17, 2007","","","https://ClinicalTrials.gov/show/NCT00545727"
85,"NCT00494273","HIV Prevention in Haitian American Adolescents",,"Completed","No Results Available","HIV Infections","Behavioral: Cognitive Behavioral and Standard Care with Healthy Living","The BART Condition will reduce HIV transmission risk behavior over time more than the SC. Assessments will be completed prior, after, 4 , 8 and 12 months after the intervention. Measure examples are|Sexual and Condom Attitudes|Self-Efficacy Scale|Behavioral Intentions scale|Health Protective Sexual Communication Scale|Comfort talking about Safer Sex measure|Condom Use Skills|Risk Behavior Assessment|Examples are|The Millon Adolescent Clinical Inventory|The Adolescent-Family Inventory of Life Events & Changes|Stephenson Multigroup Acculturation Scale|Adolescent Health Questionnaire-Adolescent and Parent Version.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 17 Years   (Child)","Phase 1|Phase 2","320","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","R01HD038458","December 2002","December 2006","December 2006","June 29, 2007","null","October 29, 2014","Center for Haitian Studies, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT00494273"
86,"NCT00494260","Managing Recurrent Abdominal Pain",,"Completed","No Results Available","Abdominal Pain","Behavioral: Social Learning and Cognitive Behavioral Therapy (SLCBT)|Behavioral: Education Support (ES)","symptoms of recurrent abdominal pain|disability|parent behaviors|child coping behaviors","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 17 Years   (Child)","Phase 2","200","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","R01HD036069-07","November 2003","June 2010","June 2010","June 29, 2007","null","March 31, 2016","Goryeb Children's Hospital/ Atlantic Health System, Morristown, New Jersey, United States|University of Washington/ Children's Hospital and Regional Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00494260"
87,"NCT00494104","Prevention of Vitamin D Deficiency",,"Completed","No Results Available","Vitamin D Deficiency","Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day","Plasma concentrations of 25-hydroxyvitamin D, parathyroid hormone, alkaline phosphatase|whole body mineral content by DEXA","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 5 Weeks   (Child)","Not Applicable","398","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","R01HD048870","September 2006","September 2011","September 2011","June 29, 2007","null","December 18, 2012","MTF, 2501 Crosspark Rd, Coralville, Iowa, United States","","https://ClinicalTrials.gov/show/NCT00494104"
88,"NCT00491790","Montelukast With Status Asthmaticus, Ages 2-5",,"Unknown status","No Results Available","Status Asthmaticus|Asthma","Drug: Montelukast|Other: Sterile water","Effectiveness of Montelukast as adjunctive therapy|Estimate the first dose pharmacokinetic parameters of Montelukast","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Pediatric Pharmacology Research Units Network","All","2 Years to 5 Years   (Child)","Phase 2|Phase 3","52","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PPRU 10854","December 2006","January 2010","October 2010","June 26, 2007","null","December 16, 2008","Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00491790"
89,"NCT00491413","Erythropoietin for Infants With Brain Injuries Due to Oxygen Deprivation at Birth",,"Unknown status","No Results Available","Asphyxia","Drug: epoetin","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Hours   (Child)","Phase 1","15","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21HD042308","null","null","null","June 26, 2007","null","June 26, 2007","All Children's Hospital, St. Petersburg, Florida, United States","","https://ClinicalTrials.gov/show/NCT00491413"
90,"NCT00469872","Focus on Function Study for Children With Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy","Procedure: Context-focused compared to child-focused interventions","activities (performance of functional tasks, motor function)|body function and structure (range of motion)|particpation|parental empowerment","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH)","All","12 Months to 5 Years   (Child)","Not Applicable","128","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01HD044444","June 2006","January 2009","January 2009","May 7, 2007","null","September 25, 2014","University of Alberta, Edmonton, Alberta, Canada|McMaster University, Hamilton, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00469872"
91,"NCT00459082","A Pharmacokinetic Study of Dexmedetomine in Infants",,"Completed","No Results Available","Cardiac Surgical Procedures","Drug: Dexmedetomine","Pharmacodynamics: vital signs, cardiac rhythm, oxygen saturation, laboratory evaluations and adverse events will be monitored to determine the safety of dexmedetomine.|Pharmacokinetics: will measure plasma concentrations for dose escalations of dexmedetomine to determine the maximum tolerated dose (MTD).|Pharmacodynamics: The Bispectral Index Scale(BIS) and the University of Michigan sedation scale will be used to measure the level of sedation and dexmedetomine plasma drug concentrations.|Pharmacogenetics: will examine the relationship between genotype, drug exposure and drug response in infants postoperative form cardiac surgery.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 24 Months   (Child)","Phase 1","36","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","PPRU 10760","May 2004","null","November 2006","April 11, 2007","null","April 11, 2007","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00459082"
92,"NCT00442039","Lithium for the Treatment of Pediatric Mania",,"Completed","No Results Available","Bipolar I Disorder Without Psychotic Symptoms","Drug: Lithium Carbonate|Drug: Placebo","Mean Change in YMRS summary score by treatment|Mean change in YMRS parent score|Mean change in YMRS child score|Rate of treatment emergent adverse events|Dosing - PK","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 17 Years   (Child)","Phase 2","61","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-2005-07-01|DUNS No. 07-775-8407","December 2006","April 2009","September 2009","March 1, 2007","null","February 28, 2012","CASE Western Reserve University, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00442039"
93,"NCT00377767","Improving Primary Care to Prevent Childhood Obesity",,"Unknown status","No Results Available","Overweight in Preschool Age Children|Risk of Overweight in Preschool Age Children","Behavioral: To change structure and roles of primary care teams to optimize prevention of obesity","Body mass index (BMI) at 1 year.|Television viewing behaviors at 1 year post intervention.|Sugar-sweetened beverages intake at 1 year post intervention.|Fast food intake at 1 year post intervention.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Harvard School of Public Health","All","2 Years to 6 Years   (Child)","Phase 1|Phase 2","500","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","R01HD050966","September 2006","null","September 2009","September 18, 2006","null","September 18, 2006","Harvard Vanguard Medical Associates, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00377767"
94,"NCT00368485","Neural Control of Non-invasive Ventilation in the Preterm",,"Completed","No Results Available","Respiratory Distress Syndrome, Newborn|Infant, Premature","Device: Neurally Controlled Mechanical Ventilation","patient ventilator interaction|breathing pattern|diaphragm activity","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Months   (Child)","Phase 1","24","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21HD045047","August 2006","June 2008","June 2008","August 24, 2006","null","September 21, 2011","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00368485"
95,"NCT00365092","Middle Ear Disease Before Age 3, Treatment With Ear Tubes, and Literacy and Attentional Abilities at Ages 9 to 11",,"Completed","No Results Available","Otitis Media|Middle Ear Effusion","Procedure: Insertion of tympanostomy tubes","All measures at 9 to 11 years of age:|Woodcock Reading Mastery Tests-Revised-Normative Update|Number of words in a grade-level passage read correctly in one minute|Dictation Samples subtest of the Woodcock-Johnson III Tests of Achievement, Standard Battery|Writing Samples subtests of the Woodcock-Johnson III Tests of Achievement, Standard Battery|Elision and Rapid Letter Naming subtests of the Comprehensive Test of Phonological Processing|Children’s version of the Hearing in Noise Test|Disruptive Behavior Disorders Rating Scale|Child Behavior Checklist, parent report|Child Behavior Checklist, teacher report|Impairment Rating Scales, parent report|Impairment Rating Scales, teacher report|Computerized visual continuous performance test|Computerized auditory continuous performance test|Wechsler Abbreviated Scale of Intelligence|Computational subtest of the Woodcock-Johnson III Tests of Achievement, Standard Battery","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 61 Days   (Child)","Not Applicable","400","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","R01HD042080","April 2002","null","March 2005","August 17, 2006","null","August 17, 2006","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00365092"
96,"NCT00356343","Strength Training Using Neuromuscular Electrical Stimulation For Children With Cerebral Palsy",,"Unknown status","No Results Available","Spastic Diplegic Cerebral Palsy","Device: NMES Strength Training|Other: Volitional Strength Training","Force generating ability of quadriceps femoris and triceps surae (MVIC)|Voluntary muscle activation during a Maximal Volitional Isometric Contraction (MVIC)|Antagonist coactivation during an agonist MVIC|Contractile properties as assessed via electrically-elicited tests|Fatiguability of muscle as assessed via electrically-elicited tests|Muscle cross-sectional area of quadriceps femoris and triceps surae (via MRI with fat suppression)|Spatiotemporal parameters of gait|Gross Motor Function Measure|Timed Up and Go|Parent and child report via questionnaires (PODCI, COPM)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Shriners Hospitals for Children|University of Delaware","All","7 Years to 12 Years   (Child)","Phase 1","45","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD043859","July 2004","September 2009","null","July 26, 2006","null","January 11, 2011","Shriners Hospitals for Children, Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00356343"
97,"NCT00301197","Childhood Obesity Treatment: A Maintenance Approach",,"Completed","No Results Available","Obesity","Behavioral: Behavioral Skills Maintenance|Behavioral: Social Facilitation Maintenance","Weight (child and parent)|Weight related behaviors|Psychological functioning (specific and general)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 12 Years   (Child)","Not Applicable","216","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5R01HD036904","August 1999","null","April 2004","March 10, 2006","null","March 10, 2006","Washington University School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00301197"
98,"NCT00273286","Family Management of Type 1 Diabetes in Children",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Behavioral: family diabetes management intervention","glycemic control|treatment adherence|quality of life","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","108 Months to 174 Months   (Child)","Phase 2","422","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","FMOD","January 2006","March 2009","March 2009","January 9, 2006","null","May 13, 2011","Nemours Children's Clinic, Jacksonville, Florida, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00273286"
99,"NCT00166686","Clonidine for Neurocognitive Sequelae",,"Withdrawn","No Results Available","Treatment-Related Cancer","Drug: Clonidine","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 16 Years   (Child)","Phase 1|Phase 2","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","PPRU 10706","null","null","null","September 14, 2005","null","January 11, 2013","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00166686"
100,"NCT00166660","Preterm Fetal Growth Restriction and Developmental Care",,"Unknown status","No Results Available","Preterm Birth","Behavioral: NIDCAP (Newborn Individualized Developmental Care)","Assessment of Preterm Infants' Behavior (APIB)|Quantified Electroencephalography (qEEG)|Magnetic Resonance Imaging(MRI)|Parent Stress Level","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","28 Weeks to 33 Weeks   (Child)","Phase 2","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01HD046855","July 2004","December 2008","June 2009","September 14, 2005","null","April 3, 2009","Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00166660"
101,"NCT00166582","Parent-Youth Teamwork in Pediatric Asthma Management",,"Completed","No Results Available","Asthma","Device: electronic medication monitoring system|Behavioral: parent-adolescent communication and problem-solving skills","medication adherence, parental involvement , perceived parent-adolescent conflict, associated health outcome","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 15 Years   (Child)","Phase 2","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R03HD039767","April 2002","null","September 2005","September 14, 2005","null","July 2, 2007","Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|West Virginia Univeristy, Morgantown, West Virginia, United States","","https://ClinicalTrials.gov/show/NCT00166582"
102,"NCT00135668","Dose-Response Study of Sodium Nitroprusside in Children Requiring Controlled Hypotension in the Operating Room",,"Completed","No Results Available","Hypotension","Drug: nitroprusside","The primary efficacy endpoint is the change in mean arterial pressure (MAP) from the baseline MAP after 30 minutes of blinded study drug administration with sodium nitroprusside|Secondary efficacy endpoints are:Offset MAP and time to return to offset MAP after the cessation of study medication;|The change from baseline MAP during the initial 20 and 25 minutes of sodium nitroprusside infusion during the blinded infusion;|The infusion rate of sodium nitroprusside that reduces MAP to a predetermined clinically meaningful target value +/- 10%;|The proportion of patients who reach target MAP;|The change in vital signs (i.e., systolic blood pressure [SBP], diastolic blood pressure [DBP], and heart rate [HR]) from baseline to 10, 15, 20, and 30 minutes post-infusion initiation.|Analyses will be stratified by age","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Stanford University|Duke University","All","up to 17 Years   (Child)","Phase 2","203","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-2003-09-DR|NO1-HD-4-3386","August 2005","March 2008","February 2009","August 26, 2005","null","May 27, 2009","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT00135668"
103,"NCT00117728","Pediatric Nevirapine Resistance Study",,"Unknown status","No Results Available","AIDS|HIV Infections","Drug: nevirapine","Virologic suppression at 6 months after randomization|To compare the time to virologic failure up to 18 months post randomization|to examine the associations between detection of drug resistance mutation and virologic response to treatment|to compare the toxicity profiles and adherence in the two groups|to describe the emergence of genotypic resistance in the two groups","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Columbia University|University of Witwatersrand, South Africa","All","up to 24 Months   (Child)","Phase 3","250","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","5R01HD047177","April 2005","null","September 2010","July 8, 2005","null","June 29, 2007","Coronation Hospital, Johannesburg, South Africa","","https://ClinicalTrials.gov/show/NCT00117728"
104,"NCT00114569","Lorazepam for the Treatment of Status Epilepticus in Children",,"Completed","No Results Available","Status Epilepticus","Drug: lorazepam","Description of the pharmacokinetics of two different doses (0.05 and 0.1 mg/kg) IV lorazepam|safety of IV lorazepam","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation","All","3 Months to 17 Years   (Child)","Phase 1","69","NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HHSN275200403393C","March 2005","April 2007","February 2009","June 16, 2005","null","May 23, 2016","Children's National Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00114569"
105,"NCT00110292","Preventing Learning Problems in Young Children: A Public Health and Physician-Based Outreach",,"Unknown status","No Results Available","Developmental Disabilities|Language Development Disorders","Behavioral: Age-specific parenting newsletters and developmental toys|Behavioral: Parent-completed Ages & Stages Questionnaires|Behavioral: Clinic-based distribution of children's books","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Months to 7 Months   (Child)","Phase 1","600","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Prevention","R01HD040388","March 2002","null","February 2006","May 6, 2005","null","June 24, 2005","Montefiore Comprehensive Health Care Center, Bronx, New York, United States|North Central Bronx Hospital Pediatric Clinic, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT00110292"
106,"NCT00109616","Community Trial of Newborn Skin and Umbilical Cord Cleansing on Neonatal Mortality in Nepal",,"Completed","No Results Available","Neonatal Mortality","Behavioral: Newborn skin cleansing with 0.25% chlorhexidine solution|Behavioral: Cleansing of umbilical cord with soap and water solution|Behavioral: Cleansing of umbilical cord with 4% chlorhexidine","neonatal mortality|umbilical cord infection","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation","All","up to 10 Days   (Child)","Phase 3","17000","NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","R01HD044004","October 2002","null","January 2006","May 2, 2005","null","May 1, 2013","Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|Nepal Nutrition Intervention Project-Sarlahi, Kathmandu and Sarlahi District, Nepal","","https://ClinicalTrials.gov/show/NCT00109616"
107,"NCT00109551","Community Trial of Zinc Supplementation on Preschool Child Mortality and Morbidity in Southern Nepal",,"Completed","No Results Available","Nutrition","Drug: zinc sulphate dietary supplement|Drug: iron sulphate-folic acid dietary supplement","Death among children 1-36 months of age|Incidence rates of selected morbidities including diarrhea, dysentery, acute respiratory infections","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|United States Agency for International Development (USAID)|Bill and Melinda Gates Foundation","All","1 Month to 36 Months   (Child)","Phase 3","58000","NIH|U.S. Fed|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention","R01HD038753","October 2001","null","January 2006","April 29, 2005","null","May 1, 2013","Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States|Cornell University Division of Nutritional Sciences, Ithaca, New York, United States|Nepal Nutrition Intervention Project-Sarlahi, Kathmandu and Sarlahi District, Nepal","","https://ClinicalTrials.gov/show/NCT00109551"
108,"NCT00099385","Comprehensive Elementary School Risk Prevention",,"Completed","No Results Available","Risk Behavior","Behavioral: Social Development Instruction","Self reports of risky behaviors|Academic test scores|Measure of social problem solving skills: Social Problem Solving Dilemma","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 14 Years   (Child)","Not Applicable","2620","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD045362","September 2004","June 2010","July 2010","December 14, 2004","null","February 17, 2012","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00099385"
109,"NCT00099359","Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission",,"Completed","Has Results","Disease Transmission, Vertical|Vertical Human Immunodeficiency Virus Transmission|HIV Infections","Drug: Zidovudine|Drug: Nevirapine (NVP)|Drug: Epivir (3TC)|Drug: Nelfinavir (NFV)","Infant HIV Infection Status|Participants With Serious Adverse Events|Infant HIV-1 Infection Status|Participant Deaths|Clinical Covariates of HIV-1 Infection|3TC and NFV Pharmacokinetics|Risk Factors for Perinatal HIV-1 Transmission|NVP Pharmacokinetics","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","All","up to 2 Days   (Child)","Phase 3","1735","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NICHD/HPTN 040 (P1043)","February 2004","February 2011","February 2011","December 13, 2004","December 4, 2012","December 4, 2012","Miller Children's Hospital, Long Beach, California, United States|University of FL, Gainesville, Florida, United States|University of FL-HSC, Jacksonville, Florida, United States|University Medical and Dental School of NJ-Newark Campus, Newark, New Jersey, United States|Texas Childrens Hospital, Houston, Texas, United States|Hospital I. G. A. Dr. Diego Paroissien, Buenos Aires, Argentina|Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil|Universidade de Sao Paulo (USP) , MD, São Paulo, Ribeirão Preto, Brazil|Hospital Fêmina S.A. Unidade Perinatal de Transmissão Vertical, Porto Alegre, Rio Grande do Sul, Brazil|Hospital Santa Casa (HSC), Porto Alegre, Rio Grande do Sul, Brazil|Hospital Nossa Senhora da Conceicao (GHC), Porto Alegre, Rio Grande do Sul, Brazil|Hospital dos Servidores do Estado (HSE), Rio de Janeiro, Brazil|Hospital Geral de Novo Iguacu, Rio de Janeiro, Brazil|5088 - Universidade Federal de Sao Paulo (UFSP), São Paulo, Brazil|San Juan Hospital, San Juan, Puerto Rico|Tygerberg Hospital, Cape Town, South Africa|Chris Hani Baragwanath Hospital, Johannesburg, South Africa","","https://ClinicalTrials.gov/show/NCT00099359"
110,"NCT00069550","Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett Syndrome",,"Unknown status","No Results Available","Rett Syndrome","Drug: dextromethorphan|Drug: donepezil hydrochloride","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Year to 15 Years   (Child)","Phase 3","90","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HD024448|5P01HD024448","September 2004","null","June 2008","September 30, 2003","null","June 24, 2005","Kennedy Krieger Institute, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00069550"
111,"NCT00069173","Preventing Osteoporosis in Adolescent Girls",,"Unknown status","No Results Available","Osteoporosis","Behavioral: Project FAB (Fitness and Bone)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years to 17 Years   (Child)","Phase 1","250","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD037746","July 2000","null","null","September 17, 2003","null","June 24, 2005","University of California at Irvine, Irvine, California, United States","","https://ClinicalTrials.gov/show/NCT00069173"
112,"NCT00068835","Using fMRI to Evaluate Instructional Programs for Children With Developmental Dyslexia",,"Unknown status","No Results Available","Developmental Dyslexia","Behavioral: Lindamood-Bell training for dyslexia","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 12 Years   (Child)","Not Applicable","160","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training","5R01HD037890","June 2000","null","May 2005","September 11, 2003","null","June 24, 2005","Georgetown University, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00068835"
113,"NCT00067925","A School-Based Osteoporosis Prevention Program for Adolescent Girls",,"Completed","No Results Available","Osteoporosis","Behavioral: Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","10 Years to 13 Years   (Child)","Phase 1","718","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD037767","September 2000","null","June 2002","September 4, 2003","null","October 19, 2010","","","https://ClinicalTrials.gov/show/NCT00067925"
114,"NCT00067600","Improving Bone Health in Adolescent Girls: The Youth Osteoporosis and Understanding Total Health (YOUTH) Study",,"Completed","No Results Available","Osteoporosis","Behavioral: Diet with increased fruits, vegetables, and calcium|Behavioral: Increased high impact activity and resistance training","Total Body Bone Mineral Density (TBBMD)|Serum osteocalcin, alkaline phosphatase, and urinary n-telopeptide|Plasma carotenoids and red cell folate","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 16 Years   (Child)","Phase 1","228","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD037744","August 2000","September 2003","September 2003","August 26, 2003","null","October 29, 2014","Kaiser Permanente Center for Health Research, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00067600"
115,"NCT00065962","Secretin for the Treatment of Autism",,"Completed","No Results Available","Autism","Drug: secretin, synthetic porcine|Drug: secretin, biologically derived porcine","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Deafness and Other Communication Disorders (NIDCD)","All","3 Years to 12 Years   (Child)","Phase 3","85","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","5P01HD035465|NICHD-23|57-937|Supplement CRC99-3|3P01HD035468","June 1999","null","May 2000","August 5, 2003","null","June 24, 2005","Children's Hospital, Denver, Colorado, United States|Center on Human Development and Disability, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00065962"
116,"NCT00065949","Magnesium Sulfate to Prevent Brain Injury in Premature Infants",,"Unknown status","No Results Available","Brain Injuries|Cerebral Palsy","Drug: magnesium sulfate","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 12 Hours   (Child)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","HD21453|NICHD-13|NICHD-0523|5R01HD021453","August 1987","null","February 2003","August 5, 2003","null","June 24, 2005","Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00065949"
117,"NCT00065910","Improving Attention Skills of Children With Autism",,"Completed","No Results Available","Autism","Behavioral: Caregiver joint attention intervention","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","12 Months to 36 Months   (Child)","Phase 1|Phase 2","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21MH064927","September 2001","null","January 2006","August 5, 2003","null","July 2, 2007","University of California, Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00065910"
118,"NCT00065832","Reading Problems in Children Living in Urban Areas",,"Completed","No Results Available","Dyslexia","Behavioral: Reading Instruction","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 8 Years   (Child)","Phase 3","1400","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R01HD30995-9","July 1993","null","June 2002","August 4, 2003","null","June 3, 2015","","","https://ClinicalTrials.gov/show/NCT00065832"
119,"NCT00065364","Improving Brain Development in Medically Healthy Premature Infants",,"Completed","No Results Available","Premature Birth","Behavioral: Newborn Individualized Developmental Care Assessment Program","neurodevelopmental function|EEG|MRI","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","28 Weeks to 33 Weeks   (Child)","Not Applicable","90","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Prevention","R01HD038261","May 2000","null","null","July 23, 2003","null","June 24, 2005","Children's Hospital Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00065364"
120,"NCT00065247","The BONES Project: Building Healthy Bones in Children",,"Unknown status","No Results Available","Osteoporosis","Behavioral: Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 9 Years   (Child)","Not Applicable","1500","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD037752","June 1999","null","May 2004","July 22, 2003","null","June 24, 2005","Tufts University Gerald J. and Dorothy R. Friedman School of Nutrition, Science and Policy, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00065247"
121,"NCT00063596","Vitamin A Supplementation in Preterm Infants",,"Unknown status","No Results Available","Infant, Premature","Drug: Vitamin A supplementation","Response to Hepatitis B vaccine|Chronic lung disease|Length of hospital stay|Respiratory and GI infections to 9 months of age|T-cell cytokine production and development|T-cell subset development","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 3 Days   (Child)","Not Applicable","220","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","5R01HD037263","January 2000","null","May 2004","July 2, 2003","null","June 24, 2005","Women's and Children's Hospital of Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00063596"
122,"NCT00063037","Building Better Bones in Children",,"Unknown status","No Results Available","Osteoporosis","Behavioral: Behavioral modification - nutrition education","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)","All","7 Years to 10 Years   (Child)","Not Applicable","139","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Prevention","R01HD037748","June 1999","null","May 2005","June 20, 2003","null","June 24, 2005","The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00063037"
123,"NCT00063024","Program to Prevent Osteoporosis in Girls",,"Unknown status","No Results Available","Osteoporosis","Behavioral: Increased calcium intake|Behavioral: Weight-bearing physical activity","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","9 Years to 11 Years   (Child)","Phase 3","322","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD037743","June 1999","null","May 2004","June 20, 2003","null","June 24, 2005","Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT00063024"
124,"NCT00063011","Bone Development in Adolescent Girls: Effects of Calcium and Exercise",,"Unknown status","No Results Available","Osteoporosis","Behavioral: Calcium rich diet|Behavioral: Weight bearing exercise","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","9 Years to 10 Years   (Child)","Phase 1|Phase 2","107","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD036601","May 1998","null","null","June 20, 2003","null","June 24, 2005","Creighton University, Omaha, Nebraska, United States","","https://ClinicalTrials.gov/show/NCT00063011"
125,"NCT00062959","Preventing Problem Behavior Among Middle School Students",,"Completed","No Results Available","Substance Use Disorders|Health Promotion","Behavioral: Going Places: School program to prevent problem behavior","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 12 Years   (Child)","Not Applicable","2768","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Prevention","N01HD33207|Z01HD002110-07PR|NO1-HD-3-3207|NICHD-400","June 1994","null","June 2000","June 19, 2003","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00062959"
126,"NCT00062829","Young Driver Intervention Study: Preventing Motor Vehicle Crashes",,"Completed","No Results Available","Accidents, Traffic|Health Behavior","Behavioral: Teen Driving: Program for parents","Risky Driving","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Centers for Disease Control and Prevention","All","16 Years to 16 Years   (Child)","Not Applicable","3743","NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","N01HD83285|Z01HD001707-01|N01-HD-8-3285","September 1998","September 2000","September 2005","June 18, 2003","null","September 25, 2014","","","https://ClinicalTrials.gov/show/NCT00062829"
127,"NCT00061139","Constraint-Based Therapy to Improve Motor Function in Children With Cerebral Palsy",,"Unknown status","No Results Available","Cerebral Palsy|Motor Deficits","Behavioral: Pediatric Constraint-Induced Movement therapy|Behavioral: Conventional pediatric motor rehabilitation therapy","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 6 Years   (Child)","Phase 2","52","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment","R01HD040692","September 2002","null","September 2006","May 22, 2003","null","June 24, 2005","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00061139"
128,"NCT00060957","Botulinum Toxin (BOTOX) for Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy|Muscle Spasticity","Drug: Botulinum toxin type A","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Phase 2","40","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1R01HD035750-01","July 1997","June 2002","null","May 19, 2003","null","September 26, 2016","Children's Hospital and Regional Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00060957"
129,"NCT00060788","Antisocial Behavior: Passing From Parent to Child to Grandchild",,"Unknown status","No Results Available","Dyssocial Behavior|Antisocial Personality Disorder","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","36 Months to 48 Months   (Child)","","663","NIH","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","1R01HD42259-1","September 2001","null","December 2005","May 14, 2003","null","March 7, 2006","Joint Child Health Project, Quatre Bornes, Mauritius","","https://ClinicalTrials.gov/show/NCT00060788"
130,"NCT00060619","Migraine and Recurrent Abdominal Pain in Children",,"Unknown status","No Results Available","Migraine|Abdominal Pain","Behavioral: thermal biofeedback|Behavioral: relaxation training|Behavioral: cognitive coping skills|Behavioral: parent education","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 17 Years   (Child)","Not Applicable","180","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","5R01HD38647-3","May 1999","null","June 2004","May 12, 2003","null","June 24, 2005","Pain Treatment Service, Children's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00060619"
131,"NCT00059527","Healthy Youth Places: A Program to Promote Nutrition and Physical Activity in Adolescents",,"Completed","No Results Available","Health Behavior","Behavioral: Healthy Youth Places: a behavior change model","Moderate and Vigorous Physical Activity|Vigorous Physical Activity|Fruit and Vegetable Consumption|Self-efficacy","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 16 Years   (Child)","Phase 4","2000","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","5R01HD37367-3","March 1999","null","May 2003","April 29, 2003","null","October 30, 2014","","","https://ClinicalTrials.gov/show/NCT00059527"
132,"NCT00059241","The ""Reach For Health"" Program: Delaying Sexual Activity in Children",,"Unknown status","No Results Available","Sex Behavior|Child Behavior","Behavioral: Parent-child communication education|Behavioral: Service learning|Behavioral: Classroom health curriculum","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 14 Years   (Child)","Phase 2","1200","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R01HD39537-2","July 2000","null","null","April 23, 2003","null","June 24, 2005","Education Development Center, Inc., Newton, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00059241"
133,"NCT00058760","Delaying Sexual Activity in African American Adolescent Girls",,"Unknown status","No Results Available","Adolescent Behavior|Sex Behavior","Behavioral: NIA intervention (after school health promotion didactic program)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","11 Years to 14 Years   (Child)","Phase 1","240","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","1R01HD39757-1","February 2001","null","January 2006","April 15, 2003","null","June 24, 2005","Dr. Willa Doswell, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00058760"
134,"NCT00056953","Peer Mentors for Adolescents in HIV Affected Families",,"Completed","No Results Available","Adolescent Behavior|Health Behavior|HIV Seronegativity","Behavioral: Peer mentoring program","substance use; association with substance using peers","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 15 Years   (Child)","Phase 2","160","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R01HD37350-3","September 1999","null","November 2004","March 27, 2003","null","July 29, 2005","Health People, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00056953"
135,"NCT00056680","Three-Part Program for Parents With Premature Infants",,"Completed","No Results Available","Premature Birth","Behavioral: Psychoeducational video|Behavioral: Infant massage|Behavioral: Brazelton Neonatal Behavioral Assessment Scale","Anthropometrics (weight, height, head circumference), Bayley Scales of Infant Development, infant behavioral problems and behavioral competencies, maternal sensitivity, infant-parent attachment|Maternal self-efficacy, parenting stress, perceptions of infant temperament","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","32 Weeks to 37 Weeks   (Child)","Not Applicable","173","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Prevention","1R01HD38982-1A6","July 2001","null","December 2006","March 24, 2003","null","June 20, 2007","Children's National Medical Center, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|The Pennsylvania State University, University Park, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00056680"
136,"NCT00006516","Home Stimulation for Brain-Asphyxiated Infants",,"Completed","No Results Available","Hypoxia, Brain|Hypoxia-Ischemia, Brain","Behavioral: Infant stimulation","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 1 Month   (Child)","Phase 2","120","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","NICHD-0115|1R01HD038600-01","September 1999","August 2004","null","November 22, 2000","null","September 26, 2016","University of California at Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00006516"
137,"NCT00006507","Occupational Therapy to Treat Children Who Over or Under React to Their Environment",,"Completed","No Results Available","Sensory Disorders","Behavioral: Occupational Therapy","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","54 Months to 11 Years   (Child)","Phase 2","null","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single|Primary Purpose: Treatment","NICHD-0104|2K08 HD01183-02","March 1999","null","February 2002","November 6, 2000","null","January 17, 2007","University of Colorado Health Sciences Center, Littleton, Colorado, United States","","https://ClinicalTrials.gov/show/NCT00006507"
138,"NCT00006446","Preventing Problems in Children's Social Behavior",,"Completed","No Results Available","Behavior Disorders","Procedure: Training in parenting skills and communication","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","3 Years to 6 Years   (Child)","Not Applicable","180","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-0500|2P30HD015052|NIMH R01MH54629","July 1996","null","June 2001","November 6, 2000","null","February 22, 2007","Institute of Language, Social and Cognitive Development, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00006446"
139,"NCT01990625","A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings",,"Completed","No Results Available","Pregnancy|Eclampsia|Placenta Previa|Stillbirth|Fetal Growth Restriction","Device: Antenatal Ultrasound Scan","Composite outcome|Rate of Women with Complicated Deliveries at Health Facilities","NICHD Global Network for Women's and Children's Health|Bill and Melinda Gates Foundation|GE Healthcare","Female","12 Years to 55 Years   (Child, Adult)","Not Applicable","45038","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GN First Look Ultrasound","April 2014","August 2016","September 2016","November 21, 2013","null","September 29, 2016","Kinshasa School of Public Health, Gemena, Equateur, Congo|IMSALUD / San Carlos University, Guatemala City, Guatemala|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT01990625"
140,"NCT00098319","Oral Cleft Prevention Trial in Brazil",,"Completed","No Results Available","Cleft Lip|Cleft Palate","Drug: Folic acid (0.4mg vs. 4.0mg)","Recurrence of nonsyndromic cleft lip with or without cleft palate (NSCL/P) in offspring of trial mothers|Recurrence of NSCL/P compared to a historical control group; Overall and high versus low dose|Serum and red cell folate levels|Severity of NSCL/P in offspring of trial mothers|Twinning rate|Miscarriage rate|Preeclampsia|Rates of other birth defects|Birth weight|Gestational age","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|National Institute of Dental and Craniofacial Research (NIDCR)|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Cancer Institute (NCI)|RTI International|University of Iowa|Hospital de Reabilitação de Anomalias Craniofaciais (HRAC) - Brazil","Female","16 Years to 45 Years   (Child, Adult)","Phase 3","2200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","GN 04 Aim III","January 2004","null","April 2007","December 7, 2004","null","December 17, 2013","Hospital de Reabilitação de Anomalias Craniofaciais (HRAC), Bauru, Sao Paulo, Brazil|Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, Brazil|Hospital Santo Antonio-Centrinho: Obras Sociais Irma Dulce, Salvador, Brazil","","https://ClinicalTrials.gov/show/NCT00098319"
141,"NCT03223649","Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth",,"Recruiting","No Results Available","Healthy|Obesity|Overweight","Behavioral: Walking Bouts|Behavioral: Sedentary","Insulin iAUC obtained during the oral glucose tolerance test at the final experimental visit.|Glucose iAUC obtained during the oral glucose tolerance test on day # 6 of intervention.|Mean iAUC as obtained from 24hr- continuous glucose monitoring throughout 6 days of study intervention.|Mean Amplitude Glycemic Excursion (MAGE) as obtained from 24hr- continuous glucose monitoring throughout 6 days of intervention.|Cognitive function (working memory, inhibition, attention, and processing speed), mood, anxiety.|Daily physical activity (steps counts/day).|Dietary intake at the final test meal.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 11 Years   (Child)","Phase 2","150","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","170130|17-CH-0130","July 26, 2017","June 28, 2019","June 28, 2020","July 21, 2017","null","April 2, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03223649"
142,"NCT02977403","Mobile Attention Retraining in Overweight Female Adolescents",,"Recruiting","No Results Available","Obesity|Overweight|Binge Eating|Healthy Volunteers","Behavioral: Attention Bias Retraining|Behavioral: Booster Attention Retraining","Neural activity during attention bias task|Changes in laboratory measured attention bias|Changes in EMA-measured attention bias|Changes in self-reported eating pattern|Changes in reaction times to palatable foods at the baseline laboratory visit vs. the post-EMA visit), neural activity during the social threat Attention Bias task","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","12 Years to 17 Years   (Child)","Phase 2","120","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","170014|17-CH-0014","November 29, 2016","October 31, 2020","December 31, 2020","November 30, 2016","null","April 11, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02977403"
143,"NCT01888939","Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children",,"Completed","No Results Available","Healthy Volunteer","Other: Walking on a Treadmill|Other: Sedendary Activities Only","Lower insulin incremental area under the curve (iAUC) during 3 hours after the OGTT.|Lower postprandial glucose iAUC during 3 hours after the OGTT.|Differences in executive functioning and attention scores.|Differences in positive and negative affect scores.|Differences in anxiety.|Differences in post-test dietary intake.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Cancer Institute (NCI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","All","7 Years to 11 Years   (Child)","Phase 1|Phase 2","89","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130169|13-CH-0169","June 26, 2013","March 8, 2017","January 29, 2018","June 28, 2013","null","January 31, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01888939"
144,"NCT01986439","The Contraceptive Choice Project",,"Unknown status","No Results Available","Unintended Pregnancy|Teen Births|Abortion|Contraception","","Distribution of contraceptive method chosen|Method Continuation|Method Satisfaction|Teen Pregnancy Rates|Repeat Abortion Rates|Sexually transmitted infection rates","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 45 Years   (Child, Adult)","","9256","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","201101982","August 2007","December 2016","December 2016","November 18, 2013","null","April 14, 2015","Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT01986439"
145,"NCT01425905","Mood and Insulin Resistance in Adolescents At-Risk for Diabetes",,"Completed","No Results Available","Depression|Impaired Glucose Tolerance","Other: The Blues Program|Other: Hey Durham","Insulin Resistance at 12 months in CB depression prevention versus HE control group.|Depressive symptoms at 12 months in CB depression prevention versus HE control group.|CB, depression, prevention, group, will, show, greater, improvements, in, mediators, (eating, behavior, fitness, and stress biomarkers) than the HE control group.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC)","Female","12 Years to 17 Years   (Child)","Phase 2","174","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","110239|11-CH-0239","August 23, 2011","August 10, 2015","August 10, 2015","August 30, 2011","null","April 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01425905"
146,"NCT01536509","Improving Medication Adherence in Pediatric Inflammatory Bowel Disease","TEAM","Unknown status","No Results Available","Crohn's Disease|Ulcerative Colitis|Indeterminate Colitis|Inflammatory Bowel Disease","Behavioral: Telehealth Behavioral Treatment (TBT)|Behavioral: Education Only (EO)","Medication adherence|Health-related quality of life|Disease Severity|Health care utilization","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 18 Years   (Child, Adult)","Phase 3","140","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","R01HD067174","February 2012","July 2017","null","February 22, 2012","null","September 22, 2016","University of California San Francisco Benioff Children's Hospital, San Francisco, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|University of Cincinnati, Cincinnati, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oklahoma State University, Stillwater, Oklahoma, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Childrens Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01536509"
147,"NCT01237041","Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children",,"Terminated","Has Results","Obesity|Short Stature|Growth Hormone Deficiency","Drug: Niacin First|Drug: Placebo First|Drug: Dose-Establishing Study 1 Niacin 250mg|Drug: Dose-Establishing Study 1 Niacin 500mg|Drug: Dose-Establishing Study 2 Niacin 500mg","Growth Hormone Secretion Area Under the Curve in Response to Niacin and Placebo Over Time|Free Fatty Acids (FFA) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours|Growth Hormone-releasing Hormone (GHRH) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours|Somatostatin (SST) Area Under the Curve in Response to Niacin and Placebo Over 4 Hours","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 14 Years   (Child)","Phase 1|Phase 2","37","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","110004|11-CH-0004","July 1, 2011","October 17, 2017","December 13, 2017","November 9, 2010","December 17, 2018","December 17, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01237041/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01237041"
148,"NCT01322191","Morphine PK Subgroup Analysis",,"Completed","No Results Available","Post Operative Pain","Drug: Morphine","Chemical analysis of the plasma and urine samples for morphine concentration using high performance liquid chromatography coupled to atmospheric pressure ionization mass spectrometry|Pharmacokinetic analysis of morphine, M3G, and M6G in urine to determine clearance and percent of dose excreted|Analgesic efficacy using drug concentration and area under the curve ratio correlated with the level of analgesia measured with the age-appropriate scale","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 18 Years   (Child, Adult)","Phase 4","48","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","10920","April 2008","November 2010","November 2010","March 24, 2011","null","October 29, 2012","Children's Hospital of Michigan, Detroit, Michigan, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01322191"
149,"NCT00999375","Cultivating Healthy Environments in Families With Type 1 Diabetes (CHEF)",,"Completed","No Results Available","Type I Diabetes","Behavioral: Education|Behavioral: Problem Solving|Behavioral: Social Learning|Behavioral: Behavior Modification","Change in glycemic control, change in dietary intake|Change in social cognitive mediators of behavior; change in psychosocial status; change in body composition, lipids, oxidative stress, and inflammation","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","8 Years to 17 Years   (Child)","Phase 2","293","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","999909234|09-CH-N234","September 18, 2009","November 27, 2013","November 27, 2013","October 21, 2009","null","September 25, 2018","Joslin Diabetes Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00999375"
150,"NCT01203527","A Study of the Pharmacology of Tamiflu in Pregnancy",,"Completed","No Results Available","H1N1 Influenza Treatment During Pregnancy","","Apparent oral clearance of oseltamivir in singletons|Apparent oral clearance of oseltamivir in twins|Apparent renal clearance of oseltamivir carboxylate in non-pregnant women (ancillary study)|Concentration of oseltamivir carboxylate and oseltamivir at times 0 and 12h to ascertain steady state status|Plasma esterase activity. (ancillary study)|Maternal side effects -GI upset, pregnancy loss, neuropsychiatric disorder|Maternal and cord blood oseltamivir and oseltamivir carboxylate concentrations","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 45 Years   (Child, Adult)","","63","NIH","Observational","Observational Model: Cohort","OPRU Tamiflu","March 2007","October 2012","October 2012","September 16, 2010","null","October 9, 2013","Indiana University School of Medicine, Indianapolis, Indiana, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01203527"
151,"NCT00965068","Cholesterol in ASD: Characterization and Treatment",,"Completed","No Results Available","Autism|Asperger Disorder|PDD-NOS","Other: Cholesterol","Behavioral Changes","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","4 Years to 12 Years   (Child)","Phase 1|Phase 2","44","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","090203|09-CH-0203","July 28, 2009","null","November 14, 2013","August 25, 2009","null","July 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00965068"
152,"NCT00797095","Health Behaviors in School-age Children: 2009-2010",,"Completed","No Results Available","Obesity|Substance Abuse|Violence|Mental Health","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","11 Years to 15 Years   (Child)","","12651","NIH","Observational","Time Perspective: Retrospective","999909023|09-CH-N023","November 19, 2008","null","October 20, 2014","November 25, 2008","null","April 5, 2018","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00797095"
153,"NCT00906724","An Exercise Intervention Study in Insulin-Resistant Adolescents","3290","Unknown status","No Results Available","Insulin Resistance|Obesity","Procedure: Aerobic exercise","Insulin sensitivity index|Levels of change in fibrinolytic markers","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Research Institute","All","14 Years to 18 Years   (Child, Adult)","","40","NIH|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","U10HD030447","March 2005","June 2009","December 2009","May 21, 2009","null","May 21, 2009","Children's National Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00906724"
154,"NCT00680979","Preventing Excessive Weight Gain in Adolescent Girls at High-Risk for Adult Obesity",,"Completed","No Results Available","Obesity|Overweight|Binge Eating","Behavioral: Interpersonal Psychotherapy|Behavioral: Health Education","Girls with LOC eating will be randomly assigned to IPT-WG or HE to examine their expected BMI change based upon CDC BMI growth chart data versus their actual in BMI over the course of two years.|Efficacy of IPT-WG in improving socia","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","12 Years to 17 Years   (Child)","Phase 2","166","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","080139|08-CH-0139","May 15, 2008","April 16, 2015","April 16, 2015","May 20, 2008","null","April 12, 2019","United States Uniformed Health Service, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00680979"
155,"NCT00631644","Eating Behavior in Adolescents",,"Completed","No Results Available","Overweight|Eating Behavior|Binge Eating","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","13 Years to 17 Years   (Child)","","301","NIH","Observational","Time Perspective: Prospective","080085|08-CH-0085","March 5, 2008","null","September 8, 2015","March 10, 2008","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00631644"
156,"NCT00809887","Micafungin Lock Therapy",,"Terminated","No Results Available","Catheter-Related Fungal Infections","Drug: Micafungin lock therapy","Central vascular catheter preserved during lock therapy as a result of resolution of symptoms and negative cultures within 96h.|Descriptive analysis of safety profile of patients receiving ALT and systemic micafungin","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 18 Years   (Child, Adult)","Phase 1","20","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10882","June 2006","June 2008","November 2008","December 17, 2008","null","December 17, 2008","Children's Medical Center of Dallas/University of Texas Southwestern Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00809887"
157,"NCT00621478","Efficacy and Safety Study Comparing Lorazepam and Diazepam for Children in the Emergency Department With Seizures (Status 2)",,"Completed","No Results Available","Status Epilepticus","Drug: lorazepam or diazepam","cessation of convulsions within 10 minutes of the initial administration of the study drug and a sustained absence of convulsions for 30 minutes from the initial administration of the study drug.|To determine population pharmacokinetics (PK) of lorazepam using sparse sampling.|feasibility of identifying patients for informed consent prior to arrival in status epilepticus for a randomized controlled trial|the experience of community consultation and public disclosure|feasibility of enrolling pediatric patients under an exception from informed consent|determine patients' and parents' attitudes and reactions to an exception from informed consent approach|severe or life-threatening respiratory depression","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 18 Years   (Child, Adult)","Phase 2|Phase 3","259","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","N01HD043393|275200403393C","February 2008","May 2012","May 2012","February 22, 2008","null","December 18, 2012","University of California- Davis Medical Center, Davis, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington DC, District of Columbia, United States|University of Maryland Hospital for Children, Baltimore, Maryland, United States|University of Michigan Emergency Medicine Research, Ann Arbor, Michigan, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Hospital of Buffalo, Buffalo, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Medical Center Dallas, Dallas, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Utah Pediatric Emergency Medicine, Salt Lake City, Utah, United States|Medical College of Wisconsin Children's Corporate Center, Milwaukee, Wisconsin, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00621478"
158,"NCT00386789","Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese Children Injected at 2-5 Years or at 5-8 Years of Age",,"Completed","No Results Available","Typhoid Fever","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","10 Years to 13 Years   (Child)","","0","NIH","Observational","Time Perspective: Other","999907004|07-CH-N004","October 5, 2006","null","June 17, 2008","October 12, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States|Dong Thap Provincial Hospital, Dong Thap, Vietnam|National Institute of Hygiene and Epidemiology, Hanoi, Vietnam|Pasteur Institute, Ho Chi Minh City, Vietnam","","https://ClinicalTrials.gov/show/NCT00386789"
159,"NCT00368316","Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel",,"Completed","Has Results","Shigellosis","Biological: Shigella conjugate vaccines","Number of Participants With Adverse Events|Geometric Mean Immunoglobulin G (IgG) Anti-Lipopolysaccharide (LPS) Levels|Percentage of Efficacy","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Chaim Sheba Medical Center|Schneider Children's Medical Center, Israel|National Institutes of Health Clinical Center (CC)","All","1 Year to 4 Years   (Child)","Phase 3","2799","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","999900003|OH00-CH-N003","January 2003","January 2008","February 2009","August 24, 2006","June 19, 2012","June 22, 2012","Schneider Childrens Hospital, Petach Tikva, Israel|Chaim Sheba Medical Center, Tel Aviv, Israel","","https://ClinicalTrials.gov/show/NCT00368316"
160,"NCT00368043","Endocrine and Psychological Evaluation of Adopted Children",,"Terminated","No Results Available","Psychosocial Adjustment","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","10 Months to 4 Years   (Child)","","38","NIH","Observational","","060223|06-CH-0223","August 18, 2006","null","March 30, 2015","August 24, 2006","null","April 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00368043"
161,"NCT00362076","The Role of Motion in Infants' Ability to Categorize",,"Completed","No Results Available","Child Development","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Months to 6 Years   (Child)","","941","NIH","Observational","","980155|98-CH-0155","September 3, 1998","null","April 19, 2012","August 9, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00362076"
162,"NCT00341510","Health Behaviors in School-age Children: A World Health Organization Cross-National Study",,"Completed","No Results Available","Health Behavior","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 16 Years   (Child)","","14350","NIH","Observational","","999906017|06-CH-N017","October 17, 2005","null","November 28, 2006","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00341510"
163,"NCT00340795","Media-Smart Youth Program Evaluation Study",,"Completed","No Results Available","Adolescent","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","11 Years to 13 Years   (Child)","","0","NIH","Observational","","999905197|05-CH-N197","August 4, 2005","null","March 7, 2007","June 21, 2006","null","July 2, 2017","Academy for Education Development, Washington, D.C., District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00340795"
164,"NCT00340470","Michigan Driver Education Study",,"Completed","No Results Available","Behavioral Intervention","Behavioral: Driver Education","Adoption of the parent-teen driving agreement.|Prent-imposed driving restrictions during the first 12 months of driving.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","15 Years to 16 Years   (Child)","Phase 3","0","NIH","Interventional","Primary Purpose: Treatment","999903262|03-CH-N262","July 24, 2003","null","February 6, 2007","June 21, 2006","null","July 2, 2017","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00340470"
165,"NCT00340093","Diabetes Management Personal Trainer",,"Completed","No Results Available","Diabetes","Behavioral: Managing Diabetes","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","11 Years to 16 Years   (Child)","Phase 1","0","NIH","Interventional","Primary Purpose: Treatment","999902290|02-CH-N290","August 23, 2002","null","March 6, 2007","June 21, 2006","null","July 2, 2017","Johns Hopkins University, Baltimore, Maryland, United States|Mount Washington Pediatric Hospital, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00340093"
166,"NCT00494572","Montelukast With Status Asthmaticus, Ages 6-18",,"Unknown status","No Results Available","Status Asthmaticus|Asthma","Drug: Montelukast|Other: sterile water","Evaluate effectiveness of Montelukast as adjunctive therapy|Estimate the first dose pharmacokinetic parameter of Montelukast","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Pediatric Pharmacology Research Units Network","All","6 Years to 18 Years   (Child, Adult)","Phase 2|Phase 3","52","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PPRU 10856","December 2006","January 2010","October 2010","June 29, 2007","null","December 16, 2008","Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00494572"
167,"NCT00494468","Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children",,"Completed","No Results Available","Insomnia|Sleep Disorder","Drug: Zolpidem","Safety will be assessed by collection of reported adverse events or findings on physical examination or laboratory assessments.|The primary pharmacokinetic outcome measures for this study will include the Zolpidem Cmax, Tmax, t1/2, AUC (zero to 12 hours and zero to infinity).|Polysomnography, including an electroencephalogram, electrooculogram and electromyogram will be performed on two occasions and represents the primary pharmacodynamic outcome assessment for this study.|Measures will include:|Global sleep parameters: time to sleep, total sleep time, duration of sleep period, sleep efficiency, frequency of shifts between sleep stages and number and duration of awakenings|Sleep Latencies; sleep onset latency, Rapid Eye Movement, (REM) latency, slow-wave sleep,(SWS) latency|Sleep Stages (as absolute and relative proportions thereof: sleep stages I, II, III and IV; sleep stage REM; stage awake|Non-Rem/REM Cycle Parameters: duration of the cycles, REM sleep per cycle, SWS sleep per cycle, number of cycles;|Pharmacodynamic outcomes also will be assessed using activity-based monitoring or actigraphy. This technique has demonstrated ability to measure dose-related effects of hypnotics.|Secondary outcome pharmacokinetic outcome measures will include estimation of the apparent Zolpidem Vd/F and CI/F.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Sanofi-Synthelabo","All","2 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","63","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPRU-10590","October 2002","null","March 2004","June 29, 2007","null","June 29, 2007","Arkansas Children's Hospital Research Center Inc., Little Rock, Arkansas, United States|University of California at San Diego, La Jolla, California, United States|National Jewish Medical and Research Center, Denver, Colorado, United States|Louisiana State University Health Sciences Center, Shreveport, Louisiana, United States|Children's Mercy Hospital & Clinics, Kansas City, Missouri, United States|Children's Hospital Research Foundation, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Children's Hospital, Columbus, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Tennessee College of Medicine, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00494468"
168,"NCT00491946","A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer",,"Unknown status","No Results Available","Cancer","Drug: Actinomycin-D|Drug: Vincristine","Characterization of Plasma Pharmacokinetics to examine the optimal dosing, metabolites and inter-patient variability of actinomycin-D in children with cancer during any sample of chemotherapy.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 18 Years   (Child, Adult)","Phase 4","24","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPRU 10762","June 2004","null","null","June 26, 2007","null","June 26, 2007","Abramson Research Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00491946"
169,"NCT00320177","Eating Behavior in Children",,"Completed","No Results Available","Eating Behaviors","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","8 Years to 17 Years   (Child)","","263","NIH","Observational","","040050|04-CH-0050","November 26, 2003","null","October 28, 2014","May 3, 2006","null","April 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00320177"
170,"NCT00315172","Non-Exercise Activity Thermogenesis (NEAT) in Children",,"Completed","No Results Available","Non-exercise Activity Thermogenesis","Procedure: Non-Exercise Activity Thermogenesis (NEAT)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 11 Years   (Child)","Phase 1","120","NIH","Interventional","Primary Purpose: Treatment","060141|06-CH-0141","April 13, 2006","null","November 7, 2008","April 17, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00315172"
171,"NCT00436306","Stage Matched Intervention to Increase Dual Method Use","PROTECT","Completed","No Results Available","Contraception|Sexually Transmitted Diseases|Pregnancy","Behavioral: Individualized Intervention|Behavioral: Computer-based contraceptive information","Behavioral: reported use of dual methods of contraception|Biological: incident sexually transmitted infection or unintended pregnancy|Secondary outcomes will include intermediate outcomes variables such as|changes in stage of change, processes of change, decisional balance, and self-efficacy.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years to 35 Years   (Child, Adult)","Phase 4","550","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD036663","October 1999","December 2005","December 2005","February 19, 2007","null","October 8, 2015","Women & Infants Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT00436306"
172,"NCT00263536","Pilot Program for Targeted Prevention of Child or Adolescent Weight Gain",,"Completed","No Results Available","Overweight Adolescents|Overweight","Procedure: Interpersonal Psychotherapy","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","8 Years to 13 Years   (Child)","Phase 1","147","NIH","Interventional","Primary Purpose: Treatment","060039|06-CH-0039","December 5, 2005","August 16, 2016","August 16, 2016","December 8, 2005","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00263536"
173,"NCT00114634","Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome",,"Completed","Has Results","Smith-Lemli-Opitz Syndrome","Dietary Supplement: Egg yolk preparation with cholesterol|Dietary Supplement: Egg substitute, without cholesterol","Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C).|ABC Irritability Sub-scale|ABC Lethargy Sub-scale|ABC Stereotypy Sub-scale|ABC Inappropriate Behavior Sub-scale|ABC Total Score","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","4 Years to 17 Years   (Child)","Phase 2","13","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","050168|05-CH-0168","June 2005","February 2009","February 2009","June 16, 2005","April 9, 2014","January 29, 2016","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00114634"
174,"NCT00102258","Role of Nutrition and Hormones in Boys With Disordered Growth",,"Completed","No Results Available","Short Stature|Constitutional Delay of Growth and Development|Dwarfism, Pituitary","Drug: Growth Hormone Therapy","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Male","7 Years to 10 Years   (Child)","Phase 2","20","NIH","Interventional","Primary Purpose: Treatment","050077|05-CH-0077","January 19, 2005","null","October 2, 2007","January 26, 2005","null","July 2, 2017","Nemours Children's Clinic, Jacksonville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00102258"
175,"NCT00166647","Thiopurine Methyltransferase Polymorphisms Evaluation",,"Withdrawn","No Results Available","Cancer","Procedure: Blood Sampling","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 18 Years   (Child, Adult)","","0","NIH","Observational","","PPRU-10728","February 2004","null","null","September 14, 2005","null","January 11, 2013","Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00166647"
176,"NCT00142766","Sedation Management in Pediatric Patients Supported on Mechanical Ventilation",,"Completed","No Results Available","Respiratory Failure","Behavioral: Nurse Implemented Goal-Directed Comfort Algorithm","Duration of Mechanical Ventilation|Time to Recovery of Lung Injury|Duration of Weaning from Mechanical Ventilation|Occurrence of Adverse Events|Total Exposure to Comfort Medications|Occurrence of Iatrogenic Abstinence Syndrome|PICU Length of Stay|Barriers to Successful Implementation of the Intervention|PICU costs","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Gustavus and Louise Pfeiffer Research Foundation","All","up to 18 Years   (Child, Adult)","Phase 2","245","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21HD045020","February 2004","July 2006","March 2007","September 2, 2005","null","October 7, 2015","Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT00142766"
177,"NCT00109395","Lorazepam Sedation for Critically Ill Children",,"Completed","No Results Available","Critical Illness","Drug: Lorazepam|Drug: Midazolam|Drug: Lorazepam CI","Rate of Severe Adverse Events|Number of bolus doses required to achieve a comfort score of 17 ≤ 26|Drug dose required to maintain a target comfort score of 17 ≤ 26","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Case Western Reserve University|The EMMES Corporation","All","up to 18 Years   (Child, Adult)","Phase 2|Phase 3","179","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HHSN275200403367C (contract)","September 2004","September 2007","September 2007","April 28, 2005","null","May 23, 2016","Case Western Reserve University, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00109395"
178,"NCT00091728","Hormonal Contraception and Risk of Chlamydia and Gonorrhea",,"Terminated","No Results Available","Chlamydia Infection|Neisseriaceae Infection","Drug: Depo Medroxyprogesterone acetate|Drug: Combined oral contraceptives","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 45 Years   (Child, Adult)","","1200","NIH","Observational","Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Longitudinal|Time Perspective: Prospective","HD7034","September 1997","null","August 2001","September 20, 2004","null","November 7, 2005","","","https://ClinicalTrials.gov/show/NCT00091728"
179,"NCT00053469","Infant s Examination and Manipulation of Objects",,"Completed","No Results Available","Healthy|Infant","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 2 Years   (Child)","","350","NIH","Observational","","030069|03-CH-0069","January 28, 2003","null","March 30, 2015","January 30, 2003","null","April 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00053469"
180,"NCT00068848","Quick Start Approach to Birth Control Pills",,"Completed","No Results Available","Pregnancy|Contraception","Behavioral: Quick start oral contraceptive initiation","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","up to 24 Years   (Child, Adult)","Phase 4","2000","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HD42413","February 2003","null","March 2005","September 11, 2003","null","April 10, 2007","Emory University School of Medicine, Atlanta, Georgia, United States|Mt. Sinai School of Medicine, New York, New York, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT00068848"
181,"NCT00067522","Preventing Unplanned Pregnancies in HIV Infected Zambian Couples",,"Unknown status","No Results Available","Pregnancy|HIV Infections","Behavioral: User-independent contraception program|Behavioral: Future Planning Perspectives program","pregnancy","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years to 38 Years   (Child, Adult)","Not Applicable","5000","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Prevention","HD40125|1R01HD040125-01A1","January 2002","null","null","August 25, 2003","null","June 29, 2007","Zambia Emory HIV Research Project, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00067522"
182,"NCT00067509","Emergency Contraception (ECP): Reducing Unintended Pregnancies",,"Completed","No Results Available","Contraception|Pregnancy","Drug: emergency contraception (estrogen/progesterone)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 39 Years   (Child, Adult)","Phase 4","1100","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HD38515","June 2001","null","May 2004","August 25, 2003","null","June 24, 2005","Family Planning Council, Philadelphia, Pennsylvania, United States|Family Health Council, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00067509"
183,"NCT00065936","Self-Injury: Diagnosis and Treatment",,"Unknown status","No Results Available","Self-Injurious Behavior|Mental Retardation","Drug: Naltrexone hydrochloride|Procedure: Transcutaneous sensory nerve stimulation","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 25 Years   (Child, Adult)","Phase 3","37","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","R29HD35862|R29 HD35862|NICHD-0525","July 1997","null","June 2002","August 5, 2003","null","June 24, 2005","Frank Porter Graham Child Development Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Research Training Institute, Western Carolina Center, Morganton, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00065936"
184,"NCT00065884","Valproate Response in Aggressive Autistic Adolescents",,"Unknown status","No Results Available","Autism","Drug: Valproate","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","6 Years to 21 Years   (Child, Adult)","Phase 3","30","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment","P30HD002528|K08MH001516","null","null","null","August 5, 2003","null","June 24, 2005","Outpatient MR/Autism Clinic, University of Kansas, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT00065884"
185,"NCT00065273","Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay",,"Completed","No Results Available","Mental Retardation|Developmental Delay Disorder","Drug: risperidone|Drug: clozapine|Drug: olanzapine","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 60 Years   (Child, Adult)","Phase 3","50","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","5P01HD026927","July 1998","null","June 2001","July 22, 2003","null","June 24, 2005","University of Kansas, Lawrence, Kansas, United States","","https://ClinicalTrials.gov/show/NCT00065273"
186,"NCT00064597","Noninvasive Prenatal Diagnosis: Using Fetal Cells From Maternal Blood",,"Unknown status","No Results Available","Chromosome Disorders","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 45 Years   (Child, Adult)","","3500","NIH","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Prospective","NICHD-NIFTY|1N01HD43201|1N01HD43202|1N01HD43203|1N01HD43204","December 1987","null","December 2003","July 11, 2003","null","June 24, 2005","University of Illinois at Chicago, Chicago, Illinois, United States|New England Medical Center Hospital, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Jefferson Medical College, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00064597"
187,"NCT00061399","Prospective Memory in Children With Traumatic Brain Injury",,"Completed","No Results Available","Traumatic Brain Injury","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 18 Years   (Child, Adult)","","178","NIH","Observational","Time Perspective: Prospective","K23HD040896","July 2002","December 2006","December 2006","May 28, 2003","null","October 29, 2014","","","https://ClinicalTrials.gov/show/NCT00061399"
188,"NCT00061230","Relaxation Training to Decrease Pain and Improve Function in Adolescents With Cerebral Palsy",,"Unknown status","No Results Available","Cerebral Palsy","Behavioral: biofeedback-monitored relaxation training","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 20 Years   (Child, Adult)","Not Applicable","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","P01HD33988-00606A1","March 2003","null","March 2006","May 23, 2003","null","June 24, 2005","University of Washington Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00061230"
189,"NCT00060463","Increased Access to Emergency Contraceptive Pills",,"Unknown status","No Results Available","Pregnancy|Sexually Transmitted Diseases","Behavioral: Increased access to emergency contraceptive pills","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 24 Years   (Child, Adult)","Not Applicable","1490","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01HD039907","October 2002","null","October 2005","May 7, 2003","null","June 24, 2005","Planned Parenthood Mar Monte / University of California at San Francisco, Reno, Nevada, United States|Planned Parenthood of Central North Carolina, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00060463"
190,"NCT00028262","Cystagon to Treat Infantile Neuronal Ceroid Lipofuscinosis",,"Completed","Has Results","Infantile Neronal Ceroid Lipofuscinosis","Drug: Cystagon","Change in Cellular Granular Osmiophilic Deposits (GRODs) in Electron Micrographs of Peripheral White Blood Cells.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","6 Months to 3 Years   (Child)","Phase 4","10","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","010086|01-CH-0086","February 2001","November 2013","November 2013","December 18, 2001","January 21, 2015","October 27, 2016","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00028262"
191,"NCT00005901","Pamidronate to Treat Osteogenesis Imperfecta in Children",,"Completed","Has Results","Osteogenesis Imperfecta","Drug: Pamidronate (Aredia)","Change in Bone Mineral Density in Response to Pamidronate","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 16 Years   (Child)","Phase 3","34","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","000136|00-CH-0136","June 2000","May 2014","March 2015","June 7, 2000","March 1, 2016","March 1, 2016","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005901"
192,"NCT00004838","Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned Children",,"Completed","No Results Available","Lead Poisoning","Drug: succimer","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Nationwide Children's Hospital|Office of Rare Diseases (ORD)","All","up to 6 Years   (Child)","Not Applicable","175","NIH|Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","199/13576|CHRF-96-HS-066|CH-OHIO-5F32ES05651","September 1997","null","July 1998","February 25, 2000","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00004838"
193,"NCT00001950","The Development of Categorization",,"Completed","No Results Available","Cognition Disorder|Healthy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","1 Year to 3 Years   (Child)","","219","NIH","Observational","","000035|00-CH-0035","December 14, 1999","null","May 23, 2012","January 19, 2000","null","September 13, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001950"
194,"NCT00001343","The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome",,"Completed","No Results Available","Dwarfism|Turner's Syndrome","Drug: Humatrope|Drug: Oxandrolone","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","10 Years to 14 Years   (Child)","Phase 2","80","NIH","Interventional","Primary Purpose: Treatment","930054|93-CH-0054","December 11, 1992","null","October 10, 2007","November 4, 1999","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00001343"
195,"NCT00001305","Growth Hormone Therapy in Osteogenesis Imperfecta",,"Completed","Has Results","Osteogenesis Imperfecta","Drug: Humatrope","Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 16 Years   (Child)","Phase 3","42","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","920034|92-CH-0034","November 5, 1991","May 19, 2017","May 19, 2017","November 4, 1999","January 29, 2019","January 29, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT00001305/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/05/NCT00001305/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00001305"
196,"NCT00004458","Longitudinal and Biological Study of Childhood Disintegrative Disorder",,"Terminated","No Results Available","Pervasive Child Development Disorders|Autism","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yale University|Office of Rare Diseases (ORD)","All","2 Years to 9 Years   (Child)","","220","NIH|Other","Observational","Primary Purpose: Screening|Time Perspective: Longitudinal","199/13682|YALE-5P01HD0300830|YALE-HIC-5895","May 1997","null","null","October 19, 1999","null","June 24, 2005","Yale Child Study Center, New Haven, Connecticut, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00004458"
197,"NCT00004392","Incidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for Sudden Infant Death Syndrome (SIDS)",,"Completed","No Results Available","Sudden Infant Death Syndrome|Apnea","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yale University|Office of Rare Diseases (ORD)","All","up to 1 Year   (Child)","","900","NIH|Other","Observational","Primary Purpose: Screening","199/12190|YALESM-CHIME-HD9102","May 1994","null","August 1999","October 19, 1999","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00004392"
198,"NCT00004382","Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns",,"Completed","No Results Available","Hyperbilirubinemia","Drug: tin mesoporphyrin|Procedure: Phototherapy","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Rockefeller University|Office of Rare Diseases (ORD)","All","up to 24 Hours   (Child)","Phase 2","80","NIH|Other","Interventional","Allocation: Randomized|Primary Purpose: Treatment","199/12022|RUH-0330795B","December 1999","August 2007","null","October 19, 1999","null","September 9, 2008","","","https://ClinicalTrials.gov/show/NCT00004382"
199,"NCT00004381","Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia",,"Completed","No Results Available","Glucosephosphate Dehydrogenase Deficiency|Hyperbilirubinemia|Hemolytic Disease of Newborn","Drug: tin mesoporphyrin","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Rockefeller University|Office of Rare Diseases (ORD)","All","up to 24 Hours   (Child)","Phase 2","null","NIH|Other","Interventional","Primary Purpose: Treatment","199/12021|RUH-0330795A","December 1999","null","null","October 19, 1999","null","June 24, 2005","New England Medical Center Hospital, Boston, Massachusetts, United States|Rockefeller University Hospital, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00004381"
200,"NCT00006445","Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters",,"Unknown status","No Results Available","Down Syndrome|Chromosome Abnormalities","Procedure: Ultrasound|Procedure: Serum screen","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 45 Years   (Child, Adult)","Not Applicable","38000","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NICHD-0511|1 RO1 HD37523","null","null","null","November 6, 2000","null","February 22, 2007","University of Colorado Health Sciences Center, Denver, Colorado, United States|New England Medical Center, Boston, Massachusetts, United States|William Beaumont Hospital Research Institute, Royal Oak, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|New York University School of Medicine, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Women and Infants Hospital, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Swedish Medical Center, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00006445"
201,"NCT01954056","Hydrocortisone for Term Hypotension",,"Completed","Has Results","Infant, Newborn, Diseases|Cardiovascular Insufficiency","Drug: Hydrocortisone|Drug: Placebo","Death|Number of Participants With Neurodevelopmental Impairment|Number of Participants With Death or Neurodevelopmental Impairment|Duration of Mechanical Ventilation|Days to Full Feeds|Number of Participants With Need for Gastronomy Tube|Duration of Oxygen Requirement|Number of Participants With Need for Home Oxygen|Hospital Length of Stay|Number of Participants With Renal Insufficiency|Number of Participants With Necrotizing Enterocolitis|Number of Participants With Need for ECMO Therapy|Number of Participants With Inotrope Exposure|Inotrope Duration|Maximum Inotrope Dose|Oxygenation Index|Respiratory Severity|Number of Participants With Fluid Boluses Given|Number of Boluses Given","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","34 Weeks and older   (Child, Adult, Older Adult)","Phase 3","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NICHD-NRN-0052|U10HD021364|U10HD040689|U10HD021385|U10HD027851|U10HD027853|U10HD027856|U10HD027904|U10HD027880|U10HD034216|U10HD021373|U10HD040492|U10HD053109|U10HD040461|U10HD068244|U10HD068263|U10HD068270|U10HD068278|U10HD068284|U10HD036790","June 19, 2014","March 20, 2018","March 20, 2018","October 1, 2013","April 2, 2019","April 2, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Wayne State University, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of New Mexico, Albuquerque, New Mexico, United States|University of Rochester, Rochester, New York, United States|RTI International, Durham, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/56/NCT01954056/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01954056"
202,"NCT03901300","An Intervention to Improve Motor Skills in Young Children","PLAY","Not yet recruiting","No Results Available","Physical Activity|Fundamental Motor Skills|Development, Child|Self-regulation","Behavioral: Fundamental Motor Skills App|Behavioral: Unstructured Physical Activity App","App Adherence|Test of Gross Motor Development (TGMD-3)","Pennington Biomedical Research Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 5 Years   (Child)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","PBRC 2018-041|1R21HD095035-01A1","May 1, 2019","December 1, 2020","July 1, 2021","April 3, 2019","null","April 4, 2019","","","https://ClinicalTrials.gov/show/NCT03901300"
203,"NCT03873831","Effects of Therapy Dogs on Social Behavior in Group Social Skills Instruction With Children With Autism",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder|Social Skills","Behavioral: Animal-assisted intervention|Behavioral: Social skills group","Verbal utterances|Direction of utterances|Quality of utterance|Unwanted behavior|Social behavior|Heart Rate|Electrodermal activity|Salivary cortisol|Quality of instruction: correct and timely feedback|Quality of instruction: adherence to the program script|Quality of instruction: attention to children","Texas Tech University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 17 Years   (Child)","Not Applicable","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Therapy Dogs Group Autism|R21HD095206","May 1, 2019","December 31, 2020","December 31, 2020","March 14, 2019","null","March 14, 2019","Texas Tech University, Lubbock, Texas, United States","","https://ClinicalTrials.gov/show/NCT03873831"
204,"NCT03850821","Social Mechanisms for Promoting Physical Activity in After School Programs for Underserved Middle School Youth",,"Completed","No Results Available","Physical Activity|Obesity Prevention","Behavioral: Connect Social Mechanisms Intervention","Greater increases (change) in MVPA (using 7-day omni-directional accelerometers) of youth receiving the Connect Social Mechanisms intervention compared to the typical ASP curriculum control.|Greater improvements (change) in the Social Mechanisms intervention ASPs compared to control ASPs in targeted social mechanisms within the ASP for promoting physical activity using a social climate observation tool.|Greater improvements (change) in targeted youth PA-based social motivational outcomes of youth receiving the Connect Social Mechanisms intervention compared to the Typical ASP control.|Greater improvements (change) in targeted youth PA-based cognitive motivational outcomes of youth receiving the Connect Staff-based PA intervention compared to the Typical ASP curriculum control.|Greater improvements (change) in targeted youth PA-based social motivational outcomes of youth receiving the Connect Social Mechanisms intervention compared to the Typical ASP curriculum control.|Greater improvements (change) in youth-staff PA-based social connections for promoting physical activity among youth receiving the Connect Social Mechanisms intervention compared to the Typical ASP curriculum control.|Greater improvements (change) in youth PA-based peer social support among youth receiving the Connect Social Mechanisms intervention compared to youth in the Typical ASP curriculum control.|Greater improvements (change) in youth PA-based positive peer connections among youth receiving the Connect Social Mechanisms intervention compared to youth in the Typical ASP curriculum control.|4. Document the feasibility of the Connect program through adequate dose and fidelity of program implementation as indicated by weekly process evaluation.","University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 16 Years   (Child)","Not Applicable","224","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Pro00037559|R21HD077357","September 18, 2014","March 3, 2017","March 3, 2017","February 22, 2019","null","February 22, 2019","","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT03850821/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03850821"
205,"NCT03849066","Parent-Reported Symptom Assessments in Children Taking Multiple Medications","PRSA","Recruiting","No Results Available","Neurologic Disorder|Chronic Disease|Pediatric Disorder","Other: Parent-Reported Symptom Assessment","Global Symptom Score (Part1: Cross-Sectional PRSA)|Specific Symptom Scores (Part 1: Cross-Sectional PRSA)|Change in Global Symptom Score (Part 2: Longitudinal PRSA)|Change in Specific Symptom Scores (Part 2: Longitudinal PRSA)","University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 17 Years   (Child)","","300","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","16-2538|5K23HD091295","April 1, 2019","July 31, 2021","July 31, 2022","February 21, 2019","null","April 8, 2019","Children's Hospital Colorado, Aurora, Colorado, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03849066/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03849066"
206,"NCT03800407","Contributing Factors for Poor HIV Treatment Response in Children With TB/HIV Coinfection",,"Recruiting","No Results Available","Tuberculosis|Human Immunodeficiency Virus|Coinfection","Other: Observational study","TB coinfection status and HIV RNA < 200 copies/mL on EFV-based ART in HIV-infected children.|Efavirenz plasma mid-dose concentration and HIV RNA suppression < 200 copies/mL.|Random efavirenz concentration below the limit of detection (poor ART adherence) and HIV RNA suppression rate.|CYP2B6 516G>T genotype status and random efavirenz concentration below the limit of detection (poor ART adherence).|CYP2B6 516G>T genotype status and HIV RNA suppression < 200 copies/mL.|TB coinfection status and risk of virological failure on EFV-based ART.","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 14 Years   (Child)","","236","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201801820 TB/HIV - N|2R01HD071779","January 28, 2019","January 31, 2023","August 31, 2023","January 11, 2019","null","January 30, 2019","Kwame Nkrumah University of Science and Technology, Kumasi, Ghana","","https://ClinicalTrials.gov/show/NCT03800407"
207,"NCT03800381","Adequacy of the New Pediatric Isoniazid/Rifampin/Pyrazinamide (HRZ) Tablet",,"Recruiting","No Results Available","Tuberculosis|Human Immunodeficiency Virus|Coinfection","Other: Observational PK study","Peak concentration (Cmax) of isoniazid, rifampin and pyrazinamide in the new pediatric HRZ FDC tablet.|Area under the time-concentration curve from 0-8 hours (AUC0-8h) of isoniazid, rifampin and pyrazinamide in the new pediatric HRZ FDC tablet.|Cmax of isoniazid, rifampin and pyrazinamide in children with TB with and without HIV coinfection|AUC0-8h of isoniazid, rifampin and pyrazinamide in children with TB with and without HIV coinfection.|AUC0-8h of isoniazid, rifampin and pyrazinamide in the new versus old pediatric HRZ FDC tablet.|Cmax of isoniazid, rifampin and pyrazinamide in the new versus old pediatric HRZ FDC tablet.|Proportion of children treated with new pediatric HRZ FDC tablet who develop with liver enzymes elevations.|Identify optimal weight-band dosages of the new HRZ FDC tablet","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 14 Years   (Child)","","92","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201801820 - HRZ PK -N|2R01HD071779","January 28, 2019","August 30, 2022","August 31, 2023","January 11, 2019","null","January 30, 2019","Kwame Nkrumah University of Science and Technology, Kumasi, Ghana","","https://ClinicalTrials.gov/show/NCT03800381"
208,"NCT03713125","Executive Function in Early Childhood",,"Recruiting","No Results Available","Reading Disability","Behavioral: Reading Tutoring","Woodcock Johnson Tests of Achievement, Fourth Edition (WJ-IV)|Change in Woodcock Johnson Tests of Achievement, Fourth Edition (WJ-IV)","Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 9 Years   (Child)","Not Applicable","260","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","181739|1R37HD095519-01A1","August 1, 2019","August 31, 2028","August 31, 2028","October 19, 2018","null","February 25, 2019","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03713125"
209,"NCT03693144","Improving Nutritional Choices in Adolescents","LIITA3H","Not yet recruiting","No Results Available","Overweight and Obesity","Other: Full LIITA3H App|Other: Partial LIITA3H App|Other: LIITA3H Location only","Visits to fast food restaurants|Calories purchased from fast food restaurants|Percentage of times app identifies presence in fast food restaurant|Percentage of times app delivers appropriate tailored message|Participants' perception of the experience of using the app","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","HUM00083980|1R21HD093835-01","April 2019","November 30, 2019","November 30, 2019","October 2, 2018","null","April 1, 2019","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03693144"
210,"NCT03688919","Adolescent Interventions to Manage Self-regulation of T1D (AIMS T1D)",,"Not yet recruiting","No Results Available","Self-regulation|Medication Adherence","Behavioral: Self-Regulation Intervention","Change from baseline in Backwards Digit Span at 8 weeks|Change from baseline in Forward Digit Span at 8 weeks|Change from baseline in Go No Go score at 8 weeks|Change from baseline in Behavior Rating Inventory of Executive Functioning, 2nd Edition (BRIEF-2)-Parent Report at 8 weeks|Change from baseline in Behavior Rating Inventory of Executive Functioning, 2nd Edition (BRIEF-2)-Self Report at 8 weeks|Change from baseline in NIH Toolbox Perceived Stress Scale-Parent Report score at 8 weeks|Change from baseline in NIH Toolbox Perceived Stress Scale-Self Report score at 8 weeks|Change from baseline in Affect Dysregulation Scale score at 8 weeks|Change from baseline in Patient Health Questionnaire-9 (PHQ-9) score at 8 weeks|Change from baseline in Generalized Anxiety Disorder 7-item (GAD-7) score at 8 weeks|Change from baseline in NIH Perceived Self-Efficacy-Parent Report score at 8 weeks|Change from baseline in NIH Perceived Self-Efficacy Self Report score at 8 weeks|Change from baseline in Consideration of Future Consequences Scale score at 8 weeks|Change from baseline in 5-trial Delay Discounting Task score at 8 weeks|Change from baseline in blood glucose monitoring at 8 weeks|Change from baseline in insulin administration adherence at 8 weeks|Change from baseline in Self-Care Inventory Revised at 8 weeks|Change from baseline in HbA1c at 8 weeks|Change from baseline in Pediatric Quality of Life Inventory (PedsQL) at 8 weeks|Change from baseline in Pediatric Quality of Life Inventory (PedsQL) Diabetes Module at 8 weeks|Change from baseline in number of clinic visits for T1D-related health events at 8 weeks","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","94","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","UH3HD087979","April 1, 2019","October 31, 2020","October 31, 2020","September 28, 2018","null","March 20, 2019","","","https://ClinicalTrials.gov/show/NCT03688919"
211,"NCT03626103","Intervention to Prevent Peer Violence & Depressive Symptoms Among At-Risk Adolescents","iDOVE2","Recruiting","No Results Available","Depressive Disorder|Violence","Behavioral: + Brief ED Intervention (BI)|Behavioral: + Text","Conflict Tactics Scale-2, physical subset (CTS-2)|Center for Epidemiologic Studies Depression Scale Revised (CESD-R)|Change in ED Visits for Assault-Related Injury|Conflict in Adolescent Dating Relationships Inventory, physical subset (CADRI)|Illinois Bully Scale (IBS)|Student School Survey","Rhode Island Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R01HD093655","August 1, 2018","August 2022","February 2023","August 10, 2018","null","March 29, 2019","Rhode Island Hospital/Hasbro Children's Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03626103"
212,"NCT03611062","VR-based EF Rehabilitation for Pediatric TBI",,"Recruiting","No Results Available","Traumatic Brain Injury","Behavioral: VR Executive Functions Training|Behavioral: VR Placebo Game","Incidence of Simulator Sickness [Feasibility and Safety]|Incidence of Physical Fatigability [Feasibility and Safety]|Incidence of Perceived Virtual Reality Experience [Feasibility]|Incidence of Treatment-Emergent Adverse or Serious Adverse Events [Safety and Tolerability]|Performance-based Executive Function Skills in Virtual Reality|Real-life Executive Function Skills|Performance-based Attention Problems|Physical, Emotional, and Social Health and School Functioning [Quality of Life]|Parent Report-based Attention and Behavior Problems|Performance-based Executive Function Skills-Inhibitory Control and Attention|Performance-based Executive Function Skills-Working Memory|Performance-based Executive Function Skills-Cognitive Flexibility and Attention","Nationwide Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 17 Years   (Child)","Not Applicable","30","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","IRB18-00472|1K99HD093814-01A1","August 15, 2018","June 30, 2020","June 30, 2020","August 2, 2018","null","November 21, 2018","Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03611062"
213,"NCT03606343","Teaching Academic Success Skills to Students With Autism Spectrum Disorders in Clinical Setting","TASK-R21","Recruiting","No Results Available","Autism Spectrum Disorder","Behavioral: Teaching Academic Skills to Kids","change in scores on Children's Organizational Skills Scale|change in scores on Behavior Rating Inventory of Executive Function - Second Edition|change in scores on Homework Problem Checklist|change in scores on Woodcock Johnson Tests of Achievement - Third Edition|change in ratings on Classroom Performance Survey|change in ratings on Academic Performance Rating System|change in scores on Parenting Relationship Questionnaire","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 14 Years   (Child)","Phase 1","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R21HD090334-01A1","September 1, 2017","August 31, 2019","August 31, 2019","July 30, 2018","null","July 30, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03606343"
214,"NCT03467009","Bullying Prevention Intervention for Adolescent Primary Care Patients","iPACT","Recruiting","No Results Available","Cyberbullying","Behavioral: iPACT Intervention|Other: Control: Enhanced Usual Care (EUC)|Behavioral: iPACT Intervention- app","Intervention Acceptability: Enrollment Rate|Intervention Acceptability: Change in Follow Up Rate from 8 weeks post-enrollment to 16 weeks post-enrollment|Intervention Acceptability: Participant Satisfaction|Intervention Feasibility: Participant Engagement|Change in cyber-victimization between enrollment, 8 weeks post-enrollment, and 16 weeks post-enrollment|Change in cyber-victimization emotional impact between enrollment, 8 weeks post-enrollment, and 16 weeks post-enrollment|Change in cyber-victimization related behaviors between enrollment, 8 weeks post-enrollment, and 16 weeks post-enrollment","Rhode Island Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","R21HD088739","March 6, 2018","July 31, 2019","July 31, 2019","March 15, 2018","null","March 29, 2019","Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03467009"
215,"NCT03462407","Imitation-based Dog Assisted Intervention, for Children With Developmental Disabilities.",,"Recruiting","No Results Available","Physical Activity|Social Responsibility","Behavioral: DAID|Behavioral: Dog walking","Physical activity Change","Oregon State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 17 Years   (Child)","Not Applicable","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","7848|1R21HD091895-01","May 1, 2017","April 30, 2019","April 30, 2019","March 12, 2018","null","March 20, 2019","Oregon State University, Corvallis, Oregon, United States","","https://ClinicalTrials.gov/show/NCT03462407"
216,"NCT03457402","Shaping Tolerance for Delayed Rewards","DelTA","Recruiting","No Results Available","Impulsivity","Behavioral: Shaping Delay Tolerance","Indifference point|Percent change in preference for longer, larger (LL) rewards|ADHD-RS-IV Preschool Version and Attention and Behavior Rating Form|The Preschool Life Skills Questionnaire|The Children's Behavior Questionnaire (CBQ)|Snack Delay Task|Dinky Toy Task|Gift Wrap and Gift Delay Task","University of California, Davis|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 6 Years   (Child)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Basic Science","921404|R03HD087091-01A1","September 12, 2017","May 2020","May 2021","March 7, 2018","null","October 12, 2018","UC Davis MIND Institute, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT03457402"
217,"NCT03430570","An Emotion Regulation Intervention for Early Adolescent Risk Prevention",,"Recruiting","No Results Available","Risk Behavior|Risk Reduction|Emotion Regulation","Behavioral: Tablet TRAC Emotion Regulation Intervention","Emotion Regulation/Difficulties in Emotion Regulation Scale|Emotion Recognition/DANVA|Emotion Regulation/Emotion Regulation Checklist|Emotion Regulation/ The Regulation of Emotions Questionnaire|Emotion Regulation/Self Efficacy Questionnaire for Children|Emotion Regulation/Emotion Regulation Behavior Scale|Emotion Regulation/Affect Dysregulation Scale|Assessment Risk Behavior/Youth Risk Behavior Surveillance System|Distress Tolerance","Rhode Island Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 14 Years   (Child)","Not Applicable","125","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R21HD089979","February 19, 2019","July 2019","September 2019","February 13, 2018","null","February 21, 2019","Rhode Island Hospital- Bradley Hasbro Children's Research Center, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03430570"
218,"NCT03419611","Word Learning in Children With Autism",,"Recruiting","No Results Available","Autistic Disorders Spectrum","Behavioral: Multi-Modal|Other: Treatment as Usual|Behavioral: High Intensity Multi-Modal","Expressive Word Acquisition|Change in Expressive Word Acquisition|Receptive Word Acquisition|Change in Receptive Word Acquisition|Communication Complexity Scale|Change in Communication Complexity Scale","University of Kansas|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 10 Years   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00140285|U54HD090216","November 1, 2016","May 31, 2021","May 31, 2021","February 2, 2018","null","June 28, 2018","University of Kansas, Lawrence, Kansas, United States","","https://ClinicalTrials.gov/show/NCT03419611"
219,"NCT03329066","Sleep Quality in High School Students With Asthma - II",,"Enrolling by invitation","No Results Available","Asthma|Sleep|Asthma in Children","Behavioral: MAST - Managing Asthma & Sleep in Teens|Behavioral: ASMA - Asthma Self-Management for Adol|Behavioral: Information & Referral Control Group","Change in Sleep Quality score|Change in Asthma Control score|Change in Asthma Management Skill - Symptom Prevention Total Score|Change in Asthma Management Skill - Symptom Prevention Steps|Change in Asthma Management Skill - Attack Management score|Change in Asthma Management Skill - Self-efficacy Score","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","84","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","AAAQ9707 - II|1R21HD086448-01A1","April 9, 2018","March 2019","July 2019","November 1, 2017","null","May 14, 2018","Columbia University, New York, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03329066"
220,"NCT03325647","TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY","TESTO","Recruiting","No Results Available","Klinefelter Syndrome","Drug: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Drug: Placebo injectable saline","Change in Body Fat Percentage|Change in Composite Motor Score on Alberta Infant Motor Scale|Change in C14:1 Long Chain Acylcarnitines (LCAC) through targeted metabolomics|Change in height|Change in weight|Change in weight-for-length|Change in waist circumference|Change in serum leptin|Change in lipids|Change in insulin|Change in serum Luteinizing Hormone (LH)|Change in serum Follicle Stimulating Hormone (FSH)|Change in Inhibin B (INHB)|Change in Anti-Mullerian Hormone (AMH)|Change in Total Testosterone (Total T)|Change in Gross Motor Scores on the Peabody Developmental Motor Scales 2|Change in Gross Motor Scores on the Alberta Infant Motor Scales|Change in Fine Motor Scores|Change in Cognitive and Language Composite Scores on the Bayley III|Change in Adaptive Functioning|Change in Number and Type of Adverse Events|Change in Serum BCAA, other LCAC|Change in Pathway analysis","University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","31 Days to 90 Days   (Child)","Phase 4","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Treatment","17-1317|5K23HD092588-02","November 6, 2017","April 2022","October 2022","October 30, 2017","null","January 31, 2019","Children's Hospital Colorado, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03325647"
221,"NCT03291496","Microfluidic Assessment of Clinical Outcomes in Preterm Newborns",,"Recruiting","No Results Available","Neonatal SEPSIS","Other: Blood Collection Preterm|Other: Blood Collection Term","Prediction of Sepsis in Premature Neonates|Neutrophil Function of Premature Neonate during Development","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","23 Weeks to 42 Weeks   (Child)","","800","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201701566 N|R01HD089939","November 14, 2017","September 2022","September 2022","September 25, 2017","null","May 21, 2018","UF Health, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT03291496"
222,"NCT03242772","Impact of Combined Medication and Behavioral Treatment for ASD & ADHD",,"Recruiting","No Results Available","Autism Spectrum Disorder|Attention Deficit Hyperactivity Disorder","Drug: Amphetamine|Behavioral: P-ESDM|Drug: Placebo Oral Tablet","Change in Adaptive Behavior|Change in Sustained Attention|Change in ADHD symptoms","Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","36 Months to 84 Months   (Child)","Phase 2","78","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00085179|1P50HD093074-01","May 30, 2018","July 2021","July 2021","August 8, 2017","null","December 18, 2018","Duke Center for Autism and Brain Development, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03242772"
223,"NCT03204786","Intranasal Vasopressin Treatment in Children With Autism",,"Recruiting","No Results Available","Autism|Autism Spectrum Disorder|ASD","Drug: Vasopressin (USP) Injectable Solution [Vasostrict]|Drug: Placebo","Change from baseline in parent rated Social Responsiveness Scale, Second Edition (SRS-2) total scores during treatment.|Change from baseline in Clinical Global Impression (CGI) scores during treatment.|Change from baseline in Vineland Adaptive Behavior Scales, Third Edition (VABS-3) - Social Skills and Relationships Domain during treatment.|Change from baseline in parent rated Repetitive Behavior Scale Revised (RBS-R) scores during treatment.|Change from baseline in parent rated Spence Children's Anxiety Scale (SCAS) during treatment.|Change from baseline in parent rated Pediatric Quality of Life (PedsQL) inventory scores during treatment.|Change from baseline in Overt Aggression Scale (OAS) during treatment.|Change from baseline on Eye Gaze Assessment (eye tracking) during treatment.|Change from baseline on Reading the Mind in the Eyes Test (RMET) during treatment.|Change from baseline on the Developmental Neuropsychological Assessment, Second Edition (NEPSY-II) Theory of Mind Test during treatment.|Change from baseline the Diagnostic Analysis of Nonverbal Accuracy, Second Edition (DANVA-2) Child Voices Prosody Test during treatment.|Change from baseline on the Facial Emotion Recognition Test during treatment.|Change from baseline on electrocardiogram (EKG) during treatment.|Change from baseline on blood biomarkers vasopressin levels during treatment.|Change from baseline on clinical labs during treatment.|Change from baseline on blood pressure during treatment.|Change from baseline on the Dosage Record Treatment Emergent Symptom Scale (DOTES) during treatment.|Change from baseline in parent rated Stanford Social Motivation Scale (SSMS) total scores during treatment.","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 17 Years   (Child)","Phase 2","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB-39972|1R01HD091972","February 20, 2018","December 2022","February 2023","July 2, 2017","null","May 21, 2018","Stanford University, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT03204786"
224,"NCT03152006","Adolescent Coordinated Transition Nigerian HIV+ Youth","ACT","Recruiting","No Results Available","HIV/AIDS","Other: ACT","Retention in care in care 6 months post-transfer|Retention in care 12 months post-transfer|Retention in care 24 months post-transfer|Viral Suppression|Mental Health and Wellbeing|Health Locus of Control|Social Support|Sexual Risk Behavior|Transition Readiness","University of Nevada, Las Vegas|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","216","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","990070-4|R01HD089871","June 28, 2017","May 30, 2020","June 30, 2021","May 12, 2017","null","October 17, 2017","Institute of Human Virology, Abuja, FCT, Nigeria|Center for Integrated Health Program, Abuja, Nigeria|Centre for Clinical Care and Research, Abuja, Nigeria|Family Health International, Abuja, Nigeria|AIDS Prevention Initiative Nigeria, Lagos, Nigeria","","https://ClinicalTrials.gov/show/NCT03152006"
225,"NCT03135119","Integrating Animal-Assisted Therapy Into Trauma-Focused Cognitive-Behavioral Therapy for Maltreated Youth","TF-CBT+AAT","Recruiting","No Results Available","Child Abuse|Posttraumatic Stress","Behavioral: TF-CBT|Behavioral: TF-CBT+AAT","Change in scores on the UCLA PTSD Reaction Index for DSM-5|Change in scores on the Strengths and Difficulties Questionnaire|Change in scores on the Screen for Child Anxiety Related Disorders|Change in scores on the Moods and Feelings Questionnaire|Change in scores on the Emotion Regulation Checklist|Change in scores on the Emotion Regulation Index for Children and Adolescents","Milton S. Hershey Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 17 Years   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STUDY00006612","November 15, 2017","April 30, 2020","April 30, 2020","May 1, 2017","null","February 28, 2019","Penn State Hershey Medical Center-TLC Research and Treatment Center, Harrisburg, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03135119"
226,"NCT03126292","Child Development and Primary Care",,"Recruiting","No Results Available","Parenting|Development, Child","Behavioral: Sit Down and Play|Other: Child Safety Handout","Change in parental knowledge regarding importance of verbal interactions|Participation in cognitively stimulating activities|Parent-child interactions","University of Illinois at Chicago|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Months to 3 Months   (Child)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","K23HD086295","October 20, 2017","July 2019","July 2019","April 24, 2017","null","May 1, 2018","University of Illinois at Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03126292"
227,"NCT03068910","Hyperandrogenemia and Altered Day-night LH Pulse Patterns","CRM008","Recruiting","No Results Available","Hyperandrogenism|Polycystic Ovary Syndrome|Puberty","Drug: Micronized progesterone|Drug: Spironolactone|Drug: Placebo","Luteinizing hormone (LH) pulse frequency","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","10 Years to 17 Years   (Child)","Early Phase 1","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","18489|P50HD028934","July 2016","April 2025","December 2025","March 3, 2017","null","July 2, 2018","University of Virginia Clinical Research Unit, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03068910"
228,"NCT02998684","Learning Enhancement Through Neurostimulation in Autism","LENS","Completed","Has Results","Autism","Device: Active Transcranial Direct Current Stimulation|Device: Sham Transcranial Direct Current Stimulation|Behavioral: PEERS Social Skills Training","Test of Adolescent Social Skills Knowledge (TASSK)|Social Responsiveness Scale (SRS)","Medical University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 17 Years   (Child)","Not Applicable","25","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pro00056912","July 2016","July 2017","July 2017","December 20, 2016","September 3, 2018","September 3, 2018","Medical Univeristy of South Carolina, Charleston, South Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/84/NCT02998684/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02998684"
229,"NCT02916862","Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents",,"Withdrawn","No Results Available","Osteoporosis","Dietary Supplement: Soluble Corn Fiber (SCF) without Calcium|Dietary Supplement: Soluble Corn Fiber (SCF) + Calcium|Dietary Supplement: Placebo","Change in bone mineral content (BMC)|Change in vitamin D status|Change in serum calcium|Change in serum phosphate|Change in bone alkaline phosphatase|Change in parathyroid hormone (PTH)|Change in osteocalcin|Change in bone specific alkaline phosphatase","University of Puerto Rico|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 14 Years   (Child)","Phase 2|Phase 3","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","A4540116|1SC1HD089556-01","December 2017","May 2019","June 2020","September 28, 2016","null","May 28, 2018","","","https://ClinicalTrials.gov/show/NCT02916862"
230,"NCT02847689","Listening to Mom in the NICU: Neural, Clinical and Language Outcomes",,"Recruiting","No Results Available","Premature Birth","Behavioral: Language Treatment|Behavioral: Control Treatment","White matter mean diffusivity|Length of hospital stay|Average daily weight gain|Time (days) to full oral feed|Number of significant apnea and bradycardia events requiring stimulation","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","24 Weeks to 31 Weeks   (Child)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","32638|1K99HD084749-01A1","July 2016","August 1, 2019","December 31, 2019","July 28, 2016","null","April 4, 2019","Stanford University - Lucile Packard Children's Hospital, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT02847689"
231,"NCT02813889","SmarToyGym: Smart Detection of Atypical Toy-oriented Actions in At-risk Infants",,"Recruiting","No Results Available","Cerebral Palsy|Developmental Delay|Stroke|Fine Motor Delay|Infant Development|Other Development Delays","Device: SmarToyGym","Toy contact|Grasp|Hand Kinematics|Center of Pressure|Leg kinematics","University of Pennsylvania|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 11 Months   (Child)","Not Applicable","30","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","822487|1R21HD084327-01","May 2015","May 2019","September 2019","June 27, 2016","null","January 11, 2019","Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Kristine Lima, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02813889"
232,"NCT02787174","A Computer-Based ED Intervention to Improve Pediatric Asthma Medicine Adherence","ED-AMAP","Active, not recruiting","No Results Available","Asthma","Other: Asthma Medication Adherence Education","Asthma controller medication adherence|Unscheduled healthcare use (self-report survey and chart review)|Quality-of-Life (QOL)|Sustained Asthma controller medication adherence","Rhode Island Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 12 Years   (Child)","Not Applicable","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","629210|R21HD082621","February 2016","January 2018","May 2018","June 1, 2016","null","April 10, 2018","Hasbro Children's Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT02787174"
233,"NCT02599545","Testosterone and Cortisol Levels in Infants",,"Terminated","No Results Available","Infant, Premature|Infant, Very Low Birth Weight","","measurements of maternal and neonate/infant testosterone and cortisol (T&C) levels from admission through 24-months of life to determine associations of T&C with health outcomes of neonates and infants between genders|video recorded interactions at 12- and 24-months to determine associations of testosterone and cortisol levels with quality of mother-infant interactions between genders during infancy|standard infant testing at 12- and 24-months of age to determine associations of testosterone and cortisol levels with infant cognitive/motor/language development between genders during infancy","Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","","300","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Pro00065480","October 2015","February 2, 2017","February 2, 2017","November 6, 2015","null","July 24, 2017","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02599545"
234,"NCT02588391","Brain Training in Preterm Children at Risk for Inattention, Hyperactivity, and Executive Function Impairment",,"Recruiting","No Results Available","Premature Birth","Behavioral: Brain Training (Active)|Behavioral: Brain Training (Passive)|Behavioral: Brain Training (Active or Passive)","Change from baseline on Executive Function Composite Measure at 2 months|Change from baseline on Executive Function Composite Measure at 5 months|Change from baseline on Executive Function Composite Measure at 8 months|Change from baseline on Early Academic Skills Measures at 8 months|Change from 8-month Executive Function Composite Measure at 10 months (cross over groups)","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 5 Years   (Child)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","30874|K23HD071971","October 2015","December 2018","December 2019","October 27, 2015","null","August 21, 2018","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02588391"
235,"NCT02567630","Early Childhood Constraint Therapy in Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy","Behavioral: Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy","Kinematics of reach|Somatosensory processing measurement by ERP|Bayley Scales of Infant and Toddler Development (Bayley III) — 3rd Edition","Nathalie Maitre|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Nationwide Children's Hospital","All","10 Months to 24 Months   (Child)","Not Applicable","216","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","IRB15-00547|R01HD081120-02","October 1, 2015","August 31, 2019","August 2020","October 5, 2015","null","February 23, 2018","Nationwide Children's Hospital, Columbus, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02567630"
236,"NCT02475876","PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children","PBPK","Active, not recruiting","No Results Available","Bacterial Infections","Drug: Clindamycin|Drug: trimethoprim-sulfamethoxazole","Maximum observed plasma concentration at steady state (Cmaxss) - clindamycin|Area under the plasma concentration versus time curve from the start to the end of one dosing interval at steady state (AUCss) - clindamycin|Maximum observed plasma concentration at steady state (Cmaxss) - Trimethoprim-Sulfamethoxazole|Area under the plasma concentration versus time curve from the start to the end of one dosing interval at steady state (AUCss) - Trimethoprim-Sulfamethoxazole|Number of reported AEs and SAEs|Number of Subjects Heterozygous for any CYP3A Family Genotype|Number of Subjects Heterozygous for any CYP2C9 Genotype|Number of Subjects Homozygous for any CYP3A Family Genotype|Number of Subjects Homozygous for any CYP2C9 Genotype","Michael Cohen-Wolkowiez|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","1 Month to 16 Years   (Child)","Phase 1","51","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","PRO00057185|1R01HD076676-01A1","November 2015","August 31, 2018","May 30, 2019","June 19, 2015","null","November 7, 2018","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT02475876"
237,"NCT02361762","Gaming for Autism to Mold Executive Skills Project","GAMES","Completed","Has Results","Autism Spectrum Disorders","Behavioral: Computerized executive control training","Change Task - Inhibition Function|Stroop Task (Difference in Percentage of Correct Responses for Congruent Minus Incongruent Trials)|Event-related Potentials Assessed During Child Attention Network Flanker Task|BRIEF Parent Survey (Global Executive Composite)|Backward Digit Span (Scaled Score)|Social Attribution Task (SAT)|Theory of Mind Composite: Perception Knowledge, Location Change False Belief, Unexpected-contents False Belief|TOM Test (Theory of Mind Test)|Social Skills Improvement System-Parent (SSIS) - Social Standard Score|Narrative Language Task|Performance on Hungry Donkey Task Assessed as Ratio of Safe to Risky Selections|Event-related Potentials Assessed During Cued Go/Nogo Task","Boston Children’s Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 11 Years   (Child)","Not Applicable","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P00014188|R00HD071966","February 2015","November 2017","November 2017","February 12, 2015","February 20, 2019","February 20, 2019","Boston Children's Hospital: Labs of Cognitive Neuroscience- Faja Lab, Boston, Massachusetts, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT02361762/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02361762"
238,"NCT02359422","Evaluation of a Middle School Comprehensive Sexual Health Media Literacy Education Program","MASH","Completed","No Results Available","Safe Sex","Behavioral: Media Aware-Sexual Health","Change in self-reported sexual activity assessed via questionnaire.|Change in self-reported intentions to engage in sexual activity assessed via questionnaire.|Change in self-reported attitude toward sexual activity assessed via questionnaire.|Change in self-reported attitudes toward contraception assessed via questionnaire.|Change in self-reported attitude toward sexual communication assessed via questionnaire.|Change in self-reported perceived norms regarding sexual activity assessed via questionnaire.|Change in self-reported perceived norms regarding contraception assessed via questionnaire.|Change in self-reported perceived norms regarding sexual communication assessed via questionnaire.|Change in self-reported self-efficacy to refusal sexual activity assessed via questionnaire.|Change in self-reported self-efficacy to use contraception assessed via questionnaire.|Change in self-reported self-efficacy for sexual communication assessed via questionnaire.|Change in self-reported intentions for condom/contraception use assessed via questionnaire.|Change in self-reported intentions for sexual communication assessed via questionnaire.","Innovation Research & Training|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 15 Years   (Child)","Not Applicable","1017","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","iRT-2R44HD061193-02-RCT|2R44HD061193-02","April 2014","August 2015","August 2015","February 10, 2015","null","November 20, 2015","innovation Research & Training, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02359422"
239,"NCT02276170","Pharmacology of Aminophylline for Acute Kidney Injury in Neonates","PAANS","Enrolling by invitation","No Results Available","Acute Kidney Injury","","Drug concentrations of theophylline|Change in renal Near-infrared spectroscopy (NIRS)|Change in urine output|Number of participants with adverse events|Change in urine biomarker levels|Change in serum creatinine level","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 3 Months   (Child)","","20","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","29957","October 2014","May 2018","May 2018","October 28, 2014","null","February 7, 2018","Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States","","https://ClinicalTrials.gov/show/NCT02276170"
240,"NCT02255721","Sleep Health in Preschoolers: a Randomized Controlled Trial","SHIP","Active, not recruiting","No Results Available","Sleep Initiation and Maintenance Disorders","Behavioral: SHIP (Sleep Health in Preschoolers)|Behavioral: SHIP Control Arm","Change in actigraphic and diary measured sleep quantity and quality measures|Change in actigraphic and parent report measures of sleep onset difficulties|Change in child anthropometric measures|Trajectory in child anthropometric measures|Change in parent-reported child behavioral and emotional symptoms and executive function|Change in parent & teacher-reported child behavioral and emotional symptoms (CBCL subscores for anxious/depressed, attention, somatic complaints, and aggressive behavior) and executive function (BRIEF subscores for inhibit, shift, and emotional control)|Change in parent & teacher-reported child behavioral and emotional symptoms and executive function|Change in directly assessed performance on WJIII NU achievement battery and executive function|Trajectory in actigraphic and diary measured sleep quantity and quality measures|Trajectory in actigraphic and parent report measures of sleep onset difficulties","Seattle Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","30 Months to 71 Months   (Child)","Not Applicable","500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","416530030101|R01HD071937","November 2013","November 2019","November 2019","October 2, 2014","null","October 6, 2017","Seattle Children's Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02255721"
241,"NCT02231411","Neonatal Resuscitation With Intact Cord","NRIC","Completed","No Results Available","Intraventricular Hemorrhage","Procedure: V-DCC|Procedure: Delayed cord clamping|Procedure: Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels","Peak Hematocrit|Maximum inspired oxygen (FiO2) (percentage)|Positive Pressure Ventilation given|DR interventions after delayed cord clamping complete|Maximum Peak Inspiratory Pressure (cm H2O)|Time to reach heart rate >100 beats per minute (seconds)|Time oxygen saturation within and outside of target range (seconds)|Time of the resuscitation (minutes)|Time to demonstrate cycling of end tidal CO2 (seconds)|Maximum End Tidal CO2 (mm Hg)|Intubation (yes/no) in DR/NICU and age (hours)|Surfactant (yes/no) in DR/NICU and age (hours)|SVC Flow (ml/kg/min)|Right ventricular output (ml/kg/min)|Cardiac Output by Electrical Cardiometry (ml/kg/min)|Cerebral StO2 by Near-Infrared Spectroscopy|Fractional Oxygen Extraction by Near-Infrared Spectroscopy|Color Doppler diameter of ductus arteriosus shunt (mm)|Pulsed or continuous wave Doppler assessment of ductus arteriosus shunt direction (%time right to left) and velocity (m/s)|Color Doppler diameter of inter-atrial shunt (mm)|Pulsed and continuous wave Doppler assessment of inter-atrial shunt direction (% time right to left) and velocity (m/s)|Peak velocity of the tricuspid regurgitation jet (m/sec) (to calculate arterial pressure)|Record Blood pressure (SBP/DBP, MAP) and whether hypotensive (defined as < GA on DOL 1) yes/no|Arterial and venous cord pH|Peak total serum bilirubin (mg/dL)|Duration of phototherapy days|Serum hematocrit|Admission temperatures (degree Centigrade)|Urine output (ml/kg/day)|Mean Arterial Blood pressure (mm Hg)|Use of cardiac inotropes (dopamine, dobutamine, epinephrine) (yes/no) hypotension|Use of postnatal steroids (yes/no)|Presence of intraventricular hemorrhage (yes/no)|Presence of severe intraventricular hemorrhage (Grade 3 or 4) (yes/no)|Presence of PVL (yes/no)|Mortality (yes/no)|Placental Weight|Maternal Hemoglobin|Mean Airway Pressure (MAP)|Duration of CPAP or PPV|Length of umbilical cord allows use of LifeStart bed","Sharp HealthCare|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","23 Weeks to 31 Weeks   (Child)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","NRIC|5R21HD080594","August 2014","August 2016","August 2016","September 4, 2014","null","May 30, 2017","Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT02231411"
242,"NCT02218138","Learning to BREATHE: A Randomized Controlled Trial to Lower Diabetes Risk in Adolescent Girls",,"Completed","No Results Available","Type 2 Diabetes|Depression|Obesity","Behavioral: Learning 2 BREATHE|Behavioral: Colorado Blues","Whole Body Insulin Sensitivity Index|Center for Epidemiological Studies-Depression Scale","Colorado State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","12 Years to 17 Years   (Child)","Not Applicable","35","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","13-4265H|R00HD069516","January 2013","August 2016","August 2016","August 15, 2014","null","February 13, 2017","Colorado State University, Fort Collins, Colorado, United States","","https://ClinicalTrials.gov/show/NCT02218138"
243,"NCT02216968","Increasing Vegetable Intake in Children",,"Completed","No Results Available","Obesity|Behavior|Food Habits","Behavioral: Increase vegetable intake in pre-school children","Vegetable Intake in Preschool Children","Baylor College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 5 Years   (Child)","Not Applicable","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Other","H-30554|1R21HD073608-01A1","July 2012","December 2016","December 2016","August 15, 2014","null","July 12, 2017","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02216968"
244,"NCT02155933","Assessment of Day-night Secretion of Progesterone and LH Across Puberty","LH","Recruiting","No Results Available","Puberty|Hyperandrogenism","Other: Blood sampling","Difference in mean LH frequency when awake (19:00-23:00 and 07:00-11:00) and when asleep (23:00-07:00) in girls with and without hyperandrogenemia|Daytime (awake) and nighttime (sleep) differences in hormones (LH, FSH, T, E2, P, and cortisol) in girls with and without hyperandrogenemia","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","7 Years to 17 Years   (Child)","","75","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","13502|P50HD028934","February 2008","February 2019","February 2019","June 4, 2014","null","April 12, 2018","Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02155933"
245,"NCT02140255","Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission",,"Recruiting","No Results Available","HIV Infection","Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Drug: Nevirapine (NVP)|Drug: Lopinavir/Ritonavir (LPV/r)|Drug: Raltegravir (RAL)|Drug: VRC01","Number of participants who achieve HIV remission|Frequency of Grade 3 or higher adverse events possibly, probably or definitely related to any component of the study regimen|Number of participants with viral suppression to consistent HIV-1 RNA less than LOD|Number of participants meeting all eligibility criteria for ART cessation|Number of infants meeting the selected eligibility criteria for ART cessation among infants who also met the viral suppression criteria for ART cessation .|Number of participants who experience HIV persistence|Changes in immune activation markers (%CD8+/DR+ T cells) and HIV-specific immune responses|Change in RAL and VRC01 concentrations among treated neonates and young infants","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 10 Days   (Child)","Phase 1|Phase 2","905","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT P1115|UM1AI068632|UM1AI068616|UM1AI106716|11954","January 2015","April 1, 2022","April 1, 2022","May 16, 2014","null","April 1, 2019","University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Univ. of Washington NICHD CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Buenos Aires, Argentina|Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre, Rio Greande Do Sul, Brazil|SOM Federal University Minas Gerais Brazil NICHD CRS, Minas Gerais, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio De Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio De Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio De Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, São Paulo, Brazil|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Kenya Medical Research Institute / Walter Reed Project Clinical Research Center, Kericho CRS, Kericho, Kenya|Malawi CRS, Lilongwe, Central, Malawi|Blantyre CRS, Blantyre, Malawi|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Umlazi CRS, Durban, Kwa Zulu Natal, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bankok, Bangkoknoi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Baylor-Uganda CRS, Kampala, Uganda|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda|George CRS, Lusaka, Zambia|Seke North CRS, Chitungwiza, Zimbabwe|St Mary's CRS, Chitungwiza, Zimbabwe|Harare Family Care CRS, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT02140255"
246,"NCT02139800","Sustained Aeration of Infant Lungs Trial","SAIL","Active, not recruiting","No Results Available","Preterm Birth|Extreme Prematurity","Procedure: Sustained Inflation|Procedure: Standard of Care","Combined outcome of death or bronchopulmonary dysplasia|Oxygen profile over first 24 hours|Oxygen profile with highest FiO2 level up to 48 hours|Heart rate in the Delivery Room (DR)|Detailed status on departure from the Delivery room (DR)|Use of inotropes on arrival in NICU|Need for intubation in delivery room|Pressure-volume characteristics in the Delivery room (DR)|Pneumothorax or new chest drains in the first 48 hours of life|Duration of any chest drain in-situ post-DR|Intraventricular hemorrhage by all grades|Chest x-ray between days 7-10|Death or need for positive pressure ventilation|Highest FiO2 and Area under the FiO2 curve for the first week of life|Pneumothorax and pulmonary interstitial emphysema (PIE)|Survival to discharge home without BPD, retinopathy of prematurity (grades 3 & 4), or significant brain abnormalities on head ultrasound|Duration of respiratory support (ventilation, CPAP, supplemental oxygen)|Death in hospital|Retinopathy of prematurity (ROP) stage 3 or greater requiring treatment|Use of postnatal steroids for treatment of BPD|Length of hospital stay|Neurodevelopmental and respiratory outcome at 22-26 months corrected gestational age","University of Pennsylvania|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","23 Weeks to 26 Weeks   (Child)","Not Applicable","460","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","819208|1U01HD072906-01A1","August 27, 2014","March 23, 2020","March 23, 2020","May 15, 2014","null","September 17, 2018","Loma Linda University, Loma Linda, California, United States|University of California, Davis Children's Hospital, Sacramento, California, United States|Sharp Mary Birch Hospital for Women & Newborns, San Diego, California, United States|Christiana Care, Newark, Delaware, United States|University of Michigan, Ann Arbor, Michigan, United States|Wake Med Health, Raleigh, North Carolina, United States|Hospital of the Univerity of Pennsylvania, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|Mater Mother's Hospital, Brisbane, Queensland, Australia|Royal Women's Hospital, Melbourne, Australia|Academic Teaching Hospital, Landeskrankenhaus Feldkirch, Feldkirch, Austria|Royal Alexandra Hospital,, Edmonton, Canada|University of Freiburg, Freiburg, Germany|Children's Hospital, University of Ulm, Ulm, Germany|Ospedale dei Bambini, Milan, Italy|Seoul National University Children's Hospit, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Emma Children's Hospital, AMC, Amsterdam, Netherlands|Leiden University Medical Center, Leiden, Netherlands|KK Women's and Children's Hospital, Singapore, Singapore","","https://ClinicalTrials.gov/show/NCT02139800"
247,"NCT02077387","Promoting Child Inhibitory Control Skills Around Food","CHIC Play","Completed","No Results Available","Obesity","Behavioral: CHild Inhibitory Control (CHIC) Play|Behavioral: Attention control","Caloric intake in the Eating in the Absence of Hunger (EAH) paradigm|Executive functioning","University of California, San Diego|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 6 Years   (Child)","Not Applicable","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","HD074987","June 2014","November 2015","November 2015","March 4, 2014","null","February 3, 2016","University of California, San Diego, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT02077387"
248,"NCT02043626","Study to Evaluate the Health and Wellness Policies of the New Haven Public School District.","H&A","Completed","No Results Available","Chronic Diseases|Obesity","Other: DISTRICT WELLNESS COMMITTEE|Other: NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Other: HEALTH PROMOTION AND MARKETING|Other: OPPORTUNITIES FOR PHYSICAL ACTIVITY","Change in body mass index (BMI).|Change in student nutritional habits (eating behaviors).|Change in level of physical activity.|Mental Health|Standardized test scores","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 14 Years   (Child)","Not Applicable","796","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1008007295|5R01HD070740","August 2011","June 2016","June 2016","January 23, 2014","null","January 17, 2018","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT02043626"
249,"NCT01944046","Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors","SOARS-B","Completed","No Results Available","Autism Spectrum Disorders","Drug: Placebo Nasal Spray|Drug: Oxytocin Nasal Spray","Change in ABC-SW subscale--Reciprocal Social Behavior|Change in SRS-Social Motivation Subscale|Change in Stanford Binet-5th Edition (SB-5)/Mullen|Change in Vineland II Adaptive Behavior Composite and all its subscales|Change in Caregiver Strain Questionnaire total and subscale scores|Change in Social Opportunity (Questionaire)","Linmarie Sikich|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","3 Years to 17 Years   (Child)","Phase 2","290","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pro00063950|1U01HD073984|13-0593","August 1, 2014","November 30, 2017","November 30, 2017","September 17, 2013","null","December 21, 2018","Lurie Center for Autism, Massachusetts General Hospital, Boston, Massachusetts, United States|Mount Sinai School of Medicine, New York, New York, United States|Center for Autism and the Developing Brain, White Plains, New York, United States|Duke Center for Autism and Brain Development, Durham, North Carolina, United States|Duke University , Genetics Center, Durham, North Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Seattle Children's Hospital Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01944046"
250,"NCT01937884","Supplemental Parenteral Nutrition in Pediatric Respiratory Failure","SuPPeR","Recruiting","No Results Available","Acute Respiratory Failure With Hypoxia|Malnutrition","Drug: Parenteral Nutrition","modified Prognostic Inflammatory and Nutritional Index (PINI)|Percentage of daily goal calories achieved|Organ failure free days|serum Intestinal Fatty Acid Binding Protein (I-FABP)|serum citrulline|serum claudin 3|gastrointestinal permeability","University of Arizona|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 16 Years   (Child)","Phase 2","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","13-0374|5K12HD047349-09","August 2013","August 2018","August 2018","September 10, 2013","null","March 22, 2018","University of Arizona Medical Center, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT01937884"
251,"NCT01925092","Mifepristone in Children With Refractory Cushing's Disease",,"Withdrawn","No Results Available","Cushing's Disease","Drug: mifepristone","Adverse events","Corcept Therapeutics|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 17 Years   (Child)","Phase 3","0","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13-CH-0170|02811-12","August 2013","December 2016","null","August 19, 2013","null","August 4, 2014","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01925092"
252,"NCT01880450","Project Prepared: Risks, Roles and Relationships","Prepared","Completed","No Results Available","F01.145.802.845|F01.145.802.987","Behavioral: Project Prepared|Behavioral: TEEN","Change in Intentions to engage in safer sex behavior at 6 months|Change in Intentions to engage in safer sex behavior at 1 year|Change in Cognitive Factors at 6 months|Change in Cognitive Factors at 1 year","Albert Einstein College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 14 Years   (Child)","Not Applicable","397","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","2008-551|5R01HD062079","May 2009","March 2014","December 2014","June 19, 2013","null","January 14, 2015","Albert Einstein College of Medicine, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT01880450"
253,"NCT01873755","Addressing Barriers to Physical Activity in Inner-City Schoolchildren With Asthma",,"Active, not recruiting","No Results Available","Asthma|Children|Physical Activity","Behavioral: asthma physical activity intervention","change in physical activity levels|change in Body Mass Index","Montefiore Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 12 Years   (Child)","Not Applicable","250","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","2012-443|5K23HD065742","October 2012","August 2019","August 2019","June 10, 2013","null","September 25, 2018","Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT01873755"
254,"NCT01851057","Supporting Treatment Adherence Regimens in Pediatric Epilepsy: The STAR Trial",,"Active, not recruiting","No Results Available","Epilepsy","Behavioral: STAR|Behavioral: Education Only","Adherence rate (short-term)|Adherence rate (long-term)","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 12 Years   (Child)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","R01HD073115","April 2013","December 2019","December 2020","May 10, 2013","null","January 11, 2019","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01851057"
255,"NCT01790373","Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence",,"Completed","No Results Available","HIV","Behavioral: Suubi+Adherence|Behavioral: Bolstered Standard of Care","Change from baseline to follow-up assessments of adherence to HIV treatment|Protective Health Behaviors|Cost-Effectiveness Analyses","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 16 Years   (Child)","Not Applicable","702","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","AAAK3852|1R01HD074949-01","September 7, 2013","January 23, 2018","January 23, 2018","February 13, 2013","null","July 19, 2018","Columbia University School of Social Work, New York, New York, United States|International Center for Child Health and Asset Development, Masaka, Uganda","","https://ClinicalTrials.gov/show/NCT01790373"
256,"NCT01773772","Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls","JCM017","Active, not recruiting","No Results Available","Female Puberty","Drug: Progesterone|Drug: Placebo","LH pulse frequency (number of LH pulses per hour)","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","9 Years to 14 Years   (Child)","Phase 1","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","10504|U54HD028934|P50HD028934","June 2003","January 2012","December 2019","January 23, 2013","null","April 16, 2019","University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01773772"
257,"NCT01754701","Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria",,"Completed","No Results Available","Iron Deficiency|Malaria|Nutrition|Global Health","Dietary Supplement: Immediate iron|Dietary Supplement: Delayed iron","Percent red blood cell iron incorporation on Day 0 in children in the immediate group vs. percent red blood cell iron incorporation on Day 28 in children in the delayed group|Hematological recovery in the immediate vs. delayed groups on Day 56","University of Minnesota - Clinical and Translational Science Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 59 Months   (Child)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1203M11234|1R03HD074262","June 2013","May 2015","May 2015","December 21, 2012","null","November 30, 2015","Mulago Hospital, Kampala, Uganda","","https://ClinicalTrials.gov/show/NCT01754701"
258,"NCT01754324","The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome",,"Completed","No Results Available","Neonatal Abstinence Syndrome","Drug: Methadone","Methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) blood concentration|Failed Protocol Wean|Number of participants requiring adjunctive pharmacological treatment|Length of hospitalization|Readmission to the hospital|Clinical resolution of NAS symptoms","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 1 Month   (Child)","","20","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCHMC-PK-1|5T32HD069054","December 2012","December 2013","December 2013","December 21, 2012","null","June 13, 2014","The University Hospital, Cincinnati, Ohio, United States|Mercy Hospital Anderson, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01754324"
259,"NCT01751698","Adaptive Interventions for Minimally Verbal Children With ASD in the Community","AIM-ASD","Completed","No Results Available","Autism","Behavioral: JASP-EMT|Behavioral: DTT","Primary Outcome 1: Language Sample|Secondary Aim 1: Joint Engagement|Secondary Outcome 2: Number of Unique Words (Vocabulary)|Secondary Outcome 3: Object Play","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","54 Months to 96 Months   (Child)","Not Applicable","192","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD073975","January 2013","June 2017","December 2017","December 18, 2012","null","October 11, 2018","University of California, Los Angeles, Los Angeles, California, United States|University of Rochester, Rochester, New York, United States|Weill Cornell Medical College, White Plains, New York, United States|Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01751698"
260,"NCT01729910","Primary Care Child Obesity Intervention Targeting Parents",,"Completed","No Results Available","Overweight|Obesity","Behavioral: Parent education / behavioral counseling|Behavioral: Usual Care","child body mass index percentile|Parent report of knowledge, attitudes, perceptions, intentions, and behaviors related to eating and physical activity","East Tennessee State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 11 Years   (Child)","Not Applicable","67","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R15HD054950-01A2 REVISED|1R15HD054950-01A2","September 2009","November 2010","March 2011","November 20, 2012","null","November 24, 2015","East Tennessee State University, Johnson City, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01729910"
261,"NCT01722643","Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes","Behavioral: MAxIM|Behavioral: Usual Care","HbA1c at 12 Months|Daily Frequency of Self Monitoring of Blood Glucose Checks 12 Months Following Enrollment","Dartmouth-Hitchcock Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","61","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","23559|1DP3HD076602-01","January 2014","September 2016","September 2016","November 7, 2012","June 6, 2018","June 6, 2018","Dartmouth College, Hanover, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT01722643"
262,"NCT01704144","Rifampin and Efavirenz Interactions in Older Children",,"Unknown status","No Results Available","HIV|Tuberculosis","","Area under time curve from time 0-24 hours(AUC0-24h) of efavirenz|Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects|Number of children with efavirenz 24-hour post-dose concentration (C24h) < 1000 ng/mL|Number of children who discontinue efavirenz therapy due to drug side effects|Trough concentration (C24h) of efavirenz|AUC, Cmax and clearance of efavirenz on and off rifampin-containing anti-Tb therapy in HIV/TB co-infected patients","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 14 Years   (Child)","","160","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PK-PTBHIV03|R01HD071779","October 2012","May 2017","May 2017","October 11, 2012","null","October 17, 2012","Komfo Anokye Teaching Hospital, Kumasi, Ghana","","https://ClinicalTrials.gov/show/NCT01704144"
263,"NCT01699633","Rifampin and Nevirapine Interactions in Young Children",,"Unknown status","No Results Available","Tuberculosis|HIV","","Area under time curve (AUC) of nevirapine|Number of children with grade 3 or 4 liver enzymes elevations compared to baseline, new onset of skin rash, nausea, vomiting or treatment modification due to drug side effects|Number of children with nevirapine 12-hour post-dose concentration (C12h) < 3000 ng/mL|Time to HIV-1 RNA suppression below 50 copies/mL and change in CD4 cell count from baseline|Peak concentration (Cmax) and concentration at 12-hours (C12h) post-dose of nevirapine","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 35 Months   (Child)","","58","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PK-TBHIV02|R01HD071779","October 2012","May 2017","May 2017","October 4, 2012","null","October 12, 2012","Komfo Anokye Teaching Hospital, Kumasi, Ghana","","https://ClinicalTrials.gov/show/NCT01699633"
264,"NCT01687504","Pharmacokinetics of Anti-TB Drugs in HIV/TB Co-infected Children in Ghana",,"Unknown status","No Results Available","Tuberculosis|HIV","","Descriptive statistics of PK parameters (Cmax, Tmax, AUC0-8h) of rifampin, isoniazid, pyrazinamide and ethambutol in children with TB with and without HIV coinfection|Frequency of liver enzymes elevations compare to baseline, skin rashes, nausea, vomiting and treatment discontinuation or modifications due to drug side effects in children with TB with and without HIV coinfection|Relationship between genetic polymorphisms of N-acetyltransferase type 2 (NAT2) enzyme and isoniazid plasma Cmax and AUC in Ghanaian children with TB with and without HIV|Relationship between genetic polymorphisms of SLCO1B1 transporter and rifampin plasma Cmax and AUC in Ghanaian children with TB with and without HIV|Relationship between plasma Cmax and AUC of isoniazid, rifampin, ethambutol and pyrazinamide at week 4 of therapy and frequency of anti-TB treatment discontinuation or modification|Relationship between NAT2 acelator status, SLCO1B1 genotype status and anti-TB treatment completion, discontinuation or modification|Relationship between body weight, gender, nutritional status and plasma Cmax and AUC of isoniazid, rifampin, ethambutol and pyrazinamide in Ghanaian children with TB with and without HIV","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 14 Years   (Child)","","106","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PK-PTBHIV01|R01HD071779","October 2012","May 2017","May 2017","September 19, 2012","null","October 11, 2012","Komfo Anokye Teaching Hospital, Kumasi, Ghana","","https://ClinicalTrials.gov/show/NCT01687504"
265,"NCT01624597","A Randomized Controlled Trial to Improve Teen Driving",,"Completed","No Results Available","Motor Vehicle Driving","Behavioral: In-vehicle video feedback|Behavioral: Parent communication","Driving errors by newly licensed teen drivers|Safety behaviors of newly licensed teen drivers|Parent communication","University of Iowa|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 17 Years   (Child)","Not Applicable","153","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","065095|R01HD065095","June 2011","May 2015","May 2018","June 20, 2012","null","August 31, 2018","Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT01624597"
266,"NCT01619826","Enhancing Children's Cognitive and Brain Health Through Physical Activity Training (FITKids2)","FITKids2","Completed","No Results Available","Cognitive Ability, General|Achievement","Behavioral: Physical Activity","NeuroCognitive Assessment|Structural Magnetic Resonance Imaging|Functional Magnetic Resonance Imaging|Academic Achievement|Eye Tracking|Task Performance|Event-related Brain Potentials|DXA Body Mass Assessment|Diet and Brain Function|Adiposity","University of Illinois at Urbana-Champaign|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 9 Years   (Child)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Basic Science","HD069381|R01HD069381-01A1","April 2012","May 2017","May 2017","June 14, 2012","null","July 14, 2017","Beckman Institute - Biomedical Imaging Center, Urbana, Illinois, United States|Campus Recreation Center East, Urbana, Illinois, United States|Department of Kinesiology and Community Health, Urbana, Illinois, United States|University of Illinois at Urbana-Champaign, Urbana, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01619826"
267,"NCT01594606","Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth",,"Completed","No Results Available","Conduct Disorder|Depression|Anxiety","Behavioral: Animal-assisted intervention","Change in Internalizing and Externalizing Symptoms as measured by the Achenbach Child Behavior Checklist-Teacher Report and Youth Self Report forms|Change in empathy toward other people","Wayne State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 17 Years   (Child)","Phase 3","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R03HD070621","May 2012","August 2014","June 2015","May 9, 2012","null","December 9, 2015","Macomb County Juvenile Justice Center, Mt. Clemens, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01594606"
268,"NCT01525316","Lactoferrin for Prevention of Sepsis in Infants","NEOLACTO","Completed","No Results Available","Late Onset Neonatal Sepsis","Dietary Supplement: Bovine Lactoferrin|Dietary Supplement: Maltodextrin","First episode of late-onset sepsis or sepsis-associated death|Neurodevelopment","Universidad Peruana Cayetano Heredia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Hours   (Child)","Phase 3","414","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","SIDISI 57710|1R01HD067694-01A1","May 2012","October 2016","October 2016","February 2, 2012","null","January 18, 2017","Hospital Nacional Alberto Sabogal Sologuren, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru","","https://ClinicalTrials.gov/show/NCT01525316"
269,"NCT01507090","Validation of the Mercy TAPE","TAPE","Completed","Has Results","Weight","Device: Mercy TAPE","Predictive Performance of the Mercy TAPE (Percent of Participants Predicted Within 20% of Their Actual Weight)|Predictive Performance of the Mercy TAPE (Slope)|Predictive Performance of the Mercy TAPE (Intercept)|Predictive Performance of the Mercy TAPE (Mean Error)|Predictive Performance of the Mercy TAPE (Mean Percentage Error)|Predictive Performance of the Mercy TAPE (Corelation Coefficient)|Predictive Performance of the Mercy TAPE|Equivalence of the Mercy Method and the 2D and 3D Mercy TAPEs (Ratio)|Equivalence of the Mercy Method and the 2D and 3D Mercy TAPEs (Concordance Corelation Coefficient)|Equivalence of the Mercy Method and the 2D and 3D Mercy TAPEs (% Within 10%)|Inter-rater Reliability for the 2D and 3D Mercy TAPEs.|Device Print Batch Variability|Predictive Performance of the Mercy Method (Intercept)|Predictive Performance of the Mercy Method (Slope)|Predictive Performance of the Mercy Method (Percent of Participants)|Predictive Performance of the Mercy Method (Mean Error)|Predictive Performance of the Mercy Method (Mean Percentage Error)|Predictive Performance of the Mercy Method","Susan Abdel-Rahman|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Mercy Hospital Kansas City","All","2 Months to 16 Years   (Child)","","642","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Mercy TAPE","February 2012","March 2012","April 2012","January 10, 2012","February 10, 2015","February 10, 2015","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Milton Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01507090"
270,"NCT01506544","Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia","HU","Completed","No Results Available","Sickle Cell Anemia","Drug: Hydroxyurea","Composite of Pharmacokinetics|Pharmacokinetics of HU|Bioavailability of HU","Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 17 Years   (Child)","Phase 1","39","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)","Hydroxyurea Pharmacokenetic|HHSN275201000003I","December 2011","December 2013","January 2014","January 10, 2012","null","December 12, 2014","Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Memorial Hospital (Northwestern University), Chicago, Illinois, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|UT Southwestern University Hospital, Dallas, Texas, United States|Children's Hospital of Wisconsin, Wauwatosa, Wisconsin, United States","","https://ClinicalTrials.gov/show/NCT01506544"
271,"NCT01482234","Text Messages and Physical Activity Among Teens",,"Completed","No Results Available","Physical Activity","Behavioral: TXT Me","physical activity|Psychological need satisfaction in exercise|Behavioral Regulation in Exercise|Satisfaction","Baylor College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 17 Years   (Child)","Not Applicable","160","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H-27537|R21HD066305","February 2012","August 2013","December 2013","November 30, 2011","null","January 20, 2016","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01482234"
272,"NCT01447615","Bridges to the Future: Economic Empowerment for AIDS-Orphaned Children in Uganda",,"Completed","No Results Available","Poverty|Orphaned Children|AIDS Orphans","Behavioral: Bridges|Behavioral: Bridges PLUS|Other: Usual Care","Savings and Asset Accumulation|Educational Achievement|Mental Health Functioning|Sexual Risk-Taking Behavior","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 17 Years   (Child)","Not Applicable","1410","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AAA11950|1R01HD070727-01","February 2012","January 15, 2018","January 15, 2018","October 6, 2011","null","October 12, 2018","International Center for Child Health and Asset Development, Masaka, Rakai And Masaka Districts, Uganda","","https://ClinicalTrials.gov/show/NCT01447615"
273,"NCT01441206","Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants",,"Terminated","No Results Available","Infection","Drug: rifampin","Area under the plasma concentration versus time curve 0-24 hours for rifampin|Peak plasma concentration of rifampin|Clearance of rifampin|Volume of distribution at steady state|Half life of rifampin|Number of subjects with adverse events as a measure of safety and tolerability.","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 121 Days   (Child)","Phase 1","2","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","10-2314|1K23HD068497-01","September 2011","April 2012","April 2012","September 27, 2011","null","September 14, 2012","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01441206"
274,"NCT01428245","Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition","JCM026","Active, not recruiting","No Results Available","Hyperandrogenemia|Polycystic Ovary Syndrome","Drug: Progesterone|Drug: Estrace (estrogen)","LH Pulse frequency as a function of day 7 progesterone","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","8 Years to 14 Years   (Child)","Not Applicable","10","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","14100|U54HD028934|P50HD028934","January 27, 2009","December 2019","January 2020","September 2, 2011","null","March 1, 2019","Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01428245"
275,"NCT01428193","Effects of Androgen Blockade on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone",,"Terminated","Has Results","Polycystic Ovary Syndrome|Hyperandrogenism","Drug: Flutamide|Drug: Progesterone|Drug: estrace","Slope of the Percent Change in Luteinizing Hormone (LH) Pulses as a Function of Day 7 Progesterone Level","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years to 17 Years   (Child)","Not Applicable","4","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12632|U54HD028934-18","September 2006","August 2017","August 2017","September 2, 2011","June 4, 2018","June 4, 2018","Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT01428193/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01428193"
276,"NCT01428089","Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone",,"Recruiting","No Results Available","Polycystic Ovary Syndrome|Hyperandrogenism|Normal Puberty","Drug: Progesterone|Drug: Placebo","Average luteinizing hormone (LH) interpulse interval and the total number of LH pulses|Hourly hormone measurements during sampling period.","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","7 Years to 14 Years   (Child)","Phase 1","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science","13660|P50HD028934","May 2008","December 2018","December 2018","September 2, 2011","null","January 23, 2018","Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01428089"
277,"NCT01427595","Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone",,"Active, not recruiting","No Results Available","Polycystic Ovary Syndrome|Hyperandrogenism","Drug: Metformin|Drug: Progesterone|Drug: estrace","Change in LH pulse frequency before and after Metformin treatment.","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","10 Years to 17 Years   (Child)","Not Applicable","11","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","13789|U54HD028934-18","July 22, 2008","June 28, 2019","December 2019","September 1, 2011","null","November 28, 2018","Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01427595"
278,"NCT01365793","Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis",,"Completed","Has Results","Cerebral Edema|Diabetic Ketoacidosis","Drug: 0.45% saline replacement fluid|Drug: 0.9% saline replacement fluid|Drug: 0.45% saline intravenous fluid|Drug: 0.9% saline Intravenous fluid","the Number of Participants With Glasgow Coma Score (GCS) < 14 Within the First 24 Hours of Treatment for Diabetic Ketoacidosis (DKA)|Frequency of Clinically Apparent Brain Injury|Hourly Improvement in Forward and Backward Digit Span Scores During DKA Treatment (Mean Difference Per Hour)|Mean Scores on Tests of Memory Capacity 3 Months After Recovery From DKA.|Intelligence Quotient (IQ) Testing","University of California, Davis|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 17 Years   (Child)","Phase 3","1389","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","230233|U01HD062417","November 2010","September 2016","January 2017","June 3, 2011","June 25, 2018","June 25, 2018","University of California, Davis, Sacramento, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Ann & Robert Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Washington University & St. Louis Children's Hospital, Saint Louis, Missouri, United States|Columbia University, New York, New York, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Hasbro Children's Hospital/Rhode Island Hospital, Providence, Rhode Island, United States|Texas Children's Hospital, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01365793"
279,"NCT01326806","A Parent-Based Intervention to Reduce Sexual Risk Behavior in Adolescents",,"Completed","No Results Available","Behavior and Behavior Mechanisms","Behavioral: Families Talking Together|Behavioral: Active Control on Hygiene & Nutrition","Incidence of vaginal intercourse|Incidence of condom use|Incidence of oral sex|Number of sexual partners|Behavioral intentions","New York University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 14 Years   (Child)","Not Applicable","1800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","NIH_066159|R01HD066159","July 19, 2010","May 31, 2016","May 31, 2016","March 31, 2011","null","September 15, 2017","New York University, Silver School of Social Work, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01326806"
280,"NCT01293500","Goal-directed Resuscitative Interventions During Pediatric Inter-facility Transport (The GRIPIT Trial)","GRIPIT","Terminated","No Results Available","SIRS (Systemic Inflammatory Response Syndrome(","Procedure: Goal-directed Therapeutic Protocol","Incidence of Multiple Organ Dysfunction|Required ICU Interventions|Hospital Length of Stay|Changes in cerebral and somatic oxygenation","Arkansas Children's Hospital Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 17 Years   (Child)","Not Applicable","230","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R21HD060171-01A2","October 2010","November 2014","November 2014","February 10, 2011","null","May 5, 2016","Arkansas Children's Hospital, Little rock, Arkansas, United States","","https://ClinicalTrials.gov/show/NCT01293500"
281,"NCT01277185","Calcium Metabolism in Mexican American Adolescents",,"Completed","No Results Available","Osteoporosis","Dietary Supplement: Low Calcium Diet|Dietary Supplement: High Calcium Diet","Calcium Absorption and Retention|Bone Density","Purdue University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 15 Years   (Child)","Not Applicable","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Camp Calcium 11|1R01HD061908-01A2","April 2010","August 2010","August 2010","January 14, 2011","null","May 9, 2018","Purdue University, West Lafayette, Indiana, United States","","https://ClinicalTrials.gov/show/NCT01277185"
282,"NCT01232725","Donor Human Milk and Neurodevelopmental Outcomes in Very Low Birthweight (VLBW) Infants",,"Completed","No Results Available","Neurodevelopmental Outcomes of VLBW Infants","Dietary Supplement: Donor Human Milk","Cognitive scale score of the Bayley Scales of Infant Development, III|Late Onset sepsis|length of hospital stay","Tarah T Colaizy|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Iowa","All","up to 24 Months   (Child)","Not Applicable","121","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","200708746|K23HD057232","August 2009","December 2014","May 2016","November 2, 2010","null","August 4, 2017","University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT01232725"
283,"NCT01217242","Activity and Participation in Ambulatory Cerebral Palsy","APCP","Completed","No Results Available","Cerebral Palsy","","Community walking activity with the STEPWATCH accelerometer|Participation in day to day life activities","Seattle Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 9 Years   (Child)","","128","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","K23HD060764","August 2009","August 2011","December 2011","October 8, 2010","null","January 5, 2012","Seattle Children's Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01217242"
284,"NCT01214473","Probiotics for Prevention Neonatal Infection",,"Terminated","No Results Available","Neonatal Sepsis|Sepsis|Neonatal Infections","Other: Synbiotics|Other: Maltodextrin","Clinical sepsis and/or death|Incidence of culture proven sepsis (Gram-negative vs. Gram-positive)|Incidence of other infections|Effect on weight gain","University of Nebraska|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 3 Days   (Child)","Phase 2|Phase 3","4556","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","332-10 FB|5R01HD053719","June 2007","June 2012","November 2013","October 5, 2010","null","August 26, 2014","Center for Advanced Research on Alternative Medicine, Bhubaneswar, Orissa, India|Ispat General Hospital, Rourkela, Orissa, India","","https://ClinicalTrials.gov/show/NCT01214473"
285,"NCT01207778","Brain Imaging and Developmental Follow up of Infants Treated With Erythropoietin","BRITE","Unknown status","No Results Available","Prematurity","","neurocognition|Brain imaging","University of New Mexico|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 47 Months   (Child)","","105","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","10-153|R01HD059856","March 2010","December 31, 2016","December 2018","September 23, 2010","null","February 1, 2017","MIND Research Network, Albuquerque, New Mexico, United States|UNM, Albuquerque, New Mexico, United States|PCMC/University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01207778"
286,"NCT01206478","Trial of Amitriptyline for Chronic Oral Food Refusal in Children 9 Months to 8 Years of Age",,"Completed","Has Results","Chronic Oral Food Refusal","Drug: Amitriptyline|Drug: Placebo|Drug: Megestrol","% Calories Taken Orally|Change in Non-communicating Children's Pain Checklist - Revised (NCCPC-R) Scores","Ann Davis, PhD, MPH, ABPP|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Kansas Medical Center","All","9 Months to 8 Years   (Child)","Phase 2","21","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","12261|R21HD066629","August 2010","December 2014","December 2014","September 21, 2010","August 15, 2016","August 15, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01206478"
287,"NCT01188616","IT-Supported Early Treatment Of Childhood Overweight","HEAT","Completed","No Results Available","Childhood Obesity|Technology Based Obesity Intervention","Behavioral: Telephone Linked Care-HEAT (TLC-HEAT)","","Boston Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 12 Years   (Child)","Phase 2","null","Other|NIH","Interventional","Primary Purpose: Treatment","H-24963|R21HD050939-01","July 2005","May 2010","null","August 25, 2010","null","August 25, 2010","Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01188616"
288,"NCT01184651","Tweens to Teens Project at Penn State","T2T@PSU","Completed","No Results Available","Congenital Adrenal Hyperplasia","Behavioral: Questionnaires/Interviews","","Penn State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","10 Years to 13 Years   (Child)","","188","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","PSU ORP#30695|1R01HD057930-01A1","August 2009","July 2013","July 2013","August 19, 2010","null","January 8, 2018","The Pennsylvania State University, Dept. of Psychology - Tweens to Teens Project, University Park, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01184651"
289,"NCT01171937","Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior","ProjectV","Completed","No Results Available","Autism","Drug: Risperidone|Drug: Placebo","Aberrant Behavior Checklist","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 16 Years   (Child)","Phase 2","41","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","07-06-033|P50HD055784","September 2008","September 2016","December 2016","July 29, 2010","null","May 3, 2017","UCLA, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01171937"
290,"NCT01152489","A Test of the Effectiveness of a Device and Distraction for Pediatric Immunization Pain",,"Completed","No Results Available","Procedural Pain","Device: Device: Buzzy|Device: Buzzy: sham device","Pain of immunization|Pain from immunization using observational measures|Treatment satisfaction","MMJ Labs LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Months to 12 Years   (Child)","Phase 2|Phase 3","345","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","H09501|R44HD056647-01A2","April 2010","April 2011","April 2011","June 29, 2010","null","June 22, 2011","","","https://ClinicalTrials.gov/show/NCT01152489"
291,"NCT01139411","The Role of Parents in Adolescent Weight Loss",,"Completed","Has Results","Adolescent Obesity","Behavioral: Behavioral Weight Control with Enhanced Parent Involvement|Behavioral: Behavioral Weight Control with Minimal Parent Involvement","Body Mass Index|Parent Modeling 1: Dietary Choices (WCSS)|Parent Modeling 2: Self-monitoring (WCSS)|Parent Modeling 3: Physical Activity (WCSS)|Parent Modeling 4: Weight and Body Concerns (FERF-Q)|Communication 1: Negative Maternal Weight-related Commentary (FERF-Q)|Communication 2: Observed Parent-adolescent Communication Quality (DOCS)","The Miriam Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Not Applicable","49","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GRANT00538804|R03HD060137","August 2009","December 2011","January 2012","June 8, 2010","September 30, 2016","September 30, 2016","The Miriam Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01139411"
292,"NCT01118858","Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics",,"Completed","No Results Available","Drug Metabolism Phenotype","","Characterize the change in CYP2D6 and CYP3A4 phenotype through adolescence|Identify endogenous markers of CYP2D6 activity","Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 15 Years   (Child)","","205","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","1R01HD058556-01A1|5R01HD058556","April 2010","October 2015","October 2015","May 7, 2010","null","July 21, 2017","The Children's Mercy Hospital, Kansas City, Missouri, United States|The University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01118858"
293,"NCT01093989","Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition",,"Completed","No Results Available","Anemia|Inflammation|Malaria Morbidity|Cognitive Development","Dietary Supplement: Ferrous Sulphate Syrup","Hemoglobin change, anemia prevalence, and socioemotional behavior in the immediate iron vs. delayed iron groups","University of Minnesota - Clinical and Translational Science Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","18 Months to 5 Years   (Child)","Not Applicable","239","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","0909M72852|1U01HD064698-01","June 2010","December 2014","December 2014","March 26, 2010","null","June 1, 2015","Mulago Hospital, Kampala, Uganda","","https://ClinicalTrials.gov/show/NCT01093989"
294,"NCT01028144","The Active by Choice Today (ACT) Trial to Increase Physical Activity","ACT","Completed","No Results Available","Exercise|Physical Activity|Obesity","Behavioral: Physical Activity Program|Behavioral: General Health Program","moderate to vigorous physical activity (based on accelerometry estimates)|moderate to vigorous physical activity during the intervention (based on accelerometry estimates)","University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 13 Years   (Child)","Phase 1|Phase 2","1422","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Project ACT|R01HD045693","July 2004","May 2009","May 2009","December 9, 2009","null","December 10, 2009","University of South Carolina, Columbia, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT01028144"
295,"NCT00978068","HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","PROMOTE-PEDS","Completed","Has Results","Malaria|HIV Infections","Drug: Lopinavir/Ritonavir (LPV/r)|Drug: Nevirapine (NVP)|Drug: Efavirenz (EFV)|Drug: 2 nucleoside reverse transcriptase inhibitor (NRTI)","Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk.|Percentage of Uncomplicated Malaria Episodes With Accompanying Adverse Events That Occurred in the 28 Days Following Antimalarial Therapy|Incidence-density of Malaria Defined as the Number of Incident Episodes of Complicated Malaria Per Time at Risk.|Estimates of the 6-month Risk of a First Episode of Malaria|28-day Risk of Recurrent Parasitemia|63-day Risk of Recurrent Malaria","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Months to 10 Years   (Child)","Phase 3","176","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H5747-34097|NIH PO1 HD059454|2009-114|HS-620|551/ESR/NDA/DID-08/09|H5741-34097 and 10-00991","September 2009","January 2013","January 2013","September 16, 2009","December 28, 2018","December 28, 2018","IDRC - Tororo Research Clinic, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT00978068"
296,"NCT00962247","Effect of Changing Sedentary Behavior in Youth","Effects","Completed","Has Results","Obesity","Device: Television reduction device","Physical Activity|Energy Intake","State University of New York at Buffalo|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 12 Years   (Child)","Not Applicable","61","Other|NIH","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other","HD039778|5R01HD039778","July 2006","December 2008","December 2008","August 19, 2009","August 24, 2017","August 24, 2017","University at Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT00962247"
297,"NCT00948896","Chemopreventive Therapy for Malaria in Ugandan Children","PROMOTE-Chemop","Completed","Has Results","Malaria","Drug: trimethoprim-sulfamethoxazole (TS; TMP/SMX)|Drug: sulfadoxine-pyrimethamine (SP)|Drug: dihydroartemisinin-piperaquine (DP)","Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants|Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants|Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs|Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Months to 5 Months   (Child)","Phase 3","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H9926-33953|NIH P01HD059454|2009-077|HS-580|686/ESR/NDA/DID-11/2009|H9926-33953 and 10-01489","June 2010","April 2014","April 2014","July 29, 2009","August 4, 2015","November 24, 2015","IDRC Research Clinic -Tororo District Hospital, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT00948896"
298,"NCT00942084","A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)",,"Completed","Has Results","Herpes Simplex Virus|Neonatal Sepsis","Drug: Acyclovir","Clearance (CL)|Volume of Distribution (V)|Half-life (T1/2)|Maximum Steady State Concentration (Cmaxss)|Steady State Concentration at 50% of the Dosing Interval (C50ss)|Minimum Steady State Concentration (Cminss)","Phillip Brian Smith|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","up to 45 Days   (Child)","Phase 1","32","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00028772","September 2011","June 2012","June 2012","July 20, 2009","January 8, 2014","January 8, 2019","Wesely Medical Center, Wichita, Kansas, United States|Tulane School of Medicine, New Orleans, Louisiana, United States|Duke University, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00942084"
299,"NCT00930007","Sleep-wake Changes of Luteinizing Hormone Frequency in Pubertal Girls With and Without High Testosterone","CRM005","Active, not recruiting","No Results Available","Hyperandrogenism","Other: Blood sampling","Luteinizing hormone pulse frequency (while awake and while asleep)|Progesterone concentration|Estradiol concentration|Testosterone concentrations|Luteinizing hormone amplitude|Sleep stage parameters","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","8 Years to 15 Years   (Child)","","90","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","13950","October 2008","February 2019","February 2019","June 30, 2009","null","April 12, 2018","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00930007"
300,"NCT00928759","Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls","CRM002","Recruiting","No Results Available","Obesity|Hyperandrogenemia|Polycystic Ovary Syndrome","","Morning free testosterone|Insulin-stimulated glucose disposal|Estimated 24-hour mean insulin concentration|Luteinizing hormone pulse frequency|Mean luteinizing hormone concentration","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","8 Years to 16 Years   (Child)","","40","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","13552|P50HD028934","March 2008","December 2018","December 2018","June 26, 2009","null","January 23, 2018","University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00928759"
301,"NCT00927030","Melatonin for Sleep in Children With Autism","NICHD","Completed","No Results Available","Autistic Disorder|Insomnia","Drug: supplemental liquid melatonin|Drug: flavored liquid or liquid supplemental melatonin","Determine dose-response, tolerability, and adverse effects of melatonin in 30 children with autism.|A sub-set of 12 children will be studied to characterize the pharmacokinetic profile of orally administered melatonin.|A group of behavioral and parental stress measures will be piloted for the participants in this study.","Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 10 Years   (Child)","Phase 1","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","071269","January 2008","April 2010","October 2010","June 24, 2009","null","July 2, 2012","Vanderbilt Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00927030"
302,"NCT00910611","A Test of the Effectiveness of a Device for Pediatric Immunization Pain","Buzzy","Unknown status","No Results Available","Pain","Device: Buzzy","FLACC observational pain/distress scale|Self report using Faces Pain Scale - Revised","MMJ Labs LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 6 Years   (Child)","Not Applicable","60","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Supportive Care","08-028|1R44HD056647-01A2","January 2009","June 2009","July 2010","June 1, 2009","null","June 25, 2010","Sandy Springs Pediatrics and Adolescent Medicine, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00910611"
303,"NCT00880698","Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers",,"Completed","Has Results","HIV Infection|Rotavirus Infection","Biological: RotaTeq|Biological: Placebo","Percentage of Participants Developing New Grade >=3 Adverse Events|Percentage of Participants Classified as Responders as Measured by Serum Anti-rotavirus IgA ELISA (IgA) and Serum Neutralizing Antibodies (SNA) G1, G2, G3, G4 and P1.|Number of Participants With Fecal Shedding of RotaTeq Strains After Each Vaccination|Percentage of HIV-1 Infected Participants With HIV-1 RNA <= 400 Copies/ml|Change in CD4 Percent From Entry to Last Study Visit in HIV-1 Infected Participants|Change in CD4 Count From Entry to Last Study Visit in HIV-1 Infected Participants|Number of Participants Classified at Screening or Entry as HIV-1 Uninfected, and Acquiring HIV-1 Infection on Study","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 14 Weeks   (Child)","Phase 2","202","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P1072|10638|IMPAACT P1072","December 2009","January 2014","January 2014","April 14, 2009","July 22, 2015","July 22, 2015","Gaborone CRS, Gaborone, Botswana|Molepolole CRS, Gaborone, Botswana|Kilimanjaro Christian Medical Center CRS, Moshi, Tanzania|George CRS, Lusaka, Zambia|Harare Family Care CRS, Harare, Zimbabwe|Parirenyatwa CRS, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT00880698"
304,"NCT00850122","An Open Label Study to Describe the Pharmacokinetics of Cefazolin in Preterm Neonates",,"Completed","No Results Available","Sepsis|Prematurity","Drug: cefazolin","Cefazolin pharmacokinetics including half life, clearance, and volume of distribution|Safety","Phillip Brian Smith|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","up to 120 Days   (Child)","Phase 1","9","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00012011|1K23HD060040-01","July 2013","July 2018","July 2018","February 24, 2009","null","September 3, 2018","Federal University of Sao Paulo, Sao Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT00850122"
305,"NCT00809055","MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine",,"Completed","Has Results","Apnea of Prematurity|Intraventricular Hemorrhage|Brain Injury","Drug: Caffeine citrate","White Matter Microstructural Maturation|Mortality Rates|Cerebellar Hemorrhage|Length of Time Requiring Invasive Respiratory Support|Rates of Chronic Lung Disease|Rates of Necrotizing Enterocolitis|Rates of Retinopathy of Prematurity|Evaluation of EEG Seizure Burden|Infant Neurobehavioral Scoring by Dubowitz Scale Prior to Discharge|Bayley Scales of Infant Development Cognitive Score at 2 Years of Age","Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","24 Weeks to 30 Weeks   (Child)","Phase 4","74","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","08-0849|R01HD057098-01|HRPO 08-0849","November 2008","December 2010","December 2015","December 16, 2008","February 24, 2016","February 24, 2016","St. Louis Children's Hospital, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00809055"
306,"NCT00807560","Parent-Based Treatment for Pediatric Overweight","PO","Completed","Has Results","Overweight|Obesity","Behavioral: FBT-PO|Behavioral: NEC","BMI Z Score|Percent Completion|Waist Measurement|Hip Measurement|Height|Weight|BMI|BMI Percentile","Icahn School of Medicine at Mount Sinai|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","Phase 1|Phase 2","77","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GCO 07-0216|1R21HD057394-01","September 2008","June 2013","June 2013","December 12, 2008","January 8, 2016","January 8, 2016","The University of Chicago, Chicago, Illinois, United States|Icahn School of Medicine at Mount Sinai, NY, New York, United States","","https://ClinicalTrials.gov/show/NCT00807560"
307,"NCT00802802","Efavirenz (EFV) in HIV-Infected and HIV/Tuberculosis (TB) Coinfected Children",,"Completed","No Results Available","HIV Infections|Tuberculosis","Drug: Efavirenz (EFV)|Drug: Rifampin-containing anti-TB therapy","Any treatment-related Grade 2B rash or Grade 3 or 4 toxicity requiring permanent discontinuation of efavirenz (EFV)|Death|A safety event as defined as a Grade 4 life-threatening toxicity or Grade 4 toxicity accompanying a serious adverse event (SAE) (e.g., hospitalization) or death that is judged to be at least possibly related to EFV|Failure to achieve the area under the curve (AUC) target range despite dose adjustment|A confirmed decrease (less than 1 log) from entry quantitative HIV RNA and RNA greater than 400 copies/mL","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 35 Months   (Child)","Phase 1","155","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1070|10633|IMPAACT P1070","October 2009","March 2016","March 2016","December 5, 2008","null","May 10, 2016","Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Shandukani Research CRS, Johannesburg, Gauteng, South Africa|Durban Paediatric HIV CRS, Durban, KwaZulu-Natal, South Africa|Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg, Western Cape Province, South Africa|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda|Harare Family Care CRS, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT00802802"
308,"NCT00767403","Internet Intervention for Childhood Encopresis",,"Completed","No Results Available","Encopresis","Behavioral: Internet Intervention + Stepped Care|Behavioral: Internet Intervention|Behavioral: Patient Education Website","Primary encopretic symptoms (as defined by): 1. Number of episodes of fecal soiling 2. Number of bowel movements in the toilet 3. Increased trips to the bathroom (both parent and self-prompted)|Behavior change around encopresis (as measured by): 1. Appropriate clean-out 2. Appropriate laxative use 3. Appropriate rectus abdominis straining 4. Toileting routine|Secondary encopretic symptoms (as defined by): 1. Appropriate bowel movement consistency 2. Reduced bowel-specific difficulties|Frequency and Severity of perianal pain|Costs (as measured by): 1. Time spent managing symptoms 2. Doctor visits 3. Medication usage 4. Missed school/work days 5. Diapers used 6. Therapist time in stepped-care component 7. Expenses associated with building and maintaining web program|Website Utilization (as measured by): 1. Time spent on website 2. Number of log-ins 3. Number of completed website Modules and Follow-Ups","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 12 Years   (Child)","Not Applicable","290","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13846|5R01HD028160-16","January 2010","March 2012","March 2012","October 7, 2008","null","April 3, 2012","University of Virginia Health System, Department of Psychiatry and Neurobehavioral Sciences, Behavioral Health and Technology, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00767403"
309,"NCT00556569","Evaluation of CHAM JAM Increasing Physical Activity Levels in Students",,"Completed","No Results Available","Physical Activity|Obesity","Other: CHAM JAM","pedometer-derived step count|Body mass index","Montefiore Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 10 Years   (Child)","Not Applicable","10098","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","07-08-253|RC1HD063607","December 2007","June 2012","June 2012","November 12, 2007","null","February 22, 2018","4 Elementary Schools, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT00556569"
310,"NCT00528268","Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy","STOPSMA","Completed","Has Results","Spinal Muscular Atrophy","Drug: Sodium phenylbutyrate (NaPB)","The Study Will Assess the Safety, Tolerability and Potential Efficacy of Sodium Phenylbutyrate (NaPB) in Presymptomatic Infants Genetically Confirmed to Have SMA. It Will Also Determine Selected Pharmacokinetic Parameters.|The Study Will Determine Potential Benefit of NaPB on Lean Body Mass; Overall Motor Function; Potential Cellular Response to NaPB; and Drug Compliance.","University of Utah|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Months   (Child)","Phase 1|Phase 2","14","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","22183|1R01HD054599-01","July 2007","December 2013","December 2013","September 12, 2007","July 3, 2015","July 3, 2015","University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00528268"
311,"NCT00528164","Team PLAY (Positive Lifestyles for Active Youngsters)","Team PLAY","Completed","No Results Available","Obesity","Behavioral: Team PLAY","Primary - Body Mass index|Body Composition (DXA), physical activity (accelerometry), dietary changes (Block Food Frequency), Flexibility and Cohesion Evaluation Scales, MacArthur Behavior and Health Questionnaire and Body Esteem Scale.","University of Tennessee|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 7 Years   (Child)","Phase 2|Phase 3","270","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1RO1HDO50895-01|USPHS Gr HD-050895-01","September 2006","June 2012","June 2012","September 12, 2007","null","February 18, 2013","University of Tennessee, Department of Preventive Medicine, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00528164"
312,"NCT00458991","rhGH Therapy on Hepatic Drug Metabolism",,"Completed","No Results Available","Growth Hormone Deficiency, Dwarfism","Drug: Dextromethorphan and Caffeine","","University of Louisville|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 14 Years   (Child)","","9","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PPRU 10734|U10HD045934-01","June 2001","September 2008","September 2008","April 11, 2007","null","April 27, 2017","University of California at San Diego, San Diego, California, United States|Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00458991"
313,"NCT00427297","Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya",,"Terminated","Has Results","HIV Infections","Drug: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|Drug: d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|Drug: AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|Drug: d4T/3TC/ABC (stavudine/lamivudine/abacavir)|Drug: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Drug: ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine)","Incidence of Mortality|Immunologic Failure|Viral Failure|Incidence of Severe Adverse Events (Excluding Mortality)","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 18 Months   (Child)","Phase 3","34","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00002049|2R01HD023412-16|06-1886-D 02","September 2007","May 2009","December 2009","January 29, 2007","August 27, 2018","August 27, 2018","Kenyatta National Hospital, University of Nairobi, Nairobi, Kenya","","https://ClinicalTrials.gov/show/NCT00427297"
314,"NCT00421668","A Trial of Zinc and Micronutrients in Tanzanian Children",,"Completed","No Results Available","Diarrheal Illnesses|Respiratory Illness|Growth Faltering","Drug: Zinc|Drug: Multivitamins|Drug: Placebo","Incidence of diarrhea|respiratory tract infections|Weight gain|Length/height gain","Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Weeks to 18 Months   (Child)","Phase 3","2400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HD048969","September 2007","October 2012","October 2012","January 12, 2007","null","March 3, 2017","Muhimbili Uinverstiy College of Health Sciences, Dar es Salaam, Tanzania","","https://ClinicalTrials.gov/show/NCT00421668"
315,"NCT00339040","Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children",,"Completed","Has Results","HIV Infections|Sexually Transmitted Diseases","Biological: Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|Other: Placebo/QHPV","Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs)|Percent of Participants Developing Grade 3 or 4 Adverse Events (AEs) Attributed to Study Treatment|Percent of Participants With Human Papillomavirus (HPV) Type-Specific Seroconversion|Serum Anti-HPV Antibody Titers (cLIA)|CD4 Count Over Time|CD4 Percent Over Time|HIV-1 Viral Load (Ribonucleic Acid [RNA] Copies/ml) Over Time","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 12 Years   (Child)","Phase 2","130","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","P1047|10163|PACTG P1047","October 2006","August 2009","August 2009","June 20, 2006","January 16, 2012","February 15, 2019","Usc La Nichd Crs, Alhambra, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Children's Hosp. of Orange County, Orange, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Connecticut Children's Med. Ctr., Hartford, Connecticut, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Chicago Children's CRS, Chicago, Illinois, United States|Children's Hosp., New Orleans, Louisiana, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00339040"
316,"NCT00260078","Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children",,"Completed","No Results Available","HIV Infections","Drug: Atazanavir|Drug: Darunavir|Drug: Efavirenz|Drug: Nevirapine|Drug: Ritonavir|Drug: Tenofovir disoproxil fumarate|Procedure: Pharmacokinetic Study","Predosage concentration (C0 and C12) and area under the concentration-time curve (AUC)","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 17 Years   (Child)","Phase 1|Phase 2","75","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1058|PACTG 1058|IMPAACT P1058|10050","February 2006","April 2009","April 2009","December 1, 2005","null","July 28, 2016","Usc La Nichd Crs, Alhambra, California, United States|University of California, UC San Diego CRS, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Connecticut Children's Med. Ctr., Hartford, Connecticut, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00260078"
317,"NCT00117715","Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body",,"Completed","Has Results","Healthy","Procedure: Genotyping and Phenotyping using dextromethorphan and caffeine as probes","Change in CYP2D6 Drug Metabolism Phenotype With Age|Change in CYP3A4 Drug Metabolism Phenotype With Age|Change in CYP1A2 Drug Metabolism Phenotype With Age","Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Months to 5 Years   (Child)","","121","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PPRU 10390|Internal IRB #P00 06-46","October 2000","January 2010","January 2010","July 8, 2005","August 14, 2017","September 12, 2017","Children's Mercy Hospital, Kansas City, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00117715"
318,"NCT00091702","Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents",,"Completed","No Results Available","HIV Infections|Influenza","Biological: Cold-adapted live attenuated influenza vaccine (FluMist)|Biological: Inactivated influenza vaccine (IAIV)","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 17 Years   (Child)","Phase 1|Phase 2","300","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention","P1057|10612|PACTG P1057","null","null","January 2006","September 20, 2004","null","May 18, 2012","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Univ. of South Alabama College of Medicine, Southeast Ped. ACTU, Mobile, Alabama, United States|Phoenix Children's Hosp., Phoenix, Arizona, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|Children's Hosp. of Orange County, Orange, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Connecticut Children's Med. Ctr., Hartford, Connecticut, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Children's Diagnostic & Treatment Ctr. of South Florida, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Columbus Regional HealthCare System, The Med. Ctr., Columbus, Georgia, United States|Chicago Children's CRS, Chicago, Illinois, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Lawrence Family Health Ctr., Essex St. Clinic, Lawrence, Massachusetts, United States|Lowell Community Health Ctr., Lowell, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Washington Univ. School of Medicine at St. Louis, St. Louis Children's Hosp., St. Louis, Missouri, United States|NJ Med. School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr., Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Mt. Sinai School of Medicine, Div. of Ped. Infectious Diseases, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|DUMC Ped. CRS, Durham, North Carolina, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Children's Hosp. of the King's Daughters, Infectious Disease, Norfolk, Virginia, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00091702"
319,"NCT00084058","Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIV",,"Completed","No Results Available","HIV Infections","Drug: Lopinavir/ritonavir|Drug: Saquinavir","Life-threatening adverse events attributable to study drugs|dose-limiting toxicity, defined as adverse events of Grade 3 or greater attributable to study drug and require dose reduction or interruption but are not judged to be life-threatening by the protocol team|Pharmacological success, defined as achieving an inhibitory quotient (IQ) of 15 after 2 weeks on high-dose LPV/r without life-threatening or dose-limiting toxicity|virologic success, defined by optimal response (undetectable viral load) at Week 24 or adequate response (0.75 log drop in viral load or more) from baseline to Week 24|immunologic success, defined as a CD4% increase from baseline of 5% or more points by Week 24|minimal criterion for overall success, defined as a 0.75 log drop in viral load or more or 5% point increase in CD4% from baseline to Week 24|virologic failure, defined as an inadequate (less than 0.75 log drop in viral load) or suboptimal (confirmed viral load of greater than 400 copies/ml) response at Week 24","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 17 Years   (Child)","Phase 1|Phase 2","26","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1038|10045|PACTG P1038","null","null","December 2006","June 7, 2004","null","May 21, 2012","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Jacobi Med. Ctr., Bronx, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00084058"
320,"NCT00067769","Internet-based Treatment of Early Childhood Fecal Incontinence",,"Completed","No Results Available","Encopresis","Behavioral: Internet-based intervention UCanPoopToo|Behavioral: treatment as usual","Fecal accident outcomes with online diary data|Success and cure rates|Fecal accident outcomes with retrospective data|Parent knowledge of encopresis|Virginia Encopresis Constipation Apperception Test (VECAT)|Encopresis Cost Analysis","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 12 Years   (Child)","Not Applicable","91","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11116|5R01HD028160-12","October 2003","July 2007","July 2007","August 28, 2003","null","December 7, 2015","University of Virginia Health System, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00067769"
321,"NCT00038480","Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants",,"Completed","No Results Available","HIV Infections","Drug: Lopinavir/Ritonavir","Trough concentration of LPV and pharmacokinetic parameters|Recurrent treatment-related Grade 3 and non-life threatening Grade 4 toxicity or single occurence of life-threatening Grade 4 toxicity|Change in CD4 and CD8 count and percentage from baseline. HIV-1 specific CD4 count and CD8 mediated and humoral responses|Time to virologic failure|Suppression of viral load to less than 400 copies/ml and less than 50 copies/ml","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Months   (Child)","Phase 1","31","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1030|10041|PACTG P1030","null","null","September 2007","June 3, 2002","null","May 21, 2012","Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|SOM Federal University Minas Gerais Brazil NICHD CRS, Minas Gerais, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00038480"
322,"NCT03887533","Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1",,"Recruiting","No Results Available","Niemann-Pick Disease, Type C1","Drug: VTS-270","Safety and Tolerabilty|plasma Cholestane-3B,5a,6B-triol","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","18","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190028|19-CH-0028","April 19, 2019","January 1, 2022","January 1, 2022","March 25, 2019","null","April 16, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03887533"
323,"NCT03882034","Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess",,"Recruiting","No Results Available","Pituitary Disease","Drug: Pegvisomant","Percent change of IGF-1 z-score from baseline to end of study (12 month visit).|Determine the safety and tolerability of pegvisomant in children with GH excess|Normalization of IGF-1 for age and sex from baseline to end of study (12 month visit)|Normalization of growth velocity|Improvement in signs and symptoms of GH excess and quality of life from baseline to end of study (12 month visit)|Left ventricular ejection fraction change on echocardiogram from baseline to end of study (12 month visit).|Reduction of the left ventricular mass index (LVMi) on echocardiogram from baseline to end of study (12 month visit)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 18 Years   (Child, Adult)","Phase 3","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","190071|19-CH-0071","March 27, 2019","January 1, 2022","January 22, 2022","March 20, 2019","null","March 22, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03882034"
324,"NCT00012519","Ritonavir and Indinavir in Children Failing Other Anti-HIV Treatment",,"Completed","No Results Available","HIV Infections","Drug: indinavir sulfate|Drug: ritonavir","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 17 Years   (Child)","Phase 1|Phase 2","29","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1013|10191|ACTG P1013|PACTG P1013","null","null","July 2005","August 31, 2001","null","May 21, 2012","Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Metropolitan Hosp. Ctr., New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|VCU Health Systems, Dept. of Peds, Richmond, Virginia, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00012519"
325,"NCT00006325","Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children",,"Completed","No Results Available","HIV Infections","Drug: Peginterferon alfa-2b","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 16 Years   (Child)","Phase 1","54","NIH","Interventional","Primary Purpose: Treatment","P1017|PACTG P1017|ACTG P1017|11652","null","null","March 2004","August 31, 2001","null","May 22, 2012","Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Connecticut Children's Med Ctr, Farmington, Connecticut, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Harlem Hosp Ctr, New York, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00006325"
326,"NCT00006143","Growth Hormone Treatment of Children With HIV-Associated Growth Failure",,"Completed","No Results Available","HIV Infections","Drug: Somatropin","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 13 Years   (Child)","Not Applicable","102","NIH","Interventional","Primary Purpose: Treatment","P1011|11646|ACTG P1011|PACTG P1011","null","null","July 2002","August 31, 2001","null","May 21, 2012","Phoenix Children's Hosp., Phoenix, Arizona, United States|Childrens Hosp. LA - Dept. of Ped., Div. of Clinical Immunology & Allergy, Los Angeles, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|South Florida CDC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Atlanta, Georgia, United States|Chicago Children's CRS, Chicago, Illinois, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr., Bronx, New York, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|VCU Health Systems, Dept. of Peds, Richmond, Virginia, United States|Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00006143"
327,"NCT00006064","The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children",,"Completed","No Results Available","HIV Infections|HIV Wasting Syndrome|Lipodystrophy","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 12 Years   (Child)","","100","NIH","Observational","","P1010|10814|PACTG P1010|ACTG P1010","June 2000","null","February 2005","August 31, 2001","null","October 29, 2014","Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00006064"
328,"NCT00001118","Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children",,"Completed","No Results Available","HIV Infections","Drug: Enfuvirtide","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","P1005|11642|ACTG P1005|PACTG P1005|T20-204","null","null","December 2002","August 31, 2001","null","May 21, 2012","UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00001118"
329,"NCT00001091","Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens",,"Completed","No Results Available","HIV Infections","Drug: Ritonavir|Drug: Nelfinavir mesylate|Drug: Nevirapine|Drug: Lamivudine|Drug: Stavudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Months to 17 Years   (Child)","Phase 1","200","NIH","Interventional","Primary Purpose: Treatment","ACTG 377|11338|PACTG 377","null","null","October 2000","August 31, 2001","null","May 18, 2012","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Connecticut Children's Med Ctr - Pediatric, Hartford, Connecticut, United States|Yale Univ Med School, New Haven, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Washington Hosp Ctr, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Med College of Georgia, Augusta, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr / Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|King's County Hosp Ctr / Pediatrics, Brooklyn, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Cornell Univ Med College, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00001091"
330,"NCT00000952","A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children",,"Completed","No Results Available","HIV Infections","Drug: Ritonavir|Drug: Lamivudine|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 2 Years   (Child)","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","ACTG 345|10602|PACTG 345","null","null","January 2004","August 31, 2001","null","October 29, 2014","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|NYU Med. Ctr., Dept. of Medicine, New York, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Incarnation Children's Ctr., New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00000952"
331,"NCT00000893","Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children",,"Completed","No Results Available","HIV Infections","Drug: Nelfinavir mesylate|Drug: Efavirenz","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 16 Years   (Child)","Phase 1","103","NIH","Interventional","Primary Purpose: Treatment","ACTG 382|10105|PACTG 382","October 1997","null","December 2002","August 31, 2001","null","June 4, 2015","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Univ. of Mississippi Med. Ctr Children's Hosp., Jackson, Mississippi, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Metropolitan Hosp. Ctr., New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|NYU Med. Ctr., Dept. of Medicine, New York, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000893"
332,"NCT00000879","A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers",,"Completed","No Results Available","HIV Infections|HIV Seronegativity","Biological: ALVAC(2)120(B,MN)GNP (vCP1452)|Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Biological: ALVAC-HIV MN120TMG (vCP205)","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 3 Days   (Child)","Phase 1","48","NIH","Interventional","Masking: Double|Primary Purpose: Prevention","ACTG 326|PACTG 326|10601","null","null","April 2005","August 31, 2001","null","May 18, 2012","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Children's Hosp. of Orange County, Orange, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|Univ. of Pennsylvania Health System, Hosp. of the Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00000879"
333,"NCT00000876","Safety and Effectiveness of CD4-IgG2 in HIV-Positive Children",,"Completed","No Results Available","HIV Infections","Drug: CD4-IgG2","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 12 Years   (Child)","Phase 1","12","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Treatment","PACTG 351|10699|ACTG 351","null","null","November 2006","August 31, 2001","null","May 21, 2012","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Childrens Hosp. LA - Dept. of Ped., Div. of Clinical Immunology & Allergy, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Children's Hosp. of Orange County, Orange, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Texas Children's Hosp. CRS, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00000876"
334,"NCT00000873","A Study on the Effect of High-Calorie Infant Formula on Growth and Nutrition in HIV-Infected Infants",,"Completed","No Results Available","HIV Infections","Drug: Infant Formula","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 17 Days   (Child)","Not Applicable","2400","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 247|PACTG 247|ACTG 844 Substudy|11224","null","null","September 2005","August 31, 2001","null","October 7, 2013","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|Phoenix Childrens Hosp, Phoenix, Arizona, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Connecticut Children's Med Ctr, Farmington, Connecticut, United States|Yale Univ Med School, New Haven, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Arnold Palmer Hosp for Children & Women, Orlando, Florida, United States|Sacred Heart Children's Hosp / CMS of Florida, Pensacola, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Univ of South Florida, Tampa, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Med College of Georgia, Augusta, Georgia, United States|The Med Ctr Inc, Columbus, Georgia, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|Washington Univ School of Medicine, St Louis, Missouri, United States|Cooper Hosp - Univ Med Ctr / UMDNJ - New Jersey Med Schl, Camden, New Jersey, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|St Peter's Med Ctr, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Cornell Univ Med College, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Univ of South Carolina School of Med, Columbia, South Carolina, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Univ of Texas Health Sciences Ctr, San Antonio, Texas, United States|Med College of Virginia, Richmond, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Princess Margaret Hosp, Nassau, Bahamas|Federal University of Minas, Dept. of Pediatrics, Belo Horizonte-MG, Brazil|Hosp Univ Clementino Fraga Filho, Rio de Janeiro RJ, Brazil|Hosp dos Servidores do Estado, Rio de Janeiro, Brazil|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Caguas Regional Hosp, Caguas, Puerto Rico|Mayguez Med Ctr / Regional Immunology Clinic, Mayguez, Puerto Rico|Ponce Univ Hosp, Ponce, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000873"
335,"NCT00000872","Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate|Drug: Nelfinavir mesylate|Drug: Nevirapine|Drug: Lamivudine|Drug: Stavudine|Drug: Zidovudine","Antiretroviral activity of ZDV/3TC/NVP|Durability of viral suppression|Immune competence and HIV-1 specific immune respones with prolonged viral suppression beyond 104 weeks|Antiretroviral activity of ZDV/3TC/NVP/1592U89 regimen|Antiretroviral activity of d4T/3TC/NVP/NFV regimen|Tolerance and pharmacokinetic profile of NFV","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 2 Years   (Child)","Phase 2","55","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACTG 356|10605|PACTG 356","null","null","January 2005","August 31, 2001","null","May 18, 2012","Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Univ. of Mississippi Med. Ctr Children's Hosp., Detroit, Michigan, United States|Nyu Ny Nichd Crs, New York, New York, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Children's Hosp. of the King's Daughters, Infectious Disease, Norfolk, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00000872"
336,"NCT00000864","A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 28 Days   (Child)","Phase 1","60","NIH","Interventional","Primary Purpose: Treatment","ACTG 321|11295|PACTG 321","null","null","January 2001","August 31, 2001","null","May 18, 2012","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Usc La Nichd Crs, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Emory Univ. School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Atlanta, Georgia, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Med. Univ. of South Carolina, Div. of Ped. Infectious Diseases, Charleston, South Carolina, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000864"
337,"NCT00000849","A Study to Test the Safety of Recombinant Interleukin-2 (rIL-2) in HIV-Infected Children",,"Completed","No Results Available","HIV Infections","Drug: Aldesleukin","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Phase 1","27","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","ACTG 299|11275|PACTG 299","null","null","March 2001","August 31, 2001","null","May 21, 2012","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|NYU Med. Ctr., Dept. of Medicine, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Incarnation Children's Ctr., New York, New York, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|VCU Health Systems, Dept. of Peds, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00000849"
338,"NCT00000837","A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children",,"Completed","No Results Available","HIV Infections","Biological: Varicella Virus Vaccine (Live)","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Months to 8 Years   (Child)","Phase 1","127","NIH","Interventional","Primary Purpose: Prevention","PACTG 265|10613|ACTG 265","null","null","November 2005","August 31, 2001","null","February 13, 2015","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|Children's Hosp. of Orange County, Orange, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|The Children's Hosp. (Univ. of Colorado, Denver) P7001 CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|NJ Med. School CRS, Newark, New Jersey, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. Ctr., New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00000837"
339,"NCT00000759","Neurodevelopmental and Neurological Study of Infants and Children With HIV-1 Infection and AIDS in Clinical Trials",,"Completed","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 8 Years   (Child)","","675","NIH","Observational","Observational Model: Natural History","ACTG 188","null","null","null","August 31, 2001","null","June 24, 2005","Mount Sinai Med Ctr, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00000759"
340,"NCT00005669","Metformin to Treat Obesity in Children With Insulin Resistance",,"Completed","Has Results","Hyperinsulinemia|Obesity","Drug: Metformin HCL|Drug: Placebo","Changes in Body Weight as Determined by Body Mass Index-standard Deviation Score (BMI-SDS).|Change in Body Weight as Determined by BMI|Change in Body Weight|Change in Body Fat by DEXA|Change in Body Fat by Bod Pod","Jack Yanovski, M.D.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","6 Years to 12 Years   (Child)","Phase 2","100","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","000134|00-CH-0134","May 2000","August 2009","May 2011","May 22, 2000","April 7, 2011","May 8, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005669"
341,"NCT00000567","High Frequency Ventilation in Premature Infants (HIFI)",,"Completed","No Results Available","Bronchopulmonary Dysplasia|Lung Diseases|Respiratory Distress Syndrome","Procedure: high-frequency ventilation","","National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 1 Year   (Child)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","205","August 1984","null","null","October 28, 1999","null","April 14, 2016","","","https://ClinicalTrials.gov/show/NCT00000567"
342,"NCT02769975","Evaluation of Children With Endocrine and Metabolic-Related Conditions",,"Recruiting","No Results Available","Adrenal Insufficiency|Growth Disorder|Endocrine Diseases|Metabolic Disease|Bone Diseases, Metabolic","","Recruit a diverse population of pediatric subjects with a known or suspected endocrine or metabolic disorder in order to provide NICHD investigators and trainees with hands-on experience related to the diagnosis, management, treatment, and foll...|Provide an option for patients with unusual or challenging endocrine or metabolic conditions, who may or may not be eligible for an existing research protocol, to be evaluated at NIH.|Clinical evaluation of children with unusual or challenging endocrine or metabolic conditions may include whole exome sequencing (WES) or other new molecular technologies to iidentify the molecular genetic etiology|Any prospective (including pilot investigations) or retrospective hypothesis driven research for patients enrolled in this protocol must be approved by the NICHD Office of the Clinical Director and NICHD IRB.|All studies or procedures (other than biospecimens/DNA) that are not clinically indicated need to be explicitly described in the protocol or approved by amendment.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 18 Years   (Child, Adult)","","15000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","160113|16-CH-0113","May 11, 2016","December 31, 2030","December 31, 2030","May 12, 2016","null","August 9, 2018","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02769975"
343,"NCT02225145","Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease",,"Completed","No Results Available","Hemoglobin|Stem Cell Transplant|Aplastic Anemia","","Oocyte vitrification","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 45 Years   (Child, Adult)","","22","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140177|14-CH-0177","August 15, 2014","September 9, 2016","September 20, 2017","August 26, 2014","null","June 1, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02225145"
344,"NCT02141503","Clinical Biomarkers in Alpha-mannosidosis",,"Suspended","No Results Available","Alpha-Mannosidosis","","Identify cerebrospinal fluid biomarkers that could serve as candidate surrogate markers of treatment effect in a future clinical trial.|Establish reliable clinical benchmarks for alpha-mannosidosis.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","5 Years to 60 Years   (Child, Adult)","","10","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","140106|14-CH-0106","May 15, 2014","December 31, 2021","December 31, 2022","May 19, 2014","null","April 15, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02141503"
345,"NCT01681017","Global Network Implementation of Helping Babies Breathe (HBB)",,"Completed","No Results Available","Perinatal Mortality","Behavioral: HBB/ENC Training and Equipment|Other: HBB/ENC supplies","Perinatal Mortality|Facility-based perinatal mortality|Retention of resuscitation knowledge and skills|Number of neonatal resuscitations|Delivery room checklist score|Asphyxia related perinatal mortality|Health seeking behavior|Facility deliveries|Very early newborn death (within 1 day of birth)","NICHD Global Network for Women's and Children's Health|Laerdal Medical|Indiana University School of Medicine|Christiana Care Health Services|Massachusetts General Hospital|Moi Univeristy|Jawaharlal Nehru Medical College|Lata Medical Research Foundation, Nagpur|RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","70704","Other|Industry|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GN HBB Study","September 2012","March 2014","December 2014","September 7, 2012","null","October 14, 2015","Jawaharlal Nehru Medical College, Belgaum, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya","","https://ClinicalTrials.gov/show/NCT01681017"
346,"NCT01313455","Adrenal Hyperplasia Among Young People With PCOS",,"Completed","No Results Available","Adrenal Hyperplasia|Polycystic Ovarian Syndrome|Oligomenorrhea|Obesity|Hyperandrogenism","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","16 Years to 29 Years   (Child, Adult)","","96","NIH","Observational","Time Perspective: Prospective","110119|11-CH-0119","March 10, 2011","null","October 24, 2017","March 11, 2011","null","October 4, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01313455"
347,"NCT01092208","Studies of Autistic Patients: Gene Networks and Clinical Subtypes",,"Terminated","No Results Available","Autism|Tuberous Sclerosis","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Male","4 Years to 18 Years   (Child, Adult)","","11","NIH","Observational","Time Perspective: Retrospective","100084|10-CH-0084","March 17, 2010","null","September 24, 2013","March 24, 2010","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01092208"
348,"NCT00716378","Teenage Passenger Influences on Driving Performance of Teenage Drivers",,"Completed","No Results Available","Motor Vehicle Crash Injuries","Behavioral: Teen Passenger Presence","Risky Driving Behavior","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Male","16 Years to 18 Years   (Child, Adult)","Not Applicable","36","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","999908183|08-CH-N183","July 11, 2008","November 15, 2010","November 15, 2010","July 16, 2008","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00716378"
349,"NCT00556400","Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones",,"Terminated","Has Results","Aplastic Anemia|Menorrhagia|Amenorrhea","Drug: Lo-Ovral Oral Contraceptive Pills|Drug: Placebo - sugar pill","Stop Vaginal Bleeding or Spotting.|Proportion Who Stop Uterine Bleeding by Day 14.|Total Number of Bleeding Days During the First 7 Days.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","12 Years to 55 Years   (Child, Adult)","Phase 1|Phase 2","1","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","080022|08-CH-0022","November 2007","June 2012","June 2012","November 12, 2007","July 11, 2013","July 19, 2013","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00556400"
350,"NCT00507780","Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy",,"Withdrawn","No Results Available","Ovarian Function|Preservation of Ovarian Function","Drug: GnRH antagonist","Antimullerian hormone, ovarian follicle count|Menstrual history","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","10 Years to 21 Years   (Child, Adult)","Phase 4","0","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention","070193|07-CH-0193","July 18, 2007","July 22, 2010","July 22, 2010","July 27, 2007","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00507780"
351,"NCT00504218","Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors and Hematopoietic Stem Cell Transplant Recipients",,"Terminated","No Results Available","Hypopituitarism|Hypogonadism|Thyroid Dysfunction|Bone Diseases, Metabolic","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 24 Years   (Child, Adult)","","62","NIH","Observational","Time Perspective: Other","070192|07-CH-0192","July 17, 2007","null","June 12, 2018","July 19, 2007","null","December 3, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00504218"
352,"NCT00121394","Chlorhexidine Vaginal and Infant Wash in Pakistan",,"Completed","No Results Available","Sepsis|Pregnancy","Procedure: Chlorhexidine vaginal and infant wash","Neonatal death or severe sepsis|Maternal: clinical chorioamnionitis, clinical endometritis, urinary tract infection, sepsis, length of hospitalization, readmission to hospital, death|Neonatal: receipt of antibiotics, duration of hospitalization, readmission to hospital","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|RTI International|University of Alabama at Birmingham|Aga Khan University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","5008","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","GN 09 A|U01HD040607","June 2005","June 2008","June 2008","July 21, 2005","null","July 31, 2014","Civil Hospital Karachi, Karachi, Pakistan","","https://ClinicalTrials.gov/show/NCT00121394"
353,"NCT00361829","The Influence of Maternal Age, Employment Status, and Parenthood Status on Children's Cognitive Development",,"Active, not recruiting","No Results Available","Child Development","","Measures of child adaptive functioning","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 50 Years   (Child, Adult)","","2355","NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","880032|88-CH-0032","February 17, 1988","null","null","August 9, 2006","null","April 8, 2019","Johns Hopkins Medical Center, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Universidade Do Estado Do Rio De Janeiro, Rio de Janeiro, Brazil|University of Saskatchewan, Saskatoon, Canada|Ossan College, Osani, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00361829"
354,"NCT00345436","Exercise in Insulin-Resistant Minority Adolescents",,"Completed","No Results Available","Insulin-Resistance","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","14 Years to 18 Years   (Child, Adult)","","40","NIH","Observational","Time Perspective: Prospective","999906094|06-CH-N094","February 8, 2006","null","May 11, 2011","June 28, 2006","null","July 2, 2017","Childrens National Medical Center, Washington, D.C., District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00345436"
355,"NCT00342706","Building Healthy Teen Relationships and Reproductive Practices to Increase Intervals Between Pregnancies",,"Completed","No Results Available","Teen Pregnancy","Procedure: Community based intervention","Delay of a subsequent pregnancy.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","15 Years to 19 Years   (Child, Adult)","Phase 2","750","NIH","Interventional","Primary Purpose: Treatment","999905083|05-CH-N083","January 10, 2005","April 29, 2011","April 29, 2011","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00342706"
356,"NCT00342667","Clinical, Biochemical, Histological and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients With Preterm Labor and Premature Rupture of Membranes",,"Completed","No Results Available","Preterm Labor|Infant Neurological Disorders","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","15 Years to 45 Years   (Child, Adult)","","4673","NIH","Observational","","999997066|OH97-CH-N066","December 8, 1997","null","null","June 21, 2006","null","November 19, 2018","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States|Seoul National University Hospital, Seoul, Korea, Republic of","","https://ClinicalTrials.gov/show/NCT00342667"
357,"NCT00341302","A Prospective, Observational Study of HIV-Infected Pregnant Women and Their Infants at Clinical Sites in Latin American and Caribbean Countries",,"Completed","No Results Available","HIV","","Primary Outcome Measure: To describe the characteristics of HIV-infected pregnant women and their HIV-exposed children in Latin America, including the rates of and risk factors for mother-to-child transmission|Secondary Outcome Measure: To characterize adverse events according to receipt of and exposure to ARVs (by HIV-infected women during pregnancy and postpartum and by their HIV-exposed but uninfected children in utero and during the first few week...","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","up to 50 Years   (Child, Adult)","","3554","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999902261|02-CH-N261","July 25, 2002","null","null","June 21, 2006","null","September 3, 2018","Hospital General de Agudos ""Jose Maria Ramos Mejia"", Buenos Aires, Argentina|Universidade de Caxias do Sul, Caxias do Sul, Brazil|Universidade Federal de Minas Gerais, Minas Gerais, Brazil|Hospital Geral Nova de Iguacu Setor De DST/AIDS, Nova Iguacu, Brazil|Hospital Conceicao, Porto Alegre, Brazil|Hospital Femina, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de, Porto Alegre, Brazil|Hospital dos Servidores do Estado - RJ, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria, Rio de Janeiro, Brazil|Federal University of Sao Paulo-Escola Paulista de Medicina, Sao Paulo, Brazil|Hospital das Clinicas da Falculdade De Medinica, Sao Paulo, Brazil|Unversity of San Marcos, Lima, Peru","","https://ClinicalTrials.gov/show/NCT00341302"
358,"NCT00341289","Environmental and Behavioral Risk Factors for Childhood Drowning",,"Completed","No Results Available","Drowning","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","1 Year to 20 Years   (Child, Adult)","","1430","NIH","Observational","","999903141|03-CH-N141","March 17, 2003","January 10, 2007","null","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00341289"
359,"NCT00340561","Effect of Experience on Driving Performance in New Teenage Drivers",,"Completed","No Results Available","Learning","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 55 Years   (Child, Adult)","","48","NIH","Observational","","999905070|05-CH-N070","January 2005","null","July 2006","June 21, 2006","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00340561"
360,"NCT00340275","Longitudinal Study of Vaginal Flora",,"Completed","No Results Available","Vaginal Flora","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","15 Years to 44 Years   (Child, Adult)","","5500","NIH","Observational","","999999023|OH99-CH-N023","April 14, 1999","null","November 18, 2010","June 21, 2006","null","July 2, 2017","University of Alabama, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00340275"
361,"NCT00339612","NISDI Pediatric Latin American Countries Epidemiologic Study (PLACES): A Prospective Observational Study of HIV-Infected Children at Clinical Sites in Latin American Countries",,"Completed","No Results Available","HIV","","HIV RNA copies|CD4 + T cell count","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 21 Years   (Child, Adult)","","2129","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","999902270|02-CH-N270","July 30, 2002","null","null","June 21, 2006","null","December 25, 2018","Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|Ricardo de Souza STD/HIV Clinic-Caxias do Sul, Caxias do Sul, Brazil|Hospital Conceicao, Porto Alegre, Brazil|Hospital de Clinicas, Porto Alegre, Brazil|Hospital Femina, Porto Alegre, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital dos Servidores do Estado, Rio de Janeiro, Brazil|Hospital Geral Nova de Iguacu, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira, Rio de Janeiro, Brazil|Instituto de Infectologica Emilio Ribas (IIER), San Paulo, Brazil|Federal University of Sao Paulo-Escola Paulista de Medicina, Sao Paulo, Brazil|Hospital das Clinicas da Falculdade De Medinica, Sao Paulo, Brazil|Hospital Infantil de Mexico Federico Gomez (HIM), Mexico City, Mexico|University of San Marcos, Lima, Peru","","https://ClinicalTrials.gov/show/NCT00339612"
362,"NCT00059540","The Maternal Lifestyle Study (MLS)","MLS","Completed","No Results Available","Cocaine|Substance Abuse|Infant, Newborn|Pregnancy|Pregnant Women|Prenatal Care","","Neurodevelopmental impairment","NICHD Neonatal Research Network|National Institute on Drug Abuse (NIDA)|Administration for Children & Families (ACF)|Substance Abuse and Mental Health Services Administration (SAMHSA)|Eunice Kennedy Shriver Institute of Child Health and Human Development","All","Child, Adult, Older Adult","","11811","Other|NIH|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-NRN-0008|U10HD021397|U10HD021415|U10HD027904|U10HD021385|U10DA024117|U10DA024118|U10DA024119|U10DA024128","May 1993","March 1995","March 2011","April 29, 2003","null","September 21, 2016","University of Miami, Miami, Florida, United States|Wayne State University, Detroit, Michigan, United States|RTI International, Durham, North Carolina, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00059540"
363,"NCT00088712","Event Related Potentials in Infants and Adults",,"Recruiting","No Results Available","Healthy|Child Development","","EEG response","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Months to 45 Years   (Child, Adult)","","500","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","040250|04-CH-0250","July 28, 2004","null","null","August 2, 2004","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00088712"
364,"NCT00071903","The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study",,"Completed","No Results Available","Pseudotumor Cerebri|Cystinosis","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 50 Years   (Child, Adult)","","18","NIH","Observational","","040010|04-CH-0010","October 30, 2003","null","July 18, 2008","November 4, 2003","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00071903"
365,"NCT00009620","Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage","Phenobarbital","Completed","No Results Available","Infant, Newborn|Infant, Low Birth Weight|Infant, Small for Gestational Age|Infant, Premature|Intracranial Hemorrhages","Drug: Phenobarbital|Drug: Saline","Neonatal intracranial hemorrhage or death|Intracranial hemorrhage (grade I, II, III, or IV)|Periventricular leukomalacia|Neurodevelopmental impairment","NICHD Neonatal Research Network|National Center for Research Resources (NCRR)","Female","Child, Adult, Older Adult","Phase 3","610","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","NICHD-NRN-0006|U10HD021385|U10HD027881|U10HD027871|U01HD019897|U10HD027856|U10HD021415|U10HD027880|U10HD027853|U10HD027851|U10HD021364|U10HD027904|M01RR000997|M01RR006022|M01RR000750|M01RR000070|M01RR008084","February 1993","February 1995","February 1997","February 5, 2001","null","March 22, 2019","Stanford University, Palo Alto, California, United States|Yale University, New Haven, Connecticut, United States|George Washington University, Washington, District of Columbia, United States|Emory University, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Wayne State University, Detroit, Michigan, United States|University of New Mexico, Albuquerque, New Mexico, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Brown University, Women & Infants Hospital of Rhode Island, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00009620"
366,"NCT00044174","Dyadic Interactions in Depressed and Non-Depressed Mothers and Their Infants",,"Completed","No Results Available","Depression","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 45 Years   (Child, Adult)","","701","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","020278|02-CH-0278","August 17, 2002","null","null","August 21, 2002","null","April 9, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00044174"
367,"NCT00025870","Studies of Children With Metabolic and Other Genetic Disorders",,"Completed","No Results Available","Genetic Disorder|Metabolic Disease","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 18 Years   (Child, Adult)","","1090","NIH","Observational","","020023|02-CH-0023","October 25, 2001","null","June 23, 2016","October 29, 2001","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00025870"
368,"NCT00006324","Hormonal Birth Control and the Risk of Acquiring HIV",,"Completed","No Results Available","HIV Infections","Drug: Ethinyl estradiol/levonorgestrel|Drug: Medroxyprogesterone acetate","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","16 Years to 35 Years   (Child, Adult)","Not Applicable","6360","NIH","Interventional","Primary Purpose: Treatment","HIVNET 021","December 1999","null","December 2002","August 31, 2001","null","August 7, 2008","Amy Lovvorn, Research Triangle Park, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00006324"
369,"NCT00000751","A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT)",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Anti-HIV Immune Serum Globulin (Human)|Drug: Globulin, Immune|Drug: Zidovudine","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","13 Years to 60 Years   (Child, Adult)","Phase 3","1600","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 185","null","null","August 2007","August 31, 2001","null","September 30, 2008","UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Denver Gen Hosp, Denver, Colorado, United States|Children's Hosp of Denver, Denver, Colorado, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Washington Hosp Ctr, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr, Durham, North Carolina, United States|Case Western Reserve Univ - Pediatric, Cleveland, Ohio, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Hosp of the Univ of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Temple Univ School of Medicine, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|Methodist Hosp Central, Memphis, Tennessee, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Hermann Hosp / Univ Texas Health Science Ctr, Houston, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000751"
370,"NCT00011791","Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients With Congenital Adrenal Hyperplasia",,"Completed","No Results Available","Congenital Adrenal Hyperplasia|Healthy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","9 Years to 40 Years   (Child, Adult)","","61","NIH","Observational","","010096|01-CH-0096","February 22, 2001","null","May 10, 2011","March 1, 2001","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00011791"
371,"NCT00004807","Study of the Pathogenesis of Rett Syndrome",,"Completed","No Results Available","Rett Syndrome","Drug: dextromethorphan|Drug: topiramate|Drug: Donepezil","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Johns Hopkins University|Office of Rare Diseases (ORD)","All","up to 45 Years   (Child, Adult)","Not Applicable","120","NIH|Other","Interventional","Primary Purpose: Treatment","199/12009|JHUSM-KKI-87021203","January 1995","null","null","February 25, 2000","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00004807"
372,"NCT00004656","Nutritional Aspects of Rett Syndrome",,"Completed","No Results Available","Rett Syndrome","Procedure: Metabolic assessment with body composition evaluation","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Baylor College of Medicine|Office of Rare Diseases (ORD)","Female","5 Years to 18 Years   (Child, Adult)","Not Applicable","null","NIH|Other","Interventional","Primary Purpose: Diagnostic","199/11814|BCM-CNRC-H1637","May 1993","null","null","February 25, 2000","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00004656"
373,"NCT00001594","Evaluation and Intervention for the Effects of Osteogenesis Imperfecta",,"Completed","No Results Available","Dwarfism|Osteogenesis Imperfecta","","Rehab Status|Hearing Loss|Dental Status|Bone Density|Growth|Pulmonary Function|Basilar Invagination|Cardiac Valves","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 30 Years   (Child, Adult)","","88","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","970064|97-CH-0064","January 21, 1997","null","null","November 4, 1999","null","April 3, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001594"
374,"NCT00001521","Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia",,"Active, not recruiting","No Results Available","Congenital Adrenal Hyperplasia (CAH)","Drug: Flutamide|Drug: Letrozole|Drug: Hydrocortisone","Adult height|hormone levels (plasma, urine)|Predicted adult height (Bayley-Pinneau)|Weight velocity (SD units)|Growth velocity (SD units)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 18 Years   (Child, Adult)","Phase 2","62","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","960033|96-CH-0033","February 2, 1996","December 31, 2020","December 31, 2020","November 4, 1999","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001521"
375,"NCT00001195","Endocrine Studies of Healthy Children",,"Completed","No Results Available","Healthy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 18 Years   (Child, Adult)","","1247","NIH","Observational","","840169|84-CH-0169","August 28, 1984","null","October 20, 2014","November 4, 1999","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001195"
376,"NCT01084096","Trial of the Use of Antenatal Corticosteroids in Developing Countries","ACT","Completed","No Results Available","Preterm Birth","Behavioral: Increasing use of Antenatal Corticosteroids (ACS)","Neonatal mortality at 28 days in <5th percentile birth weight infants (as a proxy measure for prematurity)|Use of antenatal corticosteroids in women at risk of preterm birth in all the study clusters","NICHD Global Network for Women's and Children's Health|RTI International|Tulane University School of Medicine|Institute for Clinical Effectiveness and Health Policy|University of Alabama at Birmingham|University Teaching Hospital, Lusaka, Zambia|University of Colorado, Denver|Universidad Francisco Marroquín|Jawaharlal Nehru Medical College|Christiana Care Health Services|Aga Khan University|Columbia University|Indiana University|Moi Univeristy|Lata Medical Research Foundation, Nagpur|Massachusetts General Hospital","Female","Child, Adult, Older Adult","Phase 3","6214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GN ACT Study","October 2011","March 2014","April 2014","March 10, 2010","null","July 31, 2014","Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina|Universidad Francisco Marroquin Facultad de Medicina, Guatemala City, Guatemala|JN Medical College, Belgaum, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|Aga Khan University, Karachi, Pakistan|University of Zambia, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT01084096"
377,"NCT01073488","Emergency Obstetric and Neonatal Care: The EmONC Trial","EmONC","Completed","No Results Available","Maternal Morbidity and Mortality|Stillbirth and Neonatal Mortality","Behavioral: Community Mobilization, HBLSS and facility improvement","Composite of either >28 week / >1000 gram stillbirth or 7 day neonatal mortality rate|Maternal mortality rate|Maternal morbidity rates|Stillbirth rate|7-day neonatal mortality rate|28-day neonatal mortality rate|Rates of mothers transported to a referral hospital.|Rates of neonates/infants transported to a referral hospital","NICHD Global Network for Women's and Children's Health","Female","Child, Adult, Older Adult","Not Applicable","267181","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","GN EmONC","December 2008","October 2011","October 2011","February 23, 2010","null","November 18, 2013","University of Buenos Aires, Buenos Aires, Argentina|IMSALUD / San Carlos University, Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belgaum, India|Indira Gandhi Government Medical College, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT01073488"
378,"NCT01073475","Maternal Newborn Health Registry","MNH","Recruiting","No Results Available","Pregnancy Outcome Trends in Low-resource Geographic Areas","Other: There is no intervention associated with this study.","Maternal mortality rate|Stillbirth rate|Early neonatal mortality rate|Cause of maternal death at less than or equal to 42 days|Cause of neonatal death at less than or equal to 28 days","NICHD Global Network for Women's and Children's Health","All","Child, Adult, Older Adult","","750000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CP MNH","May 2008","May 2020","May 2020","February 23, 2010","null","March 4, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Colorado Denver, Aurora, Colorado, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Boston University, Boston, Massachusetts, United States|Columbia University, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Virgina, Charlottesville, Virginia, United States|ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belgaum, Karnataka, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT01073475/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01073475"
379,"NCT00489619","Safe Pregnancy by Infectious Disease Control",,"Completed","No Results Available","Pregnancy|Malaria","","","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|University of North Carolina|Kinshasa School of Public Health","Female","15 Years and older   (Child, Adult, Older Adult)","","2008","Other|NIH","Observational","Time Perspective: Prospective","GN 02 - Pilot|U01HD043475","April 2004","null","March 2005","June 21, 2007","null","July 31, 2014","Binza Maternity, Kinshasa, Congo, The Democratic Republic of the|Kingasani Maternity, Kinshasa, Congo, The Democratic Republic of the","","https://ClinicalTrials.gov/show/NCT00489619"
380,"NCT00136708","First Breath: Neonatal Resuscitation in Developing Countries",,"Completed","No Results Available","Asphyxia Neonatorum","Procedure: Neonatal Resuscitation","Neonatal mortality|Neonatal mortality due to perinatal asphyxia|Hypoxic ischemic encephalopathy|Need for advanced resuscitation|Apgar score at 5 minutes|Perinatal mortality at 7 days|Stillbirth or neonatal mortality|Stillbirth and/or neonatal mortality at 28 days","NICHD Global Network for Women's and Children's Health","All","Child, Adult, Older Adult","Not Applicable","120009","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CP02 FIRST BREATH","March 2005","June 2008","June 2008","August 29, 2005","null","July 31, 2014","Buenos Aires, Argentina|Kinshasa, Congo|Guatemala City, Guatemala|Bhubaneswar, Orissa, India|Belgaum, India|Karachi, Pakistan|Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00136708"
381,"NCT00097123","RCT of Misoprostol for Postpartum Hemorrhage in India",,"Completed","No Results Available","Postpartum Hemorrhage|Pregnancy","Drug: Misoprostol","Incidence of acute postpartum hemorrhage: blood loss ≥ 500 ml within two hours of delivery|Incidence of delayed postpartum hemorrhage and secondary infection (lower abdominal pain, fever and foul discharge)|Transport to higher-level medical facility|Use of uterotonic agents|Blood transfusion|Surgical intervention including curettage, vacuum aspiration for retained placental tissue or hysterectomy|Maternal mortality for 42 days","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|University of Missouri-Columbia|Jawaharlal Nehru Medical College","Female","Child, Adult, Older Adult","Not Applicable","1600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","GN 08|U01HD042372","September 2002","December 2005","December 2005","November 18, 2004","null","July 31, 2014","KLE Society's Jawaharlal Nehru Medical College, Belgaum, Karnataka, India","","https://ClinicalTrials.gov/show/NCT00097123"
382,"NCT00097110","RCT of Antioxidant Therapy to Prevent Preeclampsia in Brazil",,"Completed","No Results Available","Preeclampsia|Eclampsia|HELLP Syndrome|Pregnancy","Drug: Vitamin C and E","Incidence of preeclampsia|Severity of preeclampsia|Incidence of gestational hypertension or preeclampsia|Frequency of abruptio placentae|Incidence of preterm birth|Incidence of small for gestational age|Incidence of low birth weight infants|Biomarker level correlation with preeclampsia","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|University of Cincinnati|Universidade Federal de Pernambuco|Feculdade de Medicina da Universidade de Sao Paulo - Brasil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, Brasil|University of Campinas, Brazil|Hospital de Clinicas de Porto Alegre","Female","Child, Adult, Older Adult","Phase 3","734","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","GN 05|U01HD040565","July 2003","null","December 2006","November 18, 2004","null","November 25, 2013","Federal University of Pernambuco, Recife, Pernambuco, Brazil","","https://ClinicalTrials.gov/show/NCT00097110"
383,"NCT00097097","Neonatal Resuscitation in Zambia",,"Completed","No Results Available","Asphyxia Neonatorum|Neonatal Mortality|Hypoxic Ischemic Encephalopathy","Procedure: Neonatal Resuscitation","Neonatal mortality at 7 days|Neonatal mortality due to perinatal asphyxia|Self efficacy, knowledge, performance, and competence in neonatal resuscitation|Apgar scores at 5 minutes","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|University of Alabama at Birmingham","All","Child, Adult, Older Adult","Phase 3","40000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GN 03|U01HD043464","October 2004","null","November 2006","November 18, 2004","null","July 31, 2014","University of Zambia, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00097097"
384,"NCT00070720","Improving Perinatal Care in Latin America",,"Completed","No Results Available","Episiotomy|Pregnancy","Behavioral: Opinion Leaders, Academic Detailing, Reminders, and Feedback","Episiotomies|Oxytocin use in third stage of labor|Perineal sutures|Postpartum hemorrhage|Birth attendants' readiness to change status","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|Latin American Center for Perinatology|Pan American Health Organization|World Health Organization|Tulane University School of Public Health and Tropical Medicine|University of North Carolina, Chapel Hill","All","Child, Adult, Older Adult","Phase 4","21780","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","GN 01|U01HD040477","September 2003","null","December 2006","October 13, 2003","null","December 17, 2013","Hospital de Clinicas, Montevideo, Uruguay","","https://ClinicalTrials.gov/show/NCT00070720"
385,"NCT00070746","Perinatal Infections in Pakistan",,"Completed","No Results Available","Bacterial Vaginosis|Fetal Membranes, Premature Rupture|Chorioamnionitis|Pregnancy","","","NICHD Global Network for Women's and Children's Health|Global Network for Women's and Children's Health Research|Bill and Melinda Gates Foundation|John E. Fogarty International Center (FIC)|National Center for Complementary and Integrative Health (NCCIH)|National Institute of Dental and Craniofacial Research (NIDCR)|National Cancer Institute (NCI)|RTI International|University of Alabama at Birmingham|Aga Khan University","Female","Child, Adult, Older Adult","","1500","Other|NIH","Observational","Time Perspective: Prospective","GN 09|U01HD040607","June 2003","null","July 2005","October 10, 2003","null","July 31, 2014","Health clinic, Hyderabad, Pakistan","","https://ClinicalTrials.gov/show/NCT00070746"
386,"NCT03106493","Upstate New York Infant Development Screening Program","Upstate KIDS","Active, not recruiting","No Results Available","Obesity|Blood Pressure|Motor Delay|Developmental Delay|Asthma|Allergies","Other: None (observational)","Blood Pressure|Motor milestone development","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|New York State Department of Health|University at Albany","All","Child, Adult, Older Adult","","6171","NIH|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HHSN275201400013C","July 1, 2008","September 2019","September 2019","April 10, 2017","null","June 27, 2017","","","https://ClinicalTrials.gov/show/NCT03106493"
387,"NCT01322529","Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be","nuMoM2b","Completed","No Results Available","Pregnancy|Pregnancy Complications","","Adverse pregnancy outcome|Preterm birth|Spontaneous preterm birth|Indicated preterm birth|Spontaneous pregnancy loss less than 20 weeks","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)|Office of Research on Women's Health (ORWH)","Female","13 Years and older   (Child, Adult, Older Adult)","","10038","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD-nuMoM2b-001|1U10HD063036-01|1U10HD063072-01|1U10HD063047-01|1U10HD063037-01|1U10HD063041-01|1U10HD063020-01|1U10HD063046-01|1U10HD063048-01|1U10HD063053-01","September 2010","May 2015","May 2015","March 24, 2011","null","January 12, 2016","Fountain Valley Regional Hospital and Medical Center- UCI MFM private practice, Fountain Valley, California, United States|Long Beach Memorial Medical Center, Women's and Children's Hospital - Women's Perinatal Group, OB Clinic, Long Beach, California, United States|University of California, Irvine, Medical Center - Prenatal care clinics and private practice, Orange, California, United States|Christiana Care Health Systems, Newark, Delaware, United States|Northwestern University, Chicago, Illinois, United States|Indiana University School of Medicine OB/GYN, Indianapolis, Indiana, United States|Columbia University Medical Center- Department of Obstetrics and Gynecology Division of Maternal Fetal Medicine, New York, New York, United States|Case Western Reserve University, MetroHealth Medical Center, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|West Penn Allegheny Health System, Pittsburgh, Pennsylvania, United States|Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|McKay Dee Hospital, Ogden, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|University of Utah, Salt Lake City, Utah, United States|Intermountain Medical Center, Salt Lake City, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01322529"
388,"NCT00782028","Integrating Well-Woman and Well-Baby Care to Improve Parenting and Family Wellness",,"Unknown status","No Results Available","Primary Care","Other: Centering parenting/Group well child care|Other: Standard Care","Improved maternal and child health behaviors will be measured using a computer assisted interview.|Better health care utilization for babies will be measured using Medical records review.|Better psychosocial outcomes for mothers, fathers and babies will be measured using a computer assisted interview.|Improved parenting skills will be assessed using a computer assisted inteview.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","170","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","R21 HDJ2810-01A1","October 2008","May 2010","May 2010","October 29, 2008","null","October 29, 2008","","","https://ClinicalTrials.gov/show/NCT00782028"
389,"NCT00729144","Adaptive Behaviors Among Women With Bowel Incontinence: The ABBI Trial","ABBI","Completed","No Results Available","Fecal Incontinence","","Adaptation Index and domains|Fecal Incontinence Severity Index (FISI)|Medical Outcome Study Short-Form (SF-12)|Pelvic Floor Distress Inventory (PFDI) and Pelvic Floor Impact Questionnaire (PFIQ)|Modified Manchester Health Questionnaire|Patient Global Impression of Improvement (PGI-I)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Office of Research on Women's Health (ORWH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","Female","Child, Adult, Older Adult","","133","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1J06-FI|U01HD041249|U10HD041250|U10HD041261|U10HD041267|U10HD054136|U10HD054214|U10HD054215|U10HD054241","June 2008","July 2010","July 2010","August 7, 2008","null","January 11, 2011","The University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, San Diego Medical Center, La Jolla, California, United States|Kaiser Permanente, San Diego, California, United States|Loyola University Medical Center, Maywood, Illinois, United States|Duke University, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Texas Southwestern, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00729144"
390,"NCT00494169","Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders",,"Recruiting","No Results Available","Hypogonadotropic Hypogonadism|Kallmann Syndrome|Puberty, Delayed|Puberty, Precocious|GnRH Deficiency","","Identification of DNA abnormalities","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","5000","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","U54HD028138","January 1999","May 2023","May 2024","June 29, 2007","null","February 5, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00494169"
391,"NCT00438516","Follow-up of Families in Early Preventive Intervention","MemphisYear9","Completed","No Results Available","Child Rearing|Adolescent Development|Reproductive Behavior|Risk Reduction Behavior","Behavioral: nurse home visitation","interval between birth of first and second children;|cumulative subsequent births per year following birth of the first child through the first child's 9th birthday;|duration of mother's relationship with current partner;|being partnered with, cohabiting with, or married to the child's biological father;|her sense of mastery;|duration of use of welfare (AFDC and TANF) and food stamps per year following birth of the first child;|the counts of maternal arrests and days jailed,|the count of substances used (3 or more drinks of alcohol 3 or more times per month in the last year, use of marijuana, and use of cocaine since last interview at child age 6)|children's grade point averages in reading, math, and behavior (conduct) from their school records|children's achievement test scores|teacher report of antisocial behavior|maternal report of child disruptive behavior disorders and depressive and anxiety disorders|counts of subsequent miscarriages, abortions, and low-birth-weight newborns;|women's reported participation in the workforce;|their depression;|whether they had experienced physical violence from any of their partners since their first child was 6;|and the portion of time their current partners were employed while they were together following birth of the first child|number of times children were retained in grades 1-3|placement in special education|teachers' assessments of children's behavior|children's deaths","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Colorado, Denver","Female","Child, Adult, Older Adult","Not Applicable","627","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","R01HD043492|5R01MH061428-02","June 2000","null","March 2003","February 22, 2007","null","January 15, 2008","University of Rochester School of Nursing, Rochester, New York, United States","","https://ClinicalTrials.gov/show/NCT00438516"
392,"NCT00419458","Inspiratory Muscle Training in Ventilator Dependent Patients",,"Completed","No Results Available","Failure to Wean|Respiratory Failure|Ventilator Dependent","Procedure: inspiratory muscle strength training","ventilator dependent status|breathing patterns during failed and passed unsupported breathing trials|maximal inspiratory pressure","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years and older   (Child, Adult, Older Adult)","Phase 1","150","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","NICHD 5R01HD42705","February 2004","July 2009","July 2009","January 8, 2007","null","November 9, 2009","Deprtment of Physical Therapy/Shands Hospital at the University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00419458"
393,"NCT00392756","Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)",,"Recruiting","No Results Available","Kallmann Syndrome|Hypogonadotropic Hypogonadism|GnRH Deficiency","Drug: gonadotropin releasing hormone (GnRH)","endogenous LH secretion pattern|testicular volume|sperm count","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","800","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","U54HD028138-024|5U54HD028138","April 1989","February 2021","February 2023","October 26, 2006","null","February 5, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00392756"
394,"NCT00364949","Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands",,"Completed","Has Results","Polycystic Ovary Syndrome","","Estradiol Level in Female Offspring|Androstenedione Level in Female Offspring|Testosterone Level in Female Offspring|17-hydroxyprogesterone Level in Female Offspring|Dihydrotestosterone Level in Female Offspring|Dehydroepiandrosterone Level in Female Offspring|Infant Birth Weight (Male and Female)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","70","NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","P50HD044405","January 2003","July 2012","July 2012","August 16, 2006","August 18, 2010","April 10, 2013","Northwestern University School of Medicine, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00364949"
395,"NCT00147433","The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children",,"Unknown status","No Results Available","Child Development Disorders|Pregnancy|Subclinical Hypothyroidism","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","5000","NIH","Observational","Observational Model: Case Control|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective","R01HD044111","February 2004","null","November 2008","September 7, 2005","null","March 31, 2006","Foundation for Blood Research, Scarborough, Maine, United States","","https://ClinicalTrials.gov/show/NCT00147433"
396,"NCT00098215","Pediatric Residency Training On Tobacco",,"Unknown status","No Results Available","Tobacco Use Disorder","Behavioral: Pediatric residency training on tobacco","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Phase 2","4000","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","1R01HD40683-1","March 2001","null","February 2006","December 6, 2004","null","November 10, 2005","UMDNJ-Robert Wood Johnson Medical School, Camden, New Jersey, United States|Mount Sinai School of Medicine (Jersey City Program), Jersey City, New Jersey, United States|Jersey Shore Medical Center, Neptune, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|St. Joseph's Hospital and Medical Center, Paterson, New Jersey, United States|Lincoln Medical Center, Bronx, New York, United States|Bronx/Lebanon Hospital, Bronx, New York, United States|Long Island College Hospital, Brooklyn, New York, United States|Woodhull Medical and Mental Health Center, Brooklyn, New York, United States|Brooklyn Hospital Center Program, Brooklyn, New York, United States|Nassau County Medical Center, East Meadow, New York, United States|New York Flushing Hospital Medical Center, Flushing, New York, United States|Winthrop-University Hospital Program, Mineola, New York, United States|New York and Presbyterian Hospital (Cornell Campus) Program, New York City, New York, United States","","https://ClinicalTrials.gov/show/NCT00098215"
397,"NCT00070850","Prenatal Screening For Smith-Lemli-Opitz Syndrome",,"Completed","No Results Available","Smith-Lemli-Opitz Syndrome|Pregnancy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","1800","NIH","Observational","Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective","R01HD038940","April 2001","null","July 2005","October 13, 2003","null","July 2, 2007","Foundation for Blood Research, Scarborough, Maine, United States","","https://ClinicalTrials.gov/show/NCT00070850"
398,"NCT00069563","Improving Mental Health Services for Economically Disadvantaged Children: Training Teachers",,"Completed","No Results Available","Psychopathology","Behavioral: Reaching Educators, Children, and Parents (RECAP)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Not Applicable","93","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2P30HD015052|1R01MH054237|NICHD-0521","September 1995","null","September 2000","September 30, 2003","null","June 24, 2005","Department of Psychology and Human Development, Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00069563"
399,"NCT00068913","Evaluating the Effectiveness of a Dichloroacetate in MELAS Syndrome",,"Unknown status","No Results Available","MELAS Syndrome","Drug: Dichloroacetate","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years and older   (Child, Adult, Older Adult)","Phase 2","35","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment","P01HD032062","March 2000","null","null","September 11, 2003","null","June 24, 2005","New York Presbyterian Hospital, New York City, New York, United States","","https://ClinicalTrials.gov/show/NCT00068913"
400,"NCT00065845","Colpopexy and Urinary Reduction Efforts (CARE) Protocol","CARE","Completed","No Results Available","Urinary Incontinence, Stress|Uterine Prolapse|Vaginal Prolapse","Procedure: Burch urethropexy at time of sacrocolpopexy","Stress urinary continence|Complications at surgery|Occurrence of other lower urinary tract symptoms|Other pelvic symptoms and health-related quality of life","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","322","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","U01HD041249|U10HD041268|U10HD041248|U10HD041250|U10HD041261|U10HD041263|U10HD041269|U10HD041267","April 2002","March 2007","April 2007","August 5, 2003","null","January 11, 2011","The University of Alabama at Birmingham, Birmingham, Alabama, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00065845"
401,"NCT00065819","HIV Symptom Management Program for African American Mothers",,"Completed","No Results Available","HIV Infections","Behavioral: HIV Symptom Education Program","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Nursing Research (NINR)","Female","Child, Adult, Older Adult","Phase 3","null","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01NR004416|RR000466GCRC","September 1996","null","August 1999","August 4, 2003","null","June 24, 2005","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00065819"
402,"NCT00065299","Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)",,"Completed","No Results Available","Phenylketonuria","Behavioral: Restricted phenylalanine diet","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Not Applicable","572","NIH","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-PKU|1N01HD23148|1N01HD23155|1N01HD23156","May 1984","null","April 2000","July 22, 2003","null","June 24, 2005","University of Southern California School of Medicine, Los Angeles, California, United States|University of Illinois at Chicago, Chicago, Illinois, United States|University of Texas Medical Branch at Galveston, Galveston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00065299"
403,"NCT00065078","Providing Birth Control Through Home Health Visits",,"Unknown status","No Results Available","Pregnancy","Procedure: Home dispensing of contraception","Pregnancy|Sexually Transmitted Disease Screening","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Not Applicable","600","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R01HD042423","June 2003","null","July 2005","July 18, 2003","null","September 13, 2005","Clackamas County Public Health Division, Oregon City, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00065078"
404,"NCT00061412","Comprehensive Program to Improve Reading and Writing Skills in At-Risk and Dyslexic Children",,"Completed","No Results Available","Dyslexia|Learning Disorders","Behavioral: Comprehensive program to improve reading and writing skills","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years and older   (Child, Adult, Older Adult)","Not Applicable","2500","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment","2P50HD33812-6","December 1995","null","November 2005","May 28, 2003","null","September 28, 2006","University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00061412"
405,"NCT00061295","Treadmill Training With Body Weight Support in Patients With Spinal Cord Injury",,"Unknown status","No Results Available","Spinal Cord Injury","Procedure: Body weight support treadmill training","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1","null","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Treatment","1U01HD037460-01","March 1999","null","February 2004","May 28, 2003","null","June 24, 2005","Upstate Medical University, Miami, Florida, United States","","https://ClinicalTrials.gov/show/NCT00061295"
406,"NCT00060697","A Mother's Role in Delaying Onset of Sexual Activity in Her Children",,"Unknown status","No Results Available","Child Behavior|Adolescent Behavior","Behavioral: Adolescent sexual activity education for mothers","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 85 Years   (Child, Adult, Older Adult)","Phase 2","1300","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single|Primary Purpose: Prevention","5R01HD39541-2","December 2000","null","May 2005","May 12, 2003","null","June 24, 2005","Emory University, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT00060697"
407,"NCT00059709","Learning to Resolve Family Conflict",,"Completed","No Results Available","Conflict|Family Relations","Procedure: Mediated Negotiation Training","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years and older   (Child, Adult, Older Adult)","Not Applicable","360","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training","5R01HD38895-2","August 2000","null","null","May 5, 2003","null","April 3, 2007","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT00059709"
408,"NCT00059683","Ultrasound-indicated Cerclage to Prevent Premature Birth in High-risk Women",,"Completed","No Results Available","Labor, Premature","Procedure: cervical cerclage","Incidence of preterm birth less than 35 weeks' gestation|Gestational age at birth","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Alabama at Birmingham","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","300","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","U01HD039939-01A1","January 2003","November 2007","October 2009","May 5, 2003","null","September 30, 2014","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00059683"
409,"NCT00059553","Retraining Walking After Spinal Cord Injury",,"Unknown status","No Results Available","Spinal Cord Injuries|Quadriplegia|Paraplegia|Central Cord Syndrome|Brown-Sequard Syndrome","Behavioral: Locomotor treadmill training with body weight support","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|US Department of Veterans Affairs","All","6 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","16","NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K01HD001348","May 2000","null","January 2005","April 29, 2003","null","June 18, 2009","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT00059553"
410,"NCT00057291","Effect of Improving Caregiving on Early Mental Health",,"Completed","No Results Available","Child Development Disorders","Behavioral: Responsive caregiving","children's physical growth|Children's development (mental, motor, social and emotional)","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 85 Years   (Child, Adult, Older Adult)","Not Applicable","1521","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","5R01HD39017-2","April 2000","March 2006","March 2006","April 1, 2003","null","October 29, 2014","Baby Home #13, St. Petersburg, Canal Gnboedora 98, Russian Federation","","https://ClinicalTrials.gov/show/NCT00057291"
411,"NCT00056927","Anti-Smoking Program for Parents: Effects on Child Smoking",,"Completed","No Results Available","Smoking","Behavioral: Anti-smoking Socialization Program","Initiation of cigarette smoking -- 3 years post treatment|Susceptibility for initiation of cigarette smoking -- 1 year post treatment","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years and older   (Child, Adult, Older Adult)","Not Applicable","1007","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Educational/Counseling/Training","2R01HD36514-5","September 1997","null","August 2002","March 27, 2003","null","October 2, 2006","","","https://ClinicalTrials.gov/show/NCT00056927"
412,"NCT00006429","Treadmill Training for Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Procedure: body weight-supported treadmill training","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","200","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single","NICHD-0103|U01HD037439","March 1999","February 2004","February 2004","November 2, 2000","null","September 26, 2016","Rancho Los Amigos Medical Center, Downey, California, United States|Shepherd Center, Atlanta, Georgia, United States|Ohio State University, Columbus, Ohio, United States|Six Franklin Plaza, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Ottawa, Ottawa, Ontario, Canada|McGill University, Montreal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT00006429"
413,"NCT00006426","Achilles Tendon Lengthening in Patients With Diabetes to Prevent Foot Ulcers",,"Completed","No Results Available","Diabetes Mellitus|Foot Ulcer|Peripheral Neuropathy","Procedure: Achilles tendon-lengthening surgery","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Phase 1","60","NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NICHD-0109|1R01HD036802","August 1998","null","May 2003","November 2, 2000","null","June 24, 2005","Barnes-Jewish Hospital, Orthopedic Surgery, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00006426"
414,"NCT03883165","How do the Neck Muscles Influence Head Acceleration During Sport-associated Impact Events in High School Athletes?",,"Not yet recruiting","No Results Available","Sport-related Concussion|Brain Concussion|Healthy","Other: high-intensity neck strengthening|Other: low-intensity neck strengthening|Other: Control group","Mean area under the net head acceleration vs. time curve during direct loading, with anticipatory bracing.|Mean area under the net head acceleration vs. time curve during indirect loading, with anticipatory bracing.","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 19 Years   (Child, Adult)","Not Applicable","108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HUM00152807|1R01HD093733-01A1","May 2019","February 2023","February 2023","March 20, 2019","null","April 10, 2019","","","https://ClinicalTrials.gov/show/NCT03883165"
415,"NCT03882957","Trial on the Effect of Media Multi-tasking on Attention to Food Cues and Cued Overeating",,"Not yet recruiting","No Results Available","Attention Concentration Difficulty|Obesity, Childhood","Behavioral: Sustained attention|Behavioral: media multi-task|Other: Video","Amount of time spent looking at food cues while playing a media game|Amount of snack foods consumed post-intervention|Daily usual media multi-tasking","Dartmouth-Hitchcock Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Dartmouth College","All","13 Years to 17 Years   (Child)","Not Applicable","125","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","D19065|1R21HD097475-01","April 2019","April 2021","April 2021","March 20, 2019","null","March 25, 2019","Dartmouth-Hithchock Medical Center, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT03882957"
416,"NCT03877965","Pharmacokinetics and Safety Profile of Digoxin in Infants With Single Ventricle Congenital Heart Disease","DGX01","Not yet recruiting","No Results Available","Congenital Heart Disease","Drug: Digoxin","Plasma concentrations of dixogin|Number of adverse events related to study procedures and serious, unexpected, suspected adverse reactions related to digoxin|Number of participants with tachyarrythmias|Number of participants with second and third degree atrioventricular conduction block|Number of participants with sinus bradycardia|Number of participants with need for temporary or permanent pacing|Frequency of death|PR interval|QRS duration|QT interval|Corrected QT interval using Bazett's formula","Christoph P Hornik, MD MPH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation|Duke University","All","up to 6 Months   (Child)","","48","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00102130|NICHD-2018-DGX01|HHSN27500002","April 15, 2019","November 15, 2020","November 15, 2020","March 18, 2019","null","March 19, 2019","","","https://ClinicalTrials.gov/show/NCT03877965"
417,"NCT03866811","Reducing Teen Pregnancy in the Emergency Department","ERICA","Recruiting","No Results Available","Reproductive Behavior|Sexual Behavior|Adolescent Behavior|Contraception","Behavioral: Dr. Erica","Potential Efficacy: Effective Contraception Initiation Rates [Time Frame: Enrollment, 12 weeks post-enrollment (2 weeks post close of intervention)]|Potential Efficacy: Contraceptive at Last Intercourse Rates [Time Frame: Enrollment, 12 weeks post-enrollment (2 weeks post close of intervention)]|Feasibility: Percentage of refusal [Baseline at enrollment]|Feasibility: Opt outs measured via mobile platform [Time Frame: Enrollment, 12 weeks post-enrollment (2 weeks post close of intervention)]|Feasibility: Loss to follow up measured via online or telephone survey [Close of intervention at 12 weeks]|Feasibility/Acceptability: Interaction with text messages measured via mobile platform provider [[Time Frame: Enrollment, 12 weeks post-enrollment (2 weeks post close of intervention)]|Acceptability: Satisfaction with the intervention measured via online or telephone survey [Time Frame: Enrollment, 12 weeks post-enrollment (2 weeks post close of intervention)]","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 19 Years   (Child, Adult)","Phase 2","250","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1K23HD096060-01","March 3, 2019","October 31, 2020","October 31, 2020","March 7, 2019","null","March 7, 2019","Morgan Stanley Children's Hospital Emergency Department, Manhattan, New York, United States","","https://ClinicalTrials.gov/show/NCT03866811"
418,"NCT03812159","Clinical Feasibility Study of Preoperative Surgical Planning",,"Not yet recruiting","No Results Available","Craniosynostoses","Device: iCSPlan","To evaluate the feasibility of a surgical planning software (iCSPlan) for open cranial vault reconstructions assessed by how often will the surgeon use or discard the surgical plan|To evaluate the utility of the surgical planning software (iCSPlan) assessed by a 5-point Likert scale questionnaire.|To evaluate the quality of the surgical strategy and the surgical outcome built by the surgical planning software (iCSPlan) surgeons will complete a 5-point Likert scale questionnaire.|To evaluate the impact of the surgical planning software (iCSplan) assessed by the difference in the length of surgery if the plan is used.|To evaluate the intra-operative impact of using a surgical planning software (iCSPlan) assessed by the amount of blood loss, and thus, the amount of transfusion needed.|To evaluate the postoperative impact of undergoing a cranial vault reconstruction following the surgical planning software (iCSPlan) measured by the complications encountered 30-days after the surgery.|To evaluate the postoperative impact of undergoing a cranial vault reconstruction following the surgical planning software (iCSPlan) measured by the length of stay.","Gary F. Rogers, MD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Research Institute","All","up to 18 Years   (Child, Adult)","Not Applicable","128","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pro00011015|R42HD081712","May 1, 2019","February 20, 2021","February 20, 2021","January 23, 2019","null","March 28, 2019","Childrens National Medical Center, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT03812159"
419,"NCT03800394","Pharmacokinetics of Intracellular TFV-DP and FTC-TP in HIV-infected Adolescents",,"Recruiting","No Results Available","Human Immunodeficiency Virus (HIV)|Tuberculosis|Coinfection","Other: Observational PK study","Average concentration (Cav) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.|Area under the time-concentration curve 0-24 hours (AUC0-24h) of intracellular TFV-DP and FTC-TP in Ghanaian HIV-infected adolescents.|Cav of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.|AUC0-24h of TFV-DP and FTC-TP PK in HIV-infected adolescents with and without TB coinfection.|Effect of age on TFV-DP and FTC-TP Cav.|Effect of age on TFV-DP and FTC-TP AUC0-24h .|Intracellular TFV-DP and FTC-TP Cav in adolescents compared to that in historical adult controls.|Intracellular TFV-DP and FTC-TP AUC0-24h in adolescents compared to that in historical adult controls.|Relationship between Adenosine triphosphate (ATP)-binding cassette subfamily C, member 2 (ABCC2), member 4 (ABCC4) and member 10 (ABCC10) SNPs and TFV-DP and FTC-TP AUC0-24h.|Prevalence and covariates of intracellular TFV-DP Cav < 95 fmol/106 cells in adolescents.","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 19 Years   (Child, Adult)","","54","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","IRB201801820 - PKAdol|2R01HD071779","January 28, 2019","August 31, 2022","August 31, 2023","January 11, 2019","null","January 30, 2019","Kwame Nkrumah University of Science and Technology, Kumasi, Ghana","","https://ClinicalTrials.gov/show/NCT03800394"
420,"NCT03766191","Genetic Predisposition to Food Cue Reactivity in Children",,"Recruiting","No Results Available","Childhood Obesity","Behavioral: Food Ads|Other: Non-food Ads","Food-cue-related neural activity|Food-cue-related Eating in the Absence of Hunger (EAH)|Change in BMI","Dartmouth-Hitchcock Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Dartmouth College","All","8 Years to 12 Years   (Child)","Not Applicable","330","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","D19064|1R01HD092604","January 10, 2019","December 31, 2023","December 31, 2024","December 6, 2018","null","March 25, 2019","Dartmouth-Hitchcock, Lebanon, New Hampshire, United States","","https://ClinicalTrials.gov/show/NCT03766191"
421,"NCT03764761","Storybook Reading in Individuals With Down Syndrome",,"Recruiting","No Results Available","Down Syndrome|Augmentative and Alternative Communication","Device: AAC Technology - Standard of Care|Device: AAC Technology - non-optimal integrated arrangement","Percent of visual fixation time on meaningful and non meaningful stimuli|Number of times the participant communicates during the intervention","Penn State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 35 Years   (Child, Adult)","Not Applicable","15","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility","Storybook|R01HD083381-01A1","April 1, 2018","November 30, 2020","November 30, 2020","December 5, 2018","null","December 5, 2018","11 Ford Building, University Park, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03764761"
422,"NCT03731325","Episodic Future Thinking and Weight-Loss",,"Not yet recruiting","No Results Available","Overweight and Obesity","Behavioral: Episodic Future Thinking Group|Behavioral: Healthy Thinking Group","BMI for parents Percent over BMI for children|Weight|Waist Circumference|Delayed discounting","State University of New York at Buffalo|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Washington University School of Medicine","All","10 Years to 14 Years   (Child)","Not Applicable","80","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","201807151|R01HD080292","November 12, 2018","July 5, 2019","July 5, 2019","November 6, 2018","null","November 6, 2018","","","https://ClinicalTrials.gov/show/NCT03731325"
423,"NCT03719339","VIRTUUS Children's Study","VIRTUUS","Recruiting","No Results Available","Renal Transplant Rejection|Pediatric Kidney Disease|End Stage Renal Disease|Nephropathy|BK Virus (Nephropathy)|Antibody-mediated Rejection|Acute Cellular Graft Rejection","","To investigate whether the adult urinary cell 3-gene signature is diagnostic and prognostic of ACR in pediatric kidney allograft recipients.|To evaluate whether a combined metabolite and the 3-gene urinary mRNA signature is diagnostic and prognostic of ACR.|To test the hypothesis that BKV-VP-1 mRNA levels in urinary cells are diagnostic of BKVN, and to test the hypothesis that a two variable prediction model composed of urinary cell level of PAI-1 mRNA and serum creatinine levels.|To create a repository of DNA samples from urine, saliva, discarded blood and tissue, and deceased donor blood and tissue.","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 18 Years   (Child, Adult)","","450","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","17-013841|1R01HD091185-01","August 10, 2017","May 31, 2022","April 30, 2023","October 25, 2018","null","October 25, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|CHOP, Philadelphia, Pennsylvania, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03719339"
424,"NCT03713034","An Accessible Digital Intervention to Promote HIV Testing/Counseling and Prevention Among Adolescents",,"Recruiting","No Results Available","HIV Prevention","Other: HTC game|Other: Control game","HTC Rate|HIV Knowledge","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","296","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","1604017531_II|5R42HD088317-03","November 1, 2018","November 15, 2021","April 15, 2022","October 19, 2018","null","January 16, 2019","Yale School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT03713034"
425,"NCT03684512","Promotion of Physical Activity in Adolescents With Intellectual and Developmental Disabilities",,"Recruiting","No Results Available","Adolescent Behavior|Intellectual Disability|Down Syndrome|Physical Activity","Behavioral: Group Exercise Sessions|Behavioral: Individual Support Sessions|Behavioral: Facebook Group","Change in Physical Activity|Change in Parent Physical Activity|Change in Sedentary Time|Change in Parent Sedentary Time|Change in Cardiovascular Fitness|Change in Muscular Strength|Change in Motor Ability|Change in Quality of Life","University of Kansas|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 21 Years   (Child, Adult)","Not Applicable","114","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","STUDY00140784|R01HD094704","January 7, 2019","July 24, 2022","January 24, 2023","September 25, 2018","null","January 18, 2019","University of Kansas, Lawrence, Kansas, United States","","https://ClinicalTrials.gov/show/NCT03684512"
426,"NCT03625570","Power Training Combined With Interval Treadmill Training","PT³","Recruiting","No Results Available","Cerebral Palsy|Central Nervous System Diseases|Brain Damage, Chronic","Behavioral: Power training combined with interval treadmill training|Behavioral: Strength training combined with traditional treadmill training","Change in Self-selected gait speed|Change in Peak power|Change in Average strides per day|Change in Fast gait speed (m/s)|Change in One minute walk test (m)|Change in Cross-sectional area|Change in Isokinetic muscle strength|Change in Walking intensity - stride rates (strides/minute)|Change in Patient-Reported Outcomes Measurement Information System (PROMIS v2.0 Pediatric Profile 49","Louisiana State University Health Sciences Center in New Orleans|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Washington","All","10 Years to 17 Years   (Child)","Not Applicable","48","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD091089","October 1, 2018","January 30, 2023","June 30, 2023","August 10, 2018","null","August 10, 2018","Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03625570"
427,"NCT03574129","Adolescent Transition To Adult Care for HIV-infected Adolescents in Kenya","ATTACH","Not yet recruiting","No Results Available","Adolescent Behavior|HIV|Transition|Adolescent Development","Behavioral: Adolescent Transition Package","Disclosure|Effective transition|Adolescent satisfaction with the transition process|Health care worker satisfaction with the transition process|Age at transition specific-milestones|Time to transition specific-milestones|Selected cost measures to be used in future cost-modeling","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 24 Years   (Child, Adult)","Not Applicable","4000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00001756|1R01HD089850-01","January 4, 2019","January 4, 2021","June 4, 2021","June 29, 2018","null","June 29, 2018","","","https://ClinicalTrials.gov/show/NCT03574129"
428,"NCT03494621","Infant Care Practices Study","ICP","Recruiting","No Results Available","Sudden Infant Death","Behavioral: Protecting Babies While they Sleep Curriculum","Implementation of safe sleeping practices|Change in Safe Sleep knowledge|Change in beliefs regarding infant safe sleep|Change in safe sleep practice","Avera McKennan Hospital & University Health Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 49 Years   (Child, Adult)","Not Applicable","150","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2017088|R01HD080544-01","March 28, 2018","September 30, 2019","September 30, 2020","April 11, 2018","null","April 11, 2018","Avera Research Institute, Rapid City, South Dakota, United States","","https://ClinicalTrials.gov/show/NCT03494621"
429,"NCT03382132","momHealth: Multiple Health Behavior Change Intervention in Teen Pregnancy & Parenting Using Mobile Technology","momHealth","Recruiting","No Results Available","Health Behavior","Behavioral: momHealth|Behavioral: Standard of Care","Duration of breastfeeding|Consumption of ""red"" foods per day|Minutes of moderate to vigorous physical activity per week|Change in depressive symptoms|Rate of any and exclusive breastfeeding","University of Kansas Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 20 Years   (Child, Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","STUDY00141254|R21HD088913-01A1","November 20, 2017","May 30, 2019","May 30, 2019","December 22, 2017","null","July 13, 2018","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT03382132"
430,"NCT03275168","Developing a Dyadic Intervention for Sexually Transmitted Infection (STI)/HIV Prevention in Youth",,"Recruiting","No Results Available","Exposure to Sexually Transmissible Disorder (Event)","Behavioral: Intervention|Behavioral: Individual evidence-based STI/HIV prevention intervention","Feasibility|Acceptability","Johns Hopkins University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years to 30 Years   (Child, Adult)","Not Applicable","40","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","IRB00148707|1R21HD090498-01A1","January 15, 2018","November 1, 2019","November 1, 2020","September 7, 2017","null","February 5, 2019","Johns Hopkins Medicine, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03275168"
431,"NCT03243552","Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD","ACEP4","Recruiting","No Results Available","ASD","Drug: L-DOPA versus Placebo|Behavioral: Social Skills Training","Change in fMRI: Social Reward Task from Baseline to week 16 (4 months)|Change on Anticipatory and Consummatory Interpersonal Pleasure Scale Adolescent (ACIPS-A)|Change on Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)|Change on Child Behavior Checklist (CBCL)|Change on Youth Self Report (YSR)|Change on Adult Behavior Checklist (ABCL)|Change on SRS Self Report|Change on SRS Parent Report|change on Social Communication Interaction Test (SCIT)","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 30 Years   (Child, Adult)","Phase 2","56","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACEPIV","June 1, 2017","June 2022","June 2022","August 9, 2017","null","January 14, 2019","University of California, Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03243552"
432,"NCT03154359","Atomoxetine PBPK-PD Clinical Study",,"Recruiting","No Results Available","ADHD","Drug: Atomoxetine Hydrochloride","Pharmacodynamic - metabolomic|Pharmacodynamic - activity|Incidence of adverse events|Therapeutic Response (responder vs. non-responder)","Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 18 Years   (Child, Adult)","","120","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","16100728|U54HD090258-01","December 12, 2017","June 30, 2022","June 30, 2022","May 16, 2017","null","February 14, 2018","Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03154359"
433,"NCT03097991","Randomized Controlled Trial of Prenatal Coparenting Intervention (CoparentRCT)","CoparentRCT","Recruiting","No Results Available","Parenting","Behavioral: Focused Coparenting Consultation","System for Coding Interactions in Dyads (SCID) Coparent Solidarity|System for Coding Interactions in Dyads (SCID) Coparent Negativity|Coparenting and Family Rating Scale (CFRS) Coparent Solidarity|Coparenting and Family Rating Scale (CFRS) Coparent Negativity|Parenting Alliance Measure","University of South Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 60 Years   (Child, Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NIH 5R01HD082211-01|R01HD082211","August 2015","April 2020","July 2020","March 31, 2017","null","March 25, 2019","University of South Florida, Tampa, Florida, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/91/NCT03097991/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT03097991"
434,"NCT03034785","Flexible Electronics for Early Assessment",,"Recruiting","No Results Available","Very Low Birth Weight Infant","Device: FlexiMitt","Design and Fabricate FlexiMitts|Demonstrate Safety|Examine group differences between Groups 1 and 2|Examine longitudinal differences between Groups 1 and 2","Wyss Institute at Harvard University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Beth Israel Deaconess Medical Center","All","13 Months to 60 Months   (Child)","Not Applicable","120","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","LCD-CS-0001|1R01HD090985-01|IRB16-1008","August 2, 2017","January 2021","January 2021","January 27, 2017","null","June 26, 2018","Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03034785"
435,"NCT03027531","eKISS: Electronic KIOSK Intervention for Safer-Sex","eKISS","Completed","No Results Available","Reproductive Behavior|Contraception|Sexually Transmitted Diseases","Behavioral: eKISS: electronic KIOSK for Safer-Sex","Unprotected sex (no condoms) from self-report via computerized survey|Unprotected sex (no birth control) from self-report via computerized survey|Number of sex partners from self-report via computerized survey|Biomarkers: urine sample tested with nucleic acid amplification test for STDs and urine sample pregnancy test","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 24 Years   (Child, Adult)","Not Applicable","272","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","32030-B|5K23HD052621","February 1, 2012","June 30, 2013","June 30, 2013","January 23, 2017","null","January 24, 2017","","","https://ClinicalTrials.gov/show/NCT03027531"
436,"NCT02998151","Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome","LAM","Enrolling by invitation","No Results Available","Fragile X Syndrome","Drug: Acamprosate|Drug: Lovastatin|Drug: Minocycline|Drug: Placebo","Change in EEG from baseline|Clinical Global Impressions Improvement|Clinical Global Impressions Severity|Aberrant Behavior Checklist|Woodcock Johnson Test of cognitive abilities - auditory attention task|Repeatable Battery for the Assessment of Neuropsychological Status|Test of Attentional Performance for Children (KiTAP)|Grooved Pegboard Test","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 55 Years   (Child, Adult)","Phase 2","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CIN001 - {LAM}","January 2016","July 2019","July 2021","December 20, 2016","null","December 20, 2016","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02998151"
437,"NCT02964884","Interventions for Reading Disabilities in NF1",,"Recruiting","No Results Available","Neurofibromatosis Type 1|Learning Disability|Reading Disability|NF1","Drug: Lovastatin|Behavioral: reading tutoring intervention|Drug: Placebo Oral Tablet|Behavioral: Other Academic ""sham"" tutoring","Woodcock Johnson Tests of Achievement IV|Woodcock Reading Mastery Test-III|Test of Word Reading Efficiency-2|Experimental Word and Pseudoword Lists|Test of Silent Contextual Reading Fluency-2|Comprehensive Test of Phonological Processing-2|Delis Kaplan Executive Function System|Visuospatial Learning and Memory, Morris Water Maze|Visuospatial Learning and Memory, Judgment of Line Orientation|Clinical Evaluation of Language Fundamentals-Fifth Edition","Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 20 Years   (Child, Adult)","Phase 2","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","161159|1R01HD089474-01","November 2016","November 2020","June 2022","November 16, 2016","null","February 22, 2019","Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02964884"
438,"NCT02895789","Oxidative Capacity and Exercise Tolerance in Ambulatory SMA",,"Recruiting","No Results Available","Spinal Muscular Atrophy Type 3|Mitochondrial Myopathy","","Change in NIRS derived index of muscle oxygen extraction|Change in Peak oxygen uptake (V02 max)|Change in Distance walked during the Six Minute Walk Test (6MWT)|Change in Lean body mass assessed with Dual Energy X-ray Absorptiometry (DEXA)","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 55 Years   (Child, Adult)","","42","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAQ9447|1K01HD084690-01A1","November 2016","July 2019","May 2020","September 12, 2016","null","May 1, 2018","Columbia University Medical Center, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02895789"
439,"NCT02810834","Understanding the Impact of School-Based Physical Activity Programs",,"Completed","No Results Available","Physical Activity","Behavioral: Walking/Running program|Behavioral: Classroom physical activity break program","School-time and total daily MVPA|Cognitive performance|Academic achievement","Tufts University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, San Diego","All","7 Years to 11 Years   (Child)","Not Applicable","1182","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","R01HD080180|1R01HD080180-01A1","September 2014","June 23, 2017","July 1, 2017","June 23, 2016","null","September 1, 2017","Gerald J. and Dorothy R. Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02810834"
440,"NCT02784821","Antibiotic ""Dysbiosis"" in Preterm Infants",,"Recruiting","No Results Available","Enterocolitis, Necrotizing|Bacteremia|Bronchopulmonary Dysplasia|Intraventricular Hemorrhage|Periventricular Leukomalacia|Chronic Lung Disease|Retinopathy of Prematurity|Ileal Perforation","Drug: Antibiotic|Other: Gastric fluid|Other: Breast milk|Other: Stool samples|Drug: Antibiotics - pre-emptive|Other: Skin swabs","Rates of necrotizing enterocolitis(NEC)|Rates of bacteremia|Microbiota 16s ribosomal ribonucleic acid (rRNA) metagenomic sequencing|Microbial diversity analysis|Calprotectin (microgram per gram) levels in stool|Metabolomic analysis (microMol per gram) in gastric aspirate, stool, and breast milk|S1000A12 (microgram per gram) in stool|Intraleukin-6 (micrograms per gram) in stool|Intraleukin-8 (micrograms per gram) in stool|Intraleukin-10 (micrograms per gram) in stool|Rates of retinopathy of prematurity (ROP)|Rates of chronic lung disease|Rates of bronchopulmonary dysplasia (BPD)|Rates of spontaneous ileal perforation|Rates of intraventricular hemorrhage|Rates of periventricular leukomalacia","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Society for Pediatric Dermatology","All","23 Weeks to 33 Weeks   (Child)","Phase 2","420","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201501045-N|R21HD088005","January 2017","September 2019","December 2019","May 27, 2016","null","September 12, 2018","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02784821"
441,"NCT02639754","Community Intervention for HIV Testing & Care Linkage Among Young MSM in Bulgaria",,"Enrolling by invitation","No Results Available","Acquired Immunodeficiency Syndrome|HIV","Behavioral: Social Network Leader Endorsement|Behavioral: HIV Counseling","Change in Frequency of HIV Testing|Change in Medical Appointment Keeping","Medical College of Wisconsin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","16 Years to 20 Years   (Child, Adult)","Not Applicable","320","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","PRO00024824|R01HD085833","December 2015","December 2019","December 2020","December 24, 2015","null","April 20, 2018","Health and Social Development Foundation, Sofia, Bulgaria","","https://ClinicalTrials.gov/show/NCT02639754"
442,"NCT02579135","Reducing HIV Risk Among Adolescents: Evaluating Project HEART",,"Completed","Has Results","HIV|Sexually Transmitted Diseases","Behavioral: Safer Sex|Behavioral: Growth Mindsets","6-item Self-report of Program Acceptability|7-item Self-report of Sexual Communication Self-efficacy|3-item Self-report of Sexual Communication Intentions Over Next 3 Months","North Carolina State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 18 Years   (Child, Adult)","Not Applicable","222","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","57033|R00HD075654","September 7, 2015","May 4, 2016","April 6, 2017","October 19, 2015","October 16, 2018","October 16, 2018","North Carolina State University, Raleigh, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02579135"
443,"NCT02561754","Weight Management for Adolescents With IDD","IDDAdol","Recruiting","No Results Available","Developmental Disabilities|Weight Loss|Body Weight|Down Syndrome|Body Weight Changes|Intellectual Disability","Dietary Supplement: Enhanced Stop Light Diet (eSLD)|Dietary Supplement: Conventional Diet (CD)|Behavioral: Face-to-face (FTF)|Behavioral: Technology (TECH)|Other: iPad with FaceTime","Weight loss between groups randomized to FTF/CD, TECH/CD and TECH/eSLD|Weight change between groups randomized to FTF/CD, TECH/CD, or TECH/eSLD|Cost of the intervention delivery","University of Kansas Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 21 Years   (Child, Adult)","Not Applicable","123","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001857|5R01HD079642","March 2015","September 2019","February 2020","September 28, 2015","null","March 26, 2019","University of Kansas Medical Center, Kansas City, Kansas, United States|Energy Balance Lab, The University of Kansas, Lawrence, Kansas, United States","","https://ClinicalTrials.gov/show/NCT02561754"
444,"NCT02487771","Kansas University DHA Outcome Study (KUDOS) Follow-Up",,"Completed","Has Results","Pregnancy","Drug: DHA|Drug: Placebo Capsule","Weschler Preschool and Primary Scale of Intelligence, 3rd Edition; Full Scale IQ|Cognitive Function Score - Peabody Picture Vocabulary Test|Cognitive Function Score - Test of Preschool Early Literacy|Weschler Preschool and Primary Scale of Intelligence, 3rd Edition; Verbal IQ|Adaptive Regulation Assessment","Susan Carlson, PhD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Kansas Medical Center","Female","16 Years to 35 Years   (Child, Adult)","Phase 3","190","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","11406|1R01HD047315","July 2008","May 2016","May 2016","July 1, 2015","September 25, 2017","February 7, 2018","University of Kansas Medical Center, Kansas City, Kansas, United States","","https://ClinicalTrials.gov/show/NCT02487771"
445,"NCT02465931","Decisional Capacity and Informed Consent in Fragile X Syndrome",,"Completed","Has Results","Fragile X Syndrome (FXS)","Other: Paper and Pencil Informed Consent|Other: Digital Informed Consent Tool","Decisional Capacity - Understanding Score","RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 40 Years   (Child, Adult)","Not Applicable","152","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","FXS|1R01HD071987-01A1","March 14, 2016","March 21, 2017","March 21, 2017","June 9, 2015","December 6, 2018","March 7, 2019","RTI International, Research Triangle Park, North Carolina, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/31/NCT02465931/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02465931"
446,"NCT02464423","Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model",,"Unknown status","No Results Available","Human Immunodeficiency Virus","Behavioral: Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)","ART Adherence Behavior Composite Self Report|Health Care Utilization (Number of Clinic Visits)","Hektoen Institute for Medical Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 21 Years   (Child, Adult)","Not Applicable","700","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01HD074977","January 2013","September 2017","September 2017","June 8, 2015","null","August 16, 2016","Cental University Hospital of Kigali - CHUK, Kigali, Rwanda|WE-ACTx for Hope, Kigali, Rwanda","","https://ClinicalTrials.gov/show/NCT02464423"
447,"NCT02344225","Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)","SPIPROP","Completed","No Results Available","Retinopathy of Prematurity","Drug: Caffeine citrate|Drug: Ibuprofen|Drug: Ketorolac","Efficacy as measured by the number of participants presenting with Retinopathy of Prematurity (ROP) and the rate of stages/grade of ROP.|Number of participants with Adverse Events as a measure of Safety and Tolerability.|Safety as measured by occurrence of intraventricular hemorrhage, corneal lesions or perinventricular leucomalacia.","State University of New York - Downstate Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Food and Drug Administration (FDA)","All","up to 28 Weeks   (Child)","Phase 2","14","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","349622|1U54HD071594","January 1, 2015","June 30, 2018","June 30, 2018","January 22, 2015","null","February 1, 2019","SUNY Downstate Medical Center/University Hospital of Brooklyn, Brooklyn, New York, United States","","https://ClinicalTrials.gov/show/NCT02344225"
448,"NCT02148237","Increase Breastfeeding Duration Among Puerto Rican Mothers","BFCM","Completed","No Results Available","Breastfeeding","Behavioral: Contingency Management","Duration of breastfeeding|Infant weight","Treatment Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 44 Years   (Child, Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R03HD077057|1R03HD077057-01A1","August 2014","April 2016","April 2016","May 28, 2014","null","May 23, 2016","Special Supplemental Nutrition Program for Women, Infants, and Children, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02148237"
449,"NCT02117063","Go Girls! Fitness Support Group Intervention Effectiveness Study","CBS002","Recruiting","No Results Available","Polycystic Ovary Syndrome|Abnormal Weight Gain|Excess Weight|Insulin Resistance|Premature Adrenarche|Type 2 Diabetes Mellitus","Behavioral: Go Girls! Fitness Support Group","Change in mean score for the PACES scale after 6-months of intervention|Change in mean score for the PACES scale after 3-months of intervention|Change in amounts of average daily moderate-vigorous exercise|Change in amounts of average daily vigorous exercise|Changes in attitudes about exercise|Changes in anthropometric and biochemical indices of metabolism and possible PCOS","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","10 Years to 18 Years   (Child, Adult)","Not Applicable","35","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16132|U54HD028934-18","April 2012","December 2018","April 2019","April 17, 2014","null","January 23, 2018","Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02117063"
450,"NCT02033642","A Family-Based Weight Loss Intervention for Youth With Intellectual Disability","HealthU","Completed","No Results Available","Obesity","Behavioral: Family Based Behavioral Intervention|Behavioral: Maintenance","Body Mass Index (BMI)|Waist circumference|Physical activity|Dietary patterns|Self-Efficacy|Psychosocial status","University of Massachusetts, Boston|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 22 Years   (Child, Adult)","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HealthU R01|5R01HD072573-03","August 2012","March 2016","March 2016","January 13, 2014","null","March 7, 2016","Eunice Kennedy Shriver Center, Charlestown, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02033642"
451,"NCT01989104","Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)",,"Completed","No Results Available","Healthy","","Cadence|Metabolic cost","Pennington Biomedical Research Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 20 Years   (Child, Adult)","","150","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","PBRC 13019|1R21HD073807-01A1","December 2013","April 2017","April 2017","November 20, 2013","null","August 31, 2018","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT01989104"
452,"NCT03556462","Sleep Health Literacy in Head Start","SLEEP","Recruiting","No Results Available","Sleep","Other: Sleep Health Education","Child Sleep Duration: Intervention vs. Control (Total)|Child Sleep Duration: >30 Minutes|Child sleep difficulties|Parent KASB (Knowledge/Attitudes/Self-Efficacy/Beliefs)|Child Sleep Duration: 1 Year Follow-Up|Classroom Climate","Albert Einstein College of Medicine|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 3 Years   (Child)","Not Applicable","540","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2014-3031|R01HD082129","May 21, 2018","October 15, 2019","October 15, 2019","June 14, 2018","null","June 14, 2018","Kingsbridge Heights Community Center, Bronx, New York, United States|Yeled v""Yalda Early Childhood Center, Inc., Brooklyn, New York, United States|Committee for Early Childhood Development D.D.C. incl, Hollis, New York, United States|East Harlem Council for Human Services, Inc., Manhattan, New York, United States|Cattaraugus and Wyoming Counties Project Head Start, Olean, New York, United States|Agri-Business Child Development, Schenectady, New York, United States|Family Services of Westchester, White Plains, New York, United States","","https://ClinicalTrials.gov/show/NCT03556462"
453,"NCT01976078","Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents",,"Completed","No Results Available","Pharmacokinetics|Voriconazole","Drug: Midazolam/Ranitidine/Esomeprazole","Voriconazole steady-state pharmacokinetics|Voriconazole drug metabolizing enzyme activity","Children's Hospital Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 18 Years   (Child, Adult)","","45","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CCI-11-00334|R01HD070996","September 2012","April 22, 2015","April 22, 2015","November 5, 2013","null","February 20, 2018","Children's Hospital Los Angeles, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT01976078"
454,"NCT01966744","Self-Management Assistance for Recommended Treatment (SMART) Portal","SMART","Completed","No Results Available","Crohn's Disease|Ulcerative Colitis|Indeterminate Colitis|Inflammatory Bowel Disease","","Medication adherence|Disease severity|Health-related quality of life","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 18 Years   (Child, Adult)","","87","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","SMART","July 2013","June 2016","June 2016","October 22, 2013","null","July 19, 2017","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|BeHealth Solutions, LLC, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01966744"
455,"NCT01966627","Genetics of Fatty Liver Disease in Children",,"Completed","No Results Available","Non Alcoholic Fatty Liver Disease","Other: ogtt|Other: genotyping|Other: abdominal and liver magnetic resonance imaging|Other: stool sample|Other: liver biopsy","gene expression|hepatic fat content|glucose tolerance","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 18 Years   (Child, Adult)","","381","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1104008388|R01HD040787","July 2011","July 2017","July 2017","October 21, 2013","null","December 8, 2017","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01966627"
456,"NCT01951794","Validation of a Community Survey Methodology for Measuring PMTCT Program Impact",,"Completed","No Results Available","HIV","","HIV-free survival among HIV-exposed infants.","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 49 Years   (Child, Adult)","","827","Other|NIH","Observational","Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional","CIDRZ 1225|R01HD075131-01","June 2014","November 2016","December 2016","September 27, 2013","null","November 15, 2018","Centre for Infectious Disease Reseach in Zambia, Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT01951794"
457,"NCT01945736","Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal","MTH01","Completed","No Results Available","Opiate Withdrawal Syndrome","Drug: Methadone","PK Parameters after multiple doses of enteral methadone|PK of methadone's primary metabolite EDDP|PK of R- and S-enantiomers of methadone|Correlation between plasma and DBS samples|Correlation between plasma and scavenge samples|Influence of CYP3A4 and CYP3B6 genetic polymorphisms on methadone PK|Methadone pharmacodynamics using the WAT-1|Adverse events","Kevin Watt|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","91 Days to 18 Years   (Child, Adult)","","26","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00044082|HHSN27500021","January 2014","February 2015","February 2015","September 19, 2013","null","December 24, 2018","All Children's Hospital, Saint Petersburg, Florida, United States|Children's Mercy Hospital, Kansas City, Kansas, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT01945736"
458,"NCT03471143","Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C",,"Recruiting","No Results Available","Niemann-Pick Disease, Type C","Drug: 2-Hydroxypropyl-Beta-Cyclodextrin","Efficacy of VTS-270 to reduce plasma levels of glycine-conjugated trihydroxycholanic acid (""bile acid biomarker""), an NPC-specific pharmacodynamic biomarker.|Effect of drug on serum transaminases|Reduction of liver and/or spleen volumes","Washington University School of Medicine|Johns Hopkins University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 6 Months   (Child)","Phase 1|Phase 2","12","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201708114|1U01HD090845-01","February 22, 2019","February 2022","February 2022","March 20, 2018","null","February 27, 2019","St. Louis Children's Hospital, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03471143"
459,"NCT01882998","Primary HIV Prevention in Pregnant and Lactating Ugandan Women","PRIMAL","Completed","No Results Available","Primary Prevention of HIV Acquisition","Behavioral: Extended repeat HIV testing and enhanced counseling","Frequency of unprotected sex|STI incidence|HIV incidence|Incidence of recurrent wanted and unwanted pregnancy","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 49 Years   (Child, Adult)","Not Applicable","1230","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD070767|1R01HD070767-01A1","February 2013","May 2016","May 2016","June 21, 2013","null","May 24, 2016","Mulago Hospital, Kampala, Uganda","","https://ClinicalTrials.gov/show/NCT01882998"
460,"NCT01879852","Muscle Weakness and Post-traumatic Knee OA",,"Completed","Has Results","Meniscectomy","Behavioral: Quadriceps intensive strengthening|Behavioral: Standard rehabilitation","Change in International Knee Documentation Committee (IKDC) Subjective Knee Form Score|Change in Tibial Articular Cartilage Volume|Single Leg Forward Hop Index|Change in Urinary Concentrations of C-terminal Crosslinking Telopeptide of Type II Collagen (CTX-II)","University of Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 35 Years   (Child, Adult)","Not Applicable","29","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","00060374|K01HD052713","October 2008","August 2013","August 2013","June 18, 2013","September 11, 2014","October 1, 2014","UF & Shands Orthopaedics and Sports Medicine Institute, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT01879852"
461,"NCT03388294","Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders","PIE","Recruiting","No Results Available","Autism Spectrum Disorder|Neurodevelopmental Disorders","Behavioral: Parents and Infants Engaged","Change in Parent Child Engagement Coding from pretest to posttest 1|Change in Parent Child Engagement Coding from pretest to posttest 2|Change in Mullen Scales of Early Learning Receptive Language T-Scores from pretest to posttest 2|Change in Mullen Scales of Early Learning Expressive Language T-scores from pretest to posttest 2|Change in Sensory Processing Assessment for Young Children from Pretest to Posttest 2|Change in The Behavioral Observation of Social Communication Change (BOSCC) from pretest to posttest 2|Change in The Attention Following Protocol (AF Protocol) from pretest to posttest 2|Baseline expressive communication level: The MacArthur-Bates Communicative Development Inventory|Change in The Sensory Experiences Questionnaire version 2.1 from pretest to posttest 1|Change in The Sensory Experiences Questionnaire version 2.1 from pretest to posttest 2|Baseline level of parent stress: Parental Stress Scale|Change in Respiratory sinus arrhythmia from pretest to posttest 1|Change in Respiratory sinus arrhythmia from pretest to posttest 2|Change in skin conductance levels from pretest to posttest 1|Change in skin conductance levels from pretest to posttest 2|Change in Parent Responsiveness to Child Prelinguistic Communication Cues from pretest to posttest 1|Change in Parent Responsiveness to Child Prelinguistic Communication Cues from pretest to posttest 2|Change in Parent Responsiveness to Child Sensory Reactivity Cues from pretest to posttest 1|Change in Parent Responsiveness to Child Sensory Reactivity Cues from pretest to posttest 2","University of North Carolina, Chapel Hill|University of Southern California|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Months to 16 Months   (Child)","Not Applicable","44","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17-0292|1R21HD091547-01","March 8, 2018","August 15, 2019","July 15, 2022","January 2, 2018","null","March 15, 2018","University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03388294"
462,"NCT01832753","Treatment Trial of Subclinical Hypothyroidism in Down Syndrome",,"Active, not recruiting","No Results Available","Down Syndrome|Subclinical Hypothyroidism","Drug: Levothyroxine","Change in non-HDL cholesterol from baseline at 6, 12 and 18 months.|Change in quality of life from baseline at 6, 12 and 18 months.","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 20 Years   (Child, Adult)","Not Applicable","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","12-009578|1R01HD071981-01A1","January 2013","October 18, 2017","July 1, 2019","April 16, 2013","null","October 8, 2018","Children's National Medical Center, Washington, District of Columbia, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01832753"
463,"NCT03232931","Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants",,"Recruiting","No Results Available","Preterm Infant","Device: Multisensory intervention|Behavioral: Standard of care","Latency of response to auditory and tactile stimuli on EEG/ERP|Infant/Toddler Sensory Profile (ITSP)|Motor and language scores on Bailey-III|Preschool Language Scales, Fifth Edition (PLS-5)","Nationwide Children's Hospital|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","32 Weeks to 35 Weeks   (Child)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB17-00025|R01HD093706","October 29, 2018","October 31, 2020","October 31, 2022","July 28, 2017","null","February 6, 2019","Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03232931"
464,"NCT01750476","Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives",,"Terminated","No Results Available","Initiation of Oral Contraception (OC)|Initiation of Depo-Provera (DMPA)|Initiation of Mirena (LNG-IUD)","Drug: Mirena|Drug: Oral contraception|Drug: Depo-Provera","Proliferative capacity (i.e., ability to respond to antigen stimulation) of T cells isolated from the cervix of women before and after initiating a hormonal contraceptive","Thomas Cherpes, DVM, MD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Ohio State University","Female","15 Years to 25 Years   (Child, Adult)","","7","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PRO12010187|R01HD072663","December 2012","April 2013","June 2013","December 17, 2012","null","January 7, 2014","UPMC Adolescent Clinic of Oakland, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01750476"
465,"NCT01747135","Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease",,"Completed","No Results Available","Niemann-Pick Disease, Type C1","Drug: VTS-270","24-hydroxycholesterol Area under the curve|Hearing loss.","Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 25 Years   (Child, Adult)","Phase 1","14","Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","130001|13-CH-0001","January 2013","March 2017","March 2017","December 11, 2012","null","April 19, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01747135"
466,"NCT01744730","Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile","CLIN01","Completed","Has Results","Bacterial Infections|Obesity","Drug: Clindamycin","Pharmacokinetics (PK) - Clearance (Cl) in Participants Who Received Multiple Doses of Intravenous (IV) Clindamycin.|PK - Volume of Distribution (V) in Participants Who Received Multiple Doses of Intravenous (IV) Clindamycin.","Phillip Brian Smith|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation|Duke University","All","2 Years to 17 Years   (Child)","Phase 1","22","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","Pro00041855|HHSN275201000003I","June 2013","August 2014","August 2014","December 7, 2012","October 19, 2016","November 29, 2016","Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Children's Mercy Hospital, Kansas City, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|Akron Children's Hospital, Akron, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01744730"
467,"NCT03162354","The CDR Implementation Trial",,"Enrolling by invitation","No Results Available","Pediatric Abusive Head Trauma","Other: Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool","High risk patients evaluated for abuse|Low risk patients evaluated for abuse|Overall diagnostic yield|Estimated cases of missed AHT|Unnecessary abuse evaluations","Milton S. Hershey Medical Center|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 3 Years   (Child)","Not Applicable","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","STUDY00005613|P50HD089922","August 1, 2017","January 31, 2020","January 31, 2021","May 22, 2017","null","August 22, 2018","Connecticut Children's Medical Center, Hartford, Connecticut, United States|Wesley Hospital, Wichita, Kansas, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of Nebraska Medical Cneter and Children's Hospital of Omaha, Omaha, Nebraska, United States|Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States|University of Texas health Sciences Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Children's Hospital of Richmond, Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03162354"
468,"NCT01688427","Perinatal Nurse Home Visiting Enhanced With mHealth Technology",,"Completed","No Results Available","Domestic Violence|Intimate Partner Violence","Behavioral: Standard IPV Assessment|Behavioral: Standard DOVE Intervention","Change in IPV assessments|Change in use of safety behaviors|Change in number of safety behaviors","Johns Hopkins University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 45 Years   (Child, Adult)","Not Applicable","433","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NA_00051481|1R01HD071771-01","October 2012","September 30, 2016","September 30, 2018","September 19, 2012","null","March 6, 2019","Johns Hopkins University, School of Nursing, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01688427"
469,"NCT01653288","A Trial of ""Coping Coach,"" a Web-based Preventive Intervention for Children",,"Completed","Has Results","Stress Disorders, Post Traumatic","Behavioral: Coping Coach","Feasibility of the Coping Coach Online Intervention|Mean Time Spent Using the Intervention|a Preliminary Assessment of the Efficacy of the Intervention","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The University of Queensland","All","8 Years to 12 Years   (Child)","Not Applicable","72","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","12-009336|1R21HD069832-01A1","March 2013","March 2016","March 2016","July 31, 2012","February 26, 2019","February 26, 2019","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01653288"
470,"NCT01631721","Couple & Family Contexts","CFC","Completed","No Results Available","Behavior and Behavior Mechanisms","","Incidence of vaginal intercourse with romantic partner|Frequency of condom use during vaginal intercourse with romantic partner|Incidence of oral sex with romantic partner|Frequency of condom use for oral sex with romantic partner|Incidence of anal intercourse with current romantic partner|Frequency of condom use for anal intercourse with romantic partner|Incidence of vaginal intercourse romantic partner","New York University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","17 Years to 19 Years   (Child, Adult)","","2960","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","NICHD_064734|R01HD064734","November 2010","January 2016","February 2016","June 29, 2012","null","March 22, 2016","Silver School of Social Work, New York University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01631721"
471,"NCT01615562","Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome",,"Terminated","No Results Available","Polycystic Ovary Syndrome (PCOS)","","Peripheral vascular imaging via ultrasonography during brachial artery flow-mediated vasodilation (FMD)|FMD with non-endothelial dependent (NED) vessel dilation","Virginia Commonwealth University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 40 Years   (Child, Adult)","","18","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","U54HD034449- Wickham Pilot|U54HD034449","December 2011","April 2014","July 2015","June 8, 2012","null","December 14, 2015","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01615562"
472,"NCT02936284","Infant Environment Study",,"Recruiting","No Results Available","Infant Development|Motivation","Behavioral: Music Enhancement|Behavioral: Play Date","Change in Infant Food Reinforcing Ratio|Infant 24-Hour Dietary Recall- Change in Energy Intake|Change in Infant z weight-for-length|Change in Home Enrichment Score","State University of New York at Buffalo|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Months to 15 Months   (Child)","Not Applicable","92","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1134699-1-75860|1R01HD087082-01A1","November 2016","January 2021","July 2021","October 18, 2016","null","February 15, 2018","University at Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT02936284"
473,"NCT02925455","Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy",,"Active, not recruiting","No Results Available","Cerebral Palsy","Device: Contralaterally-controlled functional electrical stimulation|Device: Hand therapy video games","Change in Assisting Hands Assessment at 6 weeks|Change in Melbourne 2 Motor Assessment at 6 weeks","MetroHealth Medical Center|The Cleveland Clinic|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 17 Years   (Child)","Not Applicable","18","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","16-400|1R21HD088987-01","September 2016","April 2019","April 2019","October 5, 2016","null","March 28, 2019","Cleveland Clinic Foundation, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02925455"
474,"NCT01556113","Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease",,"Completed","No Results Available","Non Alcoholic Fatty Liver Disease|Steatohepatitis|Hypertriglyceridemia|Alanine Aminotransferase, Plasma Level of, Quantitative Trait Locus 1","Other: Omega diet","reduction in hepatic fat fraction|reduction in triglycerides|lower ALT levels","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 19 Years   (Child, Adult)","Not Applicable","17","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1112009408|R01HD040787","March 2012","February 2017","February 2017","March 16, 2012","null","April 28, 2017","Yale School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01556113"
475,"NCT01458145","Minding the Baby Home Visiting: Program Evaluation",,"Completed","No Results Available","Attachment|Child Maltreatment|Maternal Sensitivity|Infant Health","Behavioral: Minding the Baby Home Visiting Program","Maternal reflective capacities|Infant Attachment|Maternal life course outcomes|child abuse or neglect|Dose of intervention|cost analysis for the program|Description of reflective functioning in pregnant adolescents","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 25 Years   (Child, Adult)","Not Applicable","151","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","17098|R01HD057947","September 2009","March 2016","December 2016","October 24, 2011","null","January 17, 2018","Fair Haven Community Health Center, New Haven, Connecticut, United States|Cornell Scott Hill Health Center, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01458145"
476,"NCT01448551","MPOWERed Messages: Tailored Mobile Messages to Enhance Weight Loss for Teens",,"Completed","No Results Available","Obesity","Behavioral: Tailored Mobile Messages to Enhance Weight Loss for Teens","Session attendance|Adherence to MPOWER program homework assignments|Satisfaction with the MPOWER program|Drop out|Change in body mass index|Objective measurement of daily participation in moderate to vigorous activity|Self-efficacy for achieving MPOWER recommendations for the 6 target behaviors|Intrinsic motivation to increase intake of fruits and vegetables and to increase physical activity|Change in self-report of the six behaviors targeted in the intervention","University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 18 Years   (Child, Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","F022685-1|5K23HD058797-02","October 2011","October 2015","October 2015","October 7, 2011","null","December 21, 2016","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT01448551"
477,"NCT02724631","TubeClear® Evaluation in Pediatric Patients (Phase I)",,"Recruiting","No Results Available","Enteral Nutrition","Device: TubeClear® intervention","Number of Successful Attempts to Restore EAD(P) Patency|Change in Age-Appropriate Pain Score","Children's Hospital of Philadelphia|Actuated Medical, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 17 Years   (Child)","Not Applicable","15","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14-011488|5R44HD065365-04","November 2016","December 2019","May 2020","March 31, 2016","null","March 19, 2019","Children's Hosptial of Philadlephia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02724631"
478,"NCT01425541","Assessment of the Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition",,"Completed","No Results Available","Hyperandrogenemia|Polycystic Ovary Syndrome (PCOS)","Drug: estrace|Drug: Progesterone","Reduction in luteinizing hormone pulse frequency after one week of estradiol and progesterone","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","8 Years to 18 Years   (Child, Adult)","Not Applicable","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","8588|JCM010|U54HD028934-18","April 2000","August 2015","August 2015","August 30, 2011","null","September 7, 2015","Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01425541"
479,"NCT01377454","Balance and Mild Traumatic Brain Injury (TBI)",,"Completed","No Results Available","Brain Concussion|Traumatic Brain Injury","","","Oregon Health and Science University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 40 Years   (Child, Adult)","","47","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Cross-Sectional","7419","June 2011","August 2012","August 2012","June 21, 2011","null","August 8, 2012","Oregon Health and Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01377454"
480,"NCT01222585","Metronidazole Pharmacokinetics (PK) in Premature Infants","PTN_METRO","Completed","Has Results","Serious Systemic Infections|Necrotizing Enterocolitis","Drug: Metronidazole","Area Under the Curve at Steady State|Loading Dose Maximum Concentration|Loading Dose Minimum Concentration|Multiple Dose Maximum Concentration|Multiple Dose Minimum Concentration|Clearance|Volume of Distribution","Michael Cohen-Wolkowiez|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation|Duke University","All","up to 90 Days   (Child)","Phase 1","24","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00024571|HHSN27500003I","January 2011","November 2011","November 2011","October 18, 2010","December 18, 2013","February 6, 2014","CHOC Children's, Orange, California, United States|Wesely Medical Center, Wichita, Kansas, United States|Duke University, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01222585"
481,"NCT02414399","Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children","Toto Bora","Recruiting","No Results Available","Pneumonia|Diarrhea|Malaria|Co-infection|Death|Malnutrition","Drug: Azithromycin|Drug: Placebo","Composite outcome of mortality and hospital readmission|Mean change in length for age z-score (LAZ) between baseline and outcome assessment|The number of children with diarrhea re-hospitalizations following randomization|The number of children with acute respiratory illness re-hospitalizations following randomization|The number of children with malnutrition re-hospitalizations following randomization|The number of children with malaria re-hospitalizations following randomization|Prevalence of enteric pathogen carriage|Prevalence of Streptococcus pneumoniae carriage|Mean Enteric Inflammation Composite Score (Myeloperoxidase, Neopterin, Alpha-anti-trypsin)|Proportion of beta-lactam or macrolide resistance or both|Mean fecal calprotectin levels","University of Washington|Kenya Medical Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 59 Months   (Child)","Phase 4","1400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00002592|R01HD079695","June 28, 2016","December 2019","December 2020","April 10, 2015","null","June 19, 2018","Kisii Teaching and Referral Hospital, Homa Bay District Hospital, St. Paul's Mission Hospital, Kisii And Homa Bay Counties, Kenya","","https://ClinicalTrials.gov/show/NCT02414399"
482,"NCT02394717","Policy to Practice: Statewide Rollout of YMCA Childhood Obesity Standards",,"Completed","No Results Available","Childhood Obesity","Behavioral: Healthy Eating and Physical Activity","Change in proportion of children meeting physical activity policy|Changes in Nutritional Quality of Snacks","University of South Carolina|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 12 Years   (Child)","Not Applicable","1000","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01HD079422-01","August 2014","May 2018","May 2018","March 20, 2015","null","July 24, 2018","University of South Carolina, Columbia, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT02394717"
483,"NCT02383849","IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants",,"Enrolling by invitation","No Results Available","Low-Birth-Weight Infant|Tuberculosis|HIV","","Apparent clearance (CL/F) of NVP, INH, RIF, and LPV/r|Primary safety endpoints","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 84 Days   (Child)","","158","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMPAACT P1106|11882","July 2015","March 2020","March 2020","March 9, 2015","null","February 8, 2019","Soweto IMPAACT CRS (8052), Johannesburg, Gauteng, South Africa|Family Clinical Research Unit (FAM-CRU) CRS (8950), Tygerberg, Western Cape Province, South Africa","","https://ClinicalTrials.gov/show/NCT02383849"
484,"NCT01133847","Interventions for Children With Attention and Reading Disorders","ICARD","Completed","Has Results","Attention Deficit Hyperactivity Disorder|Reading Disabilities","Drug: Methylphenidate|Behavioral: Intensive reading instruction|Behavioral: Parent Training|Drug: Mixed Salt Amphetamine|Drug: Atomoxetine|Drug: Guanfacine","Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Inattention|Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Parent Rating of Hyperactivity-impulsivity|Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Inattention|Swanson, Nolan, and Pelham Checklist for DSM-IV (SNAP)- Teacher Rating of Hyperactivity-impulsivity|Wechsler Individual Achievement Test-III (WIAT-III) Word Reading Subtest|Wechsler Individual Achievement Test-III (WIAT-III) Pseudoword Decoding Subtest|Wechsler Individual Achievement Test-III (WIAT-III) Reading Comprehension Subtest|Dynamic Indicators of Basic Early Literacy Skills Oral Reading Fluency Subtest (DIBELS ORF)|Test of Word Reading Efficiency (TOWRE) - Sight Word Efficiency|Test of Word Reading Efficiency (TOWRE) - Phonemic Decoding Efficiency|Test of Silent Reading Fluency and Comprehension (TOSREC)","The University of Texas Health Science Center, Houston|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Hospital Medical Center, Cincinnati","All","7 Years to 12 Years   (Child)","Phase 4","222","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-09-0531|R01HD060617","November 2010","June 2015","June 2015","May 31, 2010","April 11, 2017","April 11, 2017","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Texas Health Science Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01133847"
485,"NCT01100567","Effect Of Biomechanical Stimulation On Skeletal Health In Adolescent And Young Women With Anorexia Nervosa",,"Completed","Has Results","Anorexia Nervosa","Device: Low-magnitude mechanical stimulation platform","Change From Baseline in C-telopeptides|Change From Baseline in Bone Specific Alkaline Phosphatase","Boston Children’s Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","11 Years to 25 Years   (Child, Adult)","Not Applicable","101","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","08-10-0461","April 2009","May 2015","May 2015","April 9, 2010","May 17, 2017","May 17, 2017","Children's Hospital Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01100567"
486,"NCT02225041","Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood","RESTORE-cog","Recruiting","No Results Available","Intellectual Disability|Perceptual Disorders|Memory Disorders","","Neurocognitive function at 2.5 years post-ICU discharge, as assessed using standardized tests of attention, processing speed, learning and memory, visual-spatial skills, motor skills, language, executive function, IQ, and behavior","University of Pennsylvania|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","30 Months to 13 Years   (Child)","","810","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","1R01HD074757-01A1","August 2014","May 2019","May 2019","August 25, 2014","null","October 15, 2018","Children's Hospital of Alabama, Birmingham, Alabama, United States|University Medical Center, The University of Arizona, Tucson, Arizona, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Salter Packard Children's Hospital at Stanford, Palo Alto, California, United States|University of California Davis Medical Center, Sacramento, California, United States|Children's Hospital at University of California San Francisco Medical Center, San Francisco, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Yale-New Haven Children's Hospital, New Haven, Connecticut, United States|Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|Holtz Children's Hospital, Miami, Florida, United States|Florida Hospital for Children, Orlando, Florida, United States|Children's Memorial Hospital, Chicago, Chicago, Illinois, United States|Advocate Hope Children's Hospital, Oak Lawn, Illinois, United States|University of Maryland Hospital for Children, Baltimore, Maryland, United States|Johns Hopkins Children's Center, Baltimore, Maryland, United States|University of Massachusetts Memorial Children's Medical Center, Worcester, Massachusetts, United States|C. S. Mott Children's Hospital of the University of Michigan, Ann Arbor, Michigan, United States|Children's Mercy Hospital, Kansas City, Kansas City, Missouri, United States|St. Louis Children's Hospital, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Children's Hospital at Montefiore, Bronx, New York, United States|Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Duke Children's Hospital and Health Center, Durham, North Carolina, United States|Doernbecher Children's Hospital, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Monroe Carell, Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Medical City Children's Hospital, Dallas, Texas, United States|Children's Medical Center Dallas, Dallas, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02225041"
487,"NCT01050387","Effects of Vitamin D Dose and Genotype of the Binding Protein in Infants and Children","VitaD","Completed","No Results Available","Vitamin D Deficiency","Dietary Supplement: Vitamin D","Changes in serum 25-OH vitamin D","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Thrasher Research Fund","All","6 Months to 6 Years   (Child)","Not Applicable","193","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0909005699|1RC1HD063562|M#136410","January 2010","February 2013","February 2013","January 15, 2010","null","August 5, 2014","Yale University School of Medicine, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01050387"
488,"NCT01010230","Vibration Intervention For Bone Enhancement In Childhood Cancer Survivors",,"Completed","Has Results","Bone Mineral Density|Bone Strength","Device: LMHF mechanical stimulation active device|Device: LMHF mechanical stimulation placebo device","Percent Change in Total Bone Mineral Content (BMC) Per Height Compared Between Intervention and Placebo Groups|Percent Change in Lumbar Spine Bone Mineral Content (BMC) Compared Between Intervention and Placebo Groups|Percent Change in Total Bone Mineral Density (BMD) Compared Between Intervention and Placebo Groups|Percent Change in Lumbar Spine Bone Mineral Density (BMD) Compared Between Intervention and Placebo Groups|Percent Change in Lumbar Spine Volumetric Bone Mineral Density (BMD) Compared Between Intervention and Placebo Groups|Percent Change in Tibial Cortical Bone Compared Between the Intervention and Placebo Groups|Percent Change in Cortical Bone Per Length Compared Between the Intervention and Placebo Groups|Mean Change in Aminoterminal Propeptide of Type I Procollagen (PINP) Compared Between the Intervention and Placebo Groups|Mean Change in Osteocalcin (OC) Compared Between the Intervention and Placebo Groups|Mean Change in Alkaline Phosphatase (ALP)-Skeletal (Bone Specific) Compared Between the Intervention and Placebo Groups|Mean Change in Carboxyterminal Telopeptide of Type I Collagen (ITCP) Compared Between the Intervention and Placebo Groups|Mean Change in Collagen Cross Linked N-Telepeptide (NTx) Compared Between the Intervention and Placebo Groups|Mean Change in Bone Turnover Ratio (RANKL/OPG) Compared Between the Intervention and Placebo Groups","St. Jude Children's Research Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Gabrielle's Angel Foundation","All","7 Years to 17 Years   (Child)","Not Applicable","81","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","VIBE|R21HD059292|Gabrielle's Angel Fdn","May 2010","March 2013","March 2013","November 9, 2009","May 26, 2014","June 4, 2014","St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01010230"
489,"NCT01004341","Role of Parenting Skills and Parenting Style in Pediatric Weight Loss Programs",,"Completed","No Results Available","Pediatric Obesity","Behavioral: Family-based behavioral weight control intervention","Change in parenting skills and parenting style|Change in child BMI z-score","University of California, San Diego|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Brown University","All","8 Years to 12 Years   (Child)","Not Applicable","44","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K23HD057299","June 2009","May 2012","May 2012","October 29, 2009","null","June 19, 2013","University of California, San Diego, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT01004341"
490,"NCT01004094","Squire's Quest! II: Implementation Intentions and Children's Fruit, Juice, and Vegetable (FJV) Consumption","SQ!II","Completed","No Results Available","Obesity|Cancer","Behavioral: simple goal setting|Behavioral: goal setting plus action intentions|Behavioral: goal setting plus coping intentions|Behavioral: goal setting plus action intentions plus coping intentions","Fruit and vegetable consumption|Goal attainment","Baylor College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|United States Department of Agriculture (USDA)","All","8 Years to 12 Years   (Child)","Phase 2","800","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Thompson_Squires_Quest_II|5R01HD050595","October 2009","March 2011","March 2011","October 29, 2009","null","January 20, 2016","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01004094"
491,"NCT00992836","Safety of and Immune Response to an H1N1 Influenza Virus Vaccine in HIV Infected Children and Youth",,"Completed","Has Results","HIV Infections|H1N1 Influenza Virus","Biological: Influenza A (H1N1) 2009 monovalent vaccine","The Number of Participants Who Had at Least One Adverse Event (AE)|The Number of Participants Who Had at Least One AE Attributed to the Study Vaccine|Withholding of Second Vaccine Dose Due to Adverse Reactions Attributed to First Dose|Percent of Participants With a Hemagglutinin Inhibition (HAI) Titer of >=40|Percent of Participants With an HAI Titer >=40 at Long-term Follow-up|Geometric Mean Antibody Titers (GMT) HAI|Cell-mediated Immune Responses, Measured by B-cell and T-cell Enzyme-linked Immunosorbent Spot (ELISPOT) Assay Values|HAI Titers Against Seasonal Influenza Viruses Containing Trivalent Influenza Vaccine (TIV)|Cell-mediated Immune Responses to Influenza Viruses Contained in TIV and Other Antigens","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 25 Years   (Child, Adult)","Phase 2","155","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P1088|10840|IMPAACT P1088","October 2009","August 2010","August 2010","October 9, 2009","February 9, 2012","December 17, 2014","UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|Usc La Nichd Crs, Alhambra, California, United States|University of California, UC San Diego CRS, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00992836"
492,"NCT02063880","Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)","PUSH","Completed","Has Results","Human Immunodeficiency Virus|Immune Reconstitution Inflammatory Syndrome","Other: Urgent ART|Other: Early ART","All-cause Mortality|Number of Participants With Evidence of Immune Reconstitution and Inflammatory Syndrome (IRIS)|Number of Participants With Potential Drug Toxicity","University of Washington|University of Nairobi|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 12 Years   (Child)","Not Applicable","183","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001052|2R01HD023412-21","March 2013","November 2015","November 2015","February 17, 2014","July 25, 2017","May 14, 2018","JOOTRH, Kisumu, Kenya|Kisumu District Hospital, Kisumu, Kenya|Mbagathi District Hospital, Nairobi, Kenya|Kenyatta National Hospital, Nairobi, Kenya","","https://ClinicalTrials.gov/show/NCT02063880"
493,"NCT00946192","Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes",,"Recruiting","No Results Available","Exercise-related Amenorrhea","Drug: Transdermal 17Beta-estradiol, progesterone|Drug: Ethinyl Estradiol + Desogestrel|Dietary Supplement: Sham Comparator","Increase in bone density with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes|Improvement in bone microarchitecture with transdermal estrogen versus oral estrogen or no estrogen in amenorrheic athletes","Massachusetts General Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 21 Years   (Child, Adult)","Phase 3","230","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009P000353|R01HD060827-01A1","May 2009","December 2019","December 2019","July 24, 2009","null","June 5, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00946192"
494,"NCT00921557","Safety and Effectiveness of Alendronate for Bone Mineral Density in HIV-infected Children and Adolescents",,"Completed","Has Results","HIV Infection","Drug: Alendronate|Drug: Placebo|Dietary Supplement: Calcium carbonate/vitamin D","Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD|Percentage of Participants Developing New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures|Percent Change From Baseline to Weeks 24 and 48 in Whole Body (With Head) BMD|Percent Change From Baseline to Week 96 in Lumbar Spine BMD|Percent Change From Baseline to Week 96 in Whole Body (With Head) BMD|Safety as Measured by the Incidence of New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures|Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Lumbar Spine BMD|Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Whole Body (With Head) BMD.|Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Lumbar Spine BMD|Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Whole Body (With Head) BMD|Change From Baseline to Week 48 in Bone Marker Turnover|Correlation of Changes in Bone Marker Turnover With Changes in Lumbar Spine and Whole Body (With Head) BMD|Change From Baseline to Week 48 in Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin (RANKL/OPG) Ratio|Correlation of Changes in RANKL/OPG Ratio With Changes in Lumbar Spine and Whole Body (With Head) BMD|Change From Baseline to Week 48 in Central Fat Content|Correlation of Changes in Central Fat Content With Changes in Lumbar Spine and Whole Body (With Head) BMD|Percent of Participants With HIV-1 RNA <= 400 Copies/ml|Change in CD4 Percent From Baseline|Change in Centers for Disease Control (CDC) HIV Disease Category|Percent of Participants With Detectable Urinary Alendronate","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 24 Years   (Child, Adult)","Phase 2","52","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","P1076|10669|IMPAACT P1076","November 2009","January 2016","January 2017","June 16, 2009","March 28, 2017","July 21, 2017","David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00921557"
495,"NCT00881764","PANDA (Pediatric Anesthesia & NeuroDevelopment Assessment) Study",,"Completed","No Results Available","Cognition - Other","Procedure: Inguinal hernia surgery|Procedure: General anesthesia","Change in neurocognitive function|Change in domain-specific function related to visual memory and learning|Change in domain-specific function related to verbal memory and learning|Change in domain-specific function related to receptive language|Change in domain-specific function related to expressive language|Change in domain-specific function related to working memory|Change in domain-specific function related to all executive function components|Change in domain-specific function related to selective attention and impulsivity|Change in domain-specific function related to cognitive flexibility aspects of executive function|Change in domain-specific function related to motor and processing speed|Changes in behavior|Changes in adaptive behavior|Changes in parental relationships","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Office of Acquisitions and Grants Services (OAGS)","All","8 Years to 15 Years   (Child)","","369","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","AAAC8756|R34HD060741|HHSF223200810036C|SmartTots","May 2009","April 2015","January 2016","April 15, 2009","null","July 23, 2018","Children's Hospital Boston, Boston, Massachusetts, United States|Columbia University, 622 W. 168th St., New York, New York, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00881764"
496,"NCT00877552","Prospective Studies of the Pathogenesis of Schizophrenia",,"Active, not recruiting","No Results Available","Schizophrenia","","magnetic resonance images (structural and functional)|Cognitive development","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","up to 6 Years   (Child)","","600","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","04-1144|R01HD053000-02|P50MH064065-07","August 2002","December 2019","December 2019","April 8, 2009","null","February 26, 2019","UNC Department of Psychiatry, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00877552"
497,"NCT00851539","Evaluating Post-test HIV Counseling Videos for Teens","Control","Completed","No Results Available","HIV|HIV Infections","Behavioral: Video","Intention to use condoms|Consent to rapid HIV testing","North Bronx Healthcare Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 21 Years   (Child, Adult)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","2006-443|5K23HD054315","June 2008","November 2008","April 2011","February 26, 2009","null","December 10, 2014","Jacobi Medical Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT00851539"
498,"NCT01885325","Multi-component Intervention to Increase Physical Activity in Preschool Children","SHAPES","Completed","No Results Available","Physical Activity","Other: Physical Activity Preschool Intervention","Change in Minutes of Moderate-to- Vigorous Physical Activity (MVPA)|Change in Minutes of Sedentary Behavior|Change in Physical Activity Energy Expenditure (PAEE)|Change in Body Mass Index (BMI)","University of South Carolina|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 5 Years   (Child)","Not Applicable","708","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","5R01HD055451|1R01HD055451","August 2008","June 2012","June 2012","June 24, 2013","null","June 24, 2013","","","https://ClinicalTrials.gov/show/NCT01885325"
499,"NCT00792246","Voriconazole Pharmacokinetics in Children With Gastrointestinal Graft Versus Host Disease",,"Completed","No Results Available","Graft Versus Host Disease|Stem Cell Transplantation","Drug: voriconazole","Reduced bioavailability of oral voriconazole in pediatric patients status post stem cell transplantation with gastrointestinal graft versus host disease|Pharmacokinetics(including clearance, maximum concentration, area under the time concentration curve, and half life) of voriconazole in pediatric patients status post hematopoietic stem cell transplantation.","Phillip Brian Smith|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","up to 18 Years   (Child, Adult)","Phase 1","5","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00004318","December 2008","July 2012","July 2012","November 17, 2008","null","September 3, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00792246"
500,"NCT00766597","Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents",,"Completed","Has Results","HIV Infections","Drug: Vicriviroc","Number of Participants With Suspected Adverse Drug Reaction Leading to Treatment Termination|Number of Participants With Adverse Events of Grade 3 or Higher Severity|Number of Participants Who Failed to Meet PK Targets|Number of Participants Who Failed to Achieve =>1-log Drop From Baseline in HIV-1 Viral Load and HIV-1 Viral Load of =>400 Copies/mL (Virologic Failures)|Number of Participants With Changes in Co-receptor Tropism From Baseline|Change in CD4 Counts|Change in CD4 Percent|Change in Polymerase Genome and Envelope Sequence|Change in Plasma HIV RNA PCR","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","9","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1071|10634|IMPAACT P1071","August 2009","July 2010","August 2010","October 6, 2008","February 1, 2016","February 1, 2016","UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|Chicago Children's CRS, Chicago, Illinois, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00766597"
501,"NCT01803464","Effect of Botox and Vibration on Bone in Children With Cerebral Palsy",,"Completed","Has Results","Cerebral Palsy|Muscle Spasticity","Device: Low-magnitude vibration|Drug: Botox","Bone Structure|Muscle Volume|Bone Mass","University of Delaware|Alfred I. duPont Hospital for Children|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 12 Years   (Child)","Not Applicable","29","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R15HD071397-01|IRB # 115648-11","March 2012","February 2015","February 2015","March 4, 2013","March 20, 2018","March 20, 2018","University of Delaware, Newark, Delaware, United States|Alfred I. duPont Hospital for Children, Nemours, Wilmington, Delaware, United States","","https://ClinicalTrials.gov/show/NCT01803464"
502,"NCT01796067","Families Improving Together (FIT) for Weight Loss",,"Recruiting","No Results Available","Overweight|Obese","Behavioral: Motivational and Family Weight Loss|Behavioral: Basic Health Education|Behavioral: Online Intervention|Behavioral: Online Control","Change in Body Mass Index (z-BMI) in Adolescents|Change in Moderate to Vigorous Physical Activity (MVPA) in Parents and Adolescents|Change of 24 Hour Dietary Recall (NDRS) of Kcals in Parents and Adolescents|Change in Psychosocial Variables in Adolescents|Change in Moderate to Vigorous Physical Activity in Adolescents|Change of 24 Hour Dietary Recall (NDRS) of Kcals in Adolescents|Change in Body Mass Index (z-BMI) in Parents|Change in Body Mass Index (z-BMI) for Parents","University of South Carolina|University of Michigan|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","11 Years to 16 Years   (Child)","Not Applicable","520","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Project FIT|R01HD072153","July 2012","December 2018","December 2018","February 21, 2013","null","October 2, 2018","Obesity Research Group, Columbia, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT01796067"
503,"NCT00743210","Oral L-Citrulline and ADMA in Pregnancy",,"Completed","No Results Available","Blood Pressure","Drug: L-citrulline|Drug: Placebo","To evaluate blood pressure changes in response to oral L-citrulline or placebo treatment in uncomplicated obese pregnant women during the second trimester of pregnancy.|To evaluate the changes in plasma ADMA/L-arginine ratio, endothelial-dependent vascular function and peripheral vascular stiffness, and uterine artery Doppler resistance and flow.","University of Pittsburgh|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years to 40 Years   (Child, Adult)","Phase 1","41","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","2P01HD030367-ARG|P01HD030367-09","January 2010","June 2013","June 2013","August 28, 2008","null","July 16, 2014","Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00743210"
504,"NCT01769456","An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)",,"Completed","Has Results","HIV Infection","Behavioral: PCC|Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))","Number of Participants With Serum Creatinine Event of Grade 1 or Higher Over the Course of the Study|Lumbar Spine Bone Mineral Density: Percent Change From Baseline to Week 48|Femoral Neck Bone Mineral Density: Percent Change From Baseline to Week 48|Total Body Bone Mineral Density: Percent Change From Baseline to Week 48|Total Hip Bone Mineral Density: Percent Change From Baseline to Week 48|Number of Participants With Decrease in Bone Mineral Density|Behavioral Disinhibition/Risk Compensation: Number of Participants Reporting Unprotected Sex|Behavioral Disinhibition/Risk Compensation: Number of Male Sexual Partners|Acceptability of PrEP Regimen and Study Visits|Estimation of Medication Adherence by Dried Blood Spot (DBS) Results|Acceptability and Feasibility of Two Types of Efficacious Sexual Risk Reduction Interventions as Measured by Session Evaluation|Number of Participants Using Text Messaging Reminders|Rating of the Reasons for Missing Medications on a 4-point Likert Scale.|Demographic and/or Behavioral Difference Between Study Groups. Behavioral Disinhibition/Risk Compensation Endpoints Will be Compared.|Evaluation of the Process of Protocol Implementation|Demographic and/or Behavioral Differences Between Youth Who Are Interested in Participating in a PrEP Study Versus Those Who Are Not.","University of North Carolina, Chapel Hill|Gilead Sciences|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","15 Years to 17 Years   (Child)","Phase 2","78","Other|Industry|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ATN 113 Version 2.0","March 2013","November 2015","November 2016","January 16, 2013","November 13, 2017","January 17, 2018","Children's Hospital of Los Angeles, Los Angeles, California, United States|University of Colorado - The Children's Hospital of Denver, Aurora, Colorado, United States|Stroger Hospital of Cook County, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Fenway Institute, Boston, Massachusetts, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01769456"
505,"NCT00697580","Strength and Nutrition Outcomes for Latino Adolescents","SANO LA","Completed","No Results Available","Obesity|Type 2 Diabetes|Cardiovascular Risk|Cancer","Behavioral: Nutrition|Behavioral: Strength Training & Nutrition|Behavioral: Circuit Training & Nutrition","insulin sensitivity|adiposity","University of Southern California|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","104","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","5R01HD033064","May 2005","June 2007","July 2007","June 16, 2008","null","March 31, 2017","Veronica Atkins Lifestyle Intervention Laboratory, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT00697580"
506,"NCT01728961","Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy",,"Terminated","No Results Available","HIV Infection|Malaria","Drug: Artemether/Lumefantrine (AL)","Area under the curve from time zero to last quantifiable concentration (AUC)|Toxicity|Maximum observed plasma concentration (Cmax)|Minimum observed plasma concentration (Cmin)|HIV-1 Viral Load|NVP resistance","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Phase 4","19","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT P1079|U01AI068632","February 2012","March 2014","March 2014","November 20, 2012","null","May 19, 2014","College of Med. JHU CRS (30301), Blantyre, Malawi|University of North Carolina Lilongwe (12001), Lilongwe, Malawi|Makerere University - JHU Research Collaboration (30293), Kampala, Uganda","","https://ClinicalTrials.gov/show/NCT01728961"
507,"NCT00691444","Blind Child Melatonin Treatment Study",,"Unknown status","No Results Available","Blindness","Dietary Supplement: Melatonin|Biological: Melatonin","circadian phase marker, as measured by the melatonin levels in serial salivary and/or plasma samples.|Durability and Toxicity Side Effects Questionnaire","Oregon Health and Science University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 20 Years   (Child, Adult)","Not Applicable","26","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","eIRB 1251|R01HD042125","September 2002","March 2015","March 2015","June 5, 2008","null","November 6, 2014","Sleep and Mood Disorders Lab, Oregon Health & Science University, Portland, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00691444"
508,"NCT01697124","The Children in Action Feasibility Study","CIA","Completed","No Results Available","Obesity|Motor Activity","Behavioral: SPARK-EC","Change from baseline in physical activity at post-intervention.|Change from baseline in gross motor skills at post intervention.|Body Mass Index","Baylor College of Medicine|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 5 Years   (Child)","Not Applicable","274","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","H-20952|R21HD054836-02","September 2007","August 2009","August 2009","October 2, 2012","null","October 2, 2012","","","https://ClinicalTrials.gov/show/NCT01697124"
509,"NCT00640224","Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study",,"Completed","Has Results","Polycystic Ovary Syndrome","Drug: rosiglitazone|Drug: drospirenone/ethinyl estradiol","Peripheral Insulin Sensitivity at Baseline and 6 Months.|Hepatic Insulin Sensitivity at Baseline and 6 Months.|Glucose Tolerance Status at Baseline and 6 Months.|Total Fat Mass at Baseline and 6 Months|Total Testosterone at Baseline and 6 Months|Percent Body Fat at Baseline and 6 Months|Free Testosterone at Baseline and 6 Months|SHBG at Baseline and 6 Months|DHEAS at Baseline and 6 Months|Delta Androstenedione at Baseline and 6 Months|Delta DHEA at Baseline and 6 Months|Delta 17-OHProg at Baseline and 6 Months|Delta 17-OHPreg at Baseline and 6 Months|Cholesterol at Baseline and 6 Months|HDL at Baseline and 6 Months|LDL at Baseline and 6 Months|Triglycerides at Baseline and 6 Months|Non-HDL Cholesterol at Baseline and 6 Months|Adiponectin at Baseline and 6 Months|Leptin at Baseline and 6 Months|Hs-CRP at Baseline and 6 Months|Morning Blood Pressure at Baseline and 6 Months|Night Blood Pressure at Baseline and 6 Months","Silva Arslanian|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Pittsburgh","Female","10 Years to 20 Years   (Child, Adult)","Phase 4","65","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","0503013|2K24HD001357","March 2005","July 2015","July 2015","March 21, 2008","November 17, 2017","November 17, 2017","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00640224"
510,"NCT01674920","CHOICES: Family Physicians Treat Overweight Children","CHOICES","Completed","No Results Available","Obesity|Overweight","Behavioral: Choices","body mass index age-and-gender specific Z-score|weight for age-and-gender specific Z-score","University of Arizona|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 11 Years   (Child)","Not Applicable","35","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R21HD050962","January 2006","June 2007","June 2008","August 29, 2012","null","August 29, 2012","University of Arizona, Tucson, Arizona, United States","","https://ClinicalTrials.gov/show/NCT01674920"
511,"NCT00615550","PREGNANT Short Cervix Trial",,"Completed","Has Results","Preterm Delivery|Short Cervix|Short Uterine Cervical Length","Drug: progesterone|Drug: placebo","Number of Participants With Birth <=32 6/7 Weeks Gestation.|Number of Infants With Neonatal Morbidities Such as Respiratory Distress Syndrome (RDS), Bronchopulmonary Dysplasia (BPD), Intraventricular Hemorrhage (IVH), Proven Sepsis, and Necrotizing Enterocolitis (NEC)|Number of Subjects With Preterm Birth at ≤27 6/7, ≤34 6/7, and <36 6/7 Weeks Gestation.|Number of Neonates Who Died.|Number of Infants With a Birth Weight < 1500 Grams or < 2500 Grams","Juniper Pharmaceuticals, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 45 Years   (Child, Adult)","Phase 3","465","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","COL-1620-302|09-CH-N014","March 2008","November 2010","November 2010","February 14, 2008","March 13, 2012","March 13, 2012","University of South Alabama Dept. of OB/GYN, Mobile, Alabama, United States|St. Joseph's Hospital and Med Ctr Women's Care Center, Phoenix, Arizona, United States|UCI Medical Center, Orange, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Miami Leonard Miller School of Medicine Department of Obstetrics and Gynecology, Miami, Florida, United States|Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States|Perinatal Center of Iowa, Des Moines, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Perinatal Diagnostic Center, Lexington, Kentucky, United States|Johns Hopkins Community Physicians, Baltimore, Maryland, United States|Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Perinatology Research Branch Hutzel Women's Hospital, Detroit, Michigan, United States|Henry Ford Healthcare System, Detroit, Michigan, United States|Spectrum Health Research Department, Grand Rapids, Michigan, United States|St. Joseph Mercy-Oakland, Pontiac, Michigan, United States|Washington University School of Medicine, Dept. of OB/GYN, St. Louis, Missouri, United States|St. Louis University Health Sciences Center, St. Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Albert Einstein Hospital, Bronx, New York, United States|Winthrop University Hosital, Mineola, New York, United States|Lyndhurst Clinical Research, Winston-Salem, North Carolina, United States|UPHS Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital OB/GYN / Maternal Fetal Medicine, Philadelphia, Pennsylvania, United States|Regional Obstetrical Consultants, Chattanooga, Chattanooga, Tennessee, United States|Regional Obstetrical Consultants, Knoxville, Knoxville, Tennessee, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|Charleston Area Medical Center Clinical Trials Center, Charleston, West Virginia, United States|1st Clinical Hospital of the City of Minsk, Minsk, Belarus|Public Health Services Establishment ""Vitebsk City Clinical Hospital of First Aid"", Vitebsk, Belarus|Escuela De Medicina, Pontificia Universidad Catolica De Chile, Santiago, Chile|Maternidad Hospital DR Sotero Del Rio, Santiago, Chile|Charles University & General Teaching Hospital, Prague, Czech Republic|BJ Medical College & Sassoon Hospital, Pune, Maharashtra, India|Sri Ramchandra Medical College and Research Institute, Porur, Tamil Nadu, India|Sheth L.G. Hospital, Ahmedabad, India|MediCiti Institute of Medical Sciences, Andhra Pradesh, India|Government Medical College, Nagpur, India|Soroka University Medical Center, Beer-Sheva, Israel|Kaplan Medical Center, Rehovot, Israel|Sheba Medical Center, Tel Hashomer, Israel|Azienda Ospedaliera di Padova Centro Prenatale Divisione di Ostetricia, Padova, Italy|Limited Liability Company ""American Health Clinic"", Saint Petersburg, Russian Federation|Saint Petersburg State Healthcare Institution Maternity Hospital 17, Saint Petersburg, Russian Federation|Steve Biko Academic Hospital Dept. of OB-GYN and Maternal Fetal Medicine, Pretoria, South Africa|Municipal health care establishment ""City Maternity Clinical Hospital"", Chernovtsy, Ukraine|Department of Obstetrics and Gynecology of Dnepropetrovsk State Medical Academy, Municipal establishment ""City Maternity Hospital # 1"", Dnepropetrovsk, Ukraine|M. Gorky Donetsk National Medical University, Department of Obstetrics, Gynecology and Perinatology, Maternity Hospital of 6th Central City Clinical Hospital, Donetsk, Ukraine|Municipal clinical hospital #1, Kiev, Ukraine|Antenatal Clinic # 1, Central Polyclinics of Pechersk District, Kyiv, Ukraine","","https://ClinicalTrials.gov/show/NCT00615550"
512,"NCT00536250","Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth",,"Completed","No Results Available","Impaired Glucose Tolerance|Pre-diabetes|Childhood Obesity|Insulin Resistance|Metabolic Syndrome","","glucose tolerance|insulin resistance|hepatic fat content and abdominal fat ratio","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 22 Years   (Child, Adult)","","255","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","0102012241|R01HD040787","September 2001","March 2017","March 2017","September 27, 2007","null","January 18, 2018","47 College Street, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00536250"
513,"NCT00514358","Fluconazole Pharmacokinetics in Infants",,"Completed","No Results Available","Fungal Infection","","To develop a population PK model of fluconazole drug disposition in premature infants who are receiving fluconazole for treatment or prophylaxis against systemic fungal infections.","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Pediatric Pharmacology Research Units Network","All","up to 119 Days   (Child)","","55","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PPRU10826","November 2005","June 2007","June 2007","August 9, 2007","null","July 7, 2011","Children's Hospital of Michigan, Wayne State University, Detroit, Michigan, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|University of Virginia, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00514358"
514,"NCT01495637","GM-CSF for Immunomodulation Following Trauma (GIFT) Study","GIFT","Recruiting","No Results Available","Critical Injury (Trauma) in Children","Drug: GM-CSF","Immune function|Nosocomial infection","Mark Hall|National Institute of General Medical Sciences (NIGMS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Nationwide Children's Hospital","All","1 Year to 17 Years   (Child)","Phase 4","200","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIFT Study|R01GM094203|UG1HD083170","December 2011","June 2019","December 2019","December 20, 2011","null","October 1, 2018","Children's Hospital of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Washington University / St. Louis Children's Hospital, Saint Louis, Missouri, United States|Cincinnati Children's Medical Center, Cincinnati, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01495637"
515,"NCT00485264","Safety and Pharmacokinetics (PK) of Raltegravir in HIV (Human Immunodeficiency Virus)-Infected Children and Adolescents",,"Completed","Has Results","HIV Infections","Drug: Raltegravir poloxamer film coated tablet|Drug: Raltegravir chewable tablet|Drug: Raltegravir oral granules for suspension (20 mg/mL)","Percentage of Participants With Grade 3 or 4 Adverse Events (AEs)|Number of Participants Terminated From Treatment Due to Suspected Adverse Drug Reaction (SADR) Attributable to the Study Medication|Number of Participants Who Died|Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC12h)|PK Parameter: Maximum Plasma Concentration (Cmax)|PK Parameter: Time to Half of Maximum Plasma Concentration Cmax (T1/2)|PK Parameter: Concentration at 12 Hours Postdose (C12h)|Percentage of Participants With ≥1 log10 Drop From Baseline in HIV RNA or HIV RNA <400 Copies/mL|Change of CD4 Count From Baseline|Change of CD4 Percent From Baseline","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 18 Years   (Child, Adult)","Phase 1|Phase 2","153","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1066|10495|IMPAACT P1066","September 17, 2007","June 3, 2013","May 18, 2017","June 12, 2007","December 22, 2014","March 29, 2018","Usc La Nichd Crs, Alhambra, California, United States|University of California, UC San Diego CRS, La Jolla, California, United States|Children's Hospital of Los Angeles NICHD CRS, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Inst de Infectologia Emilio Ribas Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Shandukani Research CRS, Johannesburg, Gauteng, South Africa|Durban Paediatric HIV CRS, Durban, KwaZulu-Natal, South Africa|Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg, Western Cape Province, South Africa","","https://ClinicalTrials.gov/show/NCT00485264"
516,"NCT00383656","Pulsatile GnRH in Anovulatory Infertility",,"Recruiting","No Results Available","Hypogonadotropic Hypogonadism|Amenorrhea|Kallmann's Syndrome","Drug: GnRH|Device: Pump","ovulation|pregnancy","Massachusetts General Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 45 Years   (Child, Adult)","Phase 2","270","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1999-P-004396|5U54HD028138","January 1989","September 2020","September 2020","October 3, 2006","null","July 12, 2017","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00383656"
517,"NCT01240486","IMPAACT P1073: Study of IRIS for Infants and Children Initiating HAART at Int'l Sites",,"Completed","No Results Available","IRIS|HIV","","Proportion of study subjects having BCG-related IRIS within 48 weeks of initiating HAART.|Proportion of study subjects having unmasking and paradoxical TB-related IRIS within 48 weeks of initiating HAART.|Nadir CD4 T-cell count and percentage and plasma viral load pre-HAART initiation, and two weeks post-HAART and CD4 T-cell count and percentage and plasma viral load at the presumptive BCG or TB-IRIS event, for CASES and the matching controls.|CD4 T-cell count and percentage and plasma viral load, 48 weeks post-HAART initiation for CASES and the matching controls.|Frequency of all IRIS-like events and proportion attributed to BCG or TB.","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 72 Months   (Child)","","207","Other|NIH","Observational","Time Perspective: Prospective","IMPAACT P1073|U01AI068632","November 2010","February 2013","October 2013","November 15, 2010","null","May 19, 2014","BJ Medical College CRS (31441), Pune, Maharashtra, India|Durban Pediatric HIV CRS (20201), Durban, KwaZulu-Natal, South Africa|University of Stellenbosch, Tygerberg Hospital (8950), Cape Town, South Africa|Soweto IMPAACT CRS (8052), Johannesburg, South Africa|Kilimanjaro Christian Medical CRS (12901), IDC Research Offices, Moshi, Tanzania|Makerere University - JHU Research Collaboration (30293), Kampala, Uganda|UZ-Parirenyatwa CRS (30313), Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT01240486"
518,"NCT01217658","Measuring and Reducing Excessive Infant Crying","UTHealth THB","Completed","No Results Available","Infant Colic|Postpartum Depression","Behavioral: The Happiest Baby on The Block|Behavioral: AAP Infant Colic counseling","Mean night-time crying|Mean sleep duration|Maternal Depression, Anxiety and Somatization|Salivary Biomarkers","The University of Texas Health Science Center, Houston|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 5 Weeks   (Child)","Not Applicable","28","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-10-0392|K23HD065872","January 2011","September 2015","September 2015","October 8, 2010","null","December 8, 2015","University of Texas Health Science Center at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01217658"
519,"NCT00312091","Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children",,"Completed","No Results Available","HIV Infections","Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet|Drug: Lamivudine|Drug: Nevirapine|Drug: Stavudine","Comparative bioavailability|therapeutic adequacy|Drug absorption from standard pharmacokinetic (PK) analyses","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group","All","6 Months to 13 Years   (Child)","Phase 1|Phase 2","44","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1056|10139|PACTG P1056|IMPAACT P1056","December 2006","September 2008","September 2008","April 7, 2006","null","September 12, 2012","Queen Sirikit National Institute of Child Health, Pediatric Infectious Unit, Bangkok, Ratchathewi, Thailand|Siriraj Hospital Mahidol University CRS, Bangkok, Ratchathewi, Thailand|Chiang Mai University Pediatrics-Obstetrics CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburri, Thailand","","https://ClinicalTrials.gov/show/NCT00312091"
520,"NCT00292591","Evaluation of Vitamin D Requirements During Pregnancy",,"Completed","Has Results","Vitamin D Deficiency","Drug: cholecalciferol (vitamin D3)|Drug: cholecalciferol","25-Hydroxyvitamin D Concentration","Medical University of South Carolina|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 45 Years   (Child, Adult)","Phase 3","501","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R01HD043921|5R01HD043921","January 2004","January 2010","January 2010","February 16, 2006","August 9, 2016","September 19, 2016","Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT00292591"
521,"NCT00266825","DHA Supplementation and Pregnancy Outcome",,"Completed","Has Results","Pregnancy","Drug: DHA|Other: Placebo capsule","Percentage of Total Fatty Acids by Weight|Gestational Age|Birth Weight|Birth Length|Ponderal Index|Gender of Babies|Cord RBC-phospholipid-DHA|Head Circumference|Preterm Births","Susan Carlson, PhD|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Kansas Medical Center","Female","16 Years to 36 Years   (Child, Adult)","Phase 3","350","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10186|R01HD047315","January 2006","October 2011","October 2011","December 19, 2005","February 4, 2016","March 14, 2016","University of Kansas Medical Center, Kansas City, Kansas, United States|Truman Medical Center, Kansas City, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00266825"
522,"NCT01140724","Personalizing Perioperative Analgesia in Children",,"Active, not recruiting","No Results Available","Postoperative Pain","","Look at polymorphisms in genes that regulate pain perception, opioid transport and opioid receptor signaling to see if there is a higher susceptibility to pain and morphine requirement.|Evaluate relationship of pupil reaction and response to 5% carbon dioxide to adverse effects of morphine","Indiana University|Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 15 Years   (Child)","","1200","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","1707325115|7R01HD089458-02","April 2008","April 2019","April 2019","June 9, 2010","null","January 16, 2019","Riley Hospital for Children, Indianapolis, Indiana, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01140724"
523,"NCT00257127","Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs",,"Completed","No Results Available","HIV Infections","Biological: Pneumococcal 7-valent conjugate vaccine|Biological: Pneumococcal polysaccharide vaccine|Biological: Hepatitis B vaccine|Biological: Measles, mumps, and rubella virus vaccine, live","Grade 3 or greater hematologic and chemistry laboratory values, signs, or symptoms not present, as specified by the protocol|Seropositivity, as determined by antibody levels|Immunologic memory, as determined by primary and secondary responses, antibody levels, and additional measures of immunologic memory","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 23 Years   (Child, Adult)","Not Applicable","101","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1061s|10132|PACTG P1061s","February 2006","August 2006","August 2006","November 22, 2005","null","November 11, 2014","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Usc La Nichd Crs, Alhambra, California, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Children's Hosp., New Orleans, Louisiana, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. Ctr., New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00257127"
524,"NCT00252681","Comparison of Two Surgical Treatments for Necrotizing Enterocolitis in Human Infants",,"Completed","No Results Available","Necrotizing Enterocolitis","Procedure: laparotomy|Procedure: primary peritoneal drainage","The primary outcome variable is operative mortality, i.e. death within 90 days of intervention.|The secondary outcome is short bowel syndrome - defined as the need for chronic parenteral nutrition greater than 3 months following operation.","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)","All","up to 3 Months   (Child)","Not Applicable","130","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","R01HD038462|Gen Clin Res Ctr #M01-RR00125","July 1999","null","June 2005","November 11, 2005","null","July 21, 2006","Yale University School of Medicine Section of Pediatric Surgery, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00252681"
525,"NCT00166595","Pharmacogenetics of Risperidone in Children With Pervasive Developmental Disorder (PDD)",,"Completed","No Results Available","Child Development Disorders, Pervasive","Drug: Risperidone","","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 21 Years   (Child, Adult)","Phase 1|Phase 2","100","Other|NIH","Interventional","Primary Purpose: Treatment","PPRU 10545s","February 2003","null","March 2005","September 14, 2005","null","January 28, 2014","Children's Hospital of Michigan/Wayne State University, Detroit, Michigan, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT00166595"
526,"NCT00151411","Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)",,"Completed","Has Results","Polycystic Ovary Syndrome","Drug: Metformin|Drug: Placebo|Behavioral: Lifestyle Intervention","Change in Testosterone After 6 Months of Treatment|Ovulation Rate|Change in Insulin Sensitivity Index After 6 Months of Treatment","Milton S. Hershey Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","12 Years to 39 Years   (Child, Adult)","Phase 2","114","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2003-172|HD-02-012","October 2004","March 2008","March 2008","September 9, 2005","November 8, 2011","March 21, 2018","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00151411"
527,"NCT00151151","The S.A.F.E. Study : Computer-Aided Counseling to Prevent Teen Pregnancy/Sexually Transmitted Diseases (STDs)",,"Completed","No Results Available","Pregnancy|Sexually Transmitted Diseases","Behavioral: Computer-Assisted Motivational Intervention|Behavioral: Didactic Educational Counseling","Self-reported sexual and contraceptive behaviors recorded by a 90-day timeline follow back interview at 9 and 18 months compared to baseline|Stage of readiness to be abstinent, use condoms, spermicide, and hormonal contraception based on a computerized assessment|Reported drug and alcohol use recorded by a 90-day timeline follow back interview","University of Pittsburgh|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years to 21 Years   (Child, Adult)","Not Applicable","660","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0405473|HD41058","February 2003","December 2007","December 2007","September 8, 2005","null","September 13, 2011","Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00151151"
528,"NCT00957892","Effects of Infant Formula Composition on Infant Feeding Behaviors",,"Completed","No Results Available","Healthy Infants","","Satiation: volume of formula consumed within a feed|Satiety: the duration between feedings|Infant temperature change|Infant sleep and activity patterns|Maternal perceptions","Monell Chemical Senses Center|Ajinomoto USA, INC.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 4 Months   (Child)","","55","Other|Industry|NIH","Observational","Observational Model: Case-Crossover|Time Perspective: Cross-Sectional","809649|R01HD037119|F32HD063343-01A1","May 2009","March 2011","March 2011","August 13, 2009","null","December 18, 2017","Monell Chemical Senses Center, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00957892"
529,"NCT00102206","A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate|Drug: Emtricitabine|Drug: Lamivudine|Drug: Lopinavir/ritonavir|Drug: Saquinavir|Drug: Tenofovir disoproxil fumarate|Drug: Zidovudine","Tolerability of dual PI-based HAART versus multi-NRTI HAART salvage regimens (time to first intolerant event)|95% confidence interval (CI) for change in CD4% computed for PI-containing groups versus PI-sparing group|95% CI for change in BMD (both percent change in BMD and change in z-score from baseline) for each treatment group|HIV-1 RNA|growth and development markers|toxicity|adherence|pharmacokinetics|special virologic and immunologic parameters","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 21 Years   (Child, Adult)","Phase 2","6","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1053|10131|PACTG P1053","null","null","May 2007","January 26, 2005","null","May 21, 2012","Chicago Children's CRS, Chicago, Illinois, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00102206"
530,"NCT00087945","Blood Levels of Abacavir in HIV Infected Adolescents",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate|Drug: Abacavir sulfate, lamivudine, and zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 25 Years   (Child, Adult)","Not Applicable","30","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACTG P1052|10194","July 2004","null","December 2004","July 19, 2004","null","October 8, 2013","Usc La Nichd Crs, Alhambra, California, United States|Children's Hospital of Los Angeles NICHD CRS, Los Angeles, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|UMDNJ - Robert Wood Johnson Med. School, Div. of Allergy, Immunology & Infectious Diseases, New Brunswick, New Jersey, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00087945"
531,"NCT00079729","Directly Observed Therapy in HIV Infected Adolescent Focus Groups",,"Completed","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years to 21 Years   (Child, Adult)","","30","NIH","Observational","Time Perspective: Prospective","PACTG P1036A|10193","April 2004","null","July 2004","March 12, 2004","null","October 29, 2012","Los Angeles County Medical Center/USC, Los Angeles, California, United States|University of Miami (Pediatric), Miami, Florida, United States|St. Jude Childrens Research Hospital, Memphis, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00079729"
532,"NCT00719602","Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART",,"Completed","No Results Available","HIV Infections|Malaria","Drug: Lamivudine|Drug: Lopinavir/Ritonavir|Drug: Nevirapine|Drug: Zidovudine","Parasitemia in blood samples|Time of initiation of treatment for clinical malaria requiring conventional anti-malarial therapy|Severity of malarial disease|Measured anti-malaria IgG, protein in plasma, and mRNA transcripts in PBMC of chemokines|IL4-589C/T genotypes","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 35 Months   (Child)","Early Phase 1","105","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IMPAACT P1068s|U01AI068632","August 2009","August 2013","August 2013","July 21, 2008","null","September 19, 2016","University of North Carolina Lilongwe (12001), Lilongwe, Malawi|Makerere University - JHU Research Collaboration (30293), Kampala, Uganda|George Clinic CRS (30273), Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00719602"
533,"NCT00075907","Anti-HIV Drug Regimens With or Without Protease Inhibitors and Drug Level Monitoring in HIV Infected Adolescents",,"Completed","No Results Available","HIV Infections","Drug: Efavirenz + 2 NRTIs|Drug: Lopinavir/Ritonavir + 2 NRTIs|Procedure: Therapeutic Drug Monitoring","Proportion of patients achieving viral suppression (viral load less than 1,000 copies/ml) at Week 24 and maintaining suppression through Week 48 while remaining on study treatment|Proportion of patients achieving virologic suppression (viral load less than 1,000 copies/ml) at Week 24 and maintaining suppression through Week 96 while remaining on study treatment|adherence measured by MEMS TrackCap Monitors (percentage of doses taken, estimated using the frequency of bottle openings recorded by the MEMS TrackCap Monitors, the MEMS TrackCap Monitor tracking form, and the information recorded on the questionnaires)|adherence measured by patient self-report (binary variable of perfect adherence measured 3 days prior to any study visit reported on the adherence questionnaires and the numbers of visits with reported perfect adherence up to Week 24, 48, and 96)|adherence measured by pill count (percentage of pills taken, determined by counting the pills left in the bottles)|HIV viral load at each study visit|number and severity of symptoms of distress and central nervous system (CNS) side effects|number and severity of all adverse events of Grade 3 or more attributed to study treatment|time to virologic failure (first time viral load is measured to be 1,000 copies/ml or more after Week 24, time before discontinuing study treatment for any reason before Week 96, or time before terminating study for any reason before Week 96)|HIV resistance mutations at baseline and at time of virologic failure (viral load returning to 1,000 copies/ml or more)|baseline values for percentage and total number of CD19 (B cells), total T cells (CD3 T cells), CD4 (T helper cells), CD8 (cytotoxic T cells), naive CD4 T cells (CD62L/CD45RA/CD4), and activated CD8 T cells (HLADR/CD38/CD8)|changes from baseline to Weeks 24, 48, and 96 for percentage and total number of CD19 (B cells), total T cells (CD3 T cells), CD4 (T helper cells), CD8 (cytotoxic T cells), naive CD4 T cells (CD62L/CD45RA/CD4), and activated CD8 T cells (HLADR/CD38/CD8)","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 23 Years   (Child, Adult)","Phase 3","240","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACTG P1034|DAIDS-ES ID 10043","July 2004","null","September 2006","January 13, 2004","null","October 7, 2013","Usc La Nichd Crs, Alhambra, California, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Children's Hospital of Los Angeles NICHD CRS, Los Angeles, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Children's Hosp., New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Children's Med. Ctr. Dallas, Dallas, Texas, United States|Texas Children's Hosp. CRS, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00075907"
534,"NCT00688129","KITS: School Readiness in Foster Care Efficacy Trial","KITS","Completed","No Results Available","School Readiness","Behavioral: KITS Program","Early literacy skills|Social skills|Regulatory skills|Caregiver involvement|Academic achievement|Peer relations","Oregon Social Learning Center|National Institute on Drug Abuse (NIDA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 6 Years   (Child)","Not Applicable","192","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","R01DA021424","September 2005","December 31, 2016","December 31, 2016","June 2, 2008","null","September 19, 2017","Oregon Social Learning Center, Eugene, Oregon, United States","","https://ClinicalTrials.gov/show/NCT00688129"
535,"NCT00073424","Factors Affecting Adherence to Anti-HIV Drug Regimens in Children and Adolescents",,"Completed","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 19 Years   (Child, Adult)","","200","NIH","Observational","Time Perspective: Prospective","PACTG P1042s|10107","January 2004","null","October 2006","November 21, 2003","null","June 3, 2013","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Phoenix Children's Hosp., Phoenix, Arizona, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Denver, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Springfield, Massachusetts, United States|NJ Med. School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Jacobi Med. Ctr., Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|DUMC Ped. CRS, Durham, North Carolina, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00073424"
536,"NCT00672412","Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand",,"Completed","No Results Available","HIV Infections","Drug: GPO-Vir Z30 tablet|Drug: Lamivudine|Drug: Nevirapine|Drug: Zidovudine","Safety and comparative bioavailability measured by concentration difference between the GPO-Vir Z30 and standard liquid regimens|Therapeutic adequacy of NVP measured by treatment-specific concentration distributions|Comparisons in PK analyses between GPO-VIR Z30 and standard liquid regimens including pharmacokinetic parameters, adverse drug reactions, and the influence of SNPs on NVP pharmacokinetic parameters","National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Months to 12 Years   (Child)","Phase 1|Phase 2","42","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1069|10620|IMPAACT P1069","October 2008","January 2010","January 2010","May 6, 2008","null","September 13, 2012","Prapokklao Hosp. CRS, Muang District, Chantaburi, Thailand|Siriraj Hospital Mahidol University CRS, Bangkok, Ratchathewi, Thailand|Chiang Mai University Pediatrics-Obstetrics CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand","","https://ClinicalTrials.gov/show/NCT00672412"
537,"NCT00069004","A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth",,"Completed","No Results Available","HIV Infections|HIV-Associated Lipodystrophy Syndrome|HIV Lipodystrophy Syndrome|Lipodystrophy|Dyslipidemia|Osteoporosis|Osteopenia","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 25 Years   (Child, Adult)","","450","NIH","Observational","","P1045|10108|PACTG P1045","October 2003","null","August 2005","September 16, 2003","null","January 7, 2014","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Usc La Nichd Crs, Alhambra, California, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|UMDNJ - Robert Wood Johnson Med. School, Div. of Allergy, Immunology & Infectious Diseases, New Brunswick, New Jersey, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Lincoln Med. & Mental Health Ctr., Bronx, New York, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Jacobi Med. Ctr., Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. Ctr., New York, New York, United States|Mt. Sinai School of Medicine, Div. of Ped. Infectious Diseases, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|DUMC Ped. CRS, Durham, North Carolina, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00069004"
538,"NCT00064792","Simvastatin Therapy in Smith-Lemli-Opitz Syndrome",,"Completed","Has Results","Smith-Lemli-Opitz Syndrome","Drug: Simvastatin Susp.|Drug: OraPlus","Serum Cholesterol to Total Sterol Ratio|Cerebral Spinal Fluid Dehydrocholesterol to Total Sterol Ratio","Forbes Porter, M.D.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","4 Years to 18 Years   (Child, Adult)","Phase 2","23","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","030225|03-CH-0225","July 2003","December 2010","December 2010","July 14, 2003","June 6, 2014","June 6, 2014","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00064792"
539,"NCT00055107","Nitazoxanide for the Treatment of Chronic Diarrhea in HIV Infected Children",,"Completed","No Results Available","HIV Infections|Cryptosporidiosis","Drug: Nitazoxanide","Safety as evaluated by Grade 4 or new Grade 3 adverse reactions before Day 56 that cannot be directly attributed to another cause and are considered treatment limiting|area under the curve (AUC) of orally administered NTZ|Safety as evaluated by Grade 4 or new Grade 3 adverse reactions during longer-term follow-up (six months after Day 56 under Step I) that cannot be directly attributed to another cause and are considered treatment limiting","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 19 Years   (Child, Adult)","Phase 1|Phase 2","6","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACTG 369|10033","null","null","May 2006","February 20, 2003","null","February 16, 2012","Stellenbosch Univ. CRS, Cape Town, South Africa|Siriraj Hospital Mahidol University CRS, Bangkok, Thailand","","https://ClinicalTrials.gov/show/NCT00055107"
540,"NCT00037076","Prevalence of Hepatitis C Virus Infection in HIV-Infected Children",,"Completed","No Results Available","HIV Infections|Hepatitis C","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Year to 20 Years   (Child, Adult)","","600","NIH","Observational","","PACTG P1028S|11657","null","null","July 2003","May 15, 2002","null","October 31, 2012","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Phoenix Childrens Hosp, Phoenix, Arizona, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|Univ of California, San Diego, San Diego, California, United States|UCSF, Moffitt Hospital (Pediatric), San Francisco, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Connecticut Childrens Med Ctr (Pediatric), Farmington, Connecticut, United States|Yale Univ Med School, New Haven, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Med College of Georgia, Augusta, Georgia, United States|The Med Ctr Inc, Columbus, Georgia, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|The Univ of Chicago Children's Hosp, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hospital at SUNY Downstate, Brooklyn, New York, United States|Mount Sinai Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Univ of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University (Pediatric), Durham, North Carolina, United States|Childrens Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|St. Christopher's Hosp for Children, Philadelphia, Philadelphia, Pennsylvania, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Univ. of Puerto Rico, U. Children's Hospital AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00037076"
541,"NCT00016783","Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIV",,"Completed","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 21 Years   (Child, Adult)","","39","NIH","Observational","Time Perspective: Prospective","P1015|PACTG P1015|ACTG P1015|11650","null","null","October 2006","August 31, 2001","null","October 7, 2013","Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|St. Lukes/Roosevelt Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00016783"
542,"NCT00016718","Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs",,"Completed","Has Results","HIV Infections","Drug: Didanosine (ddI)|Drug: Efavirenz (EFV)|Drug: Emtricitabine (FTC)","Proportion of Participants Who Developed Grade 3 or 4 Adverse Events Attributed to the Study Treatment.|Proportion of Participants With Suppression of HIV Viral Load to Less Than 400 Copies/ml at Week 16|Proportion of Participants With Suppression of HIV Viral Load to Less Than 50 Copies/ml at Week 16","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","90 Days to 21 Years   (Child, Adult)","Phase 1|Phase 2","43","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1021|10038|ACTG P1021|PACTG P1021|IMPAACT P1021","August 2001","January 2009","January 2009","August 31, 2001","October 17, 2017","October 17, 2017","UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Howard Univ. Washington DC NICHD CRS, Washington, D.C., District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Nyu Ny Nichd Crs, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00016718"
543,"NCT00014014","Zidovudine and Lamivudine Given Once Versus Twice Daily",,"Completed","No Results Available","HIV Infections","Drug: Lamivudine/Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 24 Years   (Child, Adult)","Phase 1","20","NIH","Interventional","Intervention Model: Crossover Assignment|Primary Purpose: Treatment","P1012|PACTG P1012|ACTG P1012|11648","null","null","August 2002","August 31, 2001","null","October 7, 2013","Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Univ of California, San Diego, San Diego, California, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Cook County Hosp, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|St Joseph's Hosp & Med Center, Paterson, New Jersey, United States|Metropolitan Hosp Ctr, New York, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Temple University School of Medicine, Philadelphia, Pennsylvania, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00014014"
544,"NCT00013871","Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs",,"Completed","No Results Available","HIV Infections|Hepatitis B|Measles|Pneumococcal Infections|Pertussis","Biological: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|Biological: Measles-Mumps-Rubella Vaccine (Live)|Biological: Pneumococcal Vaccine, Polyvalent (23-valent)|Biological: Pneumococcal Conjugate Vaccine, Heptavalent|Biological: Hepatitis B Vaccine (Recombinant)","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 18 Years   (Child, Adult)","Not Applicable","300","NIH","Interventional","Primary Purpose: Prevention","P1024|PACTG 1024|10609|ACTG P1024","null","null","November 2004","August 31, 2001","null","November 26, 2013","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Connecticut Children's Med. Ctr., Hartford, Connecticut, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Columbus Regional HealthCare System, The Med. Ctr., Columbus, Georgia, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Chicago Children's CRS, Chicago, Illinois, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Montefiore Med. Ctr. - AECOM, Bronx, New York, United States|SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS, Brooklyn, New York, United States|Schneider Children's Hosp., Div. of Infectious Diseases, New Hyde Park, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Cornell Univ., Div. of Ped. Infectious Diseases & Immunology, New York, New York, United States|Metropolitan Hosp. Ctr., New York, New York, United States|St. Luke's-Roosevelt Hosp. Ctr., New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00013871"
545,"NCT00011479","Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","9 Years to 18 Years   (Child, Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","P1018|11653|ACTG P1018|PACTG P1018","null","null","August 2002","August 31, 2001","null","May 21, 2012","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Children's Hospital of L.A. (Pediatric), Los Angeles, California, United States|Univ of California, San Diego, San Diego, California, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Med College of Georgia, Augusta, Georgia, United States|The Med Ctr Inc, Columbus, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00011479"
546,"NCT00006304","Long-Term Effects of HIV Exposure and Infection in Children",,"Completed","No Results Available","HIV Infections|HIV Seronegativity","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 21 Years   (Child, Adult)","","4150","NIH","Observational","","ACTG 219C|ACTG 219|PACTG 219C|11196","null","null","May 2002","August 31, 2001","null","October 7, 2013","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|Phoenix Childrens Hosp, Phoenix, Arizona, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|UCLA Med Ctr / Pediatrics, Los Angeles, California, United States|UCLA Med Ctr, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Connecticut Children's Med Ctr, Farmington, Connecticut, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Yale Univ Med School, New Haven, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Sacred Heart Children's Hosp / CMS of Florida, Pensacola, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Univ of South Florida, St. Petersburg, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Med College of Georgia, Augusta, Georgia, United States|The Med Ctr Inc, Columbus, Georgia, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Children's Hospital of New Orleans, New Orleans, Louisiana, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Earl K Long Early Intervention Clinic, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Childrens Hospital of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|St. Louis Children's Hosp, St. Louis, Missouri, United States|Cooper Hosp, Camden, New Jersey, United States|Robert Wood Johnson AIDS Program, New Brunswick, New Jersey, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|Montefiore Medical / AECOM, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Beth Israel Med Ctr / Pediatrics, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Cornell Univ Med College, New York, New York, United States|New York Hosp - Cornell Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of North Carolina at Chapel Hill / Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|Oregon Health Sciences Univ, Portland, Oregon, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Rhode Island Hosp / Brown Univ, Providence, Rhode Island, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|Med College of Virginia, Richmond, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00006304"
547,"NCT00006066","Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems",,"Completed","No Results Available","HIV Infections","Biological: Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|Biological: Diphtheria and Tetanus Toxoids Adsorbed|Biological: Tetanus and Diphtheria Toxoids Adsorbed|Drug: Bacteriophage phi X 174|Drug: Aldesleukin","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 18 Years   (Child, Adult)","Phase 1","92","NIH","Interventional","Primary Purpose: Treatment","ACTG 402|10607|PACTG 402","null","null","June 2006","August 31, 2001","null","May 21, 2012","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|UCSD Maternal, Child, and Adolescent HIV CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00006066"
548,"NCT00004735","The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV",,"Completed","No Results Available","HIV Infections","Biological: Tetanus toxoid|Biological: Hepatitis A Vaccine (Inactivated)","A stimulation index of 3 or greater on at least 2 occasions to tetanus|positive serologic response to hepatitis A|four-fold increase over baseline in antibody titers for tetanus|A stimulation index of 3 or greater on at least 2 occasions to hepatitis A and Candida|increase in CD4 cell percentage by 10% and absolute CD4 number by 150 cells/ml|development of any adverse events of Grade 3 or higher attributable to vaccination","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 24 Years   (Child, Adult)","Not Applicable","81","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACTG P1006|10036","February 2000","null","September 2006","August 31, 2001","null","October 7, 2013","UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Usc La Nichd Crs, Alhambra, California, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Children's National Med. Ctr., ACTU, Washington, District of Columbia, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Schneider Children's Hosp., Div. of Infectious Diseases, New Hyde Park, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00004735"
549,"NCT00001125","Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox",,"Completed","No Results Available","HIV Infections|Chickenpox","Biological: Varicella Virus Vaccine (Live)","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 18 Years   (Child, Adult)","Phase 1","60","NIH","Interventional","Masking: None (Open Label)|Primary Purpose: Prevention","PACTG 391|10614|ACTG 391","null","null","March 2004","August 31, 2001","null","October 29, 2014","Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|Cooper Univ. Hosp., Camden, New Jersey, United States|NJ Med. School CRS, Newark, New Jersey, United States|Nyu Ny Nichd Crs, New York, New York, United States|Cornell Univ., Div. of Ped. Infectious Diseases & Immunology, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Vanderbilt Univ. Med. Ctr., Div. of Ped. Infectious Diseases, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00001125"
550,"NCT00001109","A Blood Test to Look at Cells of the Immune System in Healthy Children",,"Completed","No Results Available","HIV Infections|HIV Seronegativity","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 18 Years   (Child, Adult)","","630","NIH","Observational","","ACTG P1009|PACTG P1009","null","null","null","August 31, 2001","null","July 30, 2008","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|The Med Ctr Inc, Columbus, Georgia, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Cook County Hosp, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Tulane Univ Hosp of New Orleans, New Orleans, Louisiana, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00001109"
551,"NCT00001108","A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses",,"Completed","No Results Available","HIV Infections","Drug: Ritonavir|Drug: Nelfinavir mesylate|Drug: Saquinavir|Drug: Nevirapine|Drug: Lamivudine|Drug: Stavudine|Drug: Didanosine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years to 22 Years   (Child, Adult)","Phase 1","6","NIH","Interventional","Primary Purpose: Treatment","P1007|11643|ACTG P1007|PACTG P1007","null","null","June 2000","August 31, 2001","null","May 21, 2012","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Sacred Heart Children's Hosp / CMS of Florida, Pensacola, Florida, United States|Cook County Hosp, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|North Shore Univ Hosp, Great Neck, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Med College of Virginia, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00001108"
552,"NCT00001097","Long-Term Effects of HAART in Youth With Stronger Immune Systems Versus Youth With Weaker Immune Systems",,"Completed","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 22 Years   (Child, Adult)","","120","NIH","Observational","","ACTG 381|PACTG 381","December 1997","null","null","August 31, 2001","null","April 26, 2010","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|Phoenix Childrens Hosp, Phoenix, Arizona, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Connecticut Children's Med Ctr, Farmington, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Earl K Long Early Intervention Clinic, New Orleans, Louisiana, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00001097"
553,"NCT00001078","A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have Stopped Taking Their OI Preventive Medications",,"Completed","No Results Available","HIV Infections","Biological: Hepatitis A Vaccine (Inactivated)","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 21 Years   (Child, Adult)","Not Applicable","200","NIH","Interventional","Primary Purpose: Treatment","ACTG P1008|PACTG P1008","null","May 2005","null","August 31, 2001","null","March 2, 2011","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Phoenix Childrens Hosp, Phoenix, Arizona, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Yale Univ Med School, New Haven, Connecticut, United States|Children's Hosp of Washington DC, Washington, District of Columbia, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Med College of Virginia, Richmond, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00001078"
554,"NCT00000924","A Study to Compare Two Different Anti-HIV Drug Regimens",,"Completed","No Results Available","HIV Infections","Drug: Ritonavir|Drug: Nelfinavir mesylate|Drug: Nevirapine|Drug: Stavudine|Drug: Didanosine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Months to 21 Years   (Child, Adult)","Phase 2","120","NIH","Interventional","Primary Purpose: Treatment","ACTG 403|11358|P1001S (substudy)|P1004S (substudy)|PACTG 403","null","null","June 2001","August 31, 2001","null","May 21, 2012","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Earl K Long Early Intervention Clinic, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Bronx Municipal Hosp Ctr/Jacobi Med Ctr, Bronx, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Med Ctr of Dallas, Dallas, Texas, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|Med College of Virginia, Richmond, Virginia, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000924"
555,"NCT00307151","Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV","P1060","Completed","Has Results","HIV Infections","Drug: Lamivudine|Drug: Lopinavir/ritonavir|Drug: Nevirapine|Drug: Zidovudine","Percent of Participants With Treatment Failure, Defined as a Confirmed Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment|Time From Randomization to Treatment Failure, Defined as Virologic Failure or Permanent Discontinuation of the Randomized NNRTI or PI Component of Study Treatment|Percent of Participants Experiencing Virologic Failure|Time From Randomization to Virologic Failure|Time From Start of Study Treatment to First New Grade >=3 Lab Abnormality, Sign or Symptom Occurring on Study Treatment|Number of Participants Developing New NRTI, NNRTI or PI-resistant Virus|Change in CD4 Percent From Entry to Week 48|Time From Randomization to HIV-related Disease Progression or Death|Time From Randomization to Death","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Months to 36 Months   (Child)","Phase 2","452","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT P1060|U01AI068632","December 2005","December 2010","December 2016","March 27, 2006","August 3, 2011","April 13, 2017","BJ Medical College CRS, Pune, Maharashtra, India|University of North Carolina Lilongwe CRS, Mzimba Road, Lilongwe, Malawi|Nelson R. Mandela School of Medicine, University of Kwazulu, Natal, Durban, South Africa|University of Stellenbosch-Tygerberg Hospital, South Africa, Cape Town, South Africa|Harriet Shezi Clinic at Chris Hani Baragwanath Hospital, Johannesburg, South Africa|Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Johannesburg, South Africa|Kilimanjaro Christian Medical CRS, IDC Research Offices, Moshi, Tanzania|Makerere University, Kampala, Uganda|George Clinic CRS, Lusaka, Zambia|UZ-College of Health Sciences, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT00307151"
556,"NCT00001723","Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases",,"Completed","Has Results","Diabetes Mellitus|Hypertension|Metabolic Disease|Obesity|Sleep Apnea Syndrome","Drug: Orlistat|Drug: Placebo","Change in BMI Standard Deviation Score|Change in Body Weight|Change in Body Mass Index|Change in Body Fat (kg)|Effect of Race on Change in Weight (kg)","Jack Yanovski|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Roche Pharma AG|National Institutes of Health Clinical Center (CC)","All","12 Years to 17 Years   (Child)","Phase 2","200","NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","980111|98-CH-0111","May 1998","October 2011","October 2011","November 4, 1999","December 18, 2012","December 18, 2012","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001723"
557,"NCT00998855","Glucose and Lipid Metabolism in Adolescents",,"Unknown status","No Results Available","Exercise|Obesity|Insulin Sensitivity","Behavioral: Exercise","Fat distribution, insulin sensitivity, glucose production, gluconeogenesis, glycogenolysis|Lipolysis, blood lipids, adiponectin, leptin and CRP","National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 17 Years   (Child)","","42","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","sunehagexercise|NIHNICHDRO1 HD044609","February 2004","December 2011","December 2011","October 21, 2009","null","June 7, 2011","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00998855"
558,"NCT00841061","Cereals as a Source of Iron for Breastfed Infants","Bfe03B","Completed","No Results Available","Iron Deficiency","Dietary Supplement: electrolytic iron|Dietary Supplement: ferrous fumarate","plasma ferritin|hemoglobin","National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 1 Year   (Child)","Not Applicable","111","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","B530500|HD40315-01","July 2003","May 2006","May 2006","February 11, 2009","null","February 11, 2009","University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT00841061"
559,"NCT00760890","Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation","BFe01B1","Completed","No Results Available","Iron Deficiency","Dietary Supplement: Fer-In-Sol (ferrous sulfate)|Dietary Supplement: Iron fortified cereal","Iron status|Growth|Tolerance (gastrointestinal)","National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 24 Months   (Child)","Not Applicable","171","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD040315","June 2001","June 2005","October 2005","September 26, 2008","null","September 26, 2008","Fomon Infant Nutrition Unit, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT00760890"
560,"NCT03831958","Long-Term Follow-Up of Survivors of Pediatric Cushing Disease",,"Recruiting","No Results Available","Cushing Disease","","Difference in body mass index z-score of subjects previously treated for Cushing disease compared to general population|Prevalence of endocrine and non-endocrine abnormalities","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 90 Years   (Child, Adult, Older Adult)","","600","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","190051|19-CH-0051","March 4, 2019","January 3, 2040","January 3, 2040","February 6, 2019","null","April 11, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03831958"
561,"NCT03575221","Natural History of the Collagen-Related Disorder Osteogenesis Imperfecta and Genotype Phenotype Correlation",,"Recruiting","No Results Available","Osteogenesis Imperfecta|Short Stature","","Clinical course, underlying pathogenesis, and comorbidities in the assessed systems in individuals with OI|Correlation of genotype and phenotype|Causes of morbidities in individuals with OI|Tolerability and feasibility of each measure of the clinical battery of assessments based on clinical observation","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 100 Years   (Child, Adult, Older Adult)","","125","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","180120|18-CH-0120","July 30, 2018","December 31, 2030","December 31, 2030","July 2, 2018","null","February 28, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03575221"
562,"NCT03374215","Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks",,"Recruiting","No Results Available","Adrenal Gland Neoplasm|Hypertension|Bone Diseases, Metabolic|Cardiovascular Disease|Hyperinsulinemia","","To define the germline and/or somatic genetic events causing Primary Aldosteronism (PA) in Blacks.|To define the effects of mutations in Black subjects on adrenocortical tumor formation, function and aldosterone production.|To investigate co-secretion of other steroids in PA.|To investigate the cardiovascular, renal, metabolic, bone, and coagulopathic consequences of PA in AA, as well as any changes after one year of directed therapeutic intervention (e.g. post-adrenalectomy or mineralocorticoid receptor antagonist ...|To investigate the clinical utility of other biomarkers in the subtype classification of PA.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 70 Years   (Child, Adult, Older Adult)","","1150","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","180031|18-CH-0031","December 14, 2017","December 31, 2020","December 31, 2020","December 15, 2017","null","February 11, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03374215"
563,"NCT03307317","Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder",,"Recruiting","No Results Available","Developmental Delay","","Primary Outcome Measure: The change in neuroimaging metrics (i.e., percent mu suppression, percent oxyhemoglobin change) will be used to characterize the development of the mirror neuron system.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 65 Years   (Child, Adult, Older Adult)","","160","NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","180001|18-CH-0001","April 17, 2019","April 30, 2020","April 30, 2020","October 11, 2017","null","April 16, 2019","Child and Family Research Section, NICHD, Bethesda, Maryland, United States|University of Maryland, College Park, College Park, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03307317"
564,"NCT03307304","Investigations of Juvenile Neuronal Ceroid Lipofuscinosis",,"Recruiting","No Results Available","Juvenile Neuronal Ceroid Lipofuscinosis (CLN3, Batten Disease)|Batten Disease","","Identify clinical or biochemical markers that can be used as a therapeutic outcome measures for CLN3.|Evaluate clinical aspects of CLN3 to provide tools for future therapeutic trials.|Establish a biorepository of samples from wellcharacterized CLN3 patients for future research related to CLN3","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 100 Years   (Child, Adult, Older Adult)","","150","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","180002|18-CH-0002","November 27, 2017","December 31, 2030","December 31, 2030","October 11, 2017","null","April 11, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03307304"
565,"NCT02769949","Pediatric Patients With Metabolic or Other Genetic Disorders",,"Recruiting","No Results Available","Genetic Disorder|Asperger Disorder|Autism Spectrum Disorder|Fragile X Syndrome|Developmental Delay","","Recruit Patients with Suspected or Siagnosed genetic diseases","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","5000","NIH","Observational","Observational Model: Other|Time Perspective: Other","160103|16-CH-0103","May 3, 2016","January 1, 2029","January 1, 2029","May 12, 2016","null","April 15, 2019","National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02769949"
566,"NCT02544035","Determining Age Appropriateness of Children's Products and Toys: An Interagency Agreement With the Consumer Product Safety Commission",,"Completed","No Results Available","Healthy Volunteers Only","Other: Type of Toy|Other: Play Partner (Either parent or friend)","The primary study outcome is the video-coded measures of play complexity. We will examine differences in the mean scores of play complexity by the type of toy the child receives.|Parts and features of toys used by the child|Duration of time child spends with each toy|Child preference for the toys based on child-report (smiley face Likert scale)|Number of times child solicits parent or friend involvement","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","6 Months to 100 Years   (Child, Adult, Older Adult)","Not Applicable","532","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","999915196|15-CH-N196","September 5, 2015","August 31, 2017","August 31, 2017","September 9, 2015","null","April 11, 2019","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02544035"
567,"NCT02390765","Children s Growth and Behavior Study",,"Recruiting","No Results Available","Obesity|Eating Behaviors|Healthy Volunteers","","Differences in eating behavior","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","8 Years to 100 Years   (Child, Adult, Older Adult)","","1500","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","150096|15-CH-0096","April 21, 2015","December 31, 2027","December 12, 2028","March 18, 2015","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02390765"
568,"NCT02311322","Genetic Causes of Growth Disorders",,"Recruiting","No Results Available","Short Stature|Growth Disorder","","SNP array and whole exome sequencing data","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH)|National Institutes of Health Clinical Center (CC)","All","up to 80 Years   (Child, Adult, Older Adult)","","800","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","150022|15-CH-0022","December 5, 2014","December 31, 2024","December 31, 2024","December 8, 2014","null","April 1, 2019","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Otto-VonGuericke University, Magdeburg, Germany","","https://ClinicalTrials.gov/show/NCT02311322"
569,"NCT01950624","DS-Connect {TM}: The Down Syndrome Registry",,"Recruiting","No Results Available","Down Syndrome","","To identify individuals with DS who may be eligible for research studies or new clinical trials, based on specific information about their diagnosis and health history.|To determine the prevalence and various phenotypic manifestations of DS.|Aggregate data from individuals with DS globally. Enable researchers to use de-identified data to analyze the etiology, natural history, and/or treatment effectiveness in DS. Help medical professionals improve treatments for those with DS.|Study why individuals with DS have different symptoms. Allow individuals with DS and their families to look at their information in DS-Connect and compare it to de-identified information from other participants in the Registry.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","100000","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","999913201|13-CH-N201","September 21, 2013","August 16, 2019","August 16, 2020","September 25, 2013","null","August 31, 2018","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01950624"
570,"NCT01517048","Brain-Derived Neurotrophic Factor in Obesity and Brain Function",,"Completed","No Results Available","Obesity|Genetic Disorder|Mental Retardation|Developmental Delay","","Serum brain-derived neurotrophic factor concentration|Body Composition, Cognitive Function","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 99 Years   (Child, Adult, Older Adult)","","93","NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","120051|12-CH-0051","January 9, 2012","null","December 12, 2014","January 25, 2012","null","March 18, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|University of Alberta, Alberta, Canada","","https://ClinicalTrials.gov/show/NCT01517048"
571,"NCT01511588","Hormonal Regulation of Puberty and Fertility",,"Recruiting","No Results Available","Endocrine Disease|Infertility|Hypogonadism|Amenorrhea|Adolescents","","The main outcome is the identification of novel GnRH secretory patterns or non-reproductive phenotypic characteristics in individuals representing the complete spectrum of idiophatic hypogonadotropic hypogonadism.|Secondary outcomes are the recognition of specific pubertal phenotypes, as well as discovery of the roles of newly identified genes contributing to IHH in GnRH development and biology, for those subjects who also enroll in our genetics protocol.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Massachusetts General Hospital|National Institutes of Health Clinical Center (CC)","All","14 Years and older   (Child, Adult, Older Adult)","","200","NIH|Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","120050|12-CH-0050","December 20, 2011","null","null","January 18, 2012","null","March 29, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01511588"
572,"NCT01500447","Inherited Reproductive Disorders",,"Recruiting","No Results Available","Genetic Disorder|Infertility|Hypogonadism|Amenorrhea","","The main outcome is the identification of known and novel genetic variants in individuals representing the complete spectrum of idiopathic hypogonadotropic hypogonadism.|Phenotypic correlations, made by comparing the results of the genotypic analysis with clinical and/or biochemical characteristics, as well as discovery of genes worthy of further functional analysis.|The inheritance patterns of IHH, as well as whether these patterns are gene-specific, will be clarified through the genetic investigation of families harboring these mutations.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Massachusetts General Hospital|National Institute of Environmental Health Sciences (NIEHS)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","600","NIH|Other","Observational","Observational Model: Family-Based|Time Perspective: Prospective","120049|12-CH-0049","December 20, 2011","null","null","December 28, 2011","null","April 4, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01500447"
573,"NCT01413425","A Long-Term Study of Cholesterol Supplements for Smith-Lemli-Opitz Syndrome",,"Withdrawn","No Results Available","Smith-Lemi-Opitz Syndrome","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","0","NIH","Observational","Time Perspective: Other","110194|11-CH-0194","June 29, 2011","null","October 20, 2014","August 10, 2011","null","July 2, 2017","","","https://ClinicalTrials.gov/show/NCT01413425"
574,"NCT01375543","Next Generation to Identify Genetic Causes of Disease in Patients Participating in NICHD Clinical Protocols",,"Completed","No Results Available","Genetic Predisposition","","Gene Mutations|Deidentified sequence data","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","128","NIH","Observational","Observational Model: Other|Time Perspective: Prospective","110179|11-CH-0179","June 16, 2011","null","null","June 17, 2011","null","March 27, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01375543"
575,"NCT01059201","Exome Sequencing in Autistic Spectrum Disorder",,"Completed","No Results Available","Autism Spectrum Disorder|Autism|Autistic Disorder","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","322","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","100022|10-CH-0022","January 21, 2010","null","May 15, 2017","January 29, 2010","null","April 11, 2019","Kennedy Krieger Institute, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Ohio State University, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01059201"
576,"NCT01031160","Health Behavior in School-Age Children: NEXT Longitudinal Study 2009-2016",,"Completed","No Results Available","Adolescent Health","","Identify the trajectories of adolescent health and health behaviors, including diet and physical activity, substance use, driving, dating violence, and health status.|Identify genetic, individual, family, school, social, and other environmental factors that promote or sustain positive health, positive health behaviors and mental health.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","12 Years to 99 Years   (Child, Adult, Older Adult)","","4902","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","999909231|09-CH-N231","October 1, 2009","null","null","December 14, 2009","null","April 10, 2019","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01031160"
577,"NCT00975689","Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine",,"Completed","Has Results","Niemann-Pick Disease, Type C","Drug: N-Acetyl Cysteine","Oxysterol Levels","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Oxford|Washington University School of Medicine|National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","12 Months and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","35","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","090185|09-CH-0185","August 2009","November 2010","November 2010","September 11, 2009","July 12, 2012","May 6, 2013","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00975689"
578,"NCT00920049","Preventing Motor Vehicle Crashes Among Young Drivers: Evaluation of the Checkpoints Program Presented by the American Automobile Association",,"Completed","No Results Available","Injury","Behavioral: Persuasion","Improvements in risky driving and crash risk|Adoption of parent-teen driving agreement and adherence to graduated driver licensing policy","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","15 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","830","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention","999909165|09-CH-N165","June 5, 2009","March 29, 2012","March 29, 2012","June 12, 2009","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00920049"
579,"NCT00852904","National Children s Health Study",,"Completed","No Results Available","Health Status","","Life course assessment of the interaction between environmental exposures and genetics on child health and development","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","9942","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999909083|09-CH-N083","February 25, 2009","null","null","February 27, 2009","null","February 21, 2019","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00852904"
580,"NCT00811785","Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency",,"Active, not recruiting","No Results Available","Menkes Disease|Occipital Horn Syndrome|Unexplained Copper Deficiency","Drug: Copper Histidine","To assess neurological improvement in patients with OHS or unexplained copper deficiency treated with subcutaneous CuHis injections.|To assess survival in classic Menkes disease subjects treated with subcutaneous CuHis injections in comparison with classic Menkes patients who did not receive any type of copper treatment.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Complementary and Integrative Health (NCCIH)|National Institutes of Health Clinical Center (CC)","All","up to 80 Years   (Child, Adult, Older Adult)","Phase 3","93","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","090059|09-CH-0059","February 27, 2009","December 31, 2021","December 31, 2021","December 19, 2008","null","March 25, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00811785"
581,"NCT00758108","Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions",,"Completed","No Results Available","WAGR Syndrome|Wilm's Tumor|Aniridia|Urogenital Abnormalities|Mental Retardation","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","2 Years to 99 Years   (Child, Adult, Older Adult)","","197","NIH","Observational","Time Perspective: Other","080213|08-CH-0213","September 11, 2008","null","April 29, 2015","September 23, 2008","null","March 25, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00758108"
582,"NCT00743782","Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism",,"Completed","No Results Available","Hypoparathyroidism|Hypocalcemia","Drug: Synthetic Human Parathyroid Hormone 1-34","Assess the feasability of PTH 1-34 therapy via pump.|This pilot study is being conducted to compare PTH therapy via pump vs. twice daily subcutaneous injections.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years to 70 Years   (Child, Adult, Older Adult)","Early Phase 1","24","NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","080203|08-CH-0203","August 22, 2008","April 7, 2014","April 7, 2014","August 29, 2008","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00743782"
583,"NCT00740506","Behavioral and Environmetal Factors and Time to Delivery",,"Completed","No Results Available","Pregnancy","Behavioral: Frequency of Intercourse","Time to delivery|Rate of cesarean delivery","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 4","510","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","999908199|08-CH-N199","August 20, 2008","July 13, 2009","July 13, 2009","August 25, 2008","null","July 2, 2017","Naval Medical Center, San Diego, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT00740506"
584,"NCT00612937","Streptococcal Infection and Respiratory Distress in Newborns",,"Completed","No Results Available","Group B Streptococci|Respiratory Distress in Newborn","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","13180","NIH","Observational","Time Perspective: Prospective","999908069|08-CH-N069","February 4, 2008","null","June 19, 2015","February 12, 2008","null","April 5, 2018","Oakland Children's Hospital and Research Center, Oakland, California, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00612937"
585,"NCT00546195","Infant Immune Response to Bacterial Infection",,"Completed","No Results Available","Prematurity|Histologic Chorioamnionitis","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","45","NIH","Observational","Time Perspective: Prospective","999908011|08-CH-N011","October 15, 2007","null","March 29, 2011","October 18, 2007","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00546195"
586,"NCT00361816","Human MATER and Idiopathic Infertility",,"Completed","No Results Available","Infertility","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","","100","NIH","Observational","","020195|02-CH-0195","May 3, 2002","null","March 29, 2011","August 9, 2006","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00361816"
587,"NCT00344331","Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C",,"Recruiting","No Results Available","Neimann-Pick Disease, Type C","","Plasma Oxysterols","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 120 Years   (Child, Adult, Older Adult)","","900","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","060186|06-CH-0186","June 19, 2006","null","null","June 26, 2006","null","March 14, 2019","Kennedy Krieger Institute, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Washington University, St. Louis, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00344331"
588,"NCT00344162","Family Study on Preeclampsia",,"Completed","No Results Available","Preeclampsia","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","1000","NIH","Observational","","999905097|05-CH-N097","January 31, 2005","null","September 22, 2006","June 26, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00344162"
589,"NCT00343018","Interviewing Children About Past Events: Evaluating the NICHD Interview Protocol",,"Completed","No Results Available","Memory","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","5 Years and older   (Child, Adult, Older Adult)","","150","NIH","Observational","","999904108|04-CH-N108","January 21, 2004","null","October 5, 2006","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00343018"
590,"NCT00342628","Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants",,"Completed","Has Results","Typhoid Fever","Biological: Vi-rEPA conjugate vaccine for typhoid fever|Biological: Hib-TT|Biological: DTP","Number of Infants With Adverse Reactions After Vaccination|IgG Anti-Vi Levels|Antibody Responses to Tetanus Toxoid, Diphtheria Toxoid, and Pertussis Toxin|Antibody Responses to Hib CP","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","301","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","999999050|OH99-CH-N050","July 2006","April 2008","January 2011","June 21, 2006","June 27, 2012","June 27, 2012","Thanh Thuy District Health Center, Viet Tri, Phu Tho Province, Vietnam","","https://ClinicalTrials.gov/show/NCT00342628"
591,"NCT00342550","Cervical Volume by Three-Dimensional Ultrasound as a Predictor of Preterm Delivery",,"Completed","No Results Available","Pregnancy|Preterm Delivery|Cervical Length Measurement","","Document cervical volume and funneling changes in women with preterm labor. Determine the relationship between cervical volume and funneling changes to the risk of preterm delivery.|Study inter- and intraobserver agreement for cervical and funnel volume measurements by 3DUS. Describe the sonographic anatomy of the cervix with 3DUS. Describe the changes in cervix anatomy and dimensions during normal labor at term with 3DUS.|Determine the effect of cervical cerclage on cervical and cervical funnel volume as assessed by 3DUS. Determine diagnostic value of cervical 3DUS in assessing risk of preterm delivery improved with information provided by biological markers.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","15 Years and older   (Child, Adult, Older Adult)","","648","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","999998016|OH98-CH-N016","March 17, 1998","null","null","June 21, 2006","null","March 22, 2019","Hutzel Women's Hospital, Detroit, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00342550"
592,"NCT00342290","Early Pregnancy Evaluation by Three-Dimensional Ultrasound",,"Terminated","No Results Available","First Trimester Bleeding|Pregnancy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","15 Years and older   (Child, Adult, Older Adult)","","69","NIH","Observational","","999998018|OH98-CH-N018","March 22, 1998","null","June 29, 2012","June 21, 2006","null","April 10, 2019","Hutzel Women's Hospital, Detroit, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00342290"
593,"NCT00342277","Microarray Expression Profiling to Identify Stereotypic mRNA Profiles for Preterm Delivery in Order to Unravel the Biological Mechanisms",,"Completed","No Results Available","Preterm Birth","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","15 Years and older   (Child, Adult, Older Adult)","","6838","NIH","Observational","","999999056|OH99-CH-N056","December 21, 1999","null","null","June 21, 2006","null","January 3, 2019","Hutzel Women's Hospital, Detroit, Michigan, United States|Padova Hospital, Padova, Italy","","https://ClinicalTrials.gov/show/NCT00342277"
594,"NCT00342225","Mother-Child Relationships During Pregnancy Among Bofi Foragers",,"Completed","No Results Available","Behavior","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","60","NIH","Observational","","999903073|03-CH-N073","December 19, 2002","null","December 21, 2006","June 21, 2006","null","July 2, 2017","Central African Republic, Ngotto, Central African Republic|Republic of Condo, Sangha, Central African Republic","","https://ClinicalTrials.gov/show/NCT00342225"
595,"NCT00341796","Interventions to Decrease the Risk of Mother-to-Child Transmission of HIV in India",,"Completed","No Results Available","HIV-1","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","","400","NIH","Observational","","999902214|02-CH-N214","June 2002","null","August 2006","June 21, 2006","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00341796"
596,"NCT00341471","Building Futures for Youth - Phase III",,"Completed","No Results Available","Adolescent Pregnancy","Procedure: Risk Behavior Prevention Intervention Program","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 3","2500","NIH","Interventional","Primary Purpose: Treatment","999906078|06-CH-N078","January 18, 2006","October 8, 2008","October 8, 2008","June 21, 2006","null","July 2, 2017","Howard University Hospital, Washington, D.C., District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00341471"
597,"NCT00341224","Steppin' Up: Positive Youth Development Program",,"Completed","No Results Available","Mentoring","Behavioral: Group-mentoring intervention","Student fighting|Academic engagement","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","null","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","999903261|03-CH-N261","July 23, 2003","December 9, 2009","December 9, 2009","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00341224"
598,"NCT00340938","Family Management of Childhood Diabetes Study",,"Completed","No Results Available","Diabetes|Type 1 Diabetes","Procedure: Blood testing","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","9 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1","1298","NIH","Interventional","Primary Purpose: Treatment","999905030|05-CH-N030","November 8, 2004","March 1, 2009","August 20, 2009","June 21, 2006","null","April 11, 2019","Childrens Memorial Hospital, Chicago, Chicago, Illinois, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00340938"
599,"NCT00340730","Community Based Youth Injury Prevention Program",,"Completed","No Results Available","Violence|Intervention","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years and older   (Child, Adult, Older Adult)","","392","NIH","Observational","","999902070|02-CH-N070","December 4, 2001","null","November 2, 2006","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00340730"
600,"NCT00340639","Management of Type 1 Diabetes Among Adolescents",,"Completed","No Results Available","Type I Diabetes","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","7 Years and older   (Child, Adult, Older Adult)","","240","NIH","Observational","","999903088|03-CH-N088","January 28, 2003","null","November 2, 2006","June 21, 2006","null","July 2, 2017","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00340639"
601,"NCT00340249","Use of the Perinatal Database and Biologic Tissue Bank at The Perinatology Research Branch (PRB)",,"Completed","No Results Available","Biological Samples","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","","0","NIH","Observational","","999995040|OH95-CH-N040","July 1995","null","null","June 21, 2006","null","June 14, 2012","National Institute of Child Health and Human Development (NICHD), 9000 Rockville, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00340249"
602,"NCT00250159","Natural History Study of Patients With Excess Androgen",,"Enrolling by invitation","No Results Available","Congenital Adrenal Hyperplasia (CAH)|Familial Male-Limited Precocious Puberty (FMPP)","","To elucidate a comprehensive phenotypic profile for patients with CAH and FMPP","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 80 Years   (Child, Adult, Older Adult)","","784","NIH","Observational","Observational Model: Case-Only|Time Perspective: Other","060011|06-CH-0011","November 3, 2005","null","null","November 7, 2005","null","April 12, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00250159"
603,"NCT00242255","Epigenetics in the Aging Process",,"Completed","No Results Available","Aging","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","14 Years to 90 Years   (Child, Adult, Older Adult)","","90","NIH","Observational","","060010|06-CH-0010","October 14, 2005","null","null","October 19, 2005","null","April 4, 2019","GW University Medical Center, Washington, District of Columbia, United States|Suburban Hospital, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States|Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT00242255"
604,"NCT00156767","Adrenal Function in Critical Illness",,"Completed","No Results Available","Adrenal Insufficiency","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","15 Years to 85 Years   (Child, Adult, Older Adult)","","225","NIH","Observational","","050013|05-CH-0013","October 21, 2004","null","null","September 12, 2005","null","March 22, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00156767"
605,"NCT00123708","Hypertonia in Patients With Cerebral Palsy",,"Completed","No Results Available","Cerebral Palsy|Muscle Hypertonia","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","6 Years and older   (Child, Adult, Older Adult)","","100","NIH","Observational","","050204|05-CH-0204","July 19, 2005","November 13, 2009","null","July 25, 2005","null","July 2, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00123708"
606,"NCT00076830","Evaluation and Treatment of Patients With Connective Tissue Disease",,"Recruiting","No Results Available","Connective Tissue Disorders|Osteogenesis Imperfecta|Bone Diseases, Metabolic","","Screening and Diagnosis|Biospecimens collection","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 70 Years   (Child, Adult, Older Adult)","","400","NIH","Observational","Observational Model: Cohort|Time Perspective: Other","040077|04-CH-0077","February 3, 2004","null","null","February 4, 2004","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00076830"
607,"NCT00006073","Endocrine Studies in Health and Disease",,"Terminated","No Results Available","Endocrine Diseases","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 99 Years   (Child, Adult, Older Adult)","","3090","NIH","Observational","Time Perspective: Other","000180|00-CH-0180","July 19, 2000","null","August 31, 2016","July 14, 2003","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00006073"
608,"NCT00001455","Iron Overload in African Americans",,"Completed","No Results Available","Hemochromatosis|Iron Overload","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","500","NIH","Observational","","950142|95-CH-0142","June 1995","null","June 2000","December 10, 2002","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001455"
609,"NCT00001342","Study of Glycogen Storage Disease and Associated Disorders",,"Completed","No Results Available","Glycogen Storage Disease","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","20","NIH","Observational","","930020|93-CH-0020","November 1992","null","April 2001","December 10, 2002","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001342"
610,"NCT00001142","Metabolism and Body Shape of Healthy Children and Children With Chronic Infections",,"Completed","No Results Available","HIV Infections|Healthy|Hyperlipidemia|Lipodystrophy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","185","NIH","Observational","","000010|00-CH-0010","October 1999","null","December 2000","December 10, 2002","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001142"
611,"NCT00046202","Study of Inborn Errors of Cholesterol Synthesis and Related Disorders",,"Recruiting","No Results Available","Lysosomal Storage Disease|Cholesterol Metablism","","sample collection","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","1000","NIH","Observational","Observational Model: Other|Time Perspective: Other","020311|02-CH-0311","September 19, 2002","null","null","September 23, 2002","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00046202"
612,"NCT00041899","Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914",,"Completed","No Results Available","Healthy","Drug: CDB-2914|Drug: COB-2914","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 1","15","NIH","Interventional","Primary Purpose: Treatment","020219|02-CH-0219","May 2002","null","March 2005","July 19, 2002","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00041899"
613,"NCT00001190","Study of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature",,"Completed","No Results Available","Dwarfism|Growth Disorder","Drug: Deslorelin","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","830199|83-CH-0199","November 1983","null","October 2001","May 22, 2002","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001190"
614,"NCT00031122","Study of Genetic Risk Factors for Spina Bifida and Anencephaly","SBRR","Unknown status","No Results Available","Spina Bifida|Anencephaly","Other: No Intervention","Genetic loci identification and comparisons","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Office of Rare Diseases (ORD)","All","Child, Adult, Older Adult","","1100","NIH","Observational","Observational Model: Family-Based|Time Perspective: Retrospective","1R01HD039195-01|1R01HD039081-01","September 2000","September 2011","September 2012","February 27, 2002","null","October 5, 2010","The University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|The Texas A & M University Health Science Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00031122"
615,"NCT00029952","Long Term Post Operative Follow-Up of Cushing Syndrome",,"Completed","No Results Available","Cushing Syndrome","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","500","NIH","Observational","","930169|93-CH-0169","July 1993","null","September 2004","January 28, 2002","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00029952"
616,"NCT00017732","Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans",,"Completed","No Results Available","Smith-Lemli-Opitz Syndrome","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","2000","NIH","Observational","","010191|01-CH-0191","June 2001","null","March 2003","June 11, 2001","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00017732"
617,"NCT00016848","Effects of Dietary Carbohydrate and Fat on Hormones",,"Completed","No Results Available","Healthy|Deficiency Disease","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","80","NIH","Observational","","010183|01-CH-0183","June 2001","null","May 2003","June 7, 2001","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00016848"
618,"NCT00013546","Hormone Replacement Therapy to Treat Turner Syndrome",,"Completed","No Results Available","Osteoporosis|Turner's Syndrome","Drug: TMTDS","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","92","NIH","Interventional","Primary Purpose: Treatment","010114|01-CH-0114","March 2001","null","December 2002","March 21, 2001","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00013546"
619,"NCT00009659","Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause",,"Completed","No Results Available","Postmenopause","Drug: CDB 2914","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","58","NIH","Interventional","Primary Purpose: Treatment","010081|01-CH-0081","January 2001","null","December 2001","February 5, 2001","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00009659"
620,"NCT00006334","Turner Syndrome: Genotype and Phenotype",,"Completed","No Results Available","Turner's Syndrome","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Human Genome Research Institute (NHGRI)|National Institutes of Health Clinical Center (CC)","All","10 Years and older   (Child, Adult, Older Adult)","","1017","NIH","Observational","","000219|00-CH-0219","September 26, 2000","null","July 8, 2014","October 5, 2000","null","October 6, 2017","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00006334"
621,"NCT00006278","Study of Cushing's Syndrome Not Related to ACTH Production",,"Completed","No Results Available","Cushing's Syndrome|Healthy","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","18","NIH","Observational","","000178|00-CH-0178","September 2000","null","September 2002","September 15, 2000","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00006278"
622,"NCT00005927","Study of Adrenal Gland Tumors",,"Recruiting","No Results Available","Adrenal Gland Neoplasm","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 70 Years   (Child, Adult, Older Adult)","","2000","NIH","Observational","","000160|00-CH-0160","July 1, 2002","null","null","June 29, 2000","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005927"
623,"NCT00005760","Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes",,"Completed","No Results Available","Glucose Intolerance|Hyperinsulinemia|Diabetes Mellitus, Non Insulin Dependent|Obesity","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","","10","NIH","Observational","","000115|00-CH-0115","May 2000","null","January 2002","May 29, 2000","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00005760"
624,"NCT00004847","Diagnosis of Pheochromocytoma",,"Recruiting","No Results Available","Pheochromocytoma|Endocrine Disease|Endocrine Diseases","Drug: Fluorodopamine|Drug: F-18 Fluorodopa","To study specific genotypes, biochemical and imaging phenotypes of patients with various pheochromocytomas and paragangliomas.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 150 Years   (Child, Adult, Older Adult)","Phase 1","2400","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","000093|00-CH-0093","March 1, 2000","November 30, 2048","November 30, 2048","March 3, 2000","null","April 11, 2019","Johns Hopkins University, Baltimore, Maryland, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00004847"
625,"NCT00004773","Study of Cardiac and Paroxysmal Abnormalities in Rett Syndrome",,"Completed","No Results Available","Rett Syndrome","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Baylor College of Medicine|Office of Rare Diseases (ORD)","Female","Child, Adult, Older Adult","","95","NIH|Other","Observational","Primary Purpose: Screening","199/11798|BCM-H2465","August 1995","null","June 1997","February 25, 2000","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00004773"
626,"NCT00001850","Evaluation of Women With Endocrine and Reproductive-Related Conditions",,"Recruiting","No Results Available","Endocrine Disease|Infertility|Leiomyoma|Endometriosis|Fibroids","","To provide a mechanism for reproductive endocrine fellows and staff to evaluate woman with medical conditions of interest for fellow training and clinical training and education.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","1 Year to 85 Years   (Child, Adult, Older Adult)","","900","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","990103|99-CH-0103","May 6, 1999","null","null","November 4, 1999","null","April 11, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001850"
627,"NCT00001848","The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis",,"Completed","No Results Available","Endometriosis|Pelvic Pain","Drug: Raloxifene","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","612","NIH","Interventional","Primary Purpose: Treatment","990012|99-CH-0012","November 1998","null","January 2006","November 4, 1999","null","September 22, 2016","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001848"
628,"NCT00001722","Fat Tissue Microperfusion to Measure Leptin Secretion and Its Relations With Fat Breakdown in Humans",,"Completed","No Results Available","Healthy|Obesity","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","70","NIH","Observational","","980103|98-CH-0103","April 1998","null","July 2003","November 4, 1999","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001722"
629,"NCT00001721","Study of Smith-Lemli-Opitz Syndrome",,"Recruiting","No Results Available","Abnormalities|Inborn Errors of Metabolism|Mental Retardation|Muscle Hypotonia|Smith Lemli Opitz Syndrome","","biochemical biomarkers","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","up to 100 Years   (Child, Adult, Older Adult)","","200","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","980081|98-CH-0081","March 23, 1998","null","null","November 4, 1999","null","April 10, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001721"
630,"NCT00001720","Treatment of Childhood Osteoporosis With Alendronate (Fosamax)",,"Completed","No Results Available","Osteoporosis","Drug: Alendronate","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","50","NIH","Interventional","Primary Purpose: Treatment","980077|98-CH-0077","March 1998","null","June 2003","November 4, 1999","null","September 22, 2016","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001720"
631,"NCT00001595","An Investigation of Pituitary Tumors and Related Hypothalmic Disorders",,"Recruiting","No Results Available","Panhypopituitarism|Gigantism/Acromegaly|Prolactinoma|Cushing Disease","","a tissue and blood DNA collection|training vehicle for our Endocrinology fellows.|To evaluate the cognitive,psychological, and patientreported health status of mental and social well-being and symptoms of adrenal insufficiency associated with Cushing syndrome in children with this disease.|To investigate the usefulness of a new MRI of the pituitary gland|to collect peripheral blood DNA samples and tumor tissues and examine the molecular genetics of the specimens, in an effort to elucidate developmental pathways leading to pituitarygland oncogenesis and/or other defects|To identify the clinical and genetic features of pituitary tumors by investigating their inheritance pattern and possible association with other conditions in the families of the patients","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 70 Years   (Child, Adult, Older Adult)","","2000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","970076|97-CH-0076","February 13, 1997","null","null","November 4, 1999","null","April 15, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001595"
632,"NCT00001522","Metabolic Differences of Overweight Children and Children of Overweight Parents",,"Completed","No Results Available","Obesity","","Adiposity","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","6 Years and older   (Child, Adult, Older Adult)","","246","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","960101|96-CH-0101","June 6, 1996","null","April 12, 2018","November 4, 1999","null","May 21, 2018","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001522"
633,"NCT00001452","Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex",,"Recruiting","No Results Available","Cushing's Syndrome|Hereditary Neoplastic Syndrome|Lentigo|Pituitary Adenoma|Testicular Neoplasm|Carney Complex|Primary Pigmented Nodular Adrenocortical Disease|Peutz-Jeghers Syndrome","","Genotype and clinical phenotype correlation in patients with PPNAD, Carney Complex, Peutz-Jeghers Syndrome and related conditions.","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 70 Years   (Child, Adult, Older Adult)","","100000","NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","950059|95-CH-0059","January 24, 1995","null","null","November 4, 1999","null","April 3, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001452"
634,"NCT00001304","Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34",,"Completed","Has Results","Hypoparathyroidism","Drug: Synthetic Human Parathyroid Hormone 1-34|Drug: Calcitriol & Calcium","Serum Calcium Level|Urine Calcium Excretion Level|Serum 1,25-hydroxyvitamin D Level|Serum 25-hydroxyvitamin D Level|Serum Magnesium Level|Serum Phosphorus Level|Urinary Creatinine Clearance","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","17 Years to 69 Years   (Child, Adult, Older Adult)","Phase 2","27","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","920011|92-CH-0011","October 1991","March 2014","April 2014","November 4, 1999","December 15, 2015","December 15, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001304"
635,"NCT00001262","Copper Histidine Therapy for Menkes Diseases",,"Completed","Has Results","Kinky Hair Syndrome","Drug: Copper Histidine","Gross Motor Development at 36 Mos of Age or at Death (Mos)|Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)|Personal-Social Development at 36 Mos of Age or at Death (Mos)|Language Development at 36 Mos of Age or at Death (Mos)|Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile|Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile|Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 1|Phase 2","60","NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","900149|90-CH-0149","June 1990","July 2012","July 2013","November 4, 1999","October 30, 2015","October 30, 2015","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001262"
636,"NCT00001253","The Effects of Estrogen on Cognition in Girls With Turner Syndrome",,"Completed","No Results Available","Gonadal Dysgenesis|Turner's Syndrome","Behavioral: cognitive tests and scales","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","Phase 2","950","NIH","Interventional","Primary Purpose: Treatment","900123|90-CH-0123","May 1990","null","March 2004","November 4, 1999","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001253"
637,"NCT00001221","Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome",,"Completed","No Results Available","Gonadal Dysgenesis|Turner's Syndrome","Drug: Growth Hormone (Humatrope)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","160","NIH","Interventional","Primary Purpose: Treatment","870152|87-CH-0152","September 1987","null","September 2003","November 4, 1999","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001221"
638,"NCT00001202","Treatment of Boys With Precocious Puberty",,"Completed","No Results Available","Precocious Puberty","Drug: Spironolactone|Drug: Testolactone|Drug: Deslorelin","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Male","Child, Adult, Older Adult","Phase 2","80","NIH","Interventional","Primary Purpose: Treatment","850016|85-CH-0016","January 1985","null","January 2004","November 4, 1999","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001202"
639,"NCT00001181","Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty",,"Completed","No Results Available","Polyostotic Fibrous Dysplasia|Precocious Puberty","Drug: Testolactone","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","Female","Child, Adult, Older Adult","Phase 2","100","NIH","Interventional","Primary Purpose: Treatment","820165|82-CH-0165","October 1982","null","May 2003","November 4, 1999","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001181"
640,"NCT00001180","Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency",,"Completed","No Results Available","Adrenal Gland Hyperfunction|Adrenal Gland Hypofunction|Cushing's Syndrome|Healthy","Drug: Ovine Corticotropin-Releasing Hormone (oCRH)","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","Child, Adult, Older Adult","","2250","NIH","Observational","","820045|82-CH-0045","March 1982","null","June 2005","November 4, 1999","null","March 4, 2008","National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT00001180"
641,"NCT00004341","Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders",,"Unknown status","No Results Available","X-Linked Agammaglobulinemia|X-Linked Hyper IgM Syndrome|Wiskott-Aldrich Syndrome|Leukocyte Adhesion Deficiency Syndrome","","","Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Washington|Office of Rare Diseases (ORD)","All","Child, Adult, Older Adult","","null","NIH|Other","Observational","Primary Purpose: Screening","199/11900|UW-533","July 1995","null","null","October 19, 1999","null","June 24, 2005","University of Washington School of Medicine, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00004341"
642,"NCT03635775","Single-session tDCS in Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy|Perinatal Stroke|Periventricular Leukomalacia","Device: Active tDCS|Device: Sham tDCS","Change in MEP amplitude|Change in Movement accuracy","University of Minnesota - Clinical and Translational Science Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Minnesota Medical School/University of Minnesota Foundation","All","7 Years to 21 Years   (Child, Adult)","Not Applicable","32","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","STUDY00002820|P2CHD086844|K01HD078484","May 1, 2018","June 30, 2019","June 30, 2021","August 17, 2018","null","August 17, 2018","Samuel Nemanich, Minneapolis, Minnesota, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03635775/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/75/NCT03635775/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03635775"
643,"NCT03124160","Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard",,"Active, not recruiting","No Results Available","Healthy Women|Female Contraception","Drug: Mona Lisa® NT Cu380 Mini|Drug: ParaGard® CuT380A","Pregnancy Rate|IUD continuation at months 12, 24 and 36 as measured by confirmation of IUD placement (visible or palpable)|Failed IUD insertion as measured by inability to place the IUD correctly|Uterine perforation as measured by ultrasound|IUD expulsion (complete and partial)|Vaginal bleeding patterns|Pelvic pain as measured in the subject diary|Dysmenorrhea|Other side effects as measured by adverse and/or other events|Pain with and shortly after insertion as measured by visual analog scale completed by study subjects|Ease of IUD insertion as measured by asking the investigator to assess ease of insertion|Overall product satisfaction as measured by acceptability questions asked of subjects","Health Decisions|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|FHI 360 - IND Holder","Female","16 Years to 40 Years   (Child, Adult)","Phase 3","1000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","CCN016","May 26, 2017","May 1, 2021","November 1, 2021","April 21, 2017","null","March 12, 2019","Essential Access Health, Los Angeles, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado, Denver, Colorado, United States|University of Hawaii, Honolulu, Hawaii, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Medical Center Corporation, Boston, Massachusetts, United States|Planned Parenthood League of Massachusetts, Boston, Massachusetts, United States|Planned Parenthood of New York, New York, New York, United States|Columbia University, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Utah, Salt Lake City, Utah, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03124160"
644,"NCT02993861","Pharmacokinetics of Anti-epileptic Drugs in Obese Children",,"Recruiting","No Results Available","Epilepsy|Obese","Other: Anti-epileptics","Steady-state pharmacokinetics area under the curve|Steady-state pharmacokinetics maximum concentration|Steady-state pharmacokinetics time to reach maximum concentration|Steady-state pharmacokinetics oral apparent volume of distribution|Steady-state pharmacokinetics half life|Steady-state pharmacokinetics oral apparent clearance|Steady-state pharmacokinetics absorption rate constant|Serious adverse events","Christoph P Hornik, MD MPH|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation|Duke University","All","2 Years to 18 Years   (Child, Adult)","","96","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00070924","December 9, 2016","September 2019","September 2019","December 15, 2016","null","December 27, 2018","The Children's Hospital Colorado, Aurora, Colorado, United States|Nemours Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Childrens Healthcare of Atlanta, Atlanta, Georgia, United States|Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Louisville Norton Childrens Hospital, Louisville, Kentucky, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Coastal Children's Services, Wilmington, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Texas Southwestern Medical Center Dallas, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02993861"
645,"NCT03660046","Hormonal Contraceptive Methods on Immunologic Changes in the Female Genital Tract (FGT) and Systemically",,"Recruiting","No Results Available","Hormonal Contraception","Drug: Depot medroxyprogesterone acetate (DMPA)|Drug: Etonogestrel implant (Eng-Implant)|Drug: Levonorgestrel IUD (Lng-IUD)","Change in mean total leukocytes and CD4+ T-cells expressing CCR5 in the lower female genital tract (FGT) among the three intervention groups pre and post contraception|Change in Nugent's score among the three intervention groups pre and post contraception|Percent of expression of 16S rRNA gene sequencing among the three intervention groups pre and post contraception","Emory University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","up to 45 Years   (Child, Adult)","","225","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB00104017|R01HD095741-01A1","December 7, 2018","September 2023","September 2023","September 6, 2018","null","February 28, 2019","Grady Health System, Atlanta, Georgia, United States|The Emory Clinic, Bldg A., 2nd Floor, 1365 Clifton Road, NE, Atlanta, Georgia, United States|Atlanta Women's Center, Atlanta, Georgia, United States","","https://ClinicalTrials.gov/show/NCT03660046"
646,"NCT02041923","Feeding and Transition to Home for Preterms at Social Risk","H-HOPE","Completed","No Results Available","Premature Birth","Behavioral: H-HOPE","Infant Behavioral Organization|Maternal Outcomes|Mother-Infant Interaction|Infant Growth|Health care cost|Infant development","University of Illinois at Chicago|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Nursing Research (NINR)","All","up to 45 Years   (Child, Adult)","Not Applicable","230","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2005-0139|1R01HD050738","January 2007","October 2012","June 2013","January 22, 2014","null","January 22, 2014","Mercy Hospital and Medical Center, Chicago, Illinois, United States|Mount Sinai Medical Center, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT02041923"
647,"NCT03501264","Evaluation of an Online Intervention to Help LGBTQ Youth Cope With Bullying",,"Active, not recruiting","No Results Available","Bullying of Child","Behavioral: Online Game|Behavioral: LGBTQ Resources","Number of Participants With Changes in Help Seeking Scores","University of Pittsburgh|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 18 Years   (Child, Adult)","Not Applicable","480","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","PRO17060347|5R21HD083561-02","April 17, 2018","May 1, 2019","May 1, 2019","April 17, 2018","null","March 26, 2019","University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03501264"
648,"NCT03495388","PG and PK of Oxycodone to Personalize Post-op Pain Management Following Surgery in Children",,"Recruiting","No Results Available","Postoperative Pain|Opioid Dependence","","Look at genetic factors predisposing children to immediate postoperative opioid-adverse effects (RD and PONV).|Look at genetic factors predisposing children to inadequate surgical pain relief with oxycodone.|Look at the impact of CYP2D6 variants on oxycodone's clinical dosing in children to see if specific variants correlate with a need for lower or higher doses of analgesic.","Indiana University|Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 18 Years   (Child, Adult)","","500","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","1707525204|7R01HD089458-02","April 1, 2018","March 2020","March 2022","April 12, 2018","null","October 24, 2018","Riley Hospital for Children, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03495388"
649,"NCT03282565","Functional Resistance Training to Improve Knee Function After ACL Reconstruction",,"Recruiting","No Results Available","Anterior Cruciate Ligament Injury","Other: Functional Resistance Training|Other: Control","Changes in quadriceps muscle strength|Changes in quadriceps voluntary activation|Knee flexion angle symmetry|Knee flexion moment symmetry","University of Michigan|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 40 Years   (Child, Adult)","Not Applicable","45","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HUM00133860|R21HD092614","March 17, 2018","November 2020","November 2020","September 14, 2017","null","March 14, 2019","University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03282565"
650,"NCT03098329","Check it: A New Approach to Controlling Chlamydia Transmission in Young People",,"Recruiting","No Results Available","Chlamydia Trachomatis Infection|Gonorrhea","Other: Ct/GC screening","Rate of chlamydia in women|Rate of gonorrhea in women","Tulane University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","15 Years to 24 Years   (Child, Adult)","Not Applicable","4854","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","16-964337|1R01HD086794-01A1","May 22, 2017","April 1, 2022","December 31, 2022","March 31, 2017","null","September 12, 2018","Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT03098329"
651,"NCT03080402","Mechanical Perturbation Training for ACL Injury Prevention",,"Unknown status","No Results Available","Anterior Cruciate Ligament Injury|ACL","Device: Mechanical Perturbation Training","Peak knee abduction moment|Peak Quadriceps torque 60 degrees/sec|Peak Quadriceps torque 240 degrees/sec|Peak Hamstrings torque 60 degrees/sec|Peak Hamstrings torque 240 degrees/sec|Single hop for distance LSI|Crossover hop for distance LSI|Triple hop for distance LSI|6m Timed Hop LSI","University of Delaware|Simbex, LLC|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 30 Years   (Child, Adult)","Not Applicable","24","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R44HD068054|5R44HD068054","February 20, 2017","December 31, 2017","December 31, 2017","March 15, 2017","null","March 15, 2017","University of Delaware, Physical Therapy Department, Newark, Delaware, United States","","https://ClinicalTrials.gov/show/NCT03080402"
652,"NCT01627574","Contraceptive Awareness and Reproductive Education",,"Completed","No Results Available","Pregnancy|Sexually Transmitted Infections","Behavioral: Motivational Intervention|Behavioral: Didactic Educational Intervention","Timeline Followback (TLFB): Contraceptive, sexual and substance-related risk behaviors will be measured via a calendar recall for both interventions.|Urine Collection for STI Testing|Urine Collection for Pregnancy Testing","University of Rhode Island|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Brown University","Female","14 Years to 21 Years   (Child, Adult)","Not Applicable","272","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HD065942|R01HD065942","August 2012","June 30, 2018","June 30, 2018","June 26, 2012","null","September 11, 2018","Juvenile Probation, Cranston, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT01627574"
653,"NCT01572532","Maternal Genitourinary Infections and Adverse Perinatal Outcomes",,"Unknown status","No Results Available","Maternal Infection Affecting Newborn","Other: Screening treatment and referral","Number of preterm births reduced by community-based screening and treatment of abnormal vaginal flora and urinary tract infections in early pregnancy (13-19 weeks)|Proportion of early outcomes|Proportion of infants with neonatal sepsis|Prevalance abnormal vaginal flora|Accuracy of diagnostic tests for detecting bacterial vaginosis","Johns Hopkins Bloomberg School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|United States Agency for International Development (USAID)","All","up to 47 Years   (Child, Adult)","Phase 3","9000","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00003063|1R01HD066156-01","August 2010","May 2015","May 2015","April 6, 2012","null","August 20, 2014","Community Based, Sylhet, Bangladesh","","https://ClinicalTrials.gov/show/NCT01572532"
654,"NCT02913222","Movement Pattern Training in People With Intra-articular, Prearthritic Hip Disorders",,"Active, not recruiting","No Results Available","Chronic Hip Joint Pain|Prearthritic Hip Disease","Other: Rehabilitation","Percentage of participants who are adherent to treatment attendance|Improvement in function using the Hip disability and Osteoarthritis Outcome Score (HOOS) Activities in Daily Living subscale|Improvement in Hip disability and Osteoarthritis Outcome Score (HOOS) Symptoms subscale","Washington University School of Medicine|University of Pittsburgh|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 40 Years   (Child, Adult)","Not Applicable","46","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R21HD086644-01A1-201609106|R21HD086644-01A1","February 4, 2017","December 12, 2018","December 2019","September 23, 2016","null","February 15, 2019","Program in Physical Therapy, Washington University, Saint Louis, Missouri, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02913222"
655,"NCT01431326","Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","PTN_POPS","Recruiting","No Results Available","Adenovirus|Anesthesia|Anxiety|Anxiolysis|Autism|Autistic Disorder|Bacterial Meningitis|Bacterial Septicemia|Benzodiazepine|Bipolar Disorder|Bone and Joint Infections|Central Nervous System Infections|Convulsions|Cytomegalovirus Retinitis|Early-onset Schizophrenia Spectrum Disorders|Epilepsy|General Anesthesia|Gynecologic Infections|Herpes Simplex Virus|Infantile Hemangioma|Infection|Inflammation|Inflammatory Conditions|Intra-abdominal Infections|Lower Respiratory Tract Infections|Migraines|Pain|Pneumonia|Schizophrenia|Sedation|Seizures|Skeletal Muscle Spasms|Skin and Skin-structure Infections|Treatment-resistant Schizophrenia|Urinary Tract Infections|Withdrawal|Sepsis|Gram-negative Infection|Bradycardia|Cardiac Arrest|Cardiac Arrhythmia|Staphylococcal Infections|Nosocomial Pneumonia|Neuromuscular Blockade|Methicillin Resistant Staphylococcus Aureus|Endocarditis|Neutropenia|Headache|Fibrinolytic Bleeding|Pulmonary Arterial Hypertension|CMV Retinitis|Hypertension|Chronic Kidney Diseases|Hyperaldosteronism|Hypokalemia|Heart Failure|Hemophilia|Heavy Menstrual Bleeding|Insomnia","Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:","Composite of pharmacokinetic outcomes for understudied drugs in children|Composite pharmacodynamic outcomes of understudied drugs in children|Biomarkers associated with understudied drugs in children","Daniel Benjamin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation|Duke University","All","up to 21 Years   (Child, Adult)","","10000","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00029638|IND 113645|IND 114369|IND 114531|IND 118358|HHSN20100006|HHSN27500020|HHSN27500027|HHSN27500043|HHSN27500049","November 2011","February 2020","February 2020","September 9, 2011","null","April 4, 2019","Alaska Native Medical Center, Anchorage, Alaska, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of California at San Diego Medical Center, La Jolla, California, United States|Axis Clinical Trials, Los Angeles, California, United States|University of California, Los Angeles Medical Center, Los Angeles, California, United States|The Children's Hospital Colorado, Aurora, Colorado, United States|Yale New Haven Children's Hospital, New Haven, Connecticut, United States|Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Jacksonville Shands Medical Center, Jacksonville, Florida, United States|Kapiolani Womens and Childrens Medical Center, Honolulu, Hawaii, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Riley Hospital for Children at Indiana University, Indianapolis, Indiana, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Children's Mercy Hospital and Clinics, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Tulane University Health Science Center, New Orleans, Louisiana, United States|Ochsner Baptist Clinical Trials Unit, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|University of Montana, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|Kravis Children's Hospital at Mt. Sinai, New York, New York, United States|UNC Hospital Neonatal-Perinatal Medicine, Chapel Hill, North Carolina, United States|Duke University Medical Center (PICU / NICU), Durham, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Akron Children's Hospital, Cleveland, Ohio, United States|Board of Regents of the University of Oklahoma, Oklahoma City, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Medical University of South Carolina, Charleston, South Carolina, United States|University of South Carolina, Columbia, South Carolina, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|University of Utah Hospitals and Clinics, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|West Virginia University Hospital, Morgantown, West Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Kids Research Institute, Randwick, New South Wales, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada|Assaf Harofeh Medical Center, Zerifin, Tel Aviv, Israel|Schneider Children's Medical Center of Israel, Petah Tikva, Israel|KK Women's and Children's Hospital Pte Ltd, Singapore, Singapore|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Alder Hey Children's Hospital, Liverpool, Merseyside, United Kingdom|University of Bristol, Bristol, United Kingdom","","https://ClinicalTrials.gov/show/NCT01431326"
656,"NCT01421797","Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation",,"Recruiting","No Results Available","Hyperandrogenemia|Polycystic Ovary Syndrome|Obesity","Drug: Dexamethasone|Drug: Cortrosyn","Change in progesterone concentrations from the 2100-2300 time block to the 0500-0700 time block in normal weight girls compared to overweight girls.|Overnight changes in male and female hormones in response to ACTH suppression|Response to ACTH stimulation in normal weight and overweight girls","University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, San Diego","Female","7 Years to 18 Years   (Child, Adult)","Not Applicable","84","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","12702|JCM022|U54HD028934-18","October 10, 2006","March 27, 2019","March 2022","August 23, 2011","null","July 18, 2018","University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01421797"
657,"NCT02488109","Study of Refeeding to Optimize iNpatient Gains","StRONG","Enrolling by invitation","No Results Available","Anorexia Nervosa","Other: Higher Calorie Refeeding|Other: Lower Calorie Refeeding","time to achieve clinical remission|time to achieve medical stability in hospital","University of California, San Francisco|Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 24 Years   (Child, Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P0504491|1R01HD082166-01A1","February 2016","July 2019","July 2020","July 2, 2015","null","May 3, 2018","Stanford University Lucille Packard Children's Hospital, Palo Alto, California, United States|University of California, San Francisco Benioff Children's Hospital, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT02488109"
658,"NCT02455388","d13C Added Sugar Intake Biomarker: Determining Validity in Children",,"Completed","Has Results","Validation Studies","Dietary Supplement: High added sugar diet|Dietary Supplement: Low added sugar diet","delta13C Added Sugar Biomarker|Change in d13C: delta13C Added Sugar Biomarker|Diagnostic Value of d13C Biomarker","Virginia Polytechnic Institute and State University|University of Hawaii|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 18 Years   (Child, Adult)","Not Applicable","370","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","1R21HD078636-01A1|R21HD078636","April 2014","July 2016","February 2018","May 27, 2015","July 27, 2018","February 26, 2019","Virginia Tech, Blacksburg, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02455388"
659,"NCT02011711","Modulation of Immunity by Hormonal Contraceptives",,"Completed","No Results Available","Contraception","","Change in ectocervical permeability","Thomas L. Cherpes|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Stanford University","Female","15 Years to 25 Years   (Child, Adult)","","90","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2013H0235|R01HD072663","November 2013","December 2016","December 2016","December 13, 2013","null","January 16, 2017","Edwards Building, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT02011711"
660,"NCT01967849","Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children",,"Recruiting","No Results Available","Obesity|Type 2 Diabetes","Diagnostic Test: Oral Glucose tolerance test","Glucose Tolerance|Insulin resistance","Yale University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 21 Years   (Child, Adult)","Not Applicable","2000","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","11190|R01HD040787","September 1999","September 2021","September 2021","October 23, 2013","null","December 7, 2017","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01967849"
661,"NCT01945957","Brain Imaging of Intranasal Oxytocin Treatment in Autism",,"Completed","No Results Available","Autism Spectrum Disorders","Drug: Oxytocin","Aim 1a. fMRI Activation Analysis/Connectivity|Aim 1b. Proportion of Time Attending to Social Stimuli (Eye Tracking)|Plasma Oxytocin (OT) levels in aim 1b. and 2b.|Salivary Oxytocin (OT) levels for all aims.|SRS-Social Responsiveness Scale|Pervasive Developmental Disorders Behavior Inventory-Screening Version (PDDBI-SV)|ABC-lethargy/social withdrawal subscale","University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 18 Years   (Child, Adult)","Phase 1","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","12-2622|U54HD079124-01","September 2014","January 2017","January 2017","September 19, 2013","null","April 25, 2017","The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01945957"
662,"NCT01901978","Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents",,"Active, not recruiting","No Results Available","Obesity|Insulin Resistance","Behavioral: Caloric restrictive diet","Abdominal fat re-distribution with weight loss|Adipocyte cell size distrubtion and gene expression","Yale University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 32 Years   (Child, Adult)","Not Applicable","40","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","1007007067|R01HD040787","May 2011","July 2014","August 2018","July 17, 2013","null","January 17, 2018","Yale University, New Haven, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT01901978"
663,"NCT01821300","Down Syndrome Metabolic Health Study",,"Active, not recruiting","Has Results","Down Syndrome|Trisomy 21","","Non-HDL Cholesterol|Lipid Subparticles|Lipid Subparticles (Size)|Insulin Resistance|Cardiometabolic Risk Biomarker Proteins|Abnormal Glucose Tolerance|Visceral Fat|Body Mass Measures|Left Ventricular Mass|Pulse Wave Velocity|Health Related Quality of Life - PedsQL|Health Related Quality of Life - IWQOL","Children's Hospital of Philadelphia|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 20 Years   (Child, Adult)","","257","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","12-009233|1R01HD071981-01A1","February 2013","August 25, 2017","July 1, 2019","April 1, 2013","January 9, 2019","January 31, 2019","Children's National Medical Center, Washington, District of Columbia, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/00/NCT01821300/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT01821300"
664,"NCT01338025","Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Strategy","P1094","Terminated","Has Results","HIV Disease","Drug: HAART regimen|Drug: 3TC or FTC monotherapy","Number of Participants With Immunologic Deterioration|Change in CD4+ T Cell Count|Change in HIV-1 RNA Levels|Number of Participants Non-adherent as Measured by 3-day Recall","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 24 Years   (Child, Adult)","Phase 4","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT P1094|U01AI068632","March 2011","May 2013","May 2013","April 19, 2011","May 23, 2014","November 13, 2015","Univ. of California San Francisco NICHD CRS (5091), San Francisco,, California, United States|Children's National Med. Ctr. Washington DC NICHD CRS (5015), Washington, District of Columbia, United States|University of Florida (5051), Jacksonville, Florida, United States|Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|Chicago Children's CRS (4001), Chicago, Illinois, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Bronx-Lebanon Hospital (6901), Bronx, New York, United States|Metropolitan Hospital (5003), New York, New York, United States|SUNY Stony Brook NICHD CRS (5040), Stony Brook, New York, United States|DUMC Ped. CRS (4701), Durham, North Carolina, United States|Hospital General de Agudos Buenos Aires Argentina NICHD CRS (5082), Buenos Aires, Argentina|Hospital Geral De Nova Igaucu Brazil NICHD CRS (5097), Rio de Janeiro, Brazil|Insituto de Infectologia Emilio Ribas NICHD CRS (5075), Sao Paulo, Brazil|Univ of Sao Paulo Brazil NICHD CRS (5074), Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research (6601), San Juan, Puerto Rico|Siriraj Hospital Mahidol University CRS (8251), Bangkok, Ratchathewi,, Thailand|Chiang Mai University Pediatrics-Obstetrics CRS (20101), Chiang Mai, Thailand","","https://ClinicalTrials.gov/show/NCT01338025"
665,"NCT01152268","Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool",,"Completed","No Results Available","Cancer","","Investigation of factors predictive of sperm banking outcome|Develop and evaluate a Profiling and Referral Tool designed to increase clinical referrals and decrease barriers to sperm banking.","St. Jude Children's Research Hospital|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","13 Years to 21 Years   (Child, Adult)","","282","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","SBANK10|R21HD061296-01A2","July 2010","June 2014","June 2014","June 29, 2010","null","March 10, 2015","City of Hope, Duarte, California, United States|Mattel Children's Hospital, Los Angeles, California, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Dana-Farber Cancer Institute/Children's Hospital Boston, Boston, Massachusetts, United States|The University of Michigan, Ann Arbor, Michigan, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|The Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01152268"
666,"NCT00259389","Directly Observed Therapy for HIV Infected Adolescents",,"Completed","No Results Available","HIV Infections","Behavioral: Directly observed therapy (DOT)","Proportion of completed directly observed therapy (DOT) facilitator-participant interactions, among all scheduled interactions, for each participant during the second 4-week period on study|number and proportion of participants who were able to complete the recommended duration of DOT|Subject satisfaction with DOT, assessed by the Exit Survey Instrument|cost of implementing DOT per participant|effective ratio of DOT facilitators to participants, determined by the calculation of actual time spent by each DOT facilitator|reproducibility of DOT implementation across sites and participants' adherence to DOT interactions and ability to complete the prescribed duration of DOT, compared across sites|adherence for each participant in the 4-week period prior to a study visit, determined at Weeks 8 and 12 by participant self-report and adherence to DOT interactions and by pill count and participant 4-week recall at Week 24|virologic outcomes, determined by the suppression of HIV-1 viral load at Weeks 8, 12, and 24|immunologic outcome, defined by a change in absolute CD4 count from baseline to Week 24|self-efficacy (confidence), assessed by Patient Assessment Tool - Part I and Beliefs About Medicine Scale|beliefs about highly active antiretroviral therapy (HAART), assessed by Beliefs About Medicine Scale|severity of depression experienced by each participant, assessed by Beck Depression Inventory (BDI)-II|hopelessness, assessed by Beck Hopelessness Scale (BHS)|emotional and behavioral problems, assessed by Youth Self Report (YSR)/Adult Self Report (ASR)|coping of each participant, assessed by Coping Responses Inventory (CRI)-Youth and CRI-Adult|perceived barriers to adherence, assessed at baseline and Weeks 12 and 24 by Patient Assessment Tool - Part I and Beliefs About Medication Scale|substance abuse, assessed at baseline and Weeks 12 and 24 by Patient Assessment Tool - Part II|sustainability of DOT benefits, assessed as the proportion of participants adherent at Week 24 among those who successfully complete the first 8 weeks of DOT and are taken off DOT at 12 weeks","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Pediatric AIDS Clinical Trials Group","All","16 Years to 25 Years   (Child, Adult)","Not Applicable","24","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PACTG P1036B|10044","April 2006","null","September 2007","November 29, 2005","null","September 18, 2012","Childrens Hospital Los Angeles, Los Angeles, California, United States|Los Angeles County Medical Center/USC, Los Angeles, California, United States|UCSD Mother, Child & Adolescent HIV Program, San Diego, California, United States|Childrens Hospital of Michigan, Detroit, Michigan, United States|University of Rochester Medical Center, Rochester, New York, United States|St. Jude Childrens Research Hospital, Memphis, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00259389"
667,"NCT00663234","IMPAACT P1063: Safety and Effectiveness of Atorvastatin in HIV Infected Children and Adolescents With Hyperlipidemia",,"Terminated","Has Results","HIV Infections|Hyperlipidemia","Drug: Atorvastatin","Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE)|Percentage of Participants Experiencing at Least One Adverse Event (AE)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Intention to Treat)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Data Available)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria (Per Protocol)|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria and Did Not Experience a Primary Safety Endpoint Attributable to Study Drug|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by Age Group|Percentage of Participants Who Met the LDL Cholesterol (LDL-C) Efficacy Criteria by NNRTI Treatment|Percent Change in LDL Cholesterol (LDL-C) From Study Entry|Percentage of Participants Experiencing at Least One Treatment-related Adverse Event (AE) by Age Group|Percentage of Participants Experiencing at Least One Adverse Event (AE) by Age Group|Percent Change in Fasting Total Cholesterol (TC) From Study Entry|Percent Change in Triglycerides (TG) From Study Entry|Percent Change in HDL-cholesterol (HDL-C) From Study Entry|Percent Change in Apolipoprotein A1 (Apo A-1) From Study Entry|Percent Change in Apolipoprotein B (Apo B) From Study Entry|Percent Change in High-sensitivity CRP (Hs-CRP) From Study Entry|Percent Change in Interleukin 6 (IL-6) From Study Entry|Percentage of Participants With Undetectable Plasma HIV-1 RNA","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years to 23 Years   (Child, Adult)","Phase 1|Phase 2","28","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT P1063|U01AI068632|10167","August 2009","December 2014","December 2014","April 22, 2008","April 6, 2016","April 6, 2016","Univ. of Colorado Denver NICHD CRS (5052), Aurora, Colorado, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS (4201), Miami, Florida, United States|University of South Florida Tampa (5018), Tampa, Florida, United States|Chicago Children's CRS (4001), Chicago, Illinois, United States|Tulane University (5095), New Orleans, Louisiana, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital IMPAACT CRS (6901), Bronx, New York, United States|New York University NY (5012), New York, New York, United States|Metropolitan Hospital (5003), New York, New York, United States|St. Jude/UTHSC CRS (6501), Memphis, Tennessee, United States|Texas Children's Hosp. CRS (3801), Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00663234"
668,"NCT00039741","Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children",,"Completed","Has Results","HIV Infections","Drug: NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Drug: NNRTIs (EFV, NVP)|Drug: PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)","Change in Viral Load Measured in log10 HIV-1 RNA Copies/ml|Rate of Grade 3 or Higher Signs, Symptoms, or Laboratory Abnormalities Experienced|Participants With Significant HIV-related Clinical Events, Defined as CDC Category C (AIDS Defining) Diagnoses (Except for Recurrent Bacterial Infections)or Death|Time to Switching to an Alternative Class ART Regimen (Based on Initial Randomized Regimen)|Time to HIV-1 RNA of 400 Copies/ml or Greater During First-line Therapy or Permanent Discontinuation of First-line Therapy|Time to HIV-1 RNA of 30,000 Copies/ml or Greater During Second-line Therapy or Permanent Discontinuation of Second-line Therapy|Number of Children With an HIV-1 RNA Level Less Than 400 Copies/ml Regardless of Therapy at Week 204|Change in CD4% From Randomization to 4 Years|Number of Children With HIV-1 RNA Less Than 400 Copies/ml and on Original Randomized Therapy at 24 Weeks","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|PENTA Foundation","All","up to 18 Years   (Child, Adult)","Phase 2|Phase 3","266","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P390|PENPACT-1B|10106|PENTA 9/PACTG 390","August 2002","August 2009","March 2010","June 11, 2002","April 24, 2012","February 7, 2019","Usc La Nichd Crs, Alhambra, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Children's Hospital of Los Angeles NICHD CRS, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab., Oakland, California, United States|Connecticut Children's Med. Ctr., Hartford, Connecticut, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Fort Lauderdale, Florida, United States|Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy, Gainesville, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Chicago Children's CRS, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, United States|UMDNJ - Robert Wood Johnson Med. School, Div. of Allergy, Immunology & Infectious Diseases, New Brunswick, New Jersey, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|Oregon Health & Science Univ. - Dept. of Peds., Div. of Infectious Disease, Portland, Oregon, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00039741"
669,"NCT00006604","Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents",,"Completed","Has Results","HIV Infections","Drug: ATV|Drug: Ritonavir","Number of Participants Who Experienced a Safety Endpoint of Interest Attributed to ATV|Number of Participants Who Died|Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC24h)|Pharmacokinetic (PK) Parameter: Minimum Plasma Concentration (C24)|Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax)|Pharmacokinetic (PK) Parameter: Clearance (CL/F)|Percentage of Participants With HIV RNA <400 Copies/mL at Week 24|Percentage of Participants With HIV RNA <400 Copies/mL at Week 48|Percentage of Participants With HIV RNA <400 Copies/mL at Week 96|Change in CD4 Count (Cells/mm^3) From Baseline to Week 20|Change in CD4 Count (Cells/mm^3) From Baseline to Week 48|Change in CD4 Count (Cells/mm^3) From Baseline to Week 96|Change in CD4 Percent From Baseline to Week 20|Change in CD4 Percent From Baseline to Week 48|Change in CD4 Percent From Baseline to Week 96","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group","All","91 Days to 21 Years   (Child, Adult)","Phase 1|Phase 2","195","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1020A|10037|IMPAACT P1020A|PACTG P1020-A|ACTG P1020-A","November 2000","October 2011","September 2014","August 31, 2001","April 5, 2016","April 5, 2016","UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|Usc La Nichd Crs, Alhambra, California, United States|University of California, UC San Diego CRS, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|South Florida CDTC Ft Lauderdale NICHD CRS, Ft. Lauderdale, Florida, United States|Columbus Regional HealthCare System, The Med. Ctr., Columbus, Georgia, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Harlem Hosp. Ctr. NY NICHD CRS, New York, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Children's Med. Ctr. Dallas, Dallas, Texas, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Children's Hosp. of the King's Daughters, Infectious Disease, Norfolk, Virginia, United States|Childrens Hosp. of the Kings Daughters, Norfolk, Virginia, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Univ. Hosp. Ramón Ruiz Arnau, Dept. of Peds., Bayamon, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Shandukani CRS, Johannesburg, Gauteng, South Africa","","https://ClinicalTrials.gov/show/NCT00006604"
670,"NCT00310791","Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa",,"Completed","Has Results","Anorexia Nervosa","Drug: Hormone replacement therapy (estrogen/progestin)|Other: Placebo (Sugar Pill)|Drug: Dehydroepiandrosterone (DHEA)","Areal Bone Density by DXA","Boston Children’s Hospital|United States Department of Defense|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 30 Years   (Child, Adult)","Phase 2|Phase 3","80","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Anorexia04|R01HD043869","April 2004","October 2009","December 2010","April 5, 2006","February 1, 2013","April 11, 2018","Children's Hospital Boston, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT00310791"
671,"NCT00004335","Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle",,"Completed","No Results Available","Hypogonadism|Precocious Puberty","","","National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Michigan","All","7 Years to 35 Years   (Child, Adult)","","null","NIH|Other","Observational","Primary Purpose: Screening","199/11894|UMMC-271","April 1993","null","null","October 19, 1999","null","June 24, 2005","University of Michigan Health Systems, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00004335"
672,"NCT03700697","A Clinical Process Support System for Primary Care to Address Family Stress","FamilyStress","Recruiting","No Results Available","Social Determinants of Health|Child Abuse","Behavioral: Family Stress Module Intervention","Compare intervention vs control percent parents for receiving help for Family Stressors|Compare intervention vs control percent parents in rates of child maltreatment|Compare intervention vs control percent parents in rates of harsh punishment|Compare intervention vs control parents in percent reporting child behavior problems|Compare intervention vs control percent parents for rate of atypical child development.|Compare parent rating of physician competence and confidence handling family stressors between intervention and control groups|Change in physician competence and confidence handling family stressors|Compare intervention vs control group rates of missed well child visits|Compare intervention vs control group rates of missed recommended immunizations|Compare intervention vs control group parent-child relationship","Total Child Health, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Center for Promotion of Child Development through Primary Care|Foresightlogic","All","1 Month to 2 Years   (Child)","Not Applicable","16630","Industry|NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R44HD089785","July 9, 2018","August 31, 2021","August 31, 2021","October 9, 2018","null","October 9, 2018","Total Child Health, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03700697"
673,"NCT03568383","Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients","PHOENIx MDR-TB","Not yet recruiting","No Results Available","Tuberculosis, MDR","Drug: Delamanid (DLM)|Drug: Isoniazid (INH)|Dietary Supplement: Pyridoxine (vitamin B6)","Percent of participants with confirmed or probable active TB at any time between Day 0 and the week 96 study visit|Percent of participants who permanently discontinue randomized study drug (DLM or INH) due to a treatment-related adverse event|Percent of participants with confirmed active MDR-TB at any time between Day 0 and the week 96 study visit|Percent of participants who died from any cause at any time between Day 0 and 96 weeks of follow-up|Percent of participants who died from any cause at any time between Day 0 and 96 weeks of follow-up, or with confirmed or probable active TB at any time between Day 0 and the week 96 study visit|Percent of participants with a Grade 3 or higher adverse event during the period receiving randomized study drug (DLM or INH)","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Phase 3","5610","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","A5300B/I2003B/PHOENIx|12041","June 18, 2019","June 18, 2025","June 18, 2025","June 25, 2018","null","April 12, 2019","Gaborone CRS, Gaborone, South-East District, Botswana|Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro, Brazil","","https://ClinicalTrials.gov/show/NCT03568383"
674,"NCT03453840","Extended Duration Artemether-lumefantrine Treatment for Malaria in Children","EXALT","Recruiting","No Results Available","Uncomplicated Plasmodium Falciparum Malaria","Drug: Artemether-lumefantrine","Area under the plasma concentration versus time curve (AUC) for all drug analytes|Recurrent malaria following treatment by day 42 (recrudescence or new infection)|Safety of 5-day vs 3-day AL regimens evaluated via graded toxicity|Prevalence of gametocytemia following treatment in 3-day vs 5-day AL regimens determined by thick blood smears|Weight-for-age (WFA) associations with PK|Height-for-age (HFA) associations with PK|Weight-for-height (WFH) associations with PK|Diagnostic sensitivity of LAMP, HS-RDT, and microscopy for the detection of recurrent parasitemia|Metabolomic measurements in HIV infected vs HIV uninfected children|Relationship between drug resistance and treatment failure","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Yale University|Infectious Diseases Research Collaboration, Uganda","All","6 Months to 10 Years   (Child)","Phase 4","380","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-22578|2R01HD068174-06A1","February 19, 2018","August 31, 2020","August 31, 2021","March 5, 2018","null","August 20, 2018","MGH campus, Busia, Uganda|IDRC- Tororo Research Clinic and Tororo District Hospital, Tororo, Uganda","""Informed Consent Form: HIV-infected children"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03453840/ICF_000.pdf|""Informed Consent Form: HIV-uninfected Children"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03453840/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03453840"
675,"NCT03438721","Strong Futures: A Trial of Two Primary Care Based Interventions to Promote Optimal Health in Latino Infants and Toddlers",,"Recruiting","No Results Available","Childhood Obesity|Health-Related Quality of Life","Behavioral: Infant obesity prevention|Behavioral: Financial coaching","Child dietary intake|Child screen time|Parent health-related quality of life|Child anthropometrics|Parent financial stress|Child sleep|Parental feeding styles","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Health Services Research","17-24028|1K23HD080876-01A1","April 11, 2018","June 2020","March 2021","February 20, 2018","null","May 2, 2018","Children's Health Center at San Francisco General Hospital, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT03438721"
676,"NCT03429036","Biospecimen Procurement for NIDCD Clinical Protocols",,"Recruiting","No Results Available","Hearing Disorder|Oral Mucosal Disease|Pharyngeal Neoplasm|Head and Neck Neoplasms|Laryngeal Disease","","To created a biorepository of diseased and normal tissue specimens for research purposes|To share repository specimens with other approved NIH protocols to conduct analysis of cellular, molecular, genetic and genomic biology of normal processes and disorders of the ENT.","National Institute on Deafness and Other Communication Disorders (NIDCD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC)","All","3 Years to 99 Years   (Child, Adult, Older Adult)","","1000","NIH","Observational","Observational Model: Other|Time Perspective: Other","180051|18-DC-0051","May 23, 2018","January 1, 2030","June 30, 2030","February 12, 2018","null","January 10, 2019","Johns Hopkins Suburban Hospital, Bethesda, Maryland, United States|Johns Hopkins Otolaryngology Clinic, Bethesda, Maryland, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03429036"
677,"NCT03422367","JASPER Early Intervention for Tuberous Sclerosis","JETS","Recruiting","No Results Available","Tuberous Sclerosis","Behavioral: JASPER","ESCS (Early Social Communication Scales) Assessment.|Parent Caregiver Interaction assesses the amount of time the parent and child spend in engaged in the same play routine.|Structured Play Assessment (SPA)|SPA|Mullen Scales of Early Learning (MSEL)|Mullen|Social communication","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Boston Children’s Hospital|Massachusetts General Hospital","All","6 Months to 40 Months   (Child)","Not Applicable","64","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB #17-000262|1R01HD090138-01A1","October 24, 2017","June 15, 2022","June 15, 2022","February 5, 2018","null","October 3, 2018","University of California Los Angeles, Los Angeles, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT03422367"
678,"NCT03379090","Neighborhood Influence on Parenting Practices Regarding Youth Outdoor Play",,"Completed","No Results Available","Physical Activity|Adolescent Behavior|Parenting","","Perceptions of how the social environment influences parenting practices related to outdoor play and youth's physical activity.","Pennington Biomedical Research Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","30","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","2017-017-PBRC|1F32HD093282-01","March 26, 2018","July 18, 2018","July 18, 2018","December 20, 2017","null","July 24, 2018","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03379090/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/90/NCT03379090/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03379090"
679,"NCT03367845","Efficacy of Family Programs for Improving Child and Family Health and Development",,"Recruiting","No Results Available","Behavior, Infant","Behavioral: Control|Behavioral: Sensitivity Intervention|Behavioral: Couples' Intervention|Behavioral: Sensitivity and Couples' Intervention","Change in Parental Sensitivity|Change in Child Care Activities Scale|Change in Parenting Stress Index - Short Form Version III|Change in Parenting Sense of Competence Scale|Change in Spousal Attachment Questionnaire|Change in Conflict and Problem Solving Scale|Change in O'Leary Porter Scale|Change in Brief Infant Toddler Emotional Assessment|Mother-Infant Attachment|Father-Infant Attachment|Change in Couples' communication styles|Change in Infant Affect Regulation","University of Notre Dame|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months and older   (Child, Adult, Older Adult)","Not Applicable","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Other","NotreDame|R01HD087319","January 11, 2017","December 31, 2021","December 31, 2023","December 11, 2017","null","March 13, 2019","Fort Wayne Center for Children and Families, Fort Wayne, Indiana, United States|William J. Shaw Center for Children and Families, South Bend, Indiana, United States","","https://ClinicalTrials.gov/show/NCT03367845"
680,"NCT03287830","Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine","F2T","Recruiting","No Results Available","Influenza|Vaccination","Behavioral: Text message influenza vaccine reminders","Percentage of participants who receive influenza vaccination by April 30 each year|Percentage of participants who receive a second vaccination by Day 42 from the initial influenza vaccination|Number of days between first and second dose influenza vaccine or end of season (April 30th)","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Academy of Pediatrics|Children's Hospital of Philadelphia","All","6 Months to 8 Years   (Child)","Not Applicable","3870","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","AAAR4101|R01HD086045-01A1","October 4, 2017","April 30, 2019","July 31, 2019","September 19, 2017","null","July 25, 2018","American Academy of Pediatrics, Itasca, Illinois, United States|Columbia University Medical Center, New York, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03287830"
681,"NCT03263351","Depression & Insulin Sensitivity in Adolescents",,"Recruiting","No Results Available","Type2 Diabetes|Type 2 Diabetes Mellitus|Insulin Sensitivity|Insulin Resistance|Depression|Adolescent Obesity","Behavioral: Cognitive-behavioral therapy group|Behavioral: Health education group","Depressive symptoms|Insulin sensitivity|Insulin secretion|Disinhibited eating|Physical activity|Physical inactivity|Sleep|Cortisol diurnal rhythm|Daily cortisol output","Colorado State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Advancing Translational Science (NCATS)|Children's Hospital Colorado","Female","12 Years to 17 Years   (Child)","Not Applicable","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","16-2571","October 1, 2017","April 1, 2021","April 1, 2022","August 28, 2017","null","April 16, 2019","Children's Hospital Colorado, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT03263351"
682,"NCT03187561","Coparenting, Infant Sleep, and Infant Development","SIESTA-FF","Recruiting","No Results Available","Sleep|Parenting|Marital Relationship|Parent-Child Relations","Behavioral: Infant sleep-adapted coparenting intervention","Overall coparenting quality|Quality of coparenting around infant sleep contexts|Quality of infant sleep|Quality of parent sleep|Attachment Q-Set|Infant-Toddler Social and Emotional Assessment (ITSEA)|Maternal depressive symptoms (Beck Depression Inventory)|Descriptive In-home Survey of Chaos - Observer ReporteD (DISCORD)","Penn State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Month to 65 Years   (Child, Adult, Older Adult)","Not Applicable","216","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","STUDY00006724|R01HD088566","May 1, 2018","February 28, 2021","February 28, 2022","June 15, 2017","null","May 18, 2018","Douglas Teti, State College, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03187561"
683,"NCT03073187","Sleep Quality in High School Students With Asthma",,"Enrolling by invitation","No Results Available","Asthma|Sleep|Asthma in Children","","Number of subjects successfully completing the interview","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years and older   (Child, Adult, Older Adult)","","84","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","AAAQ9707 - I|1R21HD086448-01A1","April 17, 2017","September 2018","September 2018","March 8, 2017","null","January 29, 2018","Columbia University, New York, New York, United States|Rhode Island Hospital, Providence, Rhode Island, United States","","https://ClinicalTrials.gov/show/NCT03073187"
684,"NCT03025763","Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones",,"Recruiting","No Results Available","Craniosynostosis","Other: Craniosynostosis Network Environmental Survey|Other: 2D/3D Photography|Procedure: Buccal Swab Cell Sampling|Procedure: Blood sampling|Procedure: Skin Biopsy|Procedure: Tissues from a Clinically Indicated Procedure|Procedure: Pre-operative CT Scan Image Files.","Phenotype-genotype gene expression correlations|Incidence of gene mutations","Icahn School of Medicine at Mount Sinai|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 80 Years   (Child, Adult, Older Adult)","","4000","Other|NIH","Observational","Observational Model: Other|Time Perspective: Other","GCO 13-0147|P01HD078233","November 2014","June 2019","June 2029","January 20, 2017","null","January 23, 2018","The International Craniosynostosis Consortium at University of California at Davis, Davis, California, United States|Yale University, Hartford, Connecticut, United States|National Birth Defects Prevention Study at University of Iowa, Iowa City, Iowa, United States|Johns Hopkins University, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Birth Defect Registries of New York State, Albany, New York, United States|New York University, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Pennsylvania State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Pennsylvania State University, University Park, Pennsylvania, United States|Univ. of Texas at Southwestern, Dallas, Texas, United States|University of Bordeaux, Talence, Aquitaine, France|INSERM/ Hospital Necker-Enfants Malades, Paris, Cedex 14, France|University Hospital Heidelberg, Heidelberg, Germany|Hospital Sant Joan de Deu, Barcelona, Esplugues De Llobregat, Spain|Oxford University, Oxford, Oxfordshire, United Kingdom","","https://ClinicalTrials.gov/show/NCT03025763"
685,"NCT02934633","Parent Training in Child Safety Practices","BabySafety_2","Completed","No Results Available","Injury","Behavioral: Keeping Baby Safe 2-DVD package|Behavioral: The Injury Prevention Program (TIPP) sheets","Change in parent motivation to implement injury prevention strategies|Change in parent knowledge of injury prevention practices","Oregon Center for Applied Science, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","414","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","SBIR 63-2|R44HD044281","August 2006","August 2008","August 2008","October 17, 2016","null","October 17, 2016","Oregon Center for Applied Science, Eugene, Oregon, United States","","https://ClinicalTrials.gov/show/NCT02934633"
686,"NCT02901626","A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix","TOPS","Recruiting","No Results Available","Short Cervix|Preterm Delivery","Device: Pessary","Delivery or fetal demise","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Not Applicable","850","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HD36801 - TOPS|UG1HD087230|UG1HD027915|UG1HD034208|UG1HD040500|UG1HD040485|UG1HD053097|UG1HD040544|UG1HD040545|UG1HD040560|UG1HD040512|UG1HD087192|U10HD036801|UG1HD027869","February 14, 2017","July 2023","January 2024","September 15, 2016","null","February 20, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Womens, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02901626"
687,"NCT02826694","North Carolina Newborn Exome Sequencing for Universal Screening","NC_NEXUS","Active, not recruiting","No Results Available","Metabolism, Inborn Errors|Hearing Loss|Hereditary Disease","Genetic: Well infant, whole exome sequencing|Genetic: Diagnosed, whole exome sequencing","Parental decision making using decision aid.|Sensitivity of whole exome sequencing in detecting conditions by comparing results of sequencing to the appropriate genes associated with the child's underlying condition.|Participant characteristics and reactions to the study will be collected through surveys.","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Human Genome Research Institute (NHGRI)|RTI International","All","up to 5 Years   (Child)","Not Applicable","400","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","13-2409|5U19HD077632","June 2016","June 30, 2019","June 30, 2019","July 11, 2016","null","March 6, 2019","UNC Hospitals, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT02826694"
688,"NCT02742831","A Pilot Intervention With Families of Children With Special Health Care Needs",,"Withdrawn","No Results Available","Child Maltreatment|Children With Special Health Care Needs (CSHCN)","Behavioral: Intervention|Other: Control","Study Logistics - subject enrollment|Study Logistics - fidelity of intervention delivery|Re-referral to child protection team or social services|Adherence to recommended medical care","Boston Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","H-35105|1K23HD078503-01A1","August 1, 2017","August 2018","August 2018","April 19, 2016","null","August 14, 2018","Boston Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02742831"
689,"NCT02717494","Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women",,"Active, not recruiting","No Results Available","PNC Vaccine|HIV-infected Pregnant Women","Biological: PPV-23|Biological: PCV-10|Other: NaCl","Safety of PCV10 and PPV23 administered in pregnancy|Maternal Immunogenicity of PPV23 and PCV10|Persistence of Transplacentally Transmited Maternal Antibodies to PNC Vaccine Serotypes in the Infant|Ratio of Infant/Mother PNC Antibody Levels|Maternal and Infant Immunogenicity to PNC Vaccines","Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 2","345","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NICHD P1091","March 2016","May 2019","May 2019","March 23, 2016","null","April 9, 2019","FUNDEP (Belo Horizonte), Belo Horizonte, Minas Gerais, Brazil|Hospital Geral de Nova Iguaçu Avenida Henrique Duque Estrada Mayer, Nova Iguaçu, Rio De Janeiro, Brazil|Hospital dos Servidores (Rio de Janeiro), Saude, Rio De Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteria, Rio de Janeiro, RJ, Brazil|Universidade de Caxias do Sul. Brasil, Caxias do Sul, RS, Brazil|Hospital Santa Casa Porto Alegre Brazil, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Ribeirão Preto Medical School, University of São Paulo, Brazil, Ribeirao Preto, Sao Paulo, Brazil","","https://ClinicalTrials.gov/show/NCT02717494"
690,"NCT02574910","Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1",,"Recruiting","No Results Available","Congenital Adrenal Hyperplasia","Drug: Abiraterone acetate","Normalization of serum androstenedione level|17-hydroxyprogesterone levels|Dihydrotestosterone levels","University of Texas Southwestern Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Michigan|Children's Hospital Los Angeles","All","2 Years to 9 Years   (Child)","Phase 1","36","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","112014-087|1U01HD083493-01","August 1, 2017","January 23, 2020","January 23, 2020","October 14, 2015","null","January 25, 2019","Children's Hospital of Los Angeles, Los Angeles, California, United States|National Institutes of Health, Bethesda, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|North Shore/Long Island Jewish Hospital, New Hyde Park, New York, United States|Children's Medical Center, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02574910"
691,"NCT02518594","A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix","PROSPECT","Recruiting","No Results Available","Short Cervical Length","Drug: Vaginal progesterone|Drug: Placebo|Device: Arabin Pessary","Delivery prior to 35 weeks or fetal loss|Randomization to delivery interval|Gestational age at delivery|Neonatal morbidity and mortality|Lower genital tract or urinary tract infection|Physician interventions","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","630","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HD36801-PROSPECT|U10HD036801|UG1HD087230|UG1HD027869|UG1HD027915|UG1HD034208|UG1HD040500|UG1HD040485|UG1HD053097|UG1HD040544|UG1HD040545|UG1HD040560|UG1HD040512|UG1HD087192|UG1HD068282|UG1HD068258|UG1HD068268","November 13, 2015","August 2024","February 2025","August 10, 2015","null","February 20, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|University of Colorado, Denver, Colorado, United States|Northwestern University-Prentice Hospital, Chicago, Illinois, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT02518594"
692,"NCT02376816","Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy",,"Completed","No Results Available","Duchenne Muscular Dystrophy","Biological: rAAVrh74.MCK.micro-Dystrophin","Safety based on number of participants with adverse events|Transgene Expression","Jerry R. Mendell|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Nationwide Children's Hospital","Male","7 Years and older   (Child, Adult, Older Adult)","Phase 1","2","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","14-00718","March 2015","September 2017","September 2017","March 3, 2015","null","November 24, 2017","Nationwide Children's Hospital, Columbus, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02376816"
693,"NCT02343367","Health4Kids Intervention Trial for Hispanic Families","H4K","Recruiting","No Results Available","Pediatric Obesity","Behavioral: behavioral counseling|Other: Education Materials|Behavioral: Face to face counseling session|Behavioral: Text messages|Behavioral: Telephone Counseling|Behavioral: Newsletters","Change from baseline in weight (kg)|Change from baseline in waist circumference (cm)|Change from baseline in body mass index (BMI z score)|Change from baseline in fasting insulin (µIu/mL)|Change from baseline in fasting glucose (mg/dL)|Change in cholesterol (lipid panel: fasting total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides) from baseline (mg/dL)|Change from baseline in moderate-to-vigorous physical activity (minutes/week)|Change from baseline in consumption of sugar-sweetened beverages (servings/week)|Change from baseline in consumption of fruits and vegetables (servings/day)","The University of Texas Health Science Center at San Antonio|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The University of Texas at San Antonio|Bexar County Hospital District DBA University Health System","All","6 Years to 11 Years   (Child)","Not Applicable","460","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC20130465H|R01HD075936","January 2015","September 2019","September 2020","January 22, 2015","null","August 10, 2018","University of Texas Health Science Center San Antonio, San Antonio, Texas, United States","","https://ClinicalTrials.gov/show/NCT02343367"
694,"NCT02282293","Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)",,"Completed","Has Results","Malaria|Human Immunodeficiency Virus","Drug: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)|Drug: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)","Number of Participants With Placental Malaria|Incidence of Malaria, Pregnant Women|Maternal Parasitemia at Delivery by Microscopy and LAMP|Placental Parasitemia (Number of Women With Placental Blood Samples Positive for Malaria by Microscopy or PCR)|Number of Monthly Routine Visits With Positive Blood Samples for Parasites|Composite Adverse Birth Outcome (Proportion With Low Birth Weight (<2500 gm), Spontaneous Abortion (<28 Weeks), Stillbirth (Fetal Demise ≥28 Weeks), Congenital Anomaly, or Preterm Delivery (<37 Weeks)|Number of Routine Visits Measured Every 8 Weeks During Pregnancy for Which the Participants Had Anemia","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROMOTE-BC2","December 9, 2014","May 26, 2016","May 26, 2016","November 4, 2014","March 5, 2019","March 5, 2019","IDRC Research Clinic - Tororo District Hospital, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT02282293"
695,"NCT02194439","Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease",,"Active, not recruiting","No Results Available","Graft-Versus-Host Disease","","Confirm Biomarkers Predictive Efficacy|Demonstrate Efficacy of Biomarkers to Predict Non-Relapse Mortality","Indiana University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","430","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1405976232|1R01HD074587-01","January 2014","May 2019","June 2019","July 18, 2014","null","February 27, 2019","Indiana Unversity Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT02194439"
696,"NCT02163447","Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants","PROMOTE-BC1","Completed","Has Results","Malaria","Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants|Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants","Prevalence of Placental Malaria|Incidence of Malaria in Pregnant Women|Incidence of Malaria in Infants|Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP|Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery|Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (<2500g), Still Birth, Pre-term Delivery|Prevalence of Anemia in Pregnant Women|Incidence of Complicated Malaria in Infants|Incidence of Hospital Admissions in Infants|Prevalence of Gametocytemia in Pregnant Women and Infants|Prevalence of Parasitemia in Infants|Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROMOTE-BC1|P01HD059454","June 23, 2014","May 14, 2018","May 14, 2018","June 13, 2014","November 14, 2018","November 15, 2018","IDRC Research Clinic -Tororo District Hospital, Tororo, Uganda","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02163447/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/47/NCT02163447/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02163447"
697,"NCT02155296","RCT of the Restorative Practices Intervention","RPI","Completed","No Results Available","Intervention Schools (Schools Receiving RPI)|Control Schools (Schools Not Receiving RPI)","Behavioral: Restorative Practices Intervention","Change from Baseline in Perceptions of School Climate Post RPI and 1 year Post RPI|Change from Baseline in School Connectedness Post RPI and 1 year Post RPI|Change from Baseline in Peer Relationships Post RPI and 1 year Post RPI|Change from Baseline in Social Competency Post RPI and 1 year Post RPI|Change from Baseline in Bullying Post RPI and 1 year Post RPI|Change from Baseline in Administrative Data Post RPI and 1 year Post RPI|Dosage|Adherence|Participant Response|Youth program quality assessment","RAND|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","3516","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01HD072235-01","August 2014","January 12, 2019","January 12, 2019","June 4, 2014","null","April 3, 2019","Bath Middle School, Bath, Maine, United States|Boothbay school, Boothbay Harbor, Maine, United States|Bucksport school, Bucksport, Maine, United States|Bonny Eagle school, Buxton, Maine, United States|Ridge View school, Dexter, Maine, United States|Molly Ockett, Fryeburg, Maine, United States|Gorham school, Gorham, Maine, United States|Jefferson Village school, Jefferson, Maine, United States|Mt. Jefferson school, Lee, Maine, United States|Maranacook school, Readfield, Maine, United States|Oak Hill school, Sabattus, Maine, United States|Skowhegan school, Skowhegan, Maine, United States|Windham school, South Windham, Maine, United States","","https://ClinicalTrials.gov/show/NCT02155296"
698,"NCT02008695","Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo",,"Active, not recruiting","No Results Available","Mental Health Disorders","Behavioral: adult microfinance|Behavioral: Youth microfinance only|Behavioral: youth and adult micro finance","Change in baseline Mental health distress at 18 months","Johns Hopkins University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years and older   (Child, Adult, Older Adult)","Not Applicable","984","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","NA_00067820|R01HD071958","August 2012","April 2019","April 2019","December 11, 2013","null","August 29, 2018","PAIDEK, Congo, Bukavu, Congo","","https://ClinicalTrials.gov/show/NCT02008695"
699,"NCT01990612","A Randomized Trial of Induction Versus Expectant Management","ARRIVE","Completed","Has Results","Labor and Delivery","Procedure: Elective Induction of Labor","Composite of Severe Neonatal Morbidity and Perinatal Mortality|Perinatal Death (Component of Primary Outcome)|Number of Participant Infants Requiring Respiratory Support (Component of Primary Outcome)|Number of Infants With Apgar Score ≤3 at 5 Minutes (Component of Primary Outcome)|Number of Infants With Neonatal Hypoxic-ischemic Encelphalopathy (Component of Primary Outcome)|Number of Infants With Neonatal Seizure (Component of Primary Outcome)|Number of Infants With Neonatal Infection (Component of Primary Outcome)|Number of Infants With Meconium Aspiration Syndrome (Component of Primary Outcome)|Number of Infants With Birth Trauma (Component of Primary Outcome)|Number of Infants With Intracranial or Subgaleal Hemorrhage (Component of Primary Outcome)|Hypotension Requiring Vasopressor Support (Component of Primary Outcome)|Number of Participants With Cesarean Delivery|Number of Participants Who Had Uterine Incisional Extension at Cesarean Delivery|Participants Who Had Operative Vaginal Delivery|Number of Participants Who Had Chorioamnionitis|Number of Participants With Third or Fourth Degree Perineal Laceration|Number of Maternal Deaths|Number of Participants Admitted to Intensive Care Unit (ICU)|Number of Participants Experiencing Hypertensive Disorder of Pregnancy|Number of Participants With Postpartum Hemorrhage|Labor Agentry Scale Scores|Labor Pain Scores|Number of Participants With Maternal Postpartum Infection|Number of Participants With Venous Thromboembolism|Number of Participants With Indications for Cesarean Delivery|Duration of Respiratory Support|Number of Infants With Cephalohematoma|Shoulder Dystocia|Number of Infants Who Had Transfusion of Blood Products or Blood|Number of Infants With Hyperbilirubinemia|Number of Infants With Neonatal Hypoglycemia|Number Infants Admitted to NICU or Intermediate Care|Number of Hours on the Labor and Delivery Unit|Maternal Postpartum Length of Hospital Stay|Neonatal Length of Hospital Stay|Number of Participants With Indications for Operative Vaginal Delivery|Number of Participants and Breastfeeding Status at 4-8 Weeks After Delivery","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Not Applicable","6106","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HD36801-ARRIVE|UG1HD027869|UG1HD027915|UG1HD034116|UG1HD034208|UG1HD040500|UG1HD040485|UG1HD040544|UG1HD053097|UG1HD040545|UG1HD040560|UG1HD087230|UG1HD087192|UG1HD040512|UG1HD068258|UG1HD068268|U10HD036801|UG1HD068282","March 2014","November 2017","January 2018","November 21, 2013","January 25, 2019","February 21, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Stanford University, Stanford, California, United States|University of Colorado, Denver, Colorado, United States|Northwestern University-Prentice Hospital, Chicago, Illinois, United States|Columbia University-St. Luke's Hospital, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|Dept of OB/GYN, Southwestern Medical Center, University of Texas, Dallas, Texas, United States|University of Texas - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT01990612/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT01990612"
700,"NCT01978795","Interactive Training in Sports Concussion Prevention and Management",,"Completed","No Results Available","Concussion","Other: Brain 101 website|Other: Control","Change in youth athlete and parent knowledge of effective sports concussion management from before and after intervention exposure|Change in youth athlete and parent ratings of self-efficacy in sports concussion management","Oregon Center for Applied Science, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Phase 2","25","Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","HD056610|R44HD056610","August 2011","November 2011","February 2012","November 8, 2013","null","November 8, 2013","Oregon Center for Applied Science, Eugene, Oregon, United States","","https://ClinicalTrials.gov/show/NCT01978795"
701,"NCT01959321","An Observational Study of Hepatitis C Virus in Pregnancy","HCV","Active, not recruiting","No Results Available","Hepatitis C","","HCV infection of the offspring|Gestational age at delivery|Preterm delivery < 37 weeks of gestation|Gestational diabetes mellitus (GDM)|Vaginal bleeding during pregnancy|Preeclampsia|Cholestasis|Viral load in infant|HCV antibody status in infant|Birth weight of infant|Hyperbilirubinemia|Neonatal intensive care unit (NICU) admission|Small for gestational age|Neonatal infections","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","772","Other|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","HD36801-HCV|U10HD036801|UG1HD087230|UG1HD027869|UG1HD027915|UG1HD034208|UG1HD040500|UG1HD040485|UG1HD053097|UG1HD040544|UG1HD040545|UG1HD040560|UG1HD040512|UG1HD068282|UG1HD068258|UG1HD068268|UG1HD034116|UG1HD087192","October 2012","December 2020","July 2021","October 10, 2013","null","February 20, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Stanford University, Stanford, California, United States|University of Colorado, Denver, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01959321"
702,"NCT01938118","Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers",,"Completed","No Results Available","Obesity","Behavioral: Obesity Prevention Group|Behavioral: Injury Prevention Group","Mean weight-for-length z-score at 15 months of age|Proportion of infants ever breastfed and exclusively breastfed at 3 and 6 months of age|Proportion of infants fed complementary foods before 4 or 6 months of age|Infant dietary intake of fruits and vegetables, whole grains, desserts and sweets, and salty snacks at 3, 6, 9, 12 and 18 months of age|Duration of infant sleep (hours of total daily sleep, hours of nocturnal sleep, and number of night awakenings) at 3, 6, 9, 12 and 18 months of age|Infant exposure to television and electronic media (number of hours of screen time per day, proportion of infants with a T.V. or other media screen in bedroom) at 3, 6, 9, 12 and 18 months of age","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","430","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","12-0510|1R01HD073237-01","October 2013","December 2017","December 2017","September 10, 2013","null","April 19, 2018","Center for Women's Health Research, University of North Carolina, Chapel Hill, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01938118"
703,"NCT01866982","The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants","PREMOD","Completed","No Results Available","Intraventricular Hemorrhage","Procedure: Umbilical Cord Milking|Procedure: Delayed Cord Clamping","Superior Vena Cava Flow|Delivery Room Interventions|Hemoglobin|Neurodevelopmental impairment 18-36 months|Severe intraventricular hemorrhage (grade 3 or 4)|Phototherapy|Ionotropic support|Neonatal intensive care unit (NICU) length of stay|Necrotizing enterocolitis|Number of blood transfusions while in the neonatal intensive care unit|Ventilator time|Apgar score <7 at 5 minutes|Umbilical cord pH < 7.0|Blood pressure in first 2 hours of admission to neonatal intensive care unit|Polycythemia|Neonatal death|Use of uterotonic agents|Peak transcutaneous and/or serum bilirubin concentrations|Maternal hemoglobin|Intraventricular Hemorrhage detected on Head Ultrasound","Sharp HealthCare|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","197","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","PREMOD|R03HD072934-01","July 2, 2013","December 1, 2014","January 10, 2018","June 3, 2013","null","May 24, 2018","Loma Linda Medical Center, Loma Linda, California, United States|Sharp Mary Birch, San Diego, California, United States|University of California, San Diego, San Diego, California, United States","","https://ClinicalTrials.gov/show/NCT01866982"
704,"NCT01836003","An Intervention to Improve Antenatal Access to CD4 Testing and HAART in Botswana",,"Completed","No Results Available","HIV Infection|Pregnancy","Other: Tokafatso programmatic intervention","Proportion of eligible pregnant women with CD4 enumeration prior to 26 weeks gestation|Proportion of eligible women with HAART initiation prior to 30 weeks gestation|Proportion of eligible women with CD4 testing prior to delivery|Proportion of eligible women with HAART initiation prior to delivery|Gestational age of eligible women at time of CD4 enumeration|Gestational age of eligible women at the time of HAART initiation","Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","null","Child, Adult, Older Adult","Not Applicable","422","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","BHP044|3R01HD044391-06S1","July 2011","October 2012","October 2012","April 19, 2013","null","April 19, 2013","Botswana Harvard AIDS Institute, Gaborone, Botswana","","https://ClinicalTrials.gov/show/NCT01836003"
705,"NCT01831934","Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)",,"Completed","Has Results","MELAS Syndrome","Biological: Fluzone®","Clinical Safety of TIV Vaccine","Stanford University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years to 65 Years   (Child, Adult, Older Adult)","Phase 4","22","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","SU-18615|R21HD061709-01A1","September 2010","December 2011","March 2012","April 15, 2013","April 21, 2017","May 30, 2017","Stanford University School of Medicine, Stanford, California, United States","","https://ClinicalTrials.gov/show/NCT01831934"
706,"NCT01805479","Exercise Training in Depressed Traumatic Brain Injury Survivors",,"Withdrawn","No Results Available","Depression|Traumatic Brain Injury","Other: aerobic exercise|Other: stretching and flexibility program","completion of exercise protocol|neuropsychological testing|mood assessment|Columbia-Suicide Severity Rating Scale|magnetic resonance imaging|biochemical assays","Virginia Commonwealth University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)","PT107574|7K23HD067553","February 2013","June 2014","June 2014","March 6, 2013","null","December 21, 2015","Virginia Commonwealth University, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01805479"
707,"NCT03261882","Loss of a Healthy Weight Advantage Among Mexican-American Children",,"Completed","No Results Available","Overweight and Obesity","Other: Nativity","overweight/obesity","University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","4 Years to 17 Years   (Child)","","11987","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","NHANES|1T32HL129969-01A1|R24HD050924|K01DK107791","June 1, 2016","July 30, 2017","July 30, 2017","August 25, 2017","null","August 25, 2017","","","https://ClinicalTrials.gov/show/NCT03261882"
708,"NCT01735565","Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant",,"Completed","No Results Available","Bone Marrow Transplant","","Post-engraftment maturation of NET formation|Post-engraftment platelet function","University of Utah|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","23","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","56286","June 2012","March 2014","July 2016","November 28, 2012","null","August 11, 2016","Huntsman Cancer Institute, Salt Lake City, Utah, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01735565"
709,"NCT01717885","Antimalarial Pharmacology in Children and Pregnant Women in Uganda",,"Completed","No Results Available","Malaria|HIV","","Primary outcome measurement is the area under the plasma concentration versus time curve for all drug analytes.|Malaria reinfection (recrudescence or new infection)|Parasite clearance rate|AL and ART toxicity","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months and older   (Child, Adult, Older Adult)","","473","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","10-04798|R01HD068174","August 2012","December 2015","September 2016","October 31, 2012","null","October 28, 2016","IDRC- Tororo Research Clinic and Tororo District Hospital, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT01717885"
710,"NCT03142568","Safety of Sildenafil in Premature Infants","SIL02","Recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Sildenafil|Other: Placebo","Safety as determined by adverse event experienced by participants|Volume of Distribution|Clearance|Half-Life|Area Under the Curve (AUC)|Peak Plasma Concentration|Change in moderate-severe BPD or death risk from baseline","University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation","All","up to 28 Days   (Child)","Phase 2","120","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","17-2436|HHSN27500039|R01FD006099-01","April 2, 2018","June 2019","August 2019","May 5, 2017","null","January 15, 2019","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|Wesley Medical Center, Wichita, Kansas, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|Children's Hospital of Nevada at UMC, Las Vegas, Nevada, United States|Kings County Hospital Center, Brooklyn, New York, United States|Cohen Children's Medical Center of NY, New Hyde Park, New York, United States|Golisano Children's Hospital - University of Rochester Medical Center, Rochester, New York, United States|WakeMed Health and Hospitals, Raleigh, North Carolina, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT03142568"
711,"NCT03066895","BGS Neonatal Pilot Study",,"Recruiting","No Results Available","Pain From Heel Sticks","Device: BabyGentleStick|Device: Standard Lancing Device","Adverse events|Pain Response","Actuated Medical, Inc.|Milton S. Hershey Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH)","All","35 Weeks to 42 Weeks   (Child)","Not Applicable","20","Industry|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Device Feasibility","STUDY00006878","November 6, 2017","December 2018","December 2018","March 1, 2017","null","July 10, 2018","Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03066895"
712,"NCT01656733","Nicotine Replacement for Smoking Cessation During Pregnancy",,"Completed","No Results Available","Nicotine Dependence|Smoking Cessation","Drug: Nicotrol Inhaler","7 day point prevalence (PPA)|Birth weights, gestational age and cotinine concentrations|Exhaled carbon monoxide and cigarettes per day (CPD)|Birth Weight and gestational age","UConn Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 4","154","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","11-057-6|1R01HD069314-01A1","December 2010","July 2, 2017","October 25, 2017","August 3, 2012","null","March 22, 2018","Women's Ambulatory Health Services at Hartford Hospital, Hartford, Connecticut, United States|Wesson Women's Clinic at Baystate Medical Center, Springfield, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01656733"
713,"NCT01573845","The GREEN Project Lunch Box Study",,"Completed","No Results Available","Health Communication","Behavioral: Healthy Eating + Eco-Friendly Campaign|Behavioral: Healthy Eating Campaign","Changes in the quantity of fruit and vegetables brought from home to school|Changes in the quantity of sugar-sweetened beverages brought from home to school|Changes in the quantity of processed, energy-dense foods brought from home to school|Changes in trash weight associated with foods brought from home to school","Tufts University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","979","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","1R01HD065888-01|1R01HD065888","September 2011","June 2012","July 2013","April 10, 2012","null","March 25, 2015","","","https://ClinicalTrials.gov/show/NCT01573845"
714,"NCT01532791","Natural History Study - Mitochondrial Disease",,"Recruiting","No Results Available","MELAS or m.3243 A>G Mitochondrial DNA Mutation Carrier","","MRI/MRS|Biomarkers|Motor skills|Cognitive function|Clinical symptoms|Mutation load","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","4 Years and older   (Child, Adult, Older Adult)","","300","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","AAAB1425|5P01HD032062","July 2004","January 2020","January 2022","February 15, 2012","null","April 9, 2019","Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01532791"
715,"NCT01487434","A Randomized Study to Abate Truancy and Violence in Grades 3-9 in Chicago Public Schools",,"Unknown status","No Results Available","Attendance and Truancy|Student Engagement|Dropout","Behavioral: Check & Connect","Change in attendance and truancy|Criminal activity and involvement|Employment history and workforce involvement|Health and medical system participation|Academic achievement|School engagement","Northwestern University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|U.S. Department of Education|William T. Grant Foundation","All","5 Years to 16 Years   (Child)","Not Applicable","600","Other|NIH|U.S. Fed","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","STU00035771|R01HD067500|R305A100706|180140","September 2011","September 2015","September 2016","December 7, 2011","null","March 24, 2016","Chicago Public Schools, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT01487434"
716,"NCT01376778","A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)","CMV","Active, not recruiting","No Results Available","Congenital Cytomegalovirus Infection|Maternal Cytomegalovirus Infection","Drug: CMV hyperimmune globulin|Other: Placebo","Composite Outcome|Gestational hypertension|Preeclampsia|Placental abruption|Gestational age at delivery|Adverse reactions and side effects|Fetal and neonatal mortality|Primary outcome excluding terminations|Head circumference|Birth weight|Growth restriction|Microcephaly|Symptomatic CMV infection|Intraventricular hemorrhage|Ventriculomegaly|Retinopathy of prematurity (ROP)|Respiratory distress syndrome|Chronic lung disease|Necrotizing enterocolitis (NEC)|Hyperbilirubinemia|Neonatal infectious morbidity|Seizures / encephalopathy|Length of hospital stay|Infant or child death|Sensorineural hearing loss|Chorioretinitis|Cognitive and Motor Scores from the Bayley Certified Scales of Infant Development III|Infant/Child composite outcome","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","HD36801-CMV|U10HD036801|U10HD027869|U10HD027915|U10HD034116|U10HD034208|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U10HD053097|U10HD068282|U10HD068258|U10HD068268","April 2012","December 2018","August 2021","June 20, 2011","null","February 20, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Stanford University, Stanford, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve-Metrohealth, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwestern Medical Center, Dallas, Texas, United States|University of Texas - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01376778"
717,"NCT01341379","Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate",,"Withdrawn","No Results Available","Urea Cycle Disorders, Inborn|Inborn Errors of Metabolism|Propionic Acidemia|Methylmalonic Acidemia|Carbamyl Phosphate Synthetase Deficiency","Drug: N-carbamylglutamate","Rate of ureagenesis","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2","0","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-007806|R01HD058567","December 2010","August 2012","August 2012","April 25, 2011","null","May 29, 2014","","","https://ClinicalTrials.gov/show/NCT01341379"
718,"NCT02527798","Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)",,"Active, not recruiting","No Results Available","Bronchopulmonary Dysplasia","Drug: Furosemide Cohort 1|Drug: Furosemide Cohort 2|Drug: Furosemide Cohort 3|Other: Placebo","Safety as determined by adverse event experienced by participants. Description of safety of furosemide in premature infants at risk of BPD|Change in moderate-severe BPD or death risk from baseline|Clearance|Volume of distribution|Half life|Area under the plasma concentration versus time curve (AUC) of furosemide|Maximum concentration Peak Plasma Concentration (Cmax) of furosemide","University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation","All","up to 28 Days   (Child)","Phase 2","120","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","15-1978|HHSN27500033|HHSN27500035|5R01FD005101-02","August 2015","June 2019","June 2020","August 19, 2015","null","October 8, 2018","Arkansas Children's Hospital/University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Florida Jacskonville Shands Medical Center, Jacksonville, Florida, United States|Wolfson Children's Hospital, Jacksonville, Florida, United States|John's Hopkins Al Children's Hospital, Saint Petersburg, Florida, United States|South Miami Hospital, South Miami, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Kentucky Medical Center, Lexington, Kentucky, United States|Floating Hospital for Children at Tufts Medical Center, Boston, Massachusetts, United States|UMass Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|The University of North Carolina at Chapel Hill/North Carolina Children's Hospital, Chapel Hill, North Carolina, United States|New Hanover Regional Medical Center, Wilmington, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Nationwide Children's Hospital/The Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Virginia Commonwealth University, Richmond, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States","","https://ClinicalTrials.gov/show/NCT02527798"
719,"NCT01288040","Locomotor Training for Neurological Disease",,"Completed","No Results Available","Stroke|Hemiparesis","Behavioral: Split Belt treadmill","Whether different schedules and types of long term training on a custom split belt treadmill are likely to change/improve walking symmetry","Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 80 Years   (Child, Adult, Older Adult)","Phase 1","92","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NA_00010292|1R01HD048741","January 2011","January 2015","January 2015","February 2, 2011","null","April 1, 2015","Motion Analysis Lab in the Kennedy Krieger Institute, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT01288040"
720,"NCT02406768","A Sub-study of PREDICT Neurodevelopment Protocol",,"Completed","No Results Available","Neurocognitive Development","","neurodevelopment changes (composite of cognitive, fine motor and behavioral)","The HIV Netherlands Australia Thailand Research Collaboration|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","1 Year to 15 Years   (Child)","","300","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","HIV-NAT 035.4","October 2010","August 2011","August 2011","April 2, 2015","null","April 2, 2015","National Center for HIV/AIDS, Dermatology and STDs (NCHADS), Phnom Penh, Cambodia|National Pediatric Hospital, Phnom Penh, Cambodia|Pediatric Infectious Diseases Unit Department of Pediatrics Faculty of Medicine Chulalongkorn University, Bangkok, Thailand|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), The Thai Red Cross AIDS Research Center, Bangkok, Thailand|Prapokklao Hospital, Chantaburi, Thailand|Nakornping Hospital, Chiang Mai, Thailand|Chiangrai Regional Hospital, Chiang Rai, Thailand|Queen Savang Vadhana Memorial Hospital, Pediatric Department,, Chonburi, Thailand|Department of Pediatrics Faculty of Medicine Khon Kaen University, Khon Kaen, Thailand|Bamrasnaradura Institute, Nonthaburi, Thailand","","https://ClinicalTrials.gov/show/NCT02406768"
721,"NCT01177969","Cognitive Behavioral Therapy (CBT) for Anxiety Disorders in Autism: Adapting Treatment for Adolescents",,"Completed","Has Results","Anxiety Disorders in Youth With Autism, Asperger's Syndrome, and Pervasive Developmental Disorder Not Otherwise Specified","Behavioral: Cognitive-Behavioral Therapy|Behavioral: Wait-list","Pediatric Anxiety Rating Scale.|Anxiety Disorders Interview Schedule: Child and Parent Versions","University of South Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, Los Angeles|University of Miami","All","11 Years to 14 Years   (Child)","Phase 1|Phase 2","33","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1R34HD065274-01","November 2009","April 2014","April 2014","August 9, 2010","July 1, 2014","July 1, 2014","Univeristy of California at Los Angeles, Los Angeles, California, United States|University of South Florida, St. Petersburg, Florida, United States","","https://ClinicalTrials.gov/show/NCT01177969"
722,"NCT01161238","Amputee Residual Limb Volume Fluctuation",,"Completed","No Results Available","Amputation","Other: Monitored for limb volume","Residual limb fluid volume","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","28","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","30863-E/B|R01HD060585","May 2010","September 2011","September 2011","July 13, 2010","null","April 25, 2014","University of Washington, Bioengineering Department, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT01161238"
723,"NCT01095380","Comparison of Post-pinal Cord Injury (SCI) Locomotor Training Techniques",,"Completed","No Results Available","Spinal Cord Injury","Other: Locomotor training","Walking speed|Functional walking capacity","University of Miami|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","74","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","R01HD041487","November 2003","November 2008","November 2008","March 30, 2010","null","March 30, 2010","","","https://ClinicalTrials.gov/show/NCT01095380"
724,"NCT03851796","Parent Involvement in Adolescent Obesity Treatment","TEENS+","Not yet recruiting","No Results Available","Pediatric Obesity","Behavioral: TEENS+Parents as Coaches|Behavioral: TEENS+Parent Weight Loss","Adolescent weight loss maintenance|Parent weight loss|Physical activity|Dietary intake|Parenting Style|Role Modeling|Child Feeding|Home Environment|Weight control practices","Virginia Commonwealth University|University of North Carolina|University of Tennessee|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 16 Years   (Child)","Not Applicable","420","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HM20014304|R01HD095910-01A1","June 1, 2019","August 31, 2023","August 31, 2023","February 22, 2019","null","March 25, 2019","Children's Hospital of Richmond at VCU Healthy Lifestyles Center, Henrico, Virginia, United States","","https://ClinicalTrials.gov/show/NCT03851796"
725,"NCT00993031","Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women","PROMOTE-PIs","Completed","Has Results","Malaria|HIV Infections","Drug: Lopinavir/ritonavir|Drug: Efavirenz|Drug: Zidovudine|Drug: Lamivudine","Prevalence of Malaria Defined as Positive Placental Blood Smear|Prevalence of Malaria Defined as Positive Placental Blood PCR|Placental Malaria Defined as Positive Placental RDT|Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk During Pregnancy|Prevalence of Composite Clinical Outcome Defined by LBW, Stillbirth(Intrauterine Fetal Demise >20wks GA), Late Spontaneous Abortion(Miscarriage 12-20wks GA), Preterm Delivery(<37wks Gestation), Neonatal Death(Death of Liveborn Infant Within First 28days)|Placental Malaria Defined Placental Histopathologic Analysis|Maternal Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk After Pregnancy","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","389","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","H5741-34342|P01HD059454|2009-141|HS-670|592/ESR/NDA/DID-09/2009|H5741-34342 and 10-02958","December 15, 2009","July 2013","July 2013","October 9, 2009","December 2, 2017","November 16, 2018","Tororo District Hospital, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT00993031"
726,"NCT01978288","Upper Airway Microbial Development During the First Year of Life",,"Recruiting","No Results Available","Asthma","","Change in airway bacteria diversity during first 12 months of life.|Change in inflammatory markers (IL-4, IL-5 and IL-13) during first 12 months of life.|Change in airway function measurements FEV0.5 during 12 months of life.","Indiana University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","All","up to 1 Week   (Child)","","180","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","1308055098|K23AI135094|5K12HD068371","January 2014","December 2019","December 2019","November 7, 2013","null","May 28, 2018","Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, United States","","https://ClinicalTrials.gov/show/NCT01978288"
727,"NCT01941069","School Climate and Children's Behavioral Health","Project Access","Completed","No Results Available","Consultation (LLS)|Consultation and Coaching (HLS)","Behavioral: Friends for Life|Behavioral: Coping Power Program","Level of Support During Implementation|Cost Benefit Analyses","Children's Hospital of Philadelphia|Devereux Foundation, Pennsylvania|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The School District of Philadelphia","All","8 Years to 15 Years   (Child)","Not Applicable","437","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","12-009477|5R01HD073430-02","January 2013","June 30, 2018","December 31, 2018","September 13, 2013","null","February 4, 2019","The School District of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT01941069"
728,"NCT00845897","Botulinum Toxin Effects on Plantar Ulcer Recurrence",,"Completed","Has Results","Diabetes Mellitus|Peripheral Neuropathy|Plantar Ulcers","Drug: Botulinum Toxin|Drug: Saline","Plantar Flexor Muscle Strength|Barefoot Plantar Pressure","Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","17","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04-0493|R21HD048972","March 2005","March 2010","March 2010","February 18, 2009","February 2, 2012","February 3, 2012","Washington University, St. Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT00845897"
729,"NCT00843921","N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia",,"Completed","No Results Available","Inborn Errors of Metabolism","Drug: N-carbamylglutamate","Rate of ureagenesis as determined by 13C enrichment of urea|Plasma ammonia concentration|Plasma amino acid levels|Urine Orotic Acid|Blood Urea Nitrogen (BUN)|Routine safety laboratory tests (CBC, LFTs, Creatinine)","Mendel Tuchman|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Research Institute","All","up to 70 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","52","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CNMC 3694|1R01HD058567-01","August 2008","April 25, 2018","April 25, 2018","February 13, 2009","null","May 3, 2018","Childrens Research Institute, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT00843921"
730,"NCT00810160","The Impact of Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Premature Infants",,"Completed","No Results Available","Fecal Microflora in the Formula Fed Premature Infant","Dietary Supplement: ProlactPlus|Dietary Supplement: GOS galacto-oligosaccharides|Dietary Supplement: Bifidobacterium infantis|Dietary Supplement: Bifidobacterium animalis","To determine the optimum dose and optimum dietary supplement to promote a fecal microflora in the formula fed premature infant that is similar to that of the term breast fed infant (a predominance of bifidobacteria).","University of California, Davis|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Phase 1","59","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","243213|R01HD059127|HD059127-01","June 2009","November 2015","November 2015","December 17, 2008","null","July 13, 2017","UC Davis Medical Center, Sacramento, California, United States","","https://ClinicalTrials.gov/show/NCT00810160"
731,"NCT00790062","Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT",,"Completed","Has Results","Uterine Atony|Postpartum Hemorrhage","Drug: Oxytocin","Number of Subjects Reporting Uterine Atony or Postpartum Hemorrhage Requiring Medical (Medication or Blood Transfusion), Surgical or Other Interventional Treatment|Women in Each Group With Risk Factors for Atony or Postpartum Hemorrhage|Risk to Using Increasing Doses of Oxytocin Based on Pre-specified Risk Factors|Change in Pre- to Post-delivery Hematocrit (%)|Number of Participants Experiencing Individual Treatment or Intervention in the Primary Outcome|Number of Participants Experiencing Postpartum Hemorrhage (Clinical Estimate Greater Than 500cc)|Number of Subjects With Hospital Stays Greater Than 4 Days|Number of Subjects Requiring Hypotension Warranting Pressor Agent or Fluid Bolus","University of Alabama at Birmingham|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 4","1798","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","F070910007|5K12HD001258-09","November 2008","June 2010","June 2010","November 13, 2008","January 30, 2014","April 8, 2016","University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT00790062"
732,"NCT00787709","Translational Obesity Research","Pathways","Completed","No Results Available","Obesity","Behavioral: Pathways","Food Intake|Physical Activity|Body Mass Index|Executive Cognitive Function|Stress|Attitudes toward healthy eating and physical activity","University of Southern California|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","1005","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HS-08-00437|R01HD052107","May 2007","April 2011","February 28, 2014","November 7, 2008","null","March 27, 2017","University of Southern California, Alhambra, California, United States","","https://ClinicalTrials.gov/show/NCT00787709"
733,"NCT01818258","IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children",,"Completed","No Results Available","HIV Positive|Malnourished","Drug: ZDV+3TC+LPV/r","Safety/tolerability of ZDV, 3TC and LPV/r in severely and normal/mildly malnourished children|PK exposure comparison between severely malnourished and normal/mildly malnourished children|Minimum concentration comparison between severely malnourished children with children with normal/mild malnutrition|LPV protein binding comparison between severely malnourished children with children with normal/mild malnutrition","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","6 Months to 36 Months   (Child)","Phase 4","52","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT P1092|U01AI068632","October 26, 2015","April 11, 2017","September 29, 2017","March 26, 2013","null","January 19, 2018","Kilimanjaro Christian Medical Centre (5118), Moshi, Tanzania|Makerere University-Johns Hopkins University (MUJHU) Research Collaboration (30293), Kampala, Uganda|Harare Family Care (31890), Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT01818258"
734,"NCT00734539","Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight",,"Completed","Has Results","Candidiasis","Drug: fluconazole|Drug: placebo","Death or Candidiasis|Neurodevelopmental Impairment|Candidiasis|Stage II or Higher Necrotizing Enterocolitis|Focal Intestinal Perforation|Chronic Lung Disease|Patent Ductus Arterious Requiring Surgical Ligation|Periventricular Leukomalacia|Retinopathy of Prematurity Requiring Laser Surgery|Length of Hospitalization|Positive Bacterial Infection From a Sterile Site|Intraventricular Hemorrhage","Daniel Benjamin|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Thrasher Research Fund|Food and Drug Administration (FDA)|Duke University","All","up to 5 Days   (Child)","Phase 3","362","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Pro00001538|1R01HD057956-01|Pro00017720","November 2008","December 2011","April 2013","August 14, 2008","July 17, 2014","March 1, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Arkansas Childrens Hospital, Little Rock, Arkansas, United States|Children's Hospital of Orange County, Orange, California, United States|University of California-San Diego, San Diego, California, United States|University of Florida, Gainesville, Florida, United States|Baptist Medical Center, Jacksonville, Florida, United States|Shands Jacksonville Medical Center, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Riley Hospital, Indianapolis, Indiana, United States|Memorial Hospital, South Bend, Indiana, United States|Wesley Medical Center, Wichita, Kansas, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Tulane University School of Medicine, New Orleans, Louisiana, United States|Wayne State University, Detroit, Michigan, United States|University of Minnesota, Fairview Medical Center, Minneapolis, Minnesota, United States|University of Nevada School of Medicine, Las Vegas, Nevada, United States|West Jersey Hospital - Voorhees, Voorhees, New Jersey, United States|Brookdale University Medical Center, Brooklyn, New York, United States|Kings County Hospital Center, Brooklyn, New York, United States|SUNY Dowstate Medical Center, Brooklyn, New York, United States|Columbia University Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Pitt County Memorial Hospital, Greenville, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Oregon Health Sciences Center, Portland, Oregon, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|University of Tennessee, Memphis, Tennessee, United States|Parkland Memorial Hospital, Dallas, Texas, United States|Cooks Children's Medical Center, Fort Worth, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|Texas Children's Hospital/Baylor College of Medicine, Houston, Texas, United States|University of Texas - Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00734539"
735,"NCT03260816","Advancing Child Competencies by Extending Supported Services (ACCESS) for Families Program","ACCESS","Recruiting","No Results Available","Developmental Delay|Disruptive Behavior","Behavioral: Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Other: Referrals as Usual (RAU)","Child Behavior Checklist, Ages 1.5-5 (CBCL, 1.5-5)|Body Mass Index (BMI)|Sutter-Eyberg Behavior Inventory, Revised (SESBI-R)|Multidimensional Assessment of Preschool Disruptive Behavior (MAP-DB): Temper Loss Scale|Impossibly Perfect Circle (IPC)|Child Rearing Inventory (CRI)|Parenting Practices Inventory (PPI)|Parent-Child Book Reading|Family Impact Questionnaire (FIQ)|Depression, Anxiety, Stress Scale- 21 (DASS-21)|Bracken School Readiness Assessment-3 (BSRA-3)|Preschool Language Scale-5 (PLS-5)|Clinical Global Impression (CGI-I)|Technology Experience and Attitude Rating Scale (TEARS)|Therapy Attitude Inventory (TAI)|Client Satisfaction Questionnaire-8 (CSQ-8)|Telepresence in Videoconferencing Scale|Barriers to Treatment Participation Scale (BTPS)|Parental Attitudes Toward Psychological Services Inventory (PATPSI): Stigmatization Scale and Help-Seeking Attitudes Scale|Child's Sleep Habits Questionnaire|Dyadic Parent-Child Interaction Coding System-IV (DPICS-4)|Eyberg Child Behavior Inventory (ECBI)","Florida International University|University of Miami|Nicklaus Children's Hospital f/k/a Miami Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","30 Months to 60 Months   (Child)","Not Applicable","124","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IRB-15-0134|R01HD084497","March 16, 2016","March 16, 2021","March 16, 2021","August 24, 2017","null","August 29, 2018","University of Miami, Early Steps North, Miami, Florida, United States|Florida International University, Miami, Florida, United States|Nicklaus Children's Hospital, Early Steps South, Palmetto Bay, Florida, United States","","https://ClinicalTrials.gov/show/NCT03260816"
736,"NCT01670136","Pharmacokinetics of Sildenafil in Premature Infants",,"Completed","No Results Available","Persistent Pulmonary Hypertension of the Newborn","Drug: 1 dose of sildenafil","Area under the plasma concentration versus time curve 0-24 hours for sildenafil|Peak plasma concentration of sildenafil|Clearance of sildenafil|Volume of distribution at steady state|Half life of sildenafil|Number of subjects with adverse events as a measure of safety and tolerability.|Correlation between serum and dried blood spot samples|Evaluate P450 single nucleotide polymorphisms (SNPs)","University of North Carolina, Chapel Hill|Duke University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation","All","up to 364 Days   (Child)","Phase 1","34","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","11-1646|HHSN27500014","February 2013","July 2016","July 2016","August 21, 2012","null","November 2, 2016","University of Alabama at Birmingham, Birmingham, Alabama, United States|Riley Hospital, Indianapolis, Indiana, United States|Kosair Pediatric Research Unit, Louisville, Kentucky, United States|Albany Medical Center, Albany, New York, United States|Kings County Hospital Center/SUNY Downstate Medical Center, Brooklyn, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States","","https://ClinicalTrials.gov/show/NCT01670136"
737,"NCT02948400","Virtual Reality by Mobile Phone: Improving Child Pedestrian Safety",,"Recruiting","No Results Available","Child Pedestrian Safety","Behavioral: pedestrian safety training in pedestrian virtual environment","participants' number of risky crossings in virtual pedestrian environment","University of Alabama at Birmingham|National Institutes of Health (NIH)|Drexel University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","7 Years to 8 Years   (Child)","Not Applicable","498","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD088415-01|R01HD088415","December 2016","November 2020","April 2021","October 28, 2016","null","November 29, 2018","UAB Youth Safety Lab, University of Alabama at Birmingham, Birmingham, Alabama, United States","","https://ClinicalTrials.gov/show/NCT02948400"
738,"NCT00513240","Erythropoetin Neuroprotection for Neonatal Cardiac Surgery",,"Unknown status","Has Results","Congenital Heart Disease|Hypoplastic Left Heart Syndrome|Transposition of the Great Arteries|Aortic Arch Hypoplasia or Interruption","Drug: Erythropoetin|Drug: Normal saline","MRI Severity of Injury Score|Scores on Bayley Scales of Infant Development III at Age 1 Years.|EEG Seizure Burden in the First 72 Postoperative Hours. (Total Minutes of EEG Seizures).|Pharmacokinetics of High Dose Erythropoetin: 7 Erythropoetin Levels in First 24 Hours After First Dose.","Baylor College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The Dana Foundation|Texas Children's Hospital","All","up to 30 Days   (Child)","Phase 1|Phase 2","62","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","R21HD5550101|FDA IND #100011|Baylor GCRC #0942","September 2006","September 2012","January 2017","August 8, 2007","May 19, 2014","January 6, 2017","Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00513240"
739,"NCT02839915","Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder",,"Not yet recruiting","No Results Available","Autism Spectrum Disorder","Drug: Folinic Acid|Other: Placebo","Change in Core-Clinical Evaluation of Language Fundamentals (Core-CELF) Score|Change in Clinician Global Impression for Improvement (CGI-I) Score|Change in Aberrant Behavior Checklist (ABC) Score|Home Situations Questionnaire- Modified for ASD (HSQ-ASD):|Children's Yale-Brown Obsessive-Compulsive Scales-ASD (CYBOCS-ASD)","Emory University|Phoenix Children's Hospital|Harvard University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 12 Years   (Child)","Phase 2","162","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB00089662|R01HD088528","April 2019","January 1, 2022","January 1, 2023","July 21, 2016","null","March 28, 2019","Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Healtcare of Atlanta, Atlanta, Georgia, United States|Harvard University, Lexington, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02839915"
740,"NCT02793999","Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia",,"Recruiting","No Results Available","Hypoxic Ischemic Brain Injury|Neonatal Encephalopathy","Device: Near-Infrared Spectroscopy (NIRS)","Compare metrics such as hemoglobin oxygen saturation and cerebral metabolic rate of oxygen consumption as obtained from novel NIRS technology in neonates at risk for brain injury to normal controls.|Perform NIRS, MRI and Neurodevelopmental testing (using Bayley Scales for Infant Development) between 2-12 months.|Perform Neurodevelopmental testing at 16-24 months using Bayley Scales for Infant Development.","Boston Children’s Hospital|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 2 Years   (Child)","","125","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00012473|R01HD076258-02","May 2015","May 2020","May 2022","June 8, 2016","null","May 30, 2018","Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02793999"
741,"NCT00439374","RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix","SCAN","Terminated","Has Results","Preterm Delivery|Cervical Length","Drug: 17 alpha-hydroxyprogesterone caproate|Other: Placebo Oil","Number of Participants Delivering Before 37 Weeks Gestation|Mean Gestational Age at Delivery|Number of Participants With Preterm Premature Rupture of Membranes|Number of Participants Who Delivered Before 35 Weeks Gestation|Number of Participants Who Delivered Before 32 Weeks Gestation|Number of Participants Who Delivered Before 28 Weeks Gestation|Number of Participants Who Visited the Hospital Due to Preterm Labor|Number of Participants Who Underwent Tocolytic Therapy|Number of Participants Who Underwent Corticosteroid Therapy|Number of Participants Who Had a Cerclage Placement|Number of Participants Experiencing Gestational Hypertension or Preeclampsia|Number of Participants With Gestational Diabetes Mellitus|Number of Participants Experiencing Cholestasis|Number of Participants Who Experienced Placental Abruption|Number of Participants Who Experienced Chorioamnionitis|Number of Participants Who Had Cesarean Delivery|Number of Participants Who Reported Side Effects|Number of Participants Meeting the Composite Adverse Perinatal Outcome and Components|Mean Birth Weight|Birth Weight by Count of Participants|Number of Neonates Who Measured Small for Gestational Age|Number of Participants With Apgar Score of Less Than 7 at 5 Minutes|Number of Neonates With a Major Congenital Anomaly|Number of Neonates With Patent Ductus Arteriosus|Number of Neonates Experiencing Seizures|Number of Neonates Admitted to NICU|Median Length of NICU Stay","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","657","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","HD36801 SCAN|U10HD021410|U10HD027869|U10HD027917|U10HD027860|U10HD027915|U10HD034116|U10HD034208|U10HD034136|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U10HD036801","April 2007","May 2011","December 2011","February 23, 2007","April 11, 2019","April 11, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University-Prentice Hospital, Chicago, Illinois, United States|Dept of OB/GYN, Hutzel Hospital, Detroit, Michigan, United States|Columbia University-St. Luke's Hospital, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Case Western Reserve-Metrohealth, Cleveland, Ohio, United States|Ohio State University Hospital, Columbus, Ohio, United States|Oregon Health & Sciences University, Portland, Oregon, United States|University of Pittsburgh-Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University -Women and Infants Hospital, Providence, Rhode Island, United States|Dept of OB/GYN, Southwestern Medical Center, University of Texas, Dallas, Texas, United States|University of Texas Medical Branch - Galveston, Galveston, Texas, United States|University of Texas-Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00439374"
742,"NCT02611128","Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia","DENND1A","Recruiting","No Results Available","Polycystic Ovary Syndrome|Hyperandrogenism|Puberty","Other: Phenotype/genotype assessment","Urinary exosomal DENND1A.V2|Serum free testosterone|Bone age|BMI z-score|Morning luteinizing hormone|Fasting insulin","University of Virginia|Penn State University|Virginia Commonwealth University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","8 Years to 17 Years   (Child)","","65","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","17633|P50HD028934","August 2014","December 2019","December 2019","November 20, 2015","null","April 16, 2019","Center for Research in Reproduction, Charlottesville, Virginia, United States","","https://ClinicalTrials.gov/show/NCT02611128"
743,"NCT02601339","NIRS Monitoring in Premature Infants",,"Recruiting","No Results Available","Hemorrhage|Premature Infants|Newborn|Hydrocephalus","Procedure: ETV/CPC","CMRO2","Boston Children’s Hospital|Brigham and Women's Hospital|Beth Israel Deaconess Medical Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 12 Months   (Child)","","70","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2014P001713|1K99HD083512-01|P00014042","April 2015","July 2020","July 2022","November 10, 2015","null","April 27, 2018","Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02601339"
744,"NCT02431975","Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial","LEOPARD","Active, not recruiting","No Results Available","HIV","Drug: Nevirapine|Drug: Zidovudine|Drug: Lamivudine|Drug: LPV/r","Percent of patients with initial viral suppression|Percent of patients maintaining viral suppression|Prevalence of CD4 percentage greater than 30|Prevalence of growth along curve within one standard deviation or upward trend|Prevalence of detection of specific HIV antibody classes|Size of the viral reservoir (copies/million cell)","Columbia University|National Institutes of Health (NIH)|University of Witwatersrand, South Africa|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 48 Hours   (Child)","Phase 4","60","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAO5011|U01HD080441","August 2015","July 31, 2020","July 31, 2020","May 1, 2015","null","February 6, 2019","Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa","","https://ClinicalTrials.gov/show/NCT02431975"
745,"NCT01130792","Probiotics for Infectious Diarrhea in Children in South India",,"Completed","No Results Available","Infectious Gastroenteritis","Dietary Supplement: Lactobacillus GG|Dietary Supplement: Inulin","IgG To Rotavirus VP6 Or Cryptosporidial Gp15|lactulose:mannitol test","Christian Medical College, Vellore, India|Indian Council of Medical Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Tufts Medical Center","All","6 Months to 5 Years   (Child)","Phase 1|Phase 2","124","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","MCHPROBIO|R03HD057736|CTRI/2010/091/000339","May 2010","July 2011","July 2011","May 26, 2010","null","February 4, 2015","Christian Medical College, Vellore, Tamil Nadu, India","","https://ClinicalTrials.gov/show/NCT01130792"
746,"NCT02302040","Applying Interactive Mobile Health to Asthma Care in Teens (AIM2ACT)","AIM2ACT","Completed","No Results Available","Asthma","Behavioral: AIM2ACT|Behavioral: Self-guided","Family asthma management system scale (FAMSS) will be measured for changes in baseline, 4 months, and 8 months.|Spirometry will be used to measure a change in lung function at baseline, 4 months, and 8 months.|Asthma control test questionnaire will be used to measure a change in symptoms at baseline, 4 months, and 8 months.|Asthma-related quality of life questionnaires will be given to measure the overall quality of life changes in baseline, 4 months, and 8 months..|Self-efficacy for asthma management questionnaire will be given to measure the overall improvement of the quality of life change in baseline, 4 months, and 8 months.|Family communication during asthma-management tasks will be assessed via the Decision Making Involvement Scale caregiver- and adolescent-reports at baseline and 4 months.","University of Florida|The Miriam Hospital|Rhode Island Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Years to 15 Years   (Child)","Not Applicable","92","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB201400921 - N|1R21HD083830-01A1","December 2015","February 22, 2019","February 22, 2019","November 26, 2014","null","March 14, 2019","University of Florida, Gainesville, Florida, United States|Benton Pediactrics, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02302040"
747,"NCT00224952","Pathogenesis of Adverse Drug Reactions",,"Completed","Has Results","Seizures","Other: No intervention; Urine Collection","Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine|Age-related Changes in Bioactivation","Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Utah|University of Louisville","All","1 Year to 16 Years   (Child)","","274","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PPRU 10606|NIH Grant HD044239","July 2002","March 2010","March 2010","September 23, 2005","August 14, 2017","August 14, 2017","Kosair Children's Hospital, Louisville, Kentucky, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Primary Children's Hospital, Pediatric Neurology, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00224952"
748,"NCT00223314","Safer Choices 2 - HIV, STD, & Pregnancy Prevention Program",,"Completed","No Results Available","HIV|Sexually Transmitted Diseases|Pregnancy|HIV Infections","Behavioral: HIV, STD, Pregnancy Prevention Curriculum","Among those reporting intercourse: # of occasions students had unprotected sexual intercourse and # of sexual partners with whom students had unprotected intercourse; proportion of students initiating sexual intercourse in the past 3 months.|Alcohol use behavior: frequency of drinking alcohol or being drunk before having sexual intercourse in the past three months.|Drug use behavior: frequency of other drug use before having sex in the past three months.|Drug use behavior: frequency of needle-sharing behavior during the past 12 months (one item).|Number of lifetime tests for HIV infection,|Number of lifetime tests for STD infection other than HIV.","The University of Texas Health Science Center, Houston|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","1000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01HD038457-01","November 2000","null","February 2004","September 22, 2005","null","December 21, 2007","University of Texas Houston Health Science Center - School of Public Health, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00223314"
749,"NCT00212576","Promoting Early School Readiness in Primary Health Care",,"Active, not recruiting","No Results Available","Language Development Disorders","Behavioral: Video Interaction Project|Behavioral: Building Blocks Project","Discipline assessed using the Discipline Survey|Stress related to interactions and lack of warmth will be assessed using The Parenting Stress Index - Short Form (PSI)|Bayley Scales of Infant and Toddler Development|Woodcock-Johnson III Tests of Cognitive Abilities","New York University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","35 Weeks and older   (Child, Adult, Older Adult)","Not Applicable","675","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","12582|2R01HD047740-05","November 2005","July 3, 2018","July 3, 2019","September 21, 2005","null","October 17, 2018","New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT00212576"
750,"NCT00194207","Risk Factors of Ectopic Pregnancy",,"Completed","No Results Available","Ectopic Pregnancy","","","University of Pennsylvania|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","3000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","103700|R01HD036455-01A1","October 1999","January 2007","January 2007","September 19, 2005","null","August 17, 2016","University of Pennsylvania Reproductive Research Unit, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00194207"
751,"NCT00166608","Cytokines Polymorphisms and Acetaminophen Toxicity",,"Completed","No Results Available","Drug Toxicity","Procedure: Blood sampling","To investigate the relationships of cytokines and toxicity in acetaminophen overdose, blood sampleswere collected from patients following acute ingestions of acetaminophen.","Arkansas Children's Hospital Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","111","Other|NIH","Observational","Time Perspective: Prospective","PPRU-10369s","December 2002","May 2007","September 2007","September 14, 2005","null","April 12, 2012","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|University of North Carolina--Chapel Hill, Chapel Hill, North Carolina, United States|Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Texas Children's Hospital, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00166608"
752,"NCT00135902","Omega-3 Fatty Acid Supplementation to Prevent Preterm Birth in High Risk Pregnancies",,"Completed","No Results Available","Preterm Birth","Drug: 17 alpha-Hydroxyprogesterone Caproate and Omega-3 fish oils","Delivery less than 37 completed weeks gestation including any miscarriages occurring after randomization|MATERNAL: Delivery less than 35 weeks|Delivery less than 32 weeks|Spontaneous preterm delivery|Indicated preterm delivery|Tocolytic therapy|Time from randomization to delivery|Delivery on or after 41 weeks of gestation|Occurrence of gestational hypertension or preeclampsia|Maternal hospital days|Fatty acid constituents in maternal plasma samples, before and after supplementation|Postpartum hemorrhage|FETAL AND NEONATAL: Fetal and neonatal death|Gestational age at delivery|Small for gestational age|Birth weight|Apgar score at 1 and 5 minutes|Number of days of neonatal respiratory therapy|Admission to NICU and total number of days in hospital|Intraventricular hemorrhage|Retinopathy of prematurity|Necrotizing enterocolitis|Deep infection|Periventricular leukomalacia|Bronchopulmonary dysplasia|Respiratory distress syndrome|Composite neonatal outcome","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HD36801-Omega-3|HD21410|HD27869|HD27917|HD27860|HD27915|HD34116|HD34208|HD34136|HD40500|HD40485|HD40544|HD40545|HD40560|HD40512","February 2005","March 2007","March 2008","August 26, 2005","null","April 10, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwest, Dallas, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00135902"
753,"NCT02162602","Bone Mineral Accretion in Young Children",,"Recruiting","No Results Available","Bone Mineral Density Reference Data","","Bone mineral density|Bone mineral content","Children's Hospital Medical Center, Cincinnati|Children's Hospital of Philadelphia|University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Year to 5 Years   (Child)","","520","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIN-001_Bone Mineral Accretion|R01HD076321","May 2014","December 2018","December 2018","June 13, 2014","null","June 26, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02162602"
754,"NCT00099164","Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS)",,"Completed","No Results Available","Preterm Birth|Pregnancy|Multifetal","Drug: 17 alpha-hydroxyprogesterone caproate (17P)","Delivery prior to 35 weeks 0 days gestation|Maternal randomization to delivery interval of first fetus|pPROM - spontaneous rupture of the membranes at least one hour prior to the start of labor, regular contractions accompanied by cervical change|Indicated preterm delivery|Spontaneous preterm delivery|Cesarean delivery|Gestational age at delivery|Placement of cervical cerclage|Maternal hospital days|Maternal complications such as preeclampsia, gestational diabetes, placental abruption, chorioamnionitis.|Composite neonatal outcome, comprised of fetal or infant death, RDS, IVH (grades 3 and 4), PVL, NEC (stage II and III), BPD/chronic lung disease, ROP (stage III or higher), early onset sepsis including meningitis|Fetal and neonatal death|Stillbirth|Twin-twin transfusion syndrome|Birth weight and degree of birth weight discordance|Infant days in hospital, *Respiratory distress syndrome (RDS)|Transient tachypnea of the newborn (TTN)|Bronchopulmonary dysplasia (BPD)/chronic lung disease|Persistent pulmonary hypertension of the newborn (PPHN)|Duration of ventilator support|Duration of supplemental oxygen|Periventricular leukomalacia (PVL)|Intraventricular hemorrhage (IVH)|Necrotizing enterocolitis (NEC)|Neonatal sepsis/meningitis/urinary tract infection/ pneumonia|Seizures, as documented by the attending physician|Retinopathy of prematurity (ROP)|Small for gestational age (<10th percentile).","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","795","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HD36801-STTARS|HD21410|HD27869|HD27917|HD27860|HD27915|HD34116|HD34208|HD34136|HD40500|HD40485|HD40544|HD40545|HD40560|HD40512|HD36801","April 2004","August 2006","September 2007","December 9, 2004","null","February 21, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Dexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwest, Dallas, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00099164"
755,"NCT00098709","Fetal Pulse Oximetry Trial (FOX)",,"Terminated","No Results Available","Pregnancy","Device: Fetal pulse oximeter","cesarean delivery (any indication)|cesarean delivery for non-reassuring fetal heart rate|cesarean delivery for dystocia|neonatal morbidity","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","10000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HD36801-FOX|U10HD021410|U10HD027869|U10HD027917|U10HD027860|U10HD034116|U10HD034208|U10HD034136|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U10HD036801","May 2002","null","February 2005","December 8, 2004","null","December 28, 2017","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western University, Cleveland, Ohio, United States|Dexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwest, Dallas, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00098709"
756,"NCT00086359","Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV",,"Completed","No Results Available","HIV Infections","Drug: Abacavir sulfate, lamivudine, and zidovudine|Drug: Lamivudine/zidovudine|Drug: Lopinavir/ritonavir","Proportion of women in each treatment group with virologic suppression to less than 400 copies/ml at 34th week of pregnancy (or last viral load prior to delivery, if delivery occurs before 34th week of pregnancy) while continuing on assigned therapy|Primary outcome, evaluating ART naive and ART experienced women|HIV-related health status of women at delivery, determined by CD4 counts and plasma HIV-1 viral load in the two treatment groups and in ART naive and ART experienced women|study treatment adherence and health status by self report|HIV-related health status of women postpartum, determined by CD4 counts and plasma HIV-1 viral load|development of HIV-1 genotypic resistance among women in each treatment group|incidence of abnormal glucose tolerance, gestational diabetes, and abnormal lactate levels during pregnancy in each treatment group|incidence of anemia, hypoglycemia, abnormal liver function studies, prematurity, low birth weight, or perinatal HIV transmission among infants born to women in each treatment group|predictive value, sensitivity, and specificity of polymorphisms in HLA-B57, HLA-DR7, and HLA-DQ3 in identifying pregnant women at risk for development of ABC hypersensitivity|concentration of T cell receptor rearrangement excision DNA circles","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 3","19","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P1039|10046|PACTG P1039","July 2004","null","September 2007","July 1, 2004","null","December 23, 2014","Usc La Nichd Crs, Los Angeles, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Bronx-Lebanon CRS, Bronx, New York, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00086359"
757,"NCT00084045","Voluntary HIV Counseling, Testing, and Medication for Pregnant Women to Prevent Mother-to-Child HIV Transmission",,"Completed","No Results Available","HIV Infections","Procedure: Intrapartum HIV counseling/testing|Procedure: Postpartum HIV counseling/testing","Time required to obtain informed consent|time from initiation of HIV pre-test counseling until test results are available|proportion of test evaluations completed before delivery|proportion of test evaluations completed before hospital discharge|proportion of women who agree to HIV testing|proportion of women identified as HIV infected during labor who accept ARV prophylaxis|proportion of women identified as HIV infected after birth who accept ARV therapy for their infants|timing of infant ARV prophylaxis initiation after birth, as a proportion of infants born to women identified as HIV infected after birth and as a continuous variable|timing of mother ARV initiation as a proportion of women identified as HIV infected during labor and as a continuous variable|qualitative measures (defined as available space, study staff allocation, support for counseling and testing, and women's perceptions and opinions of counseling and testing)|Proportion of women with undocumented HIV infection who are tested and determined to be HIV infected peripartum|performance of rapid HIV tests as measured by sensitivity and specificity|proportion of infants who complete the Week 6 study visit and efforts needed to accomplish this visit|proportion of infants being fed according to the method chosen at discharge (defined as exclusive breastfeeding, exclusive formula feeding, or mixed feeding), as reported by the mother at Week 6|proportion of HIV-exposed infants who acquire HIV infection during delivery and after birth|acceptance of HIV counseling and testing among clinical personnel at primary, secondary, and tertiary care facilities","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","283","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PACTG P1031A|MIRIAD","November 2004","null","December 2006","June 7, 2004","null","October 30, 2012","Hottentots Holland Hospital, Cape Town, South Africa|Maccassar Community Health Clinic, Cape Town, South Africa","","https://ClinicalTrials.gov/show/NCT00084045"
758,"NCT01640561","Enhancing Ugandan HIV-Affected Child Development With Caregiver Training","MISC","Completed","No Results Available","HIV","Behavioral: MISC|Behavioral: UCOBAC","Change in Child Neurodevelopment post treatment|Change in caregiver mental health and well being|Midterm change in child neurodevelopment|Change in long term child neurodevelopment outcomes|Change in child physical health and well-being","Johns Hopkins Bloomberg School of Public Health|Michigan State University|Global Health Uganda|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","1 Year to 5 Years   (Child)","Not Applicable","341","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","JHU-MSU-UGANDA-2012|R01HD070723-01","January 2012","December 2015","March 2016","July 13, 2012","null","October 15, 2018","Global Health Uganda, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT01640561"
759,"NCT00042289","Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy",,"Recruiting","No Results Available","HIV Infections","Drug: atazanavir/cobicistat|Drug: darunavir/ritonavir|Drug: darunavir/cobicistat|Drug: etravirine|Drug: elvitegravir/cobicistat|Drug: dolutegravir|Drug: tenofovir alafenamide fumarate (TAF)|Drug: TAF/cobicistat|Drug: TAF/ritonavir|Drug: efavirenz|Drug: lopinavir/ritonavir|Drug: nevirapine|Drug: rifampicin|Drug: ethambutol|Drug: isoniazid|Drug: pyrazinamide|Drug: kanamycin|Drug: amikacin|Drug: capreomycin|Drug: moxifloxacin|Drug: levofloxacin|Drug: ofloxacin|Drug: ethionamide/prothionamide|Drug: terizidone/cycloserine|Drug: para-aminosalicylic acid (PAS)|Drug: high dose isoniazid (INH)|Drug: bedaquiline|Drug: clofazamine|Drug: delamanid|Drug: linezolid|Drug: pretomanid|Drug: atazanavir/ritonavir/tenofovir|Drug: ethinyl estradiol oral contraceptive|Drug: etonogestrel implant","Drug parameter: Area under the curve from 0 to 12 hours (AUC 0-12)|Drug parameter: Area under the curve from 0 to 24 hours (AUC 0-24)|Drug parameter: Maximum concentration (Cmax)|Drug parameter: Pre-dose concentration (Cdose)|Drug parameter: Minimum concentration (Cmin)|Drug parameter: Time after administration of drug when maximum plasma concentration is reached (Tmax)|Drug parameter: Clearance over systemic availability (Cl/F)|Drug parameter: Volume of distribution over systemic availability (V/F)|Drug parameter: Half-life (t1/2)|ARV concentrations in vaginal secretions|ARV concentrations in plasma|For contraceptives: plasma concentration|Ratio of cord blood concentration to maternal blood concentration|Ratio of unbound/total drug concentrations|Rate of detection of study drugs in vaginal secretions|Ratio of vaginal drug concentrations to simultaneous blood concentrations|Rate of detection of HIV RNA/DNA in vaginal secretions and comparison to level in blood|ARV exposure (as measured by area under the curve or other PK parameters) during pregnancy and postpartum according to genotype|Adverse events of grade 3 or higher|Infant neurological events of grade 1 or higher|Adverse pregnancy outcome: preterm birth|Adverse pregnancy outcome: low birth weight|Adverse pregnancy outcome: fetal demise|Adverse pregnancy outcome: congenital anomalies|Infant HIV infection status","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 4","1786","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1026s|10040|IMPAACT P1026s|IMPAACT P1025","March 2003","June 30, 2019","September 30, 2019","August 1, 2002","null","December 18, 2018","UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|UAB, Dept. of Ped., Div. of Infectious Diseases, Birmingham, Alabama, United States|Univ. of South Alabama College of Medicine, Southeast Ped. ACTU, Mobile, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Long Beach Memorial Med. Ctr., Miller Children's Hosp., Long Beach, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS, Los Angeles, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Univ. of Connecticut Health Ctr., Dept. of Ped., Farmington, Connecticut, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Children's National Med. Ctr. Washington DC NICHD CRS, Washington, District of Columbia, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Columbus Regional HealthCare System, The Med. Ctr., Columbus, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Cook County Hosp., Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|Brigham and Women's Hosp., Div. of Infectious Disease, Boston, Massachusetts, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Washington Univ. School of Medicine at St. Louis, St. Louis Children's Hosp., Saint Louis, Missouri, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon CRS, Bronx, New York, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr., Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Hahnemann Univ. Hosp., Philadelphia, Pennsylvania, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|The Children's Hosp. of Philadelphia IMPAACT CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Vanderbilt Univ. Med. Ctr., Div. of Ped. Infectious Diseases, Nashville, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|UW Medicine - Harborview Med. Ctr., Northwest Family Ctr., Seattle, Washington, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|Univ. of Washington NICHD CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Fam-Cru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Siriraj Hospital Mahidol University CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Institut de Recherche pour Developpement (IRD) - PHPT CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chiang Mai University Pediatrics-Obstetrics CRS, Chiang Mai, Thailand|Chiangrai Prachanukroh Hospital CRS, Chiangrai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda","","https://ClinicalTrials.gov/show/NCT00042289"
760,"NCT00059514","Tobacco Use Among Arab American Youth",,"Completed","No Results Available","Tobacco Use Disorder","Behavioral: Modified Project Toward No Tobacco Use","","Wayne State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 18 Years   (Child, Adult)","","2300","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","5R01HD37498-3","May 2000","April 2005","May 2006","April 29, 2003","null","April 5, 2017","Arab American Center for Economic & Social Services, Dearborn, Michigan, United States","","https://ClinicalTrials.gov/show/NCT00059514"
761,"NCT00327860","Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)","CKiD","Recruiting","No Results Available","Chronic Kidney Disease","","Time to Renal Replacement Therapy|Decline of Glomerular filtration rate (GFR)","Johns Hopkins Bloomberg School of Public Health|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)","All","6 Months to 16 Years   (Child)","","1081","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK66116|U01DK066143|U01DK066174|U01DK066116|U01DK082194","October 2003","July 2023","July 2023","May 19, 2006","null","August 9, 2018","Children's Mercy Kansas City, Kansas City, Missouri, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00327860"
762,"NCT00017797","Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women",,"Completed","No Results Available","HIV Infections|Pregnancy","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","","160","NIH","Observational","Observational Model: Case Control|Observational Model: Natural History","ACTG A5084|AACTG A5084","null","null","null","August 31, 2001","null","August 7, 2006","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|The Med Ctr Inc, Columbus, Georgia, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|The CORE Ctr, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, United States|Wishard Hosp, Indianapolis, Indiana, United States|Univ of Marlyand (Pediatric), Baltimore, Maryland, United States|Brigham and Womens Hosp, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Hutzel Hospital, Detroit, Michigan, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Hennepin County Med Ctr, Minneapolis, Minnesota, United States|Univ of Minnesota, Minneapolis, Minnesota, United States|Washington Univ (St.Louis), St.Louis, Missouri, United States|St Peter's Med Ctr, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Jacobi Med Ctr, Bronx, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Univ of Washington, Seattle, Washington, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00017797"
763,"NCT00017719","Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Lamivudine|Drug: Lamivudine/Zidovudine|Drug: Nelfinavir mesylate|Drug: Nevirapine|Drug: Zidovudine","Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery)|proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 500 copies/ml at 48 weeks postpartum|Proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 50 copies/ml at 34 weeks gestation (or the last viral load determination prior to delivery)|proportion of women in each treatment group who continue on original therapy with virologic suppression to less than 50 copies/ml at 48 weeks postpartum, and to less than 500 and 50 copies/ml at 104 weeks postpartum|study treatment adherence and health status by self-report, correlated with predose nelfinavir or nevirapine level at 34 weeks gestation and 8 weeks postpartum|difference between postpartum and pregnancy 12-hour area under the concentration curve (AUC) for nevirapine|time of trough levels in relation to the morning dose of nevirapine and nelfinavir at 34 weeks gestation and 8 weeks postpartum and correlation of trough levels with viral load|incidence of HIV viral resistance by genotype among women in each treatment group at the time of virologic failure|incidence of abnormal glucose tolerance, gestational diabetes, and abnormal lactate levels during pregnancy in each treatment group|incidence of impaired glucose tolerance, diabetes, hyperinsulinemia, and elevated cholesterol and triglycerides at 8 weeks postpartum in each treatment group|incidence of anemia, hypoglycemia, and abnormal liver function studies among infants born to women in each treatment group|incidence of prematurity (less than 37 weeks), extreme prematurity (less than 32 weeks), low birth weight (less than 2.5 kg), and very low birth weight (less than 1.5 kg) among infants born to women in each treatment group|perinatal HIV transmission among infants born to women in each treatment group","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years and older   (Child, Adult, Older Adult)","Phase 3","440","NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1022|10192|ACTG P1022|PACTG P1022","May 2002","null","March 2006","August 31, 2001","null","November 26, 2013","Usc La Nichd Crs, Los Angeles, California, United States|UCSD Mother-Child-Adolescent Program CRS, San Diego, California, United States|UCSF Pediatric AIDS CRS, San Francisco, California, United States|Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases, Torrance, California, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Howard Univ. Washington DC NICHD CRS, Washington, District of Columbia, United States|Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Columbus Regional HealthCare System, The Med. Ctr., Columbus, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease, Chicago, Illinois, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|BMC, Div. of Ped Infectious Diseases, Boston, Massachusetts, United States|Brigham and Women's Hosp., Div. of Infectious Disease, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Univ. of Mississippi Med. Ctr Children's Hosp., Jackson, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hosp. IMPAACT CRS, Bronx, New York, United States|Montefiore Med. Ctr. - AECOM, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|Strong Memorial Hospital Rochester NY NICHD CRS, Rochester, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|SUNY Upstate Med. Univ., Dept. of Peds., Syracuse, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|Case CRS, Cleveland, Ohio, United States|MetroHealth CRS, Cleveland, Ohio, United States|Oregon Health & Science Univ. - Dept. of Peds., Div. of Infectious Disease, Portland, Oregon, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States|Vanderbilt Univ. Med. Ctr., Div. of Ped. Infectious Diseases, Nashville, Tennessee, United States|Texas Children's Hosp. CRS, Houston, Texas, United States|Univ. of Washington NICHD CRS, Seattle, Washington, United States|UW Medicine - Harborview Med. Ctr., Northwest Family Ctr., Seattle, Washington, United States|UW School of Medicine - CHRMC, Seattle, Washington, United States|Seattle Children's Hospital CRS, Seattle, Washington, United States|Princess Margaret Hosp. Bahamas NICHD CRS, Nassau, Bahamas|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hosp. dos Servidores do Estado CRS, Rio de Janeiro, Brazil|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00017719"
764,"NCT00016601","Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women",,"Completed","No Results Available","HIV Infections","Drug: Indinavir sulfate|Drug: Ritonavir|Drug: Nelfinavir mesylate|Drug: Efavirenz|Drug: Nevirapine|Drug: Medroxyprogesterone acetate","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Not Applicable","76","NIH","Interventional","Primary Purpose: Treatment","A5093|ACTG A5093","June 2001","null","May 2004","August 31, 2001","null","November 2, 2012","Univ of Alabama at Birmingham, Birmingham, Alabama, United States|Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Childrens Memorial Hosp (Pediatric), Chicago, Illinois, United States|The Univ of Chicago Childrens Hosp, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, United States|Wishard Hosp, Indianapolis, Indiana, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Boston Med Ctr (Pediatric), Boston, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Beth Israel Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Community Health Network, Inc, Rochester, New York, United States|St Mary's Hosp (Univ of Rochester/Infectious Diseases), Rochester, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pennsylvania, Philadelphia, Pennsylvania, United States|Univ of Texas Galveston, Galveston, Texas, United States|Univ of Washington, Seattle, Washington, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00016601"
765,"NCT00006444","The Effects of Combination Anti-HIV Medication on Human Papillomavirus (HPV) in HIV-Infected Women",,"Completed","No Results Available","HIV Infections|Papilloma","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","","160","NIH","Observational","","A5029|AACTG A5029|ACTG A5029","November 2000","null","August 2005","August 31, 2001","null","November 20, 2013","Univ of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of California, San Diego, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|San Mateo County AIDS Program, Stanford, California, United States|Stanford Univ, Stanford, California, United States|Willow Clinic, Stanford, California, United States|Univ of Colorado Health Sciences Ctr, Denver, Denver, Colorado, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Emory Univ, Atlanta, Georgia, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Northwestern Univ Med School, Chicago, Illinois, United States|The CORE Ctr, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, United States|Wishard Hosp, Indianapolis, Indiana, United States|Univ of Maryland (Pediatric), Baltimore, Maryland, United States|Univ of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Boston Med Ctr (Harvard), Boston, Massachusetts, United States|Boston Med Ctr (Pediatric), Boston, Massachusetts, United States|Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|Beth Israel Med Ctr, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Community Health Network, Rochester, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pittsburgh, Pittsburgh, Pennsylvania, United States|Brown Univ / Miriam Hosp, Providence, Rhode Island, United States|Brown Univ / The Miriam Hosp, Providence, Rhode Island, United States|Miriam Hosp / Brown Univ, Providence, Rhode Island, United States|Julio Arroyo, West Columbia, South Carolina, United States|University of Washington (Seattle), Seattle, Washington, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00006444"
766,"NCT00000944","A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Indinavir sulfate|Drug: Lamivudine|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Prevention","ACTG 358|PACTG 358|10606","null","null","March 2003","August 31, 2001","null","May 2, 2012","UCSF Pediatric AIDS CRS, San Francisco, California, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|Jacobi Med. Ctr., Bronx, New York, United States|Montefiore Med. Ctr. - AECOM, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT00000944"
767,"NCT00000920","Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Ritonavir|Drug: Saquinavir|Drug: Lamivudine|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","ACTG 386|11345|PACTG 386","null","null","April 2003","August 31, 2001","null","May 21, 2012","Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Univ Hosp, New Orleans, Louisiana, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000920"
768,"NCT00000910","A Study to Collect Information About HIV-Positive Pregnant Women and Their Babies",,"Completed","No Results Available","HIV Infections|Pregnancy","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","2000","NIH","Observational","Time Perspective: Prospective","ACTG 367|PACTG 367|11330","null","null","June 2004","August 31, 2001","null","October 7, 2013","Brigham and Women's Hosp., Div. of Infectious Disease, Boston, Massachusetts, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT00000910"
769,"NCT00000888","Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Ritonavir|Drug: Lamivudine|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","14","NIH","Interventional","Primary Purpose: Treatment","ACTG 354|10604|PACTG 354","null","null","April 2001","August 31, 2001","null","May 18, 2012","Univ. of Miami Miller School of Medicine - Jackson Memorial Hosp., Miami, Florida, United States|Univ. of Miami Ped. Perinatal HIV/AIDS CRS, Miami, Florida, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|St. Jude/UTHSC CRS, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00000888"
770,"NCT00000887","A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Nelfinavir mesylate|Drug: Lamivudine|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 1","24","NIH","Interventional","Primary Purpose: Treatment","ACTG 353|10603|PACTG 353","null","null","July 2004","August 31, 2001","null","May 22, 2012","Usc La Nichd Crs, Los Angeles, California, United States|Tulane Univ. Health Science Ctr., Tulane Univ. Hosp. & Clinic, New Orleans, Louisiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases, Baltimore, Maryland, United States|HMS - Children's Hosp. Boston, Div. of Infectious Diseases, Boston, Massachusetts, United States|UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases, Chapel Hill, North Carolina, United States|St. Christopher's Hosp. for Children, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00000887"
771,"NCT00000878","A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Lamivudine|Drug: Stavudine|Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","13 Years and older   (Child, Adult, Older Adult)","Phase 1","26","NIH","Interventional","Primary Purpose: Treatment","ACTG 332|11304|PACTG 332","null","null","October 2001","August 31, 2001","null","May 18, 2012","Los Angeles County - USC Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Howard Univ Hosp, Washington, District of Columbia, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Temple Univ School of Medicine, Philadelphia, Pennsylvania, United States|Regional Med Ctr at Memphis, Memphis, Tennessee, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000878"
772,"NCT00000862","A Study of Zidovudine During Labor and Delivery in HIV-Infected Pregnant Women",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Zidovudine","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 1","36","NIH","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 324|11298|PACTG 324","null","null","November 2003","August 31, 2001","null","May 18, 2012","UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Univ of California, San Francisco, San Francisco, California, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami / Jackson Memorial Hosp, Miami, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000862"
773,"NCT00015002","Repeat Antenatal Steroids Trial","BEARS","Terminated","No Results Available","Complications, Pregnancy","Drug: Betamethasone","Composite outcome: including neonatal mortality/stillbirth, severe RDS, chronic lung disease, grade III/IV IVH, PVL|Neonatal morbidity|Maternal morbidity|Neonatal Growth parameters|Infant neurological parameters","The George Washington University Biostatistics Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","486","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NICHD-0801|HD21410|HD27869|HD27917|HD27860|HD27915|HD34116|HD34208|HD34136|HD40500|HD40485|HD40544|HD40545|HD40560|HD40512|HD36801","March 2000","May 2006","March 2007","April 18, 2001","null","October 3, 2016","University of Alabama, Birmingham, Alabama, United States|University of Miami, Miami, Florida, United States|Northwestern University-Prentice Hospital, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Dept of OB/GYN, Hutzel Hospital, Detroit, Michigan, United States|Columbia University, New York City, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Forsyth Memorial Hospital, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve-Metrohealth, Cleveland, Ohio, United States|Dept of OB/GYN, Ohio State University, Columbus, Ohio, United States|MCP Hahnamann, Philadelphia, Pennsylvania, United States|Dept of OB/GYN, Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University -Women and Infants Hospital, Providence, Rhode Island, United States|University of Tennessee, Memphis, Tennessee, United States|Dept of OB/GYN, Southwestern Medical Center, University of Texas, Dallas, Texas, United States|University of Texas-Houston, Houston, Texas, United States|University of Texas - San Antonio, San Antonio, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00015002"
774,"NCT01156103","Reducing Pediatric Obesity Through After-school Programs",,"Completed","No Results Available","Obesity","Behavioral: America SCORES, Bay Area","Change in BMI z-score|Change in Aerobic capacity","University of California, San Francisco|San Francisco Unified School District|America SCORES, Bay Area|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 12 Years   (Child)","Not Applicable","158","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H48814-32411-0|1K23HD054470-01A1","August 2009","May 2010","December 2010","July 2, 2010","null","May 8, 2015","","","https://ClinicalTrials.gov/show/NCT01156103"
775,"NCT00849888","Serum-Free Thymus Transplantation in DiGeorge Anomaly","SerumFree","Terminated","No Results Available","DiGeorge Anomaly","Biological: Serum Free Thymus Transplantation with Immunosuppression|Other: Serum Free Thymus Transplantation without immunosuppression","Survival|Incidence of graft-versus-host-disease (GVHD).|Thymopoiesis or graft rejection on biopsy.|Incidence of autoimmune disease.|Immune outcomes: T cell development; evaluate T cell numbers, diversity, and function.","M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","up to 2 Years   (Child)","Phase 1","2","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00006109|1R01FD003528-01|2R01AI047040-11A2|5K12HD043494-09|R01AI047040|R01AI054843|R56 Bridge R01AI4704011A1","April 2008","February 2011","February 2011","February 24, 2009","null","October 29, 2014","","","https://ClinicalTrials.gov/show/NCT00849888"
776,"NCT00715988","Methadone Pharmacokinetics and Cardiac Effects in Newborns",,"Completed","No Results Available","Pain","Drug: Methadone HCl Inject 10 mg/ml (will require dilution)|Drug: Methadone","Find the population kinetics for methadone and its enantiomers in preterm newborns and infants at 29 weeks to 48 wks PMA who are 1 week old and older|Measure the effects of R and S enantiomers of methadone on QT interval in newborns","University of Utah|Case Western Reserve University|Children's Mercy Hospital Kansas City|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","29 Weeks to 48 Weeks   (Child)","Phase 1","7","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","24569|1U10HD045986-01","October 2007","September 2012","February 10, 2017","July 15, 2008","null","April 11, 2017","University of Utah, Salt Lake City, Utah, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00715988"
777,"NCT00679003","Managing Inflammatory Bowel Disease","Managing IBD","Completed","No Results Available","Inflammatory Bowel Disease|Crohn's Disease|Ulcerative Colitis","Behavioral: SLCBT|Behavioral: ES","Functional Disability Inventory|School absences|Health care utilization for IBD|Pediatric Quality of Life","University of Washington|National Institutes of Health (NIH)|Seattle Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years to 17 Years   (Child)","Not Applicable","190","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CHRMC12395|1R01HD050345-01A2","September 2007","March 2014","March 2014","May 16, 2008","null","April 15, 2015","","","https://ClinicalTrials.gov/show/NCT00679003"
778,"NCT00277433","Histamine Pharmacogenetics in Children With Atopic Dermatitis",,"Completed","No Results Available","Dermatitis, Atopic","Other: Buccal Swab","","Virginia Commonwealth University|ACCP|PPRU|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months to 5 Years   (Child)","","751","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","PPRU 10744|1U10HD045934-01","June 2004","December 2009","December 2009","January 16, 2006","null","March 20, 2017","Arkansas Children's Hospital, Little Rock, Arkansas, United States|University of California at San Diego, San Diego, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States|Wayne State University/Children's Hospital of Michigan, Detroit, Michigan, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Baylor College of Medicine/Texas Children's Cancer Center, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00277433"
779,"NCT00100542","Psychiatric Problems in Children and Adolescents Infected With HIV at Birth",,"Completed","No Results Available","HIV Infections|Mental Disorders","Behavioral: Psychiatric interviews","","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Years to 17 Years   (Child)","","800","Other|NIH","Observational","Observational Model: Case Control|Time Perspective: Prospective","PACTG P1055|U01AI068632","April 2005","September 2006","September 2006","January 4, 2005","null","January 21, 2011","Long Beach Memorial (Pediatric), Long Beach, California, United States|Los Angeles County Medical Center/USC, Los Angeles, California, United States|UCLA Medical Center (Pediatric), Los Angeles, California, United States|4601 UCSD Mother, Child & Adolescent HIV Program, San Diego, California, United States|UCSF, Moffitt Hospital (Pediatric), San Francisco, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|Childrens Hospital (U. Colorado, Denver), Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Howard University Hospital, Washington, District of Columbia, United States|North Broward Hospital District, Fort Lauderdale, Florida, United States|University of Florida - Health Science Center, Jacksonville, Florida, United States|University of Miami (Pediatric), Miami, Florida, United States|University of South Florida, St Petersburg, Florida, United States|Chicago Childrens Memorial Hospital (Pediatric), Chicago, Illinois, United States|University of Maryland (Pediatric), Baltimore, Maryland, United States|Childrens Hospital of Boston, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Bronx Lebanon Hospital Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|New York University School of Medicine, New York, New York, United States|Metropolitan Hospital Center, New York, New York, United States|Mt. Sinai Medical Center, New York, New York, United States|State University of New York at Stony Brook, Stony Brook, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University (Pediatric), Durham, North Carolina, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Christophers Hosp. for Children, Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Childrens Research Hospital, Memphis, Memphis, Tennessee, United States|Children's Hospital and Regional Medical Center/Seattle, Seattle, Washington, United States|Northwest Family Ctr./Harborview Medical Center, Seattle, Washington, United States|University of Washington Medical Ctr., Seattle, Washington, United States|San Juan City Hospital, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00100542"
780,"NCT00000811","A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children",,"Completed","No Results Available","Bacterial Infections|Pneumonia, Pneumocystis Carinii|HIV Infections","Drug: Azithromycin|Drug: Atovaquone|Drug: Sulfamethoxazole-Trimethoprim","","National Institute of Allergy and Infectious Diseases (NIAID)|Pfizer|Glaxo Wellcome|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Months to 18 Months   (Child)","Phase 2","690","NIH|Industry","Interventional","Intervention Model: Parallel Assignment|Primary Purpose: Treatment","ACTG 254|PACTG 254|11231","null","null","November 2001","August 31, 2001","null","April 4, 2012","Univ of Alabama at Birmingham - Pediatric, Birmingham, Alabama, United States|Univ of South Alabama, Mobile, Alabama, United States|UCSD Med Ctr / Pediatrics / Clinical Sciences, La Jolla, California, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Children's Hosp of Los Angeles/UCLA Med Ctr, Los Angeles, California, United States|Los Angeles County - USC Med Ctr, Los Angeles, California, United States|Cedars Sinai / UCLA Med Ctr, Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|Harbor - UCLA Med Ctr / UCLA School of Medicine, Los Angeles, California, United States|Children's Hosp of Oakland, Oakland, California, United States|UCSF / Moffitt Hosp - Pediatric, San Francisco, California, United States|Children's Hosp of Denver, Denver, Colorado, United States|Connecticut Children's Med Ctr, Farmington, Connecticut, United States|Univ of Connecticut / Farmington, Farmington, Connecticut, United States|Yale Univ Med School, New Haven, Connecticut, United States|Howard Univ Hosp, Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|Univ of Florida Gainesville, Gainesville, Florida, United States|Univ of Florida Health Science Ctr / Pediatrics, Jacksonville, Florida, United States|Univ of Miami (Pediatric), Miami, Florida, United States|Palm Beach County Health Dept, Riviera Beach, Florida, United States|Emory Univ Hosp / Pediatrics, Atlanta, Georgia, United States|Med College of Georgia, Augusta, Georgia, United States|Cook County Hosp, Chicago, Illinois, United States|Univ of Illinois College of Medicine / Pediatrics, Chicago, Illinois, United States|Chicago Children's Memorial Hosp, Chicago, Illinois, United States|Univ of Chicago Children's Hosp, Chicago, Illinois, United States|Tulane Univ / Charity Hosp of New Orleans, New Orleans, Louisiana, United States|Earl K Long Early Intervention Clinic, New Orleans, Louisiana, United States|Univ of Maryland at Baltimore / Univ Med Ctr, Baltimore, Maryland, United States|Johns Hopkins Hosp - Pediatric, Baltimore, Maryland, United States|Children's Hosp of Boston, Boston, Massachusetts, United States|Boston City Hosp / Pediatrics, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Children's Hosp of Michigan, Detroit, Michigan, United States|Univ of Mississippi Med Ctr, Jackson, Mississippi, United States|Cooper Hosp - Univ Med Ctr / UMDNJ - New Jersey Med Schl, Camden, New Jersey, United States|UMDNJ - Robert Wood Johnson Med School / Pediatrics, New Brunswick, New Jersey, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp, Newark, New Jersey, United States|Saint Joseph's Hosp and Med Ctr/UMDNJ - New Jersey Med Schl, Newark, New Jersey, United States|Children's Hosp at Albany Med Ctr, Albany, New York, United States|Bronx Lebanon Hosp Ctr, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|SUNY - Brooklyn, Brooklyn, New York, United States|Children's Hosp Pact Prog / Children's Hosp of Buffalo, Buffalo, New York, United States|North Shore Univ Hosp, Great Neck, New York, United States|Schneider Children's Hosp, New Hyde Park, New York, United States|Beth Israel Med Ctr / Pediatrics, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Cornell Univ Med College, New York, New York, United States|Metropolitan Hosp Ctr, New York, New York, United States|Mount Sinai Med Ctr / Pediatrics, New York, New York, United States|Columbia Presbyterian Med Ctr, New York, New York, United States|Incarnation Children's Ctr / Columbia Presbyterian Med Ctr, New York, New York, United States|Harlem Hosp Ctr, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|State Univ of New York at Stony Brook, Stony Brook, New York, United States|SUNY Health Sciences Ctr at Syracuse / Pediatrics, Syracuse, New York, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Columbus Children's Hosp, Columbus, Ohio, United States|Children's Hosp of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Christopher's Hosp for Children, Philadelphia, Pennsylvania, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Saint Jude Children's Research Hosp of Memphis, Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Hermann Hosp / Univ Texas Health Science Ctr, Houston, Texas, United States|Texas Children's Hosp / Baylor Univ, Houston, Texas, United States|Children's Hosp of the King's Daughters, Norfolk, Virginia, United States|Med College of Virginia, Richmond, Virginia, United States|Children's Hospital & Medical Center / Seattle ACTU, Seattle, Washington, United States|Ramon Ruiz Arnau Univ Hosp / Pediatrics, Bayamon, Puerto Rico|Univ of Puerto Rico / Univ Children's Hosp AIDS, San Juan, Puerto Rico|San Juan City Hosp, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00000811"
781,"NCT03660514","Jovenes Sanos: Preventing IPV and RC",,"Recruiting","No Results Available","Unintended Pregnancy|Family Planning|Intimate Partner Violence (IPV)","Behavioral: Jovenes Sanos","Recent RC|Intimate Partner Violence (IPV)|Contraception discontinuation|Contraception self-efficacy|Contraception delivery|Biased and coercive FP provider practices|Knowledge of IPV services|Utilization of IPV services among those reporting IPV","University of California, San Diego|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Comision de Salud Fronteriza Mexico - Estados Unidos|Secretaria de Salud de Baja California","Female","16 Years to 20 Years   (Child, Adult)","Not Applicable","80","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","161741|K23HD084756-01A1","September 15, 2018","April 15, 2019","June 15, 2019","September 6, 2018","null","February 19, 2019","Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, United States|Centro de Salud Fransisco Villa, Tijuana, Baja California, Mexico","","https://ClinicalTrials.gov/show/NCT03660514"
782,"NCT03455881","Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients","TED","Recruiting","No Results Available","Tracheoesophageal Fistula|Esophageal Atresia|Laryngeal Cleft|Tracheal Stenosis|Bronchial Stenosis|Esophageal Bronchus|Congenital High Airway Obstruction Syndrome","","Genomic Sequencing|Anatomic phenotypes using MRI|Change in the anatomic phenotype using MRI","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Columbia University","All","Child, Adult, Older Adult","","260","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIN_PhenoandGeneticTED_001|1P01HD093363-01","March 28, 2018","January 2023","January 2024","March 7, 2018","null","March 21, 2019","Cincinnati Children's Hospital, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT03455881"
783,"NCT03334942","Addressing Traumatic Stress Symptoms in Children",,"Recruiting","No Results Available","Violence, Non-accidental|Posttraumatic Stress Disorder|Parent-Child Relations|Assault|Youth","Behavioral: Child and Family Traumatic Stress Intervention","Change in Child PTSD Symptom Scale (CPSS-5) score from baseline to 4 months post-ED visit.|Change in Revised Children's Anxiety and Depression Scale (RCADS) short form score from baseline to 4 months post-ED visit|Change in Revised Children's Anxiety and Depression Scale (RCADS) short form score from baseline to 10 months post-ED visit|Change in self-reported substance use as assessed by Behavioral Health Screen (BHS) items from baseline to 4 months post-ED visit|Change in self-reported substance use as assessed by Behavioral Health Screen (BHS) items from baseline to 10 months post-ED visit|Change in Strengths and Difficulties Questionnaire-Child and Parent Report (SDQ & SDQ-P) from baseline to 4 months post-ED visit|Change in Strengths and Difficulties Questionnaire-Child and Parent Report (SDQ & SDQ-P) from baseline to 10 months post-ED visit|Change in Child PTSD Symptom Scale (CPSS-5) score from baseline to 10 months post-ED visit.","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Drexel University|University of Colorado, Denver","All","8 Years to 18 Years   (Child, Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","17-013839|R01HD087406-01A1","November 2, 2017","December 31, 2021","May 31, 2022","November 7, 2017","null","April 16, 2019","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03334942"
784,"NCT03313310","ATN 151 Work-to-Prevent: Employment as HIV Prevention","W2P","Recruiting","No Results Available","HIV Prevention","Behavioral: Employment Intervention","Information Systems Success Model Score|Workshop Completion|Change in Job Seeking Self-Efficacy Scale Score|Change in Boundaryless Career Attitude Scale Score|Change in Protean Career Attitude Scale Score|Change in self-reported employment status|Change in self-reported sexual risk behaviors|Change in incidence of chlamydia|Change in incidence of gonorrhea|Reactive HIV Result","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","Male","16 Years to 24 Years   (Child, Adult)","Not Applicable","110","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ATN 151|5U24HD089880-02","March 20, 2018","January 2020","March 2020","October 18, 2017","null","March 27, 2019","University of Chicago, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03313310"
785,"NCT03301753","Maternal Obesity, Breast Milk Composition, and Infant Growth","(MILK)","Enrolling by invitation","No Results Available","Obesity|Pregnancy|Breastmilk Collection|Infant Overnutrition","","Milk Composition Changes|Infant Body Composition Changes","University of Minnesota - Clinical and Translational Science Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|HealthPartners Institute|University of Oklahoma","All","up to 45 Years   (Child, Adult)","","720","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","140M50203|R01HD080444","July 1, 2014","January 31, 2019","June 30, 2019","October 4, 2017","null","October 11, 2018","University of Minnesota School of Public Health, Minneapolis, Minnesota, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States","","https://ClinicalTrials.gov/show/NCT03301753"
786,"NCT03263195","Prospective Cohort Study of HIV and Zika in Infants and Pregnancy","HIV ZIP","Active, not recruiting","No Results Available","HIV|Zika Virus|Pregnant Women","","Enrollment (150 HIV-infected and 50 HIV-uninfected pregnant women within one year, with a minimum of 20 of these women having HIV/ZIKV co-infection by their end of pregnancy).|Viral suppression (in HIV-infected women with ZIKV co-infection compared to those without ZIKV co-infection during pregnancy and at the time of delivery).|Incidence of ZIKV infection (among pregnant women with HIV infection compared to those without HIV infection).|Incidence of adverse pregnancy outcomes (in women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone, and doubly uninfected women).|Incidence of vertical transmission of HIV and ZIKV (in women co-infected with HIV and ZIKV and women infected with either HIV or ZIKV alone).|Incidence of congenital malformations (among offspring of women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone, and doubly uninfected women).|Incidence of other adverse outcomes among offspring of women co-infected with HIV and ZIKV, women infected with either HIV or ZIKV alone.|Growth, as measured by length, weight, and head circumference (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Audiologic function as assessed by hearing levels, acoustic immitance, and otoacoustic emissions (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Ophthalmologic structure and function as assessed by ophthalmoscopy, fixation, and acuity card testing (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).|Neurodevelopment as assessed by the Bayley III and Ages and Stages Questionnaires- 3rd Edition (among children with in utero exposure to HIV and ZIKV, in utero exposure to either HIV or ZIKV alone, and no in utero exposure to either virus).","Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","15 Years and older   (Child, Adult, Older Adult)","","3800","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HIV-ZIP","August 23, 2017","July 2024","July 2024","August 28, 2017","null","February 8, 2019","University of Miami Pediatric/Prenatal HIV/AIDS, Miami, Florida, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Baylor College of Medicine; Texas Children's Hospital, Houston, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|University of Sao Paulo at Riberaio Preto Brazil, São Paulo, Brazil|University of Puerto Rico Pediatrics HIV/AIDS Research Program, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT03263195"
787,"NCT03048669","Long Term Outcomes of Therapy in Women Initiated on Lifelong ART Because of Pregnancy in DR Congo",,"Recruiting","No Results Available","HIV/AIDS|Antiretroviral Therapy|Pregnancy Outcomes|HIV-exposed Infants","Other: Continuous quality improvement","Loss-to-follow-up|Virological suppression|Timely Infant HIV diagnosis|Timely ART initiation|MTCT rates|Survival","Ohio State University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Kinshasa School of Public Health","All","Child, Adult, Older Adult","Not Applicable","6000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","1R01HD087993","November 2016","May 2021","May 2021","February 9, 2017","null","April 6, 2018","Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the","","https://ClinicalTrials.gov/show/NCT03048669"
788,"NCT03009110","Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial","Prevena-C","Recruiting","No Results Available","Surgical Wound Infection|Cesarean Section","Device: Prophylactic NPWT|Device: Standard Dressing","Frequency of superficial or deep surgical site infections|Frequency of superficial, deep or organ space SSIs (individual types of SSIs)|Frequency of organ space SSIs (endometritis, intraabdominal abscess)|Frequency of wound hematoma, seroma, separation (other wound complications)|Frequency of a composite of any wound complication including SSI, hematoma, seroma, separation (2cm or more).|Patient pain score|Patient satisfaction score|Patient satisfaction with aesthetics score|Frequency of physician office visit, emergency room visit, attendance at wound clinic, use antibiotics, hospital readmission for wound related problems (measures of healthcare resource utilization)|Frequency of skin blistering, erythema, wound bleeding (measures of adverse skin events)","Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|KCI USA, Inc.","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","2850","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB ID #: 201603062|1R01HD086007-01A1","February 8, 2017","January 2020","August 2021","January 4, 2017","null","March 26, 2019","University of Alabama Medical Center, Birmingham, Alabama, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|George Andrew Macones, Saint Louis, Missouri, United States|Mercy Hosptial St Louis, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT03009110"
789,"NCT02793622","Prevention of Malaria in HIV-uninfected Pregnant Women and Infants","PROMOTE-BC3","Active, not recruiting","No Results Available","Malaria","Drug: Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|Drug: Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy","Proportion of women who deliver with a composite adverse birth outcome|Incidence of malaria in infants|Comparison of estimates of gestational age at birth using two methods|Prevalence of placental malaria by histopathology|Prevalence of placental parasitemia|Prevalence of maternal malaria|Incidence of adverse events in pregnant women|Prevalence of anemia in pregnant women|Prevalence of anemia in infants|Prevalence of asymptomatic parasitemia in pregnant women|Prevalence of asymptomatic parasitemia in infants|Incidence of complicated malaria in infants|Incidence of hospital admissions in infants|Infant mortality rate","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Bill and Melinda Gates Foundation","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 3","782","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PROMOTE-BC3","September 2016","June 2019","June 2019","June 8, 2016","null","July 11, 2018","IDRC - Tororo Research Clinic, Tororo, Uganda","","https://ClinicalTrials.gov/show/NCT02793622"
790,"NCT02756195","The Impact of Non-Routine Events on Neonatal Safety",,"Recruiting","No Results Available","Neonatology","","National Surgical Quality Improvement Pediatric Mortality|National Surgical Quality Improvement Pediatric Morbidity","Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Utah|Vanderbilt University Medical Center","All","Child, Adult, Older Adult","","500","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","050488|1R01HD086792-01","November 2016","June 2020","June 2020","April 29, 2016","null","May 3, 2018","Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02756195"
791,"NCT02531594","An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients",,"Recruiting","No Results Available","Smoking Cessation","Behavioral: SBIRT|Behavioral: HHC","self-reported prolonged abstinence at 6 weeks|self-reported prolonged abstinence at 6 months|number of cigarettes smoked at 6 weeks|number of cigarettes smoked at 6 months|Number of quit attempts at 6 weeks|Number of quit attempts at 6 months|Readiness to quit at 6 weeks|Readiness to quit at 6 months|Use of cessation resources at 6 weeks|Use of cessation resources at 6 months","Children's Hospital Medical Center, Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Environmental Health Sciences (NIEHS)","All","Child, Adult, Older Adult","Not Applicable","750","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CINC 2015-1914|1R01HD083354|R01ES027815","April 6, 2016","December 31, 2020","December 31, 2022","August 24, 2015","null","December 11, 2018","Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02531594"
792,"NCT03906682","Improving Mental Health and School Performance in Urban Eighth Graders",,"Recruiting","No Results Available","Depressive Symptoms|Trauma, Psychological|Disruptive Behavior","Behavioral: RAP Club|Behavioral: Healthy Topics","Teacher Rating of Social Competence Scale (TRSCS)|Strengths and Difficulties Questionnaire (SDQ)|Academic Competence Evaluation Scale (ACES)|Academic records|Child PTSD Symptom Scale Revised (CPSSR)|Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Symptoms|Children's Depression Inventory - Short Form (CDI-S)|Youth Outcome Questionnaire Self-Report (YOQSR)|Brief Cope|Children's Response Style Questionnaire (CRSQ)","Johns Hopkins Bloomberg School of Public Health|Institute of Education Sciences (IES)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","R305A160082-17","July 1, 2016","May 30, 2020","June 30, 2021","April 8, 2019","null","April 8, 2019","Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03906682"
793,"NCT01962220","Mother Infant Retention for Health: MIR4Health","MIR4HEALTH","Completed","No Results Available","HIV/AIDS","Behavioral: Study Intervention for Retention (APFU)","Proportion of mothers and infants non-retained in care at 6 months|Proportion of women completing the 2nd ANC visit and all ANC and PN visits|Proportion of women who had a hospital delivery|Proportion of infants receiving PCR testing at 6 weeks of age and 6 months|Proportion of male partners receiving HIV testing|Proportion of infants exclusively breastfeeding at 6 months and number of months infant spent breastfeeding|Change in CD4+ cell count from study enrollment to 6 month postpartum for women|Proportion of women with undetectable HIV RNA at delivery and 6 months postpartum|Proportion of women adherent to ARV regimen during pregnancy and postpartum period|Proportion of infants adherent to postnatal ARV regimen during first six weeks of life|Proportion of women & staff reporting APFU highly acceptable","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Kenya Ministry of Health","Female","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","680","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","AAAL5557|1R01HD075163-01","March 2013","June 2015","June 2015","October 14, 2013","null","December 22, 2015","Ahero Sub-district Hospital, Ahero, Nyanza, Kenya|Ambira Sub-District Hospital, Ambira, Nyanza, Kenya|Bondo District Hospital, Bondo, Nyanza, Kenya|Got Agulu Sub-district Hospital, Got Agulu, Nyanza, Kenya|Jaramoji Oginga Oginga Referral Hospital, Kisumu, Nyanza, Kenya|Madiany District Hospital, Madiany, Nyanza, Kenya|Masogo Sub-district Hospital, Masogo, Nyanza, Kenya|Nyakatch District Hospital, Nyakatch, Nyanza, Kenya|Siaya District Hospital, Siaya, Nyanza, Kenya|Ukwala Health Center, Ukwala, Nyanza, Kenya","","https://ClinicalTrials.gov/show/NCT01962220"
794,"NCT03522597","Metabolism, Breastmilk, and Microbiome",,"Not yet recruiting","No Results Available","Obesity|Diabetes, Gestational","","Breastmilk and infant microbiomes|Hormones in breastmilk|Hormones and cytokines in maternal serum|Hormones and cytokines in infant serum","University of Minnesota - Clinical and Translational Science Institute|University of Oklahoma|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","300","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","FRD #17.29|R01HD080444","June 2018","June 2020","January 2021","May 11, 2018","null","May 11, 2018","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT03522597"
795,"NCT03511118","Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants",,"Recruiting","No Results Available","Lactating Women on Select DOI|Breastfed Infants of Mothers on Select DOI","Other: Tranexamic acid (TXA)|Other: labetalol|Other: metformin|Other: nifedipine|Other: clindamycin|Other: oxycodone|Other: azithromycin|Other: escitalopram|Other: sertraline|Other: ondansetron","Pharmacokinetics of commonly used drugs in the blood and breastmilk of lactating women and in the blood of breastfed infants|Safety profile of commonly used drugs in infants exposed to drugs in breastmilk","Kevin Watt|The EMMES Corporation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Duke University","All","Child, Adult, Older Adult","","500","Other|Industry|NIH","Observational","Observational Model: Other|Time Perspective: Prospective","Pro00088919|HHSN275201000003I/27500051","October 4, 2018","September 22, 2019","September 22, 2019","April 27, 2018","null","March 26, 2019","University of California-San Diego Medical Center, La Jolla, California, United States|Loma Linda University Health, Loma Linda, California, United States|Northwestern University, Chicago, Illinois, United States|Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States|Indiana University Health, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Children's Hospital and Clinics — Minneapolis, Minneapolis, Minnesota, United States|University of New Mexico, Health Sciences Center, Albuquerque, New Mexico, United States|University of North Carolina Hospital, Chapel Hill, North Carolina, United States|Duke University Maternal and Fetal Medicine, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania Department of Maternal Fetal Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States|University of Texas Medical Branch - Galveston, Galveston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Washington, Seattle, Washington, United States|BC Women's Hospital + Health Centre, Vancouver, British Columbia, Canada|Lawson Health Research Institute, London, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montréal, Quebec, Canada","","https://ClinicalTrials.gov/show/NCT03511118"
796,"NCT03416790","IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment",,"Enrolling by invitation","No Results Available","HIV-1-infection","","Prevalence of quantifiable cell-free HIV-1 RNA CSF|Prevalence of detectable HIV-1 DNA in CSF cell pellets|Concentrations of inflammatory and neuronal injury biomarkers in CSF|Concentrations of inflammatory and neuronal injury biomarkers in plasma|Associations of the above-listed secondary outcomes with the primary outcomes","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","13 Years to 24 Years   (Child, Adult)","","45","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","IMPAACT 2015|DAIDS ID 35123","February 6, 2019","January 2020","January 2020","January 31, 2018","null","February 8, 2019","University of Southern California (CRS 5048), Los Angeles, California, United States|David Geffen School of Medicine at University of California, Los Angeles (CRS 5112), Los Angeles, California, United States|University of California, San Diego Mother-Child-Adolescent HIV Program (CRS 4601), San Diego, California, United States|University of Colorado, Denver (CRS 5052), Aurora, Colorado, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Johns Hopkins University (CRS 5092), Baltimore, Maryland, United States|Boston Medical Center Pediatric HIV Program (CRS 5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Medical Center (CRS 5013), Bronx, New York, United States|St. Jude Children's Research Hospital (CRS 6501), Memphis, Tennessee, United States|Seattle Children's Hospital (CRS 5017), Seattle, Washington, United States|University of Puerto Rico Pediatric HIV/AIDS Research Program (CRS 6601), San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT03416790"
797,"NCT01838005","Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services",,"Completed","No Results Available","HIV","Behavioral: Conditional cash transfer","proportion of women who were adherent to all conditionalities and received the most effective ARV intervention they were eligible to receive and delivered at an affiliated maternity|Mother to child transmission rate at six weeks and HIV-free survival.|HIV-free survival at 18 month.|Proportion of HIV-exposed infants who at their six week visit received extended Nevirapine (NVP) had a DNA PCR test","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Kinshasa School of Public Health","Female","Child, Adult, Older Adult","Not Applicable","433","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Health Services Research","12-1676|1R01HD075171-01","April 2013","April 2015","April 2015","April 23, 2013","null","April 25, 2017","Kinshasa School of Public Health, Kinshasa, Congo","","https://ClinicalTrials.gov/show/NCT01838005"
798,"NCT01751646","Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART",,"Completed","Has Results","HIV Infection","Dietary Supplement: Vitamin D3 50,000 IU|Dietary Supplement: Vitamin D3 placebo","Percent Change From Baseline to Week 48 in Dual Energy X-ray Absorptiometry (DXA)-Measured BMD at the Spine for the Randomized Study Groups|Percent Change From Baseline to Week 24 of BMC of Whole Body for the Randomized Study Groups|Percent Change From Baseline to Week 48 of BMC of Whole Body for the Randomized Study Groups|Percent Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD for the Randomized Study Groups|Change From Baseline to Week 24 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups|Change From Baseline to Week 48 of Lumbar Spine (L1-L4) BMD Z-score for the Randomized Study Groups|Percent Change From Baseline to Week 24 of Femoral Neck BMD for the Randomized Study Groups|Percent Change From Baseline to Week 48 of Femoral Neck BMD for the Randomized Study Groups|Change From Baseline to Week 24 of Femoral Neck BMD Z-score for the Randomized Study Groups|Change From Baseline to Week 48 of Femoral Neck BMD Z-score for the Randomized Study Groups|Percent Change From Baseline to Week 24 of Total Hip BMD for the Randomized Study Groups|Percent Change From Baseline to Week 48 of Total Hip BMD for the Randomized Study Groups|Change From Baseline to Week 24 of Total Hip BMD Z-score for the Randomized Study Groups|Change From Baseline to Week 48 of Total Hip BMD Z-score for the Randomized Study Groups|Change in SCr From Baseline to Week 12.|Change in SCr From Baseline to Week 24.|Change in SCr From Baseline to Week 48.|Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Insulin)|Change From Baseline to Week 48 in Glucose Homeostasis (Fasting Glucose)|Change From Baseline to Week 48 in Glucose Homeostasis (Homeostasis Model Assessment of Insulin Resistance (HOMA-IR))|Change From Baseline to Week 12 in Serum Calcium (SCa)|Change From Baseline to Week 24 in Serum Calcium (SCa)|Change From Baseline to Week 48 in Serum Calcium (SCa)|Change From Baseline to Week 12 in CTX|Change From Baseline to Week 24 in CTX|Change From Baseline to Week 48 in CTX|Change From Baseline to Week 12 in OC|Change From Baseline to Week 24 in OC|Change From Baseline to Week 48 in OC|Change From Baseline to Week 12 in BAP|Change From Baseline to Week 24 in BAP|Change From Baseline to Week 48 in BAP|Change From Baseline to Week 12 in FGF23|Change From Baseline to Week 24 in FGF23|Change From Baseline to Week 48 in FGF23|Change From Baseline to Week 12 in PTH|Change From Baseline to Week 24 in PTH|Change From Baseline to Week 48 in PTH|Change From Baseline to Week 12 in Actual Free 1,25-OHD|Change From Baseline to Week 24 in Actual Free 1,25-OHD|Change From Baseline to Week 48 in Actual Free 1,25-OHD|Change From Baseline to Week 12 in 1,25-OHD|Change From Baseline to Week 24 in 1,25-OHD|Change From Baseline to Week 48 in 1,25-OHD|Change From Baseline to Week 12 in 25-OHD|Change From Baseline to Week 24 in 25-OHD|Change From Baseline to Week 48 in 25-OHD|Change From Baseline to Week 12 in TRP %|Change From Baseline to Week 24 in TRP %|Change From Baseline to Week 48 in TRP %|Change From Baseline to Week 12 in SPO4|Change From Baseline to Week 24 in SPO4|Change From Baseline to Week 48 in SPO4|Change From Baseline to Week 12 in UCa/Ucr|Change From Baseline to Week 24 in UCa/Ucr|Change From Baseline to Week 48 in UCa/Ucr|Change in Estimated GFR From Baseline to Week 12.|Change in Estimated GFR From Baseline to Week 24.|Change in Estimated GFR From Baseline to Week 48.|Change in UGluc From Baseline to Week 48|Change in URBP/UCr Ratio From Baseline to Week 48|Change in UB2MG From Baseline to Week 48|Change in UProt/ UCr Ratio From Baseline to Week 48|25-OHD Serum Concentration by Randomized Study Group at Week 12|25-OHD Serum Concentration by Randomized Study Group at Week 24|25-OHD Serum Concentration by Randomized Study Group at Week 48|Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Baseline by Efavirenz Use|Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Concentration at Week 48 by Efavirenz Use|Effect of Concurrent Treatment With Efavirenz on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Efavirenz Use|Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Baseline by Ritonavir Use|Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Concentration at Week 48 by Ritonavir Use|Effect of Concurrent Treatment With Ritonavir on 25-OHD Serum Concentration: Change in Concentration From Baseline to Week 48 by Ritonavir Use","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","All","16 Years to 24 Years   (Child, Adult)","Not Applicable","214","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","ATN 109 Version 2.0","October 2012","June 2016","June 2016","December 18, 2012","March 11, 2019","March 27, 2019","Children's Hopsital of Los Angeles, Los Angeles, California, United States|University of Southern California - NICHD Westat Site, Los Angeles, California, United States|Childrens National Medical Center, Washington, District of Columbia, United States|Children's Diagnostic and Treatment Center - NICHD Westat Site, Fort Lauderdale, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Stroger Hospital and the CORE Center, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Johns Hopkins University - NICHD Westat Site, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Fenway Institute, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Montefiore Medical Center, Bronx, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Childrens Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|San Juan City Hospital (Puerto Rico) - NICHD Westat Site, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT01751646"
799,"NCT03115463","Saturation Targets and Resuscitation in Preterm Trial","STARTPreterm","Recruiting","No Results Available","Oxidative Stress","Other: Titration of oxygen during neonatal resuscitation","Change in Oxidative Balance Ratio from Baseline|Reduction in Isoprostane,Isofluran, 8-OHdG and protein carbonyls|• Reduction in oxygen load in the delivery room|Time spent in goal saturations|Incidence of bradycardia during resuscitation|intubation in the delivery room|Grade III/IV Intraventricular hemorrhage|Bronchopulmonary dysplasia (BPD)|Necrotizing enterocolitis (NEC)|Retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), Grade 3/4 intraventricular hemorrhage (IVH), Mortality during NICU stay|Neurodevelopmental Impairment|Mortality","University of Texas Southwestern Medical Center|American Academy of Pediatrics|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","75","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","STU-062014-010|1K23HD083511-01A1","September 20, 2017","June 2019","June 2020","April 14, 2017","null","August 24, 2018","Parkland Hospital, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT03115463"
800,"NCT01618305","Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission",,"Active, not recruiting","No Results Available","HIV Infections","Drug: Lamivudine/zidovudine|Drug: Efavirenz|Drug: Raltegravir","Plasma HIV-1 viral load less than 200 copies/mL|Number of participants who discontinue efavirenz or raltegravir (whichever was assigned) prior to labor and delivery for any reason (including loss to follow-up)|Maternal adverse events of greater than or equal to Grade 3 as defined in the Division of AIDS (DAIDS) toxicity table|Infant adverse events of greater than or equal to Grade 3 as defined in the DAIDS toxicity table|Virologic suppression to below the lower limit of quantification of the assay|Number of participants with 1) successful viral load (plasma HIV-1 RNA VL) decrease from entry to Week 2 and VL less than 1,000 copies/ml at all time points after 4 weeks on study drugs, until delivery; and 2) who remain on the assigned study regimen|Viral load in maternal blood|Viral load in maternal vaginal swabs|Log10 change in viral load from entry (or screening, if there is no entry viral load) to each time point prior to delivery|Infectivity of plasma|Number of participants who experience a stillbirth/fetal demise|Number of participants who experience a premature birth (less than 34 or less than 37 weeks gestation)|Number of infants with a low birth weight (less than 1500 or less than 2500 grams)|Infant HIV infection status (per International Maternal Pediatric Adolescent AIDS Clinical Trials Group [IMPAACT] definitions)|Incidence of drug resistance in HIV-infected infants|HIV-1 drug resistance mutations at screening, at 2-4 weeks postpartum in women who have stopped antiretroviral therapy, and at the time of inadequate virologic response (defined in the protocol) using standard and ultrasensitive genotyping methods","Westat|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 4","394","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","P1081|10770|NICHD P1081","July 2013","December 11, 2018","July 2019","June 13, 2012","null","January 17, 2019","University of Southern California Medical Center, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|University of Flordia Health Science Center, Gainesville, Florida, United States|South Flordia Childrens Diagnostic & Treatment Center, Pompano Beach, Florida, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Fundacion Huesped - Hospital Juan A Fernandez, Buenos Aires, Argentina|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Univ. Caxias do Sul Brazil NICHD CRS, Caxias Do Sul - RS, Rio Grande Do Sul, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Perinatal HIV Research Unit-Chris Hani Baragwanath Hospital, Soweto, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hospital, Bangkok, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand","","https://ClinicalTrials.gov/show/NCT01618305"
801,"NCT01593943","Gender Equity-Focused, Male-Centered Family Planning for Rural India","CHARM","Completed","No Results Available","Family Planning","Behavioral: CHARM","contraception","University of California, San Diego|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Indian Council of Medical Research|Population Council","All","15 Years to 30 Years   (Child, Adult)","Phase 3","2162","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","R01HD061115","March 2012","September 2014","September 2014","May 8, 2012","null","December 4, 2014","NIRRH, Mumbai, Maharashtra, India","","https://ClinicalTrials.gov/show/NCT01593943"
802,"NCT02939131","IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among US Youth With HIV",,"Active, not recruiting","No Results Available","HIV|Depression","Behavioral: Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral: Enhanced Standard of Care","Depression Outcomes: Quick Inventory of Depression Symptomatology - Self Report (QIDS-SR) Score|Depression Outcomes: Response to Treatment, defined as a decrease in QIDS-SR score by >50%|Depression Outcomes: Remission, defined as a QIDS-SR Score <= 5|Biological Outcomes: CD4 cell count|Biological Outcomes: Plasma HIV RNA Level|Adherence Outcomes: Adherence to anti-HIV Medications|Adherence Outcomes: Adherence to Psychiatric Medications|Adherence Outcomes: Adherence to Study Visits and Psychotherapy Sessions|Depression Outcomes: QIDS-SR Score over 48 Weeks|Depression Outcomes: Response to Treatment over 48 Weeks|Depression Outcomes: Remission over 48 Weeks|Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: QIDS-SR Score (defined above)|Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Response to Treatment (defined above)|Effect of Demographic, Behavioral, and Biological Modifiers on Depression Outcomes: Remission (defined above)|Behavioral Risk Outcomes: Alcohol/Drug Use|Behavioral Risk Outcomes: Sex-Risk Behaviors|Implementation Fidelity (COMB-R sites); Counseling Strategies (ESC sites)|Patterns of Psychiatric Medication Use|Number of Interim Counseling Visits|Frequency of Psychiatric Medication Use|COMB-R and ESC Acceptability among Participants and Clinicians|Grade 3 or Higher Adverse Events, Psychological Hospitalizations, and Suicide Attempts","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)","All","12 Years to 24 Years   (Child, Adult)","Not Applicable","156","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT 2002","March 6, 2017","September 2019","March 2020","October 19, 2016","null","March 13, 2019","University of Southern California - MCA Center (CRS 5048),, Alhambra, California, United States|University California, San Diego (CRS 4601), La Jolla, California, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States|Children's Hospital of Colorado (CRS 5052), Aurora, Colorado, United States|Children's Diagnostic and Treatment Center (CRS 5055), Fort Lauderdale, Florida, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Rush University Medical Center (CRS 5083), Chicago, Illinois, United States|Johns Hopkins University School of Medicine (CRS 5092), Baltimore, Maryland, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Medical Center (CRS 5013), Bronx, New York, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States|St Jude Children's Research Hospital (CRS 6501), Memphis, Tennessee, United States|Texas Children's/Baylor (CRS 3801), Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02939131"
803,"NCT01541722","Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders",,"Terminated","No Results Available","Urea Cycle Disorders","","Laboratory values indicating oxidative stress","Mark Batshaw|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Rare Diseases Clinical Research Network|Children's Research Institute","All","Child, Adult, Older Adult","","10","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN 5109|U54HD061221","February 2012","January 2015","July 2015","March 1, 2012","null","October 2, 2015","University of California, Los Angeles, Los Angeles, California, United States|The Children's Hospital, Aurora, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mount Sinai School of Medicine, New York, New York, United States|Case Western Medical College, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT01541722"
804,"NCT02455414","Tracking Neurodegeneration in Early Wolfram Syndrome","TRACK","Completed","No Results Available","Type 1 Diabetes|Diabetes Insipidus|Diabetes Mellitus|Wolfram Syndrome","","Change in regional brain volume|Change in disease severity score","Washington University School of Medicine|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","101","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","201301004|R01HD070855-02","April 2012","July 12, 2017","July 12, 2017","May 27, 2015","null","July 11, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States","","https://ClinicalTrials.gov/show/NCT02455414"
805,"NCT02354651","Response to Diaphragmatic Pacing in Subjects With Pompe Disease",,"Recruiting","No Results Available","Pompe Disease","Other: Pulmonary function testing|Other: Resting breathing pattern|Other: Respiratory muscle endurance test|Other: Phrenic nerve stimulation|Other: Maximal inspiratory pressure|Other: Forced expiratory testing|Other: EMG","Change in off-ventilator spontaneous breathing (SB) at Baseline, Day 3, 14, and 180|Change in Pulmonary Function Test at Day 3, 14, and 180|Change in Forced expiratory tests at Screening, Baseline, Day 14, and 180|Change in Maximal Inspiratory Pressure (MIP) at Screening, Baseline, Day 14, and 180|Change in Resting Breathing Pattern at Screening, Baseline, Day 3, Day 14, and Day 180|Change in Respiratory Muscle Endurance Test at Screening, Baseline, and Day 180|Change in Electromyogram (EMG) at Baseline, Day 3, Day 14, and Day 180|Change in Severe Respiratory Insufficiency Questionnaire at Screening, Baseline, Day 90, and Day 180","University of Florida|Acid Maltase Deficiency Association|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 65 Years   (Child, Adult, Older Adult)","","16","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB201600161-N|003-2013|1R21HD090752-01","May 2013","March 2020","March 2020","February 3, 2015","null","April 11, 2019","University of Florida, Gainesville, Florida, United States","","https://ClinicalTrials.gov/show/NCT02354651"
806,"NCT01144871","Parental Knowledge and Attitudes of Confidential Sexually Transmitted Infections (STI) Services for Teens",,"Completed","No Results Available","Sexually Transmitted Infections","","Determining parental attitudes regarding confidential health services for their teens","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Kaiser Permanente","All","Child, Adult, Older Adult","","1216","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","H1095-31348|R01HD053408-01A2","September 2007","August 2011","August 2011","June 16, 2010","null","October 28, 2014","Mission Neighborhood Health Center, San Francisco, California, United States|San Francisco General Hospital, San Francisco, California, United States|Kaiser Permanente Northern California, San Francisco, California, United States","","https://ClinicalTrials.gov/show/NCT01144871"
807,"NCT01066858","Study of Effects of Tenofovir on Bone Health and Kidneys During Pregnancy and Breastfeeding",,"Completed","No Results Available","HIV Infections","Drug: Tenofovir disoproxil fumarate (TDF)","Antepartum Component: Creatinine clearance (CrCl)|Antepartum Component: Bone resorption (Dpyr)|Antepartum Component: Lumbar spine bone mineral density (BMD) via dual energy e-ray absorptiometry (DXA)|Antepartum Component: Lumbar spine bone mineral content (BMC) and whole body BMC via DXA|Antepartum Component: Length-for-age Z-score|Postpartum Component: CrCl|Postpartum Component: Dpyr|Postpartum Component: Lumbar spine BMD via DXA|Postpartum Component: Lumbar spine BMC via DXA|Postpartum Component: Length-for-age Z-score|CrCl|BMD|Dpyr|Mineral composition of breast milk|Lumbar spine BMC|Infant growth|Concentration of hormonal growth factors (for infants)","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Gilead Sciences","All","Child, Adult, Older Adult","","1765","NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","P1084s (PROMISE)|10790|IMPAACT P1084s","March 2011","November 2015","November 2015","February 10, 2010","null","January 14, 2016","Blantyre CRS, Blantyre, Malawi|Malawi CRS, Lilongwe, Malawi|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Shandukani Research CRS, Johannesburg, Gauteng, South Africa|Durban Paediatric HIV CRS, Durban, KwaZulu-Natal, South Africa|Umlazi CRS, Durban, KwaZulu-Natal, South Africa|Family Clinical Research Unit (FAM-CRU) CRS, Tygerberg, Western Cape Province, South Africa|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Mpigi, Uganda|Seke North CRS, Chitungwiza, Zimbabwe|St Mary's CRS, Chitungwiza, Zimbabwe|Harare Family Care CRS, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT01066858"
808,"NCT03874663","Acceptability and Performance of HIV Self-Testing in a Youth Population in Nigeria",,"Active, not recruiting","No Results Available","HIV Prevention","Device: Directly assisted oral HIV self-testing (HIVST)","Performance of HIV Self-testing|HIV Self-testing Acceptability|HIV self-testing knowledge","St. Louis University|Nigerian Institute of Medical Research|University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years to 24 Years   (Child, Adult)","","1000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","29882|1UG3HD096929-01","November 20, 2018","October 1, 2019","November 19, 2019","March 14, 2019","null","March 14, 2019","Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria","","https://ClinicalTrials.gov/show/NCT03874663"
809,"NCT02140944","IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence",,"Recruiting","No Results Available","HIV Infection","","Survival|Graft versus host disease|Engraftment|HIV DNA level","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","12 Months and older   (Child, Adult, Older Adult)","","25","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMPAACT P1107|UM1AI068632|UM1AI068616|UM1AI106716","February 2015","March 2023","March 2023","May 16, 2014","null","July 26, 2018","Washington University School of Medicine, Saint Louis, Missouri, United States|Weill Cornell Uptown Clinical Research Site (7803), New York, New York, United States","","https://ClinicalTrials.gov/show/NCT02140944"
810,"NCT00950118","Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science","DHREAMS","Recruiting","No Results Available","Congenital Diaphragmatic Hernia","","Percentage of patients with a genetic diagnosis|Developmental outcomes at 2 and 5 years of age|Percentage of patients with pulmonary hypertension","Columbia University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH)","All","Child, Adult, Older Adult","","2020","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AAAB2063|R01HD057036","June 2005","November 2025","November 2025","July 31, 2009","null","February 19, 2019","University of Michigan/ CS Mott Children's Hospital, Ann Arbor, Michigan, United States|Washington University Medical Center/ St. Louis Children's Hospital, Saint Louis, Missouri, United States|Children's Hospital of Omaha/ University of Nebraska, Omaha, Nebraska, United States|North Shore Long Island Jewish Hospital, Schneiders, Manhasset, New York, United States|Morgan Stanley Children's Hospital of New York- Presbyterian (Columbia University Medical Center), New York, New York, United States|Cincinnati Children's Hospital and Medical Center/ University of Cincinnati, Cincinnati, Ohio, United States|Oregon Health & Science University, Doernbecher Children's Hospital, Portland, Oregon, United States|Children's Hospital of Pittsburgh/ University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Monroe Carrell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|UT Southwestern Medical Center, Children's Health, Dallas, Dallas, Texas, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cairo University Hospital, Cairo, Egypt","","https://ClinicalTrials.gov/show/NCT00950118"
811,"NCT01803906","Tissue Sample Study for Mitochondrial Disorders",,"Enrolling by invitation","No Results Available","Mitochondrial Disorders|Mitochondrial Disease|Melas|Kearns Sayer|NARP|MNGIE|LHON|Mitochondrial Depletion Syndrome|Leigh's Disease","","Number of patients with reduced respiratory chain enzyme levels|Number of new genetic mutations","Columbia University|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","6900","Other|NIH","Observational","Observational Model: Case-Only|Time Perspective: Prospective","AAAB5754|P01HD032062","February 2012","January 2020","January 2020","March 4, 2013","null","April 9, 2019","Columbia University, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01803906"
812,"NCT01784783","Home-based Partner Education and Testing (HOPE) Study","HOPE","Completed","No Results Available","HIV","Behavioral: HOPE Intervention|Behavioral: INVITE Intervention","Male self-report of uptake of HIV testing|Female self-report of delivery location|Female self-report of delivery assistance|Female self-report of exclusive breastfeeding|Female self-report of introduction of foods other than breastmilk|Self report of number of sexual partners (female and male)|Male self-report of male condom use|Female self-report of date of first receptive intercourse after delivery|Female report of male condom use|Self-report of condom use during last sexual intercourse (male and female)|Female self-report of contraceptive use|Awareness of partner HIV-status|Awareness of partner HIV status (intervention arm)|Male self-report of linkage to HIV care|Male self-report of linkage to HIV care for CD4 testing|Male self-report of ART initiation|Male self-report of adherence to antiretroviral treatment|Female self-report of initiation of prophylaxis|Female self-report of Nevirapine treatment for infants|Female report of infant adherence to Nevirapine|Female self-report of initiation of antiretroviral treatment|Female self-report of adherence to antiretroviral treatment|Female self-report of infant mortality","University of Washington|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","601","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","44357-A|R01HD075108-01","September 2013","August 2015","August 2015","February 6, 2013","null","February 25, 2016","Kisumu District Hospital, Kisumu, Nyanza, Kenya","","https://ClinicalTrials.gov/show/NCT01784783"
813,"NCT02837497","The ICU-Resuscitation Project (ICU-RESUS)","ICU-RESUS","Recruiting","No Results Available","Cardiac Arrest","Other: ICU-RESUS CPR Improvement Bundle","Good neurological survival|Excellent CPR","Children's Hospital of Philadelphia|National Heart, Lung, and Blood Institute (NHLBI)|University of Utah|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","37 Weeks to 18 Years   (Child, Adult)","Not Applicable","1540","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","15-012576|R01HL131544|UG1HD063108","October 2016","March 2021","March 2021","July 19, 2016","null","December 13, 2018","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT02837497"
814,"NCT01222247","Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial","ALPS","Active, not recruiting","Has Results","Pregnancy|Respiratory Distress Syndrome|Pregnancy Outcomes|Preterm Birth","Drug: Betamethasone|Drug: Placebo","Neonatal Composite Outcome|Number of Neonates With Severe Respiratory Complication,|Neonates Needing Immediate Resuscitation After Birth|Number of Neonates With Respiratory Distress Syndrome|Number of Neonates With Transient Tachypnea of the Newborn|Number of Infants With Neonatal Apnea|Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen|Neonates With Pneumonia|Number of Neonates Needing Surfactant Administration|Neonatal Outcome Composite|Number of Neonates With Pulmonary Air Leak|Neonatal Death After 72 Hours of Delivery|Birth Weight|Birth Weight Less Than 10th Percentile|Gestational Age at Delivery|Number of Neonates With Necrotizing Enterocolitic (NEC)|Number of Infants With Neonatal Sepsis|Number of Neonates With Intraventricular Hemorrhage|Neonatal Morbidity Composite|Number of Neonates With Hypoglycemia|Time Until First Neonatal Feeding|Neonatal Feeding Difficulty|Neonatal Hyperbilirubinemia|Number of Neonates With Hypothermia|Length of NICU or Nursery Stay|Median Length of Hospital Stay|Maternal Outcomes (Participant-based)|Hours From Randomization to Delivery|Median Length of Maternal Hospital Stay","The George Washington University Biostatistics Center|National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","2831","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","HL98354-HD36801-ALPS|U10HD021410|U10HD027869|U10HD027917|U10HD053118|U10HD027915|U10HD034116|U10HD034208|U10HD053097|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U01HD036801|U01HL098354","October 2010","March 2015","May 2022","October 18, 2010","January 30, 2019","February 21, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Stanford University, Stanford, California, United States|University of Colorado, Denver, Colorado, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwest, Dallas, Texas, United States|University of Texas - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01222247"
815,"NCT01146873","Treatment Options for Protease Inhibitor-exposed Children","NEVEREST-III","Completed","Has Results","HIV/AIDS|HIV Infections","Drug: Efavirenz (EFV)|Drug: Lopinavir/ritonavir (LPV/r)|Drug: Stavudine (D4T)|Drug: Abacavir (ABC)","Viral Rebound|Viral Failure|CD4 Cell Percentage at 48 Weeks After Randomization|Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization|Highest Grade ALT After Randomization","Columbia University|University of Witwatersrand, South Africa|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years and older   (Child, Adult, Older Adult)","Phase 3","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAE1145|R01HD061255","July 2010","December 2014","December 2014","June 22, 2010","May 4, 2016","March 13, 2017","Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa","","https://ClinicalTrials.gov/show/NCT01146873"
816,"NCT01131260","Fetal ST Segment and T Wave Analysis in Labor","STAN","Completed","Has Results","Pregnancy|Obstetric Labor|Parturition","Device: fetal STAN monitor","Number of Participants With Primary Composite Outcome|Number of Intrapartum Fetal Deaths (Primary Outcome Component)|Number of Neonatal Deaths (Primary Outcome Component)|Number of Infants With Apgar Score < = 3 at 5 Minutes (Primary Outcome Component)|Number of Infants Who Experienced Neonatal Seizure (Primary Outcome Component)|Number of Infants With Umbilical-artery Blood pH < = 7.05 and Base Deficit in Extracellular Fluid > = 12 mmol/Liter (Primary Outcome Component)|Number of Neonates Intubated for Ventilation at Delivery (Primary Outcome Component)|Number of Infants Experiencing Neonatal Encephalopathy (Primary Outcome Component)|Number of Participants by Delivery Method|Number of Participants by Indication for Cesarean|Number of Participants With an Indication for Forceps or Vacuum Delivery|Median Duration of Labor Post-randomization|Number of Neonates With Shoulder Dystocia During Delivery|Number of Participants With Chorioamnionitis|Number of Participants Who Had a Postpartum Blood Transfusion|Number of Participants Experiencing Postpartum Endometritis|Median Length of Hospital Stay|Number of Infants Admitted to Special Care Nursery|Median Apgar Score at 5 Minutes|Number of Infants With Meconium Aspiration Syndrome|Number of Infants With a Major Congenital Malformation","The George Washington University Biostatistics Center|Neoventa Medical|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Not Applicable","11108","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Prevention","HD36801-STAN|U10HD021410|U10HD027869|U10HD027917|U10HD053118|U10HD027915|U10HD034208|U10HD053097|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U01HD036801","November 2010","April 2014","August 2014","May 26, 2010","April 5, 2019","April 5, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University - Hutzel Hospital, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Case Western University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pittsburgh - Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01131260"
817,"NCT02034214","Shaping the Health of Adolescents in Zimbabwe","SHAZ!","Completed","No Results Available","HIV","Behavioral: Life skills education|Other: Reproductive health services|Behavioral: Economic livelihoods","Intervention completion|Unintended pregnancy|Incident viral infection with HIV or HSV-2","University of California, San Francisco|UZ-UCSF Collaborative Research Programme|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 19 Years   (Child, Adult)","Not Applicable","367","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","037044|R01HD045135","February 2006","October 2008","October 2008","January 13, 2014","null","January 13, 2014","South Medical, Chitungwiza, Zimbabwe","","https://ClinicalTrials.gov/show/NCT02034214"
818,"NCT01769469","Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).",,"Completed","Has Results","HIV Infection","Drug: FTC/TDF (Truvada®)","Magnitude of Change (Fold Change) in Parathyroid Hormone (PTH) From Baseline to Week 48|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Fibroblast Growth Factor 23 (FGF23), Change From Baseline to Week 48|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Fibroblast Growth Factor 23 (FGF23), Magnitude of Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Fibroblast Growth Factor 23 (FGF23), Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Fibroblast Growth Factor 23 (FGF23), Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: 1,25 Dihydroxy Vitamin D (1,25 OHD), Change From Baseline to Week 48|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: 1,25 OHD, Magnitude of Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: 1,25 OHD, Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: 1,25 OHD, Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Tubular Reabsorption of Phosphate (TRP), Change From Baseline to Week 48|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: TRP, Magnitude of Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: TRP, Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: TRP, Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Glomerular Filtration Rate (GFR), Change From Baseline to Week 48|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: GFR, Magnitude of Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: GFR, Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: GFR, Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: PTH, Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: PTH, Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Serum Creatinine (SCr), Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: PTH, Slope of the Curve of Baseline to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: FGF23, Slope of the Curve of Baseline to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: 1,25-OHD, Slope of the Curve of Baseline to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: TRP, Slope of the Curve of Baseline to Most Extreme Fold Change|Change From Baseline to Week 48 in Serum Calcium (SCa)|Magnitude of Most Extreme Fold Change: Serum Calcium (SCa)|Time to Most Extreme Fold Change: Serum Calcium (SCa)|Slope of the Curve of Baseline to Most Extreme Fold Change: Serum Calcium (SCa)|Change From Baseline to Week 48 in Urine Calcium (UCa) / Urine Creatinine (UCr)|Magnitude of Most Extreme Fold Change: UCa/UCr Ratio|Time to Most Extreme Fold Change: UCa/UCr Ratio|Slope of the Curve of Baseline to Most Extreme Fold Change: UCa/UCr Ratio|Change From Baseline to Week 48 in Serum Phosphate (SPO4)|Magnitude of Most Extreme Fold Change: SPO4|Time to Most Extreme Fold Change: SPO4|Slope of the Curve of Baseline to Most Extreme Fold Change: SPO4|Change in Glomerular and Renal Tubular Function: Change From Baseline to Week 48 in Urine Retinol Binding Protein (URBP)/ Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Change From Baseline to Week 48 in Urine Beta-2 Microglobulin (UB2MG)|Change in Glomerular and Renal Tubular Function: Change From Baseline to Week 48 in Urine Protein (UProt) / Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Change From Baseline to Week 48 in Urine Glucose (UGluc)|Change in Glomerular and Renal Tubular Function: Change From Baseline to Week 48 in Serum Creatinine (SCr)|Change in Glomerular and Renal Tubular Function: Magnitude of Fold Change at Week 48 in Urine Retinol Binding Protein (URBP)/ Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Magnitude of Fold Change at Week 48 in Urine Beta-2 Microglobulin (UB2MG)|Change in Glomerular and Renal Tubular Function: Magnitude of Fold Change at Week 48 in Urine Protein (UProt)/ Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Magnitude of Fold Change at Week 48 in Urine Glucose (UGluc)|Change in Glomerular and Renal Tubular Function: Magnitude of Fold Change at Week 48 in Serum Creatinine (SCr)|Change in Glomerular and Renal Tubular Function: Most Extreme Fold Change in Urine Retinol Binding Protein (URBP)/ Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Most Extreme Fold Change in UB2MG|Change in Glomerular and Renal Tubular Function: Most Extreme Fold Change in UProt/UCr|Change in Glomerular and Renal Tubular Function: Most Extreme Fold Change in UGluc|Change in Glomerular and Renal Tubular Function: Most Extreme Fold Change in SCr|Change in Glomerular and Renal Tubular Function: Time to Most Extreme Fold Change in Urine Retinol Binding Protein (URBP)/ Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Time to Most Extreme Fold Change in UB2MG|Change in Glomerular and Renal Tubular Function: Time to Most Extreme Fold Change in UProt/UCr|Change in Glomerular and Renal Tubular Function: Time to Most Extreme Fold Change in UGluc|Change in Glomerular and Renal Tubular Function: Slope of the Curve of Baseline to Most Extreme Fold Change in Urine Retinol Binding Protein (URBP)/ Urine Creatinine (UCr)|Change in Glomerular and Renal Tubular Function: Slope of the Curve of Baseline to Most Extreme Fold Change in UB2MG|Change in Glomerular and Renal Tubular Function: Slope of the Curve of Baseline to Most Extreme Fold Change in UProt/UCr|Change in Glomerular and Renal Tubular Function: Slope of the Curve of Baseline to Most Extreme Fold Change in UGluc|Change in Glomerular and Renal Tubular Function: Slope of the Curve of Baseline to Most Extreme Fold Change in Scr|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Change From Baseline to Week 48 in Osteocalcin (OC)|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Change From Baseline to Week 48 in C-Telopeptide (CTX)|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Most Extreme Fold Change in Osteocalcin (OC)|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Most Extreme Fold Change in C-telopeptide (CTX)|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: OC, Time to Most Extreme Fold Change|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Time to Most Extreme Fold Change in C-telopeptide (CTX)|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Slope of the Curve of Baseline to Most Extreme Fold Change in OC|Change in Renal-endocrine-bone Biochemistry and Pathophysiology: Slope of the Curve of Baseline to Most Extreme Fold Change in CTX|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in PTH, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in PTH, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in FGF23, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in FGF23, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in 1,25 OHD, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in 1,25 OHD, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in Osteocalcin (OC), by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in Osteocalcin (OC), by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in CTX, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in CTX, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in SCr, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in SCr, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in TRP, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in TRP, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in UCa/UCr Ratio, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in UCa/UCr Ratio, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in UB2MG, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in UB2MG, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in UGluc, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in UGluc, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in URBP/UCr Ratio, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in URBP/UCr Ratio, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Percent Change From Baseline to Week 24 in Lumbar Spine BMD, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Percent Change From Baseline to Week 48 in Lumbar Spine BMD, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in Lumbar Spine BMD Z-score, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in Lumbar Spine BMD Z-score, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Percent Change From Baseline to Week 24 in Femoral Neck BMD, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Percent Change From Baseline to Week 48 in Femoral Neck BMD, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 24 in Femoral Neck BMD Z-score, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Change From Baseline to Week 48 in Femoral Neck BMD Z-score, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Percent Change From Baseline to Week 24 in Total Body BMC, by Overall Drug Exposure|Area Under the Drug Concentration by Time Curve (AUC): Percent Change From Baseline to Week 48 in Total Body BMC, by Overall Drug Exposure|Magnitude of Change in Lumbar Spine BMD at Week 48|Magnitude of Change in Lumbar Spine BMD Z-score at Week 48|Magnitude of Change in Femoral Neck BMD at Week 48|Magnitude of Change in Femoral Neck BMD Z-score at Week 48|Magnitude of Change in Total Body BMC at Week 48|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Change at EPH1 From Baseline|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Change at EPH2 From Baseline|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Change at EPH1 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Change at EPH2 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Z-score Change at EPH1 From Baseline|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Z-score Change at EPH2 From Baseline|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Z-score Change at EPH1 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Lumbar Spine BMD Z-score Change at EPH2 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Change at EPH1 From Baseline|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Change at EPH2 From Baseline|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Change at EPH1 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Change at EPH2 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Z-score Change at EPH1 From Baseline|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Z-score Change at EPH2 From Baseline|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Z-score Change at EPH1 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Femoral Neck BMD Z-score Change at EPH2 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Total Body BMC Change at EPH1 From Baseline|Changes in BMD/BMC in the Extension Phase: Total Body BMC Change at EPH2 From Baseline|Changes in BMD/BMC in the Extension Phase: Total Body BMC Change at EPH1 From Week 48 (or Last Visit on Study)|Changes in BMD/BMC in the Extension Phase: Total Body BMC Change at EPH2 From Week 48 (or Last Visit on Study)","University of North Carolina, Chapel Hill|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","15 Years to 22 Years   (Child, Adult)","","101","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATN 117 Version 2.0","November 2012","November 2015","November 2015","January 16, 2013","March 11, 2019","March 27, 2019","Children's Hopsital of Los Angeles, Los Angeles, California, United States|Children's Hospital of Denver, Aurora, Colorado, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Stroger Hospital and the CORE Center, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Johns Hopkins University, Baltimore, Maryland, United States|Fenway Institute, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Childrens Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT01769469"
819,"NCT00628693","Quantitative Measurement of Cardiopulmonary Resuscitation (CPR) During In Hospital Cardiac Arrest","Q-CPR","Completed","No Results Available","Cardiac Arrest|Cardiopulmonary Resuscitation","","To evaluate the rate, depth, and quality of chest compressions and ventilations delivered to children during in-hospital CPR.|To determine the chest wall stiffness of children in order to improve quantitative CPR modeling efforts and to facilitate the construction of more biofidelic pediatric manikins for CPR simulation and test dummies for automotive safety.","Children's Hospital of Philadelphia|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","8 Years and older   (Child, Adult, Older Adult)","","89","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","2006-6-4839|1K23HD062629-01A1","June 2006","June 2015","November 2015","March 5, 2008","null","January 27, 2016","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00628693"
820,"NCT00409591","Maternal/Infant Peripartum NVP, Versus Infant Only Peripartum NVP, or Maternal LPV/r in Addition to Standard ZDV Prophylaxis for the Prevention of Perinatal (PMTCT) HIV in Thailand","PHPT-5","Terminated","No Results Available","HIV Infections|Pregnancy","Drug: Maternal and infant nevirapine|Drug: Maternal placebo and infant nevirapine|Drug: Maternal lopinavir+ritonavir|Drug: zidovudine","Definitive HIV infection in infants as assessed by positive HIV DNA PCR on two peripheral blood samples|Safety for mothers and children of two NVP doses in neonates with and without maternal single dose NVP at onset of labor or LPV/r from 28 weeks gestation.","Institut de Recherche pour le Developpement|Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Phase 3","435","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PHPT-5 First Phase|R01HD052461|R01HD056953","July 2008","November 2010","June 2015","December 11, 2006","null","January 28, 2016","Nopparat Rajathanee Hospital, Kannayao, Bangkok, Thailand|Bhumibol Adulyadej Hospital, Saimai, Bangkok, Thailand|Chachoengsao Hospital, Muang, Chachoengsao, Thailand|Prapokklao Hospital, Muang, Chantaburi, Thailand|Nakornping Hospital, Mae Rim, Chiang Mai, Thailand|Sanpatong Hospital, Sanpatong, Chiang Mai, Thailand|Mae Chan Hospital, Mae Chan, Chiang Rai, Thailand|Mae Sai Hospital, Mae Sai, Chiang Rai, Thailand|Phan Hospital, Phan, Chiang Rai, Thailand|Chiang Saen Hospital, Chiang Saen, Chiangrai, Thailand|Chiangrai Prachanukroh Hospital, Muang, Chiangrai, Thailand|Wiangpapao Hospital, Wiangpapao, Chiangrai, Thailand|Banglamung Hospital, Banglamung, Chonburi, Thailand|Chonburi Hospital, Muang, Chonburi, Thailand|Panasnikom Hospital, Panasnikom, Chonburi, Thailand|Ao Udom Hospital, Sri Racha, Chonburi, Thailand|Kalasin Hospital, Muang, Kalasin, Thailand|Phaholpolphayuhasena Hospital, Munag, Kanjanaburi, Thailand|Khon Kaen Hospital, Muang, Khon Kaen, Thailand|Lampang Hospital, Muang, Lampang, Lampang, Thailand|Mahasarakam Hospital, Muang, Mahasarakam, Thailand|Maharaj Nakhon Si Thammarat Hospital, Muang, Nakhon Si Thammarat, Thailand|Nakhonpathom Hospital, Muang, Nakhonpathom, Thailand|Nong Khai Hospital, Muang, Nong Kai, Thailand|Pranangklao Hospital, Muang, Nonthaburi, Thailand|Pathumthani Hospital, Muang, Pathumthani, Thailand|Chiang Kham Hospital, Chiang Kham, Phayao, Thailand|Buddhachinaraj Hospital, Muang, Pitsanulok, Thailand|Rayong Hospital, Muang, Rayong, Thailand|Samutsakhon Hospital, Muang, Samutsakhon, Thailand|Songkhla Hospital, Muangsongkhla, Songkhla, Thailand|Hat Yai Hospital, Hat Yai, Songkla, Thailand|Trat Hospital, Muang, Trat, Thailand|Health Promotion Hospital Regional Center I, Bangkok, Thailand|Health Promotion Center Region 10,, Chiang Mai, Thailand|Fang Hospital, Chiang Mai, Thailand|Chomthong Hospital, Chiang Mai, Thailand|Somdej Pranangchao Sirikit Hospital, Chonburi, Thailand|Regional Health Promotion Centre 6,, Khon Kaen, Thailand|Lamphun Hospital, Lamphun, Thailand|Phayao Provincial Hospital, Phayao, Thailand|Vachira Phuket Hospital, Phuket, Thailand|Samutprakarn Hospital, Samutprakarn, Thailand","","https://ClinicalTrials.gov/show/NCT00409591"
821,"NCT00388297","Thyroid Therapy for Mild Thyroid Deficiency in Pregnancy","TSH","Completed","Has Results","Subclinical Hypothyroidism|Hypothyroxinemia|Pregnancy","Drug: Levothyroxine|Drug: Placebo for Levothyroxine","Intellectual Function of Children at 5 Years of Age in Women Diagnosed With a) Subclinical Hypothyroidism or b) Hypothyroxinemia During the First Half of Pregnancy, or Death.|Week of Gestation at Delivery|Number of Participants With Preterm Delivery|Selected Cognitive Abilities From the Subscales of the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III)|Cognitive and Achievement Levels From the Differential Ability Scales (DAS II)|Cognitive and Achievement Levels From Two DAS-II Subtests (Recall of Digits Forward and Recognition of Pictures)|Cognitive, Motor and Language Scale Scores From the Bayley Certified Scales of Infant Development III Edition|Behavioral Problems and Social Competencies at 36 and 60 Months of Age, as Measured by the Child Behavior Checklist (CBCL)|Attention Deficit Hyperactivity Disorder (ADHD) Index Score From the Connors' Rating Scales (Parent-S) - Revised|Participants With Placental Abruption|Participants With Gestational Hypertension|Participants With Preeclampsia|Gestational Diabetes Mellitus|Participants With Composite Neonatal Outcome|Participants Who Experienced a Stillbirth or Miscarriage|Number of Neonatal Deaths|Number of Infants With Apgar Score 4 at 1 Minute and < 7 at 5 Minutes|Number of Infants Admitted to NICU|Infants With Birth Weight < 10th Percentile (Gestational Age z Score)|Neonatal Head Circumference (Centimeters)|Number of Infants With Respiratory Distress Syndrome|Number of Infants With Retinopathy or Prematurity|Number of Infants With Necrotizing Enterocolitis|Number of Infants With Bronchopulmonary Dysplasia|Number of Infants With Respiratory Therapy Greater Than or Equal to 1 Day|Number of Days in the Hospital Nursery","The George Washington University Biostatistics Center|National Institute of Neurological Disorders and Stroke (NINDS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","1203","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","HD36801-TSH|U10HD021410|U10HD027869|U10HD027917|U10HD027860|U10HD027915|U10HD034116|U10HD034208|U10HD034136|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U10HD036801|U10HD053118","October 2006","August 2015","October 2015","October 16, 2006","January 30, 2019","February 21, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Case Western University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Sciences University, Portland, Oregon, United States|University of Pittsburgh Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwest, Dallas, Texas, United States|University of Texas Medical Branch - Galveston, Galveston, Texas, United States|University of Texas-Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00388297"
822,"NCT00386230","Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Drug: ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Drug: ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Drug: ZDV Long (mother)-Long (infant): Comparison of zidovudine durations","Definitive HIV infection in children as assessed by positive PCR on two peripheral blood samples collected at two separate occasions.|Safety: clinical and biological assessment.","Institut de Recherche pour le Developpement|Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","1554","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","PHPT-1|NIH 5 R01 HD33326-05","June 1997","null","August 2000","October 11, 2006","null","May 2, 2008","Phpt - Ird 174, Chiang Mai, Thailand","","https://ClinicalTrials.gov/show/NCT00386230"
823,"NCT00289315","The Louisiana (LA) Health Project",,"Completed","Has Results","Childhood Obesity","Behavioral: Primary (Environmental) Weight Gain Prevention|Behavioral: Secondary (Behavioral) Weight Gain Prevention|Behavioral: Control","% Body Fat (Boys)|BMI Z-score (Boys)|% Body Fat (Girls)|BMI Z-score (Girls)","Pennington Biomedical Research Center|United States Department of Agriculture (USDA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","2060","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","LA Health|R01HD048483-01","August 2005","May 2009","May 2009","February 9, 2006","June 12, 2018","July 10, 2018","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT00289315"
824,"NCT00135707","Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)","CAPPS","Completed","Has Results","Preeclampsia","Drug: Dietary Supplement/Vitamins|Drug: Placebo for Vitamin C and Vitamin E","Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes in the Mother or Fetus or Neonate|Severe Hypertension|Severe or Mild Pregnancy-associated Hypertension With Elevated Liver Enzyme Levels|Severe or Mild Pregnancy-associated Hypertension With Thrombocytopenia|Severe or Mild Pregnancy-associated Hypertension With an Elevated Serum Creatinine Level|Severe or Mild Pregnancy-associated Hypertension With an Eclamptic Seizure|Severe or Mild Pregnancy-associated Hypertension With an Indicated Preterm Birth Before 32 Weeks of Gestation Owing to Hypertension-related Disorders|Severe or Mild Pregnancy-associated Hypertension With a Fetus That Was Small for Gestational Age (Below the 3rd Percentile) Adjusted for Sex and Race or Ethnic Group|Severe or Mild Pregnancy-associated Hypertension With a Fetal Death After 20 Weeks of Gestation or Neonatal Death|Preeclampsia (Mild, Severe, HELLP Syndrome, Eclampsia)|Pregnancy Associated Hypertension|Medically Indicated Delivery Because of Hypertension|Aspartate Aminotransferase ≥100 U/Liter|Creatinine ≥1.5 mg/dl (133 μmol/Liter)|Antepartum Bleeding|Premature Rupture of Membranes|Placental Abruption|Cesarean Delivery|Maternal Death|Postpartum Pulmonary Edema|Hematocrit ≤24% With Transfusion|Maternal Hospital Stay|Gestational Age at Delivery|Preterm Birth|Fetal or Neonatal Death|Birth Weight|Small for Gestational Age|Birth Weight <2500 Grams|Admission to NICU|Respiratory Distress Syndrome|Intraventricular Hemorrhage, Grade III or IV|Sepsis|Necrotizing Enterocolitis|Retinopathy of Prematurity|Apgar Score <=3 at 5 Minutes|Neonatal Hospital Stay","The George Washington University Biostatistics Center|National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","10154","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HD36801-CAPPS|U10HD021410|U10HD027869|U10HD027917|U10HD027860|U10HD027915|U10HD034116|U10HD034208|U10HD034136|U10HD040500|U10HD040485|U10HD040544|U10HD040545|U10HD040560|U10HD040512|U01HD036801|U10HD053097|U10HD053118","June 2003","October 2008","January 2009","August 26, 2005","November 20, 2018","February 21, 2019","University of Alabama - Birmingham, Birmingham, Alabama, United States|Northwestern University, Chicago, Illinois, United States|Wayne State University, Detroit, Michigan, United States|Columbia University, New York, New York, United States|University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Case Western University, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Drexel University, Philadelphia, Pennsylvania, United States|University of Pittsburgh Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Brown University, Providence, Rhode Island, United States|University of Texas - Southwest, Dallas, Texas, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00135707"
825,"NCT00004778","Phase III Randomized, Double-Blind, Placebo-Controlled Study of Antenatal Thyrotropin-Releasing Hormone in Pregnant Women With Threatened Premature Delivery",,"Completed","No Results Available","Respiratory Distress Syndrome","Drug: betamethasone|Drug: dexamethasone|Drug: thyrotropin-releasing hormone","","National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Hospital of Philadelphia|Office of Rare Diseases (ORD)","Female","Child, Adult, Older Adult","Phase 3","1090","NIH|Other","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Treatment","199/11826|CHP-92536","August 1993","null","null","February 25, 2000","null","June 24, 2005","","","https://ClinicalTrials.gov/show/NCT00004778"
826,"NCT00004312","Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis",,"Completed","No Results Available","Cystinosis","","","National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of California, San Diego","All","Child, Adult, Older Adult","","400","NIH|Other","Observational","Primary Purpose: Screening","NCRR-M01RR00827-1196|UCSD-970026|UCSD-950338","October 1999","null","null","October 19, 1999","null","June 24, 2005","University of California San Diego School of Medicine, La Jolla, California, United States","","https://ClinicalTrials.gov/show/NCT00004312"
827,"NCT00046436","Rapid HIV Tests for Women Late in Pregnancy and During Labor",,"Terminated","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Centers for Disease Control and Prevention|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","13 Years and older   (Child, Adult, Older Adult)","","7500","NIH|U.S. Fed","Observational","Time Perspective: Prospective","PACTG P1031","null","null","March 2004","October 1, 2002","null","June 3, 2013","Univ. of Pennsylvania Health System, Hosp. of the Univ. of Pennsylvania, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT00046436"
828,"NCT00375089","Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity",,"Completed","No Results Available","Prader-Willi Syndrome|Obesity","Other: Group 1|Other: Group 2","Phenotypic assessments of participants|longitudinal pattern of progression","University of Florida|Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 60 Years   (Child, Adult)","","392","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN 5202|U54HD061222|ARP 5202","September 2006","January 2014","January 2014","September 12, 2006","null","September 22, 2014","University of California at Irvine, Orange, California, United States|University of Florida, Gainesville, Florida, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT00375089"
829,"NCT00028145","Prenatal and Postnatal Studies of Interventions for Prevention of Mother-To-Child Transmission",,"Completed","No Results Available","HIV Infections|Pregnancy Complications, Infectious","Behavioral: Adherence assessment","Maternal and infant response to prescribed interventions|Immune and viral parameters of participants taking prescribed interventions|Occurrences of genotypic and phenotypic resistance in HIV-infected mothers|Clinical, immunological, and virological responses in HIV-infected women|Mother-to-child transmission rates of resistance mutations|Adherence to ART among HIV-infected pregnant women during pregnancy and postpartum","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","14 Years and older   (Child, Adult, Older Adult)","","3090","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","PACTG P1025|U01AI068632","October 2002","June 2013","June 2013","December 14, 2001","null","October 10, 2014","Univ. of Alabama Birmingham NICHD CRS (5096), Birmingham, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Long Beach Memorial (Pediatric), Long Beach, California, United States|Miller Children's Hospital Long Beach (5093), Long Beach, California, United States|Los Angeles County Medical Center/USC, Los Angeles, California, United States|Usc La Nichd Crs (5048), Los Angeles, California, United States|UCLA Med Ctr / Pediatric, Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601), Los Angeles, California, United States|Univ of California, San Diego (4601), San Diego, California, United States|Univ. of California San Francisco NICHD CRS (5091), San Francisco, California, United States|Harbor-UCLA Med Ctr (5045), Torrance, California, United States|University of Colorado Denver NICHD CRS (5052), Denver, Colorado, United States|Connecticut Childrens Medical Center (Pediatric), Farmington, Connecticut, United States|University of Connecticut, Farmington, Farmington, Connecticut, United States|Yale Univ School of Med, New Haven, Connecticut, United States|Children's National Medical Center Washington DC NICHD CRS (5015), Washington, District of Columbia, United States|Washington Hospital Center NICHD CRS (5023), Washington, District of Columbia, United States|Howard Univ Hosp (5044), Washington, District of Columbia, United States|North Broward Hosp District, Fort Lauderdale, Florida, United States|South Florida CDC Ft Lauderdale NICHD CRS (5055), Ft Lauderdal, Florida, United States|University of Florida Jacksonville (5051), Jacksonville, Florida, United States|Jackson Memorial Hosp, Miami, Florida, United States|University of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|University of South Florida at Tampa (5018), St Petersburg, Florida, United States|Med College of Georgia, Augusta, Georgia, United States|The Medical Center, Columbus, Georgia, United States|Womens & Childrens HIV Program, Chicago, Illinois, United States|Mt Sinai Hosp Med Ctr / Dept of Pediatrics, Chicago, Illinois, United States|Univ of Illinois, Chicago, Illinois, United States|Cook County Hospital, Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Chicago Childrens Memorial Hosp (Pediatric), Chicago, Illinois, United States|Univ of Chicago Children's Hosp (4001), Chicago, Illinois, United States|Tulane University New Orleans (5095), New Orleans, Louisiana, United States|Tulane-Lakeside Hospital, New Orleans, Louisiana, United States|Tulane University Charity Hosp of New Orleans (7201), New Orleans, Louisiana, United States|University of Maryland Baltimore NICHD CRS (5094), Baltimore, Maryland, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Children's Hospital of Boston NICHD CRS (5009), Boston, Massachusetts, United States|Boston Med Ctr (Pediatric) (5011), Boston, Massachusetts, United States|Brigham and Women's Hosp, Boston, Massachusetts, United States|Baystate Med Ctr of Springfield, Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS (7301), Worcester, Massachusetts, United States|Univ of Massachusetts Med School, Worcester, Massachusetts, United States|Hutzel Hospital (5089), Detroit, Michigan, United States|Wayne State University Detroit Children's Hosp of Michigan (5041), Detroit, Michigan, United States|St. Louis Children's Hosp, St. Louis, Missouri, United States|Univ of Medicine & Dentistry of New Jersey / Univ Hosp (P2802), Newark, New Jersey, United States|New Jersey Medical School (2802), Newark, New Jersey, United States|Univ of Med & Dentistry of New Jersey/Univ Hosp, Newark, New Jersey, United States|Lincoln Medical & Mental Health Center, Bronx, New York, United States|Bronx-Lebanon Hospital IMPAACT (6901), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Montefiore Medical / AECOM, Bronx, New York, United States|Children's Hospital at Downstate, Brooklyn, New York, United States|New York University NY (5012), New York, New York, United States|NYU/Bellevue Hospital, New York, New York, United States|Metropolitan Hosp Ctr (5003), New York, New York, United States|Columbia IMPAACT CRS (4101), New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|State Univ of New York at Stony Brook (5040), Stony Brook, New York, United States|SUNY Upstate Medical Univ, Syracuse, New York, United States|Duke Univ (Pediatric) (DUMC) (4701), Durham, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Hahnemann University Hospital (6706), Philadelphia, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Children's Hospital of Philadelphia (6701), Philadelphia, Pennsylvania, United States|The Regional Med Ctr, Memphis (6502), Memphis, Tennessee, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States|Texas Children's Hosp / Baylor Univ (3801), Houston, Texas, United States|Univ of Washington Children's Hospital Seattle (5017), Seattle, Washington, United States|Harborview Medical Center NICHD CRS (5027), Seattle, Washington, United States|University of Washington NICHD CRS (5029), Seattle, Washington, United States|University of Puerto Rico Pediatric HIV/AIDS (6601), San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS (5031), San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00028145"
830,"NCT00014989","Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial)","BEAM","Completed","No Results Available","Cerebral Palsy|Intraventricular Hemorrhage|Periventricular Leukomalacia|Pulmonary Edema|Abruptio Placentae","Drug: magnesium sulfate","Composite outcome of death or moderate to severe cerebral palsy|Maternal|Chorioamnionitis|Endometritis|Other infectious morbidity|Pulmonary edema|Placental abruption|Neonatal|Stillbirth and neonatal death|Intraventricular hemorrhage|Neonatal infectious morbidity|Neonatal noninfectious morbidity|Birth weight|Days in NICU","The George Washington University Biostatistics Center|National Institute of Neurological Disorders and Stroke (NINDS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","Phase 3","2136","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","NICHD-0800|U10-HD40473|U10HD021410|U10HD027905|U10HD027917|U10HD027860|U10HD027915|U10HD034116|U10HD034208|U10HD034136|U10-HD40462","December 1997","February 2007","June 2007","April 18, 2001","null","September 28, 2016","University of Alabama, Birmingham, Alabama, United States|Dept of OB/GYN, University of Miami, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|Dept of OB/GYN, Hutzel Hospital, Detroit, Michigan, United States|St. Luke's - Roosevelt Hospital, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Forsyth Memorial Hospital, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|The University Hospital, University of Cincinnati, Cincinnati, Ohio, United States|Case Western University, Cleveland, Ohio, United States|Dept of OB/GYN, Ohio State University, Columbus, Ohio, United States|MCP Hahnemann University, Philadelphia, Pennsylvania, United States|Dept of OB/GYN Magee Womens Hospital, Pittsburgh, Pennsylvania, United States|Women and Infants Hospital, Providence, Rhode Island, United States|Dept of OB/GYN, Southwestern Medical Center, University of Texas, Dallas, Texas, United States|University of Texas Medical Branch - Galveston, Galveston, Texas, United States|University of Texas - Houston, Houston, Texas, United States|University of Utah Medical Center, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT00014989"
831,"NCT03781752","Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD",,"Recruiting","No Results Available","ADHD|Attention Deficit Hyperactivity Disorder","Drug: Methylphenidate","Maximum methylphenidate plasma concentration (Cmax),|Time to maximum concentration (Tmax)|Area under the plasma concentration curve (AUClast)|Area under the plasma concentration curve (AUCinf)","Icahn School of Medicine at Mount Sinai|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Florida|Children's Hospital Medical Center, Cincinnati|Seattle Children's Hospital","All","6 Years to 17 Years   (Child)","Phase 4","500","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","GCO 17-0281|1R01HD093612-01A1","March 4, 2018","July 31, 2023","July 31, 2023","December 20, 2018","null","April 10, 2019","University of Florida, Gainesville, Florida, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT03781752"
832,"NCT03401398","Stress Hydrocortisone In Pediatric Septic Shock","SHIPSS","Recruiting","No Results Available","Septic Shock","Drug: Hydrocortisone, sodium succinate|Drug: Normal saline","28-day hospital mortality or ≥25% decrease from baseline in health-related quality of life (HRQL) assessed utilizing the Pediatric Quality of Life Inventory, (PedsQL)|New or progressive multiple organ dysfunction syndrome as assessed utilizing the Pediatric Logistic Organ Dysfunction (PELOD II) instrument.","Jerry Zimmerman|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Canadian Institutes of Health Research (CIHR)|Canadian Critical Care Trials Group|Children's Hospital of Eastern Ontario|Seattle Children's Hospital","All","1 Month to 17 Years   (Child)","Phase 3","1032","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IRB-P00027662|1 R01 HD096901-01","March 11, 2019","March 10, 2023","June 10, 2023","January 17, 2018","null","March 13, 2019","Children's Hospital of Los Angeles, Los Angeles, California, United States|UCSF Benioff Children's Hospital, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|UCSF Benioff Children's Hospital San Francisco, San Francisco, California, United States|Nemours Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|The University of Chicago Comer Children's Hospital, Chicago, Illinois, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Maria Fareri Children's Hospital, Valhalla, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|The Children's Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Penn State Milton S. Hershey Children's Hospital, Hershey, Pennsylvania, United States|Le Bonheur Children's Hospital, Memphis, Tennessee, United States|Medical City Children's Hospital, Dallas, Texas, United States|The Children's Hospital of San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Alberta Children's Hospital, Calgary, Alberta, Canada|BC Children's Hospital, Vancouver, British Columbia, Canada|IWK Health Centre, Halifax, Nova Scotia, Canada|McMaster Children's Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada|Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada|Montreal Children's Hospital, Montréal, Quebec, Canada|Centre hospitalier de l'Université Laval, Québec, Quebec, Canada|Saskatoon Children's Hospital, Saskatoon, Saskatchewan, Canada","","https://ClinicalTrials.gov/show/NCT03401398"
833,"NCT03242954","Innovative Approaches for Minor Consent: Consent 2.0",,"Enrolling by invitation","No Results Available","HIV","Other: Parental Permission Required|Other: Adult permission required|Other: Autonomous consent","Mean adolescent WTP scores|Mean parent WTP scores|Mean adolescent UCSD Brief Assessment of Capacity to Consent (UBACC) scores|Mean parent UBACC scores","Indiana University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Minority Health and Health Disparities (NIMHD)","All","14 Years to 17 Years   (Child)","Not Applicable","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","17-0538|5U24HD089880-02","November 7, 2017","February 28, 2020","February 28, 2020","August 8, 2017","null","December 18, 2018","Children's Hospital Colorado/Univ of Colorado SOM, Aurora, Colorado, United States|University of South Florida, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University/SOM, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03242954"
834,"NCT03760458","The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age",,"Not yet recruiting","No Results Available","HIV Infections","Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets|Drug: Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Immediate Release Tablets (Immediate release)","Geometric mean area under the plasma concentration-time curve over 24 hours at steady-state (AUC0-24h) for ABC, DTG, and 3TC|Geometric mean maximum plasma concentration (Cmax) for ABC, DTG, and 3TC|Geometric mean concentration at 24 hours post-dose (C24h) for ABC, DTG, and 3TC|Number of participants who had adverse events|Number of participants who had Grade 3 or Grade 4 adverse events assessed as related to study drug|Number of participants who had Grade 5 adverse events assessed as related to study drug|Number of participants who had serious adverse events assessed as related to study drug|Number of participants who had adverse events assessed as related to study drug that lead to permanent discontinuation of study drug|Area under the plasma concentration-time curve over 24 hours at steady-state (AUC0-24h) for ABC, DTG, and 3TC|Concentration at time 0 (pre-dose) (C0h) for ABC, DTG, and 3TC|Concentration at 24 hours post-dose (C24h) for ABC, DTG, and 3TC|Maximum plasma concentration (Cmax) for ABC, DTG, and 3TC|Time to maximum concentration (Tmax) for ABC, DTG, and 3TC|Apparent oral clearance (CL/F) for ABC, DTG, and 3TC|Half-life (t1/2) for ABC, DTG, and 3TC|Proportion of participants with HIV-1 RNA levels meeting virologic response criteria|Number of participant with HIV-1 RNA greater than or equal to 200 copies/mL at Weeks 4, 24, and 48 (snapshot algorithm)|Number of participants with HIV-1 RNA greater than or equal to 50 copies/mL at Weeks 4, 24, and 48 (snapshot algorithm)|Median changes (with IQR) in CD4+ cell count and percentage at Weeks 4, 24, and 48|Median changes (with IQR) in CD4+ cell count and percentage through Week 144|Median changes (with IQR) in total cholesterol, HDL, LDL, and triglycerides at Weeks 24 and 48|Aggregated data on parent/guardian reported adherence to study drug at Weeks 4, 24, and 48|Aggregated data on parent/guardian reported tolerability (i.e., palatability and acceptability) of study drug at Weeks 4, 24, and 48|ARV resistance mutations at time of virologic failure (and at entry for children with resistance identified at time of virologic failure)","National Institute of Allergy and Infectious Diseases (NIAID)|International Maternal Pediatric Adolescent AIDS Clinical Trials Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|ViiV Healthcare Ltd.","All","2 Years to 12 Years   (Child)","Phase 1|Phase 2","75","NIH|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IMPAACT 2019|38504","April 2019","February 28, 2021","August 31, 2023","November 30, 2018","null","March 5, 2019","David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03760458"
835,"NCT01491919","Safety Study of Lisinopril in Children and Adolescents With a Kidney Transplant","PTN_LISINO","Completed","Has Results","Hypertension","Drug: Lisinopril","Pharmacokinetics (PK) - Area Under the Plasma Concentration-time Curve (AUC)|PK - Maximum Observed Concentration of Drug in Plasma (Cmax)|PK - Time of the Maximum Observed Concentration in Plasma (Tmax)|PK - Oral Clearance (CL/F)|PK Renal Clearance (CLrenal)|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) During/After Study Drug Administration|Change in Potassium Level From Baseline in Lisinopril-naive Participants|Worse Post-dose Decrease in Estimated Glomerular Filtration Rate (eGFR) From Baseline in Lisinopril-naive Participants|Largest eGFR Percent Decrease From Baseline in Lisinopril-naive Participants|Change in Urine Protein/Creatinine From Baseline in Lisinopril-naive Participants.|Change in Diastolic Blood Pressure From Baseline in Lisinopril-naive Participants|Change in Systolic Blood Pressure From Baseline in Lisinopril-naive Participants|Change in Systolic Blood Pressure (BP) From Baseline in Lisinopril SOC Group|Change in Diastolic Blood Pressure From Baseline in Lisinopril SOC Group","Uptal Patel|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|The EMMES Corporation|University of Rochester|OpAns, LLC|Duke University","All","2 Years to 17 Years   (Child)","Phase 1","26","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00029537|HHSN275201000003I","June 2012","September 2013","September 2013","December 14, 2011","July 8, 2015","July 8, 2015","University of Alabama, Birmingham, Alabama, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Emory University and Children's Healthcare of Atlanta, Atlanta, Georgia, United States|University of Michigan, Ann Arbor, Michigan, United States|Children's Mercy Hospitals & Clinics, Kansas City, Missouri, United States|New York University Langone Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States","","https://ClinicalTrials.gov/show/NCT01491919"
836,"NCT01843036","Durham Connects RCT Evaluation II",,"Active, not recruiting","No Results Available","Unspecified Child Maltreatment, Suspected|Unspecified Child Maltreatment, Confirmed","Other: Durham Connects","DSS Investigated and Substantiated Child Maltreatment Rates|Child Emergency Room (ER) Presentation Rates|Child Overnight Stays in Hospital|Mother Postnatal Well-Care Compliance Rates|Child Postnatal Well-Care Compliance Rates|Mother Emergency Room (ER) Presentation Rates|Mother Overnight Stays in Hospital|Mother Mental Health|Family Connections to Community Services/Resources|Mother Parenting Behaviors","Duke University|The Duke Endowment|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Coalition for Evidence-Based Policy|Laura and John Arnold Foundation","All","up to 6 Months   (Child)","Not Applicable","1650","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Pro00017478_Amd6|Pro00052735|1R01HD069981","January 2014","June 2026","June 2026","April 30, 2013","null","April 11, 2019","Center for Child and Family Policy, Duke University, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01843036"
837,"NCT00759746","Childhood Obesity Treatment: A Maintenance Approach","COMPASS","Completed","No Results Available","Childhood Overweight|Childhood Obesity","Behavioral: SFM+ Low Dose|Behavioral: Weight Maintenance Education|Behavioral: SFM+ High Dose","Child percent overweight","Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Seattle Children’s Hospital Research Institute|University of Florida|State University of New York at Buffalo","All","7 Years to 11 Years   (Child)","Not Applicable","482","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","201107083|2R01HD036904","October 2009","March 2013","March 2013","September 25, 2008","null","February 23, 2017","Washington University School of Medicine, St. Louis, Missouri, United States|Seattle Children's Hospital Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00759746"
838,"NCT01316653","Growing Right Onto Wellness (GROW): Changing Early Childhood Body Mass Index (BMI) Trajectories","GROW","Completed","No Results Available","Overweight and Obesity|Childhood Obesity","Behavioral: GROW Healthier|Behavioral: GROW Smarter","Early Childhood BMI Trajectory|Average daily energy intake (kcal)|Percentage of Energy Intake from Fat|Percentage of Energy Intake from Carbohydrates|Percentage of Energy Intake from Protein|Average daily time (minutes) spent in rest and sedentary behavior|Average daily time (minutes) spent in moderate and vigorous physical activity|Parent community center use with child|Parent BMI|Parent Waist Circumference|Parent Triceps Skinfold|Child Waist Circumference|Child Triceps Skinfold","Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Nashville Metro Parks and Recreation Department|Nashville Public Library Foundation|Vanderbilt University Medical Center","All","3 Years to 5 Years   (Child)","Not Applicable","610","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","100591|5U01HL103620-03","June 2011","June 13, 2017","July 6, 2017","March 16, 2011","null","February 8, 2019","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01316653"
839,"NCT00107042","Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths",,"Completed","Has Results","Hepatitis B","Biological: Recombivax|Biological: Twinrix","Qualitative Seroresponsiveness to Hepatitis B Surface Antigen|Safety and Tolerability of Vaccine Regimens of Recombivax and Twinrix (Number of Participants With >=1 Adverse Event (AE))|Safety and Tolerability of Vaccine Regimens of Recombivax and Twinrix: Serious Adverse Events (SAE)(Number of Subjects With >= 1 SAE)|Quantitative Vaccine Response|Unadjusted Relationship of Hepatitis B Vaccine Response (Log10 Titer) and Potential Impact Factors Among Subjects Whose Week 28 Antibody Results Are Within Week 28 Visit Window.|Outcome Measure: Qualitative Vaccine Response to Hepatitis B (Hep B) Surface Antigen (Binary); Predictor: STUDY ARM.|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: SITE EFFECT|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: AGE|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: GENDER|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: HISPANIC ETHNICITY|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: RACE|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TANNER STAGE FOR FEMALES|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TANNER STAGE FOR MALES|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: BMI at Baseline|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER SMOKED CIGARETTES|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: SEXUAL IDENTITY|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: AGE AT WHICH SUBJECT FIRST HAD SEX (NOT FORCED)|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME SEX PARTNERS|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME MALE SEX PARTNERS|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: TOTAL LIFETIME FEMALE SEX PARTNERS|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER DRANK ALCOHOL|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER SMOKED MARIJUANA|Outcome Measure: Qualitative Vaccine Response to Hepatitis B Surface Antigen (Binary); Predictor: EVER USED DRUGS NOT PRESCRIBE|Immunogenicity to Hep B 18 Months After First Immunization|Immunogenicity to Hep A in the Twinrix Arm: One Month Post 2nd Vaccination|Immunogenicity to Hep A in Twinrix Arm: Twelve Months Post 2nd Vaccination|Immunogenicity to Hep A in Twinrix Arm: Overall Response (1-month or 12-month After 2nd Vaccination)|As Treated Analysis - Adequate Antibody Response to Hep B Surface Antigen|Assessment of Youth Understanding of Vaccine Trial and Informed Consent","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)","All","12 Years to 17 Years   (Child)","Phase 2","123","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","ATN 025","February 2004","July 2008","July 2008","April 5, 2005","December 4, 2012","March 29, 2017","Children's Hospital of Los Angeles, Los Angeles, California, United States|University of California at San Diego, San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Children's Hospital National Medical Center, Washington, District of Columbia, United States|University of Southern Florida College of Medicine, Tampa, Florida, United States|Ruth M Rothstein CORE Center/ John H Stroger Jr Hospital, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Montefiore Medical Center, Bronx, New York, United States|St. Jude Childrens Research Hospital, Memphis, Tennessee, United States|Unversity of Peurto Rico School of Medicine, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT00107042"
840,"NCT03145142","PREMOD2 With Near Infrared Spectroscopy Sub-study","PREMOD2","Active, not recruiting","No Results Available","Hypoxia, Brain|Premature Birth","Procedure: Umbilical cord milking|Procedure: Delayed Cord Clamping","StO2 - 10M|StO2 - 24H|HR - 10M|HR 24H|Blood Pressure NICU","Sharp HealthCare|University of Ulm|University College Cork|University of Alberta|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","23 Weeks to 28 Weeks   (Child)","Not Applicable","121","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PREMOD2 - NIRS Sub-study|1R01HD088646-01A1","June 6, 2017","September 17, 2018","May 15, 2019","May 9, 2017","null","November 28, 2018","Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States|Governors of University of Alberta, Edmonton, Alberta, Canada|University of ULM, Ulm, Baden-Wurttemberg, Germany|Cork University Maternity Hospital, Cork, Ireland","","https://ClinicalTrials.gov/show/NCT03145142"
841,"NCT01775813","The Health Influences of Puberty (HIP) Study","HIP","Completed","No Results Available","Obesity|Insulin Resistance|Gonadal Dysfunction|Type 2 Diabetes","Drug: Metformin","Change in insulin sensitivity|Change in insulin secretion|Change in disposition index|Change in lipid measures|Change in insulin-like growth factor 1|Change in testosterone|Change in estradiol|Change in sex hormone binding globulin|Change in dehydroepiandrosterone sulfate|Change in interleukin-6|Change in high Sensitivity C-reactive protein|Change in aspartate Aminotransferase (AST)|Change in alanine transaminase (ALT)|Change in urinary Luteinizing hormone|Change in urinary Follicle-stimulating hormone|Change in urinary estradiol metabolites|Change in hemoglobin A1c|Change in leptin|Change in %body fat|Change in visceral adipose|Change in liver adipose","University of Colorado, Denver|American Diabetes Association|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Children's Hospital Colorado","All","9 Years to 17 Years   (Child)","Phase 4","77","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","07-0988|Protocol 914|1-11-JF-23|5K12HD057022","June 2011","May 31, 2018","May 31, 2018","January 25, 2013","null","July 17, 2018","Children's Hospital Colorado, Aurora, Colorado, United States","","https://ClinicalTrials.gov/show/NCT01775813"
842,"NCT02918435","Implementing an Intervention to Address Social Determinants of Health in Pediatric Practices","PROSWECARE","Not yet recruiting","No Results Available","Basic Unmet Material Needs|Patient Satisfaction|Receipt of Community Resources|Provider Referrals","Behavioral: WE CARE","Receipt of Community Resources|Provider Referrals for Unmet Material Needs at Visit|WE CARE survey distribution|Appropriate referrals made by providers|Patient satisfaction measured via the CAHPS Clinician and Group Survey (Child)|Family centeredness measured via the National Survey of Children's Health (2016)|Care coordination measured via the National Survey of Children's Health (2016)|Acceptability of WE CARE measured via questionnaires|Whether Discussion of Unmet Needs (e.g., food insecurity) occurred at child's well-child care visit|Appropriateness of WE CARE measured via questionnaire","Boston Medical Center|Pediatric Research in Office Settings|Continuity Research Network|Boston University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Months to 10 Years   (Child)","Not Applicable","2520","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Screening","H-35482|R01HD090191","May 2019","August 2021","August 2021","September 29, 2016","null","March 26, 2019","Arvin Garg, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02918435"
843,"NCT02567006","SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala","SMSVaxGuate","Active, not recruiting","No Results Available","Adherence to Vaccination Schedules|Timeliness of Vaccination|Acceptability of SMS Reminder Program","Behavioral: SMS message|Other: Usual care","Completion of vaccine primary series|Factors associated with immunization delays|Acceptability of SMS vaccine reminders|Timeliness of immunization","University of Colorado, Denver|Universidad del Valle, Guatemala|Fundacion para la Salud Integral de los Guatemaltecos CU|Ministry of Health, Guatemala|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Weeks to 6 Months   (Child)","Not Applicable","720","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","14-2170|1R21HD084115-01","March 2016","December 2018","December 2018","October 2, 2015","null","August 23, 2018","Fundacion para la Salud Integral de los Guatemaltecos CU, Coatepeque, Quetzaltenango, Guatemala|University del Valle, Guatemala, Guatemala, Guatemala","","https://ClinicalTrials.gov/show/NCT02567006"
844,"NCT01406184","Durham Connects RCT Evaluation",,"Active, not recruiting","No Results Available","Unspecified Child Maltreatment, Suspected|Unspecified Child Maltreatment, Confirmed","Other: Durham Connects","DSS Investigated and Substantiated Child Maltreatment Rates|Child Emergency Room (ER) Presentation Rates|Child Overnight Stays in Hospital|Child Postnatal Well-Care Compliance Rates|Child Social-Emotional Competence and Behavior Problems|Mother Mental Health|Family Connections to Community Services/Resources|Mother Parenting Behaviors","Duke University|The Duke Endowment|The Pew Charitable Trusts|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Robert Wood Johnson Foundation","All","up to 6 Months   (Child)","Not Applicable","2329","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Pro00020974|Pro00017478|1R01HD069981|Pro00027652","July 2009","December 2022","December 2022","August 1, 2011","null","March 29, 2019","Center for Child and Family Policy, Duke University, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01406184"
845,"NCT02396407","Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health",,"Completed","No Results Available","Helminthiasis|Diarrhea|Respiratory Infection","Behavioral: Combined water, sanitation, and hygiene","Prevalence of soil-transmitted helminths (Ascaris, hookworm, Trichuris)|Intensity of soil-transmitted helminth infections (Ascaris, hookworm, Trichuris)|Diarrhea prevalence|Respiratory illness prevalence","University of California, Berkeley|International Centre for Diarrhoeal Disease Research, Bangladesh|Stanford University|Bill and Melinda Gates Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 60 Months   (Child)","Not Applicable","1789","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","1R21HD076216-01A1","January 2015","May 2016","May 2016","March 24, 2015","null","October 26, 2016","International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh","","https://ClinicalTrials.gov/show/NCT02396407"
846,"NCT00428116","Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya",,"Terminated","Has Results","HIV Infections","Drug: HAART","Growth at 18 Months Post-randomization|Morbidity","University of Washington|Fred Hutchinson Cancer Research Center|University of Nairobi|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 54 Months   (Child)","Not Applicable","140","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00001675|R01HD023412","September 2007","July 2013","December 2014","January 29, 2007","August 20, 2015","July 25, 2018","","","https://ClinicalTrials.gov/show/NCT00428116"
847,"NCT03529695","In-home Obesity Prevention to Reach Low-income Infants",,"Enrolling by invitation","No Results Available","Obesity|Obesity, Childhood|Obesity; Familial","Behavioral: Standard HVP Curriculum|Behavioral: Obesity Prevention","Weight of mothers|Rate of weight gain of infants|Waist circumference of mothers|Mother blood glucose|Mother blood lipids|Infant leptin|Infant adiponectin|Maternal eating, feeding, and activity behaviors|Infant eating and activity behaviors|Habit strength of maternal eating, activity, and feeding behaviors|Household food environment|Household activity environment|Social network support|Social network health norms|Maternal emotional support|Maternal instrumental support|Maternal social isolation|Maternal Food Security","University of Southern California|Antelope Valley Partners for Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Cedars-Sinai Medical Center","Female","2 Months and older   (Child, Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","1R01HD092483-01","November 1, 2018","September 1, 2021","May 31, 2022","May 18, 2018","null","April 5, 2019","University of Southern California, Los Angeles, California, United States","","https://ClinicalTrials.gov/show/NCT03529695"
848,"NCT03848728","Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa",,"Not yet recruiting","No Results Available","HIV","Other: SEARCH Youth combination intervention","Effectiveness of SEARCH Youth intervention","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Infectious Diseases Research Collaboration, Uganda|Kenya Medical Research Institute|Makerere University","All","15 Years to 24 Years   (Child, Adult)","Not Applicable","1450","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","SEARCH Youth|UG3HD096915-01","March 2019","December 2024","December 2024","February 21, 2019","null","February 21, 2019","Western Kenya, Sindo, Kenya|Southwestern Uganda, Mbarara, Uganda","","https://ClinicalTrials.gov/show/NCT03848728"
849,"NCT03304717","Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","RTIAGS","Recruiting","No Results Available","Aicardi Goutières Syndrome","Drug: Tenofovir (TDF) and Emtricitabine (FTC)|Other: Placebo","Change in interferon activation as measured by interferon response genes|Determination of immune cell composition in CSF|Determination of immune cell composition in blood|Accumulation of endogenous retroelements as measured in circulating immune cells|Accumulation of endogenous retroelements as measured in circulating CSF|Change in presence of non-specific and specific autoantibodies in blood|Changes in Adverse Events - Safety monitoring laboratory tests|Changes in total days hospitalized for disease-related illnesses.","Children's Hospital of Philadelphia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Human Genome Research Institute (NHGRI)|Gilead Sciences|Emerson Resources","All","2 Years to 18 Years   (Child, Adult)","Phase 1|Phase 2","34","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","17-013715|U01HD082806-03","September 5, 2017","November 2020","November 2020","October 9, 2017","null","April 5, 2019","Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","","https://ClinicalTrials.gov/show/NCT03304717"
850,"NCT03292432","Triggered Escalating Real-time Adherence (TERA) Intervention","TERA","Recruiting","No Results Available","HIV Infections","Behavioral: TERA Intervention|Behavioral: Standard of Care","Proportion of participants with plasma Human Immunodeficiency Virus - Type I ribonucleic acid (HIV-1 RNA) levels less than (<) 50 copies/mL at week 12|Proportion of participants with HIV-1 RNA < 200 copies/mL at week 12|Proportion of participants with HIV-1 RNA < 50 copies/mL at weeks 24, 36 and 48|Proportion of participants with HIV-1 RNA < 200 copies/mL at weeks 24, 36 and 48|Proportion of participants with HIV-1 RNA < 200 copies/mL at 12 weeks and maintained through 48 weeks|Percent of days with all doses taken per week from weeks 0-12, 12-24, 24-36 and 36-48|Percent of days with all doses taken within defined acceptable windows (within 4 hours for once/day ART and within 2 hours for twice/day ART) per week from weeks 0-12, 12-24, 24-36 and 36-48|Incidence rate (per 100 days) of gaps between dosing of at least 7 consecutive days between weeks 0-12, 12-24, 24-36 and 36-48","University of North Carolina, Chapel Hill|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)|National Institute on Minority Health and Health Disparities (NIMHD)","All","13 Years to 24 Years   (Child, Adult)","Not Applicable","120","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","ATN 152|5U24HD089880-02","February 1, 2018","January 17, 2020","August 31, 2020","September 25, 2017","null","March 20, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|University of Colorado Denver Children's Hospital Colorado, Aurora, Colorado, United States|Broward Health Childrens Diagnostic and Treatment Center (CDTC), Fort Lauderdale, Florida, United States|University of Florida Center for HIV/AIDS, Research, Education & Service, Jacksonville, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins University, Baltimore, Maryland, United States|Wayne State University School of Medicine, Detroit, Michigan, United States|Bronx-Lebanon Hospital Center, Bronx, New York, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03292432"
851,"NCT03695068","Efficacy of a Two-Year Intensive Reading Intervention for Middle School English Learners With Reading Difficulties","TCLD","Recruiting","No Results Available","Learning Disorders|Dyslexia","Behavioral: RISE Intervention","Change in Reading Comprehension after two years of treatment (Gates MacGinitie Passage Comprehension)|Change in word reading after two years of treatment (Kaufman Test of Education Achievement, Third Edition, Letter Word Recognition).|Change in word reading after one year of treatment (Kaufman Test of Education Achievement, Third Edition, Letter Word Recognition).|Change in reading fluency after two years of treatment (Kaufman Test of Education Achievement, Third Edition, Word Recognition Fluency).|Change in reading fluency after one year of treatment (Kaufman Test of Education Achievement, Third Edition, Word Recognition Fluency).|Change in Reading Comprehension after one year of treatment (Gates MacGinitie Passage Comprehension)","University of Houston|University of Texas at Austin|The University of Texas Health Science Center, Houston|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","840","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FWA00005994|P50HD052117","September 1, 2018","June 15, 2022","June 15, 2022","October 3, 2018","null","October 3, 2018","University of Texas at Austin, Austin, Texas, United States|University of Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT03695068"
852,"NCT03134833","Engaging Seronegative Youth to Optimize HIV Prevention Continuum",,"Recruiting","No Results Available","HIV|Mental Health|Substance Use|STI","Behavioral: Automated Messaging & Monitoring|Behavioral: Peer Support|Behavioral: Coaching","HIV Testing|STI Testing|Condom Use Frequency|PEP Use / Adherence|PrEP Use / Adherence|Sexual Partners|Mental Health Symptoms|Substance Use|Housing Insecurity","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Tulane University Health Sciences Center|University of California, San Francisco|Friends Research Institute, Inc.","All","12 Years to 24 Years   (Child, Adult)","Not Applicable","1500","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","U19HD089886 - Study 3|U19HD089886","May 6, 2017","September 2020","September 2021","May 1, 2017","null","February 12, 2019","University of California, Los Angeles, Los Angeles, California, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT03134833"
853,"NCT03109431","Stepped Care for Youth Living With HIV",,"Recruiting","No Results Available","HIV|Mental Health|Illicit Substance Use|Sexually Transmitted Infections (STI)","Behavioral: Level 1|Behavioral: Level 2|Behavioral: Level 3","Viral Suppression reflected as VL<200|Retention in Care|ARV Adherence|Reductions in Substance Use|Sexual Partnerships|Mental Health","University of California, Los Angeles|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Wake Forest University Health Sciences|Tulane University Health Sciences Center|Columbia University","All","12 Years to 24 Years   (Child, Adult)","Not Applicable","220","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","U19HD089886 - Study 2|U19HD089886","May 6, 2017","September 2020","September 2021","April 12, 2017","null","October 11, 2018","University of California, Los Angeles, Los Angeles, California, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT03109431"
854,"NCT03103269","Challenge! Adolescent Obesity Prevention","Challenge","Completed","No Results Available","Overweight|Obesity","Behavioral: Challenge! Small Group Intervention|Other: Challenge! Environmental Intervention","Change of Body Mass Index Percentile for Age and Sex for adolescent females|Change of Dietary Quality for adolescent females","University of Maryland|Robert Wood Johnson Foundation|Johns Hopkins Bloomberg School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","10 Years and older   (Child, Adult, Older Adult)","Not Applicable","789","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","HP-00040540|R01HD054727","September 2009","January 2014","January 2014","April 6, 2017","null","April 6, 2017","Baltimore City Public Schools, Baltimore, Maryland, United States","","https://ClinicalTrials.gov/show/NCT03103269"
855,"NCT02875535","Reducing LGBTQ Adolescent Suicide","RLAS","Active, not recruiting","No Results Available","Suicide","Behavioral: RLAS","Adherence to EB strategy implementation|Reduced suicidality and depression measured by the New Mexico Youth Risk and Resiliency Study (NM-YRRS)|Substance use measured by the NM-YRRS|Feelings of safety measured by the NM-YRRS","Pacific Institute for Research and Evaluation|University of New Mexico|University of California, San Diego|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","43","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","0838.01.01|R01HD083399","May 2016","May 31, 2020","April 30, 2021","August 23, 2016","null","May 18, 2018","","","https://ClinicalTrials.gov/show/NCT02875535"
856,"NCT02689531","CTTI Risk Factors for HABP/VABP Study","PROPHETIC","Completed","No Results Available","Pneumonia, Ventilator-Associated|Pneumonia, Bacterial|Pneumonia, Hospital-Acquired","","Development of HABP/VABP|Eligibility for typical antibacterial clinical trial|In enrolled subjects, what factors are associated with the development of hospital acquired or ventilator associated pneumonia.","Duke University|Clinical Trials Transformation Initiative|Food and Drug Administration (FDA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","7530","Other|U.S. Fed|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00068313","February 2016","February 2018","February 2018","February 24, 2016","null","October 22, 2018","Birmingham, Alabama, United States|Los Angeles, California, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Detroit, Michigan, United States|Royal Oak, Michigan, United States|Saint Louis, Missouri, United States|Rochester, New York, United States|Durham, North Carolina, United States|Cleveland, Ohio, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT02689531"
857,"NCT02422511","Genomic Sequencing for Childhood Risk and Newborn Illness",,"Recruiting","No Results Available","Hereditary Disease|Genetic Predisposition to Disease","Genetic: Genomic sequencing|Other: Family history report","Change in family/physician healthcare utilization immediately after results disclosure compared to 3 and 10 months post-disclosure|Change in baseline family relationship and personal distress levels compared to immediately post-disclosure, 3 months post-disclosure and 10 months post-disclosure|Participant characteristics|Change in baseline perceived utility of genomic results compared to post-disclosure","Brigham and Women's Hospital|Boston Children’s Hospital|Baylor College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","Not Applicable","1440","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","The BabySeq Project|U19HD077671","May 2015","August 2018","August 2018","April 21, 2015","null","March 1, 2018","Boston Children's Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02422511"
858,"NCT01206556","IMPAACT P1085: Human Papilloma Virus (HPV) Type-Specific Antibody","HPV","Completed","No Results Available","Papilloma Virus, Human","","To determine the HPV-type specific antibody levels at 2, 3.5, and 5 years after completion of the QHPV vaccine schedule for each of the arms in P1047|Comparing the decline over the study interval in HPV type-specific antibody in subjects who received four doses of QHPV (Arm A) with those who received three doses of vaccine (Arm B) in P1047.|Determining the magnitude of HPV-specific antibody at different times after QHPV vaccination as a function of immune status (as defined by CD4 count and CD4 percent) and plasma HIV viral load.|Determining the persistence of HPV-specific CMI at 2, 3.5, and 5 years after completion of the QHPV schedule for each of the arms in P1047.|Evaluating potential associations of HIV plasma RNA, lymphocyte immunophenotypes, HPV-specific memory B cell lymphocytes and HPV-specific CMI with the decay of anti-HPV antibody titers.","International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Merck Sharp & Dohme Corp.","All","Child, Adult, Older Adult","","97","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","IMPAACT P1085|U01AI068632","May 2010","December 2012","August 2013","September 22, 2010","null","April 1, 2015","Miller Children's Hospital Long Beach (5093), Long Beach, California, United States|USC/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States|UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CR (3601), Los Angeles, California, United States|Univ of California, San Diego (4601), San Diego, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco,, California, United States|Univ. of Colorado Denver NICHD CRS (5052), Aurora, Colorado, United States|Children's National Med. Ctr. Washington DC NICHD CRS (5015), Washington, District of Columbia, United States|South Florida CDC Ft. Lauderdale NICHD CRS (5055), Ft. Lauderdale, Florida, United States|Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Chicago Children's CRS (4001), Chicago, Illinois, United States|Children's Hospital of Boston (5009), Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS (7301), Worcester, Massachusetts, United States|Wayne State University/Children's Hospital of Michigan NICHD CRS (5041), Detroit, Michigan, United States|New Jersey Medical School (NJ) (2802), Newark, New Jersey, United States|Bronx-Lebanon Hospital (6901), Bronx, New York, United States|Jacobi Medical Center Bronx (5013), Bronx, New York, United States|New York University NY (5012), New York, New York, United States|Strong Memorial Hospital, University of Rochester NICHD CRS (5057), Rochester, New York, United States|SUNY Stony Brook (5040), Stony Brook, New York, United States|Texas Children's Hosp / Baylor Univ (3801), Houston, Texas, United States|San Juan City Hosp. PR NICHD CRS (5031), San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT01206556"
859,"NCT01805713","Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung",,"Completed","No Results Available","Cystic Fibrosis","","Biomarkes of Lung Injury|Pulmonary Function|Pulmonary Exacerbations","University of Minnesota - Clinical and Translational Science Institute|National Institutes of Health (NIH)|Minnesota Medical Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","6 Months and older   (Child, Adult, Older Adult)","","150","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","1210M22861|K12HD068322","December 2012","December 2017","December 2017","March 6, 2013","null","January 12, 2018","University of Minnesota, Minneapolis, Minnesota, United States","","https://ClinicalTrials.gov/show/NCT01805713"
860,"NCT00076232","A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes",,"Completed","No Results Available","HIV Infections|HIV Seronegativity|Herpes Genitalis","Drug: Acyclovir|Drug: Acyclovir placebo","Serologically confirmed HIV infection|Occurrence and frequency of genital ulcers|Proportion of doses missed by study participants assigned to twice-daily acyclovir and twice-daily placebo","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Phase 3","3682","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","HPTN 039|1R01AI052054|5U01AI047981-05|DAIDS-ES ID 10066","April 2005","June 2007","November 2007","January 16, 2004","null","December 30, 2010","San Francisco Department of Public Health, AIDS Office, Research Section, San Francisco, California, United States|New York Blood Center, New York City, New York, United States|University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00076232"
861,"NCT00074412","Using Nevirapine to Prevent Mother-to-Child HIV Transmission During Breastfeeding",,"Completed","Has Results","HIV Infections","Drug: Nevirapine|Drug: Nevirapine placebo","HIV Infection in Infants Determined to be HIV Uninfected at 6 Weeks Enrolled in Each Arm of the Study|Frequency and Severity of Adverse Reactions Among Participating Infants|Proportion of Infants Who Are Alive and HIV-uninfected in the Two Arms|Relative Rates of HIV Infection in the Two Arms|Infant Survival Rates (Mortality Regardless of HIV Infection) in the Two Arms|Frequency and Duration of Maternal Plasma and Breast Milk NVP-resistant HIV Strains and the Relationship With HIV Transmission|Relationship Between Maternal Plasma and Breast Milk RNA Levels and the Risk of MTCT|Frequency and Duration of NVP-resistant HIV Strains in Plasma of HIV-infected Infants|Rates of Disease Progression as Defined by CD4 Counts, HIV-1 RNA PCR, and Mortality in Infected Infants in the Two Arms|NVP Concentrations in Infants Determined to be HIV-infected and in a Sample of HIV-uninfected Infants","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","All","Child, Adult, Older Adult","Phase 3","2026","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","HPTN 046|10142","January 2007","September 2011","November 2011","December 15, 2003","September 16, 2013","September 16, 2013","CAPRISA Umlazi CRS, Umlazi, KwaZulu-Natal, South Africa|Muhimbili University of Health and Allied Sciences (MUHAS) CRS, Dar es Salaam, Tanzania|Makerere University- JHU Research Collaboration {MUJHU CARE LTD} CRS, Kampala, Mpigi, Uganda|Seke North CRS, Chitungwiza, Zimbabwe|St Mary's CRS, Chitungwiza, Zimbabwe","","https://ClinicalTrials.gov/show/NCT00074412"
862,"NCT01545674","Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial","PreNATUS","Active, not recruiting","No Results Available","Trisomy 13|Trisomy 18|Trisomy 21|Aneuploidy","Procedure: Blood Draw","Sensitivity and Specificity of the test to diagnose aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y.","Natera, Inc.|Columbia University|George Washington University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child, Adult, Older Adult","","1000","Industry|Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","GSN012B|1R44HD062114","January 2012","April 2014","December 2019","March 7, 2012","null","March 30, 2018","University of Alabama, Birmingham, Alabama, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|University of Miami, Miami, Florida, United States|Adventist Hinsdale Hospital, Hinsdale, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|NY Methodist Hospital, Brooklyn, New York, United States|Madonna Perinatal, Mineola, New York, United States|New York University, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|Columbia University, New York, New York, United States|Carnegie Imaging for Women, New York, New York, United States|Montefiore Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|University of South Carolina, Columbia, South Carolina, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Wisconsin, Madison, Wisconsin, United States|Mt Sinai Hospital, Toronto, Canada|Royal College of Surgeons in Ireland, Dublin, Ireland|University of Perugia, Perugia, Italy|Hamchoon Women's Clinic, Seoul, Korea, Republic of|Institut Universitari Dexeus, Barcelona, Spain","","https://ClinicalTrials.gov/show/NCT01545674"
863,"NCT00048282","HIV Prevention Preparedness Study",,"Completed","No Results Available","HIV Infections|HIV Seronegativity","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Mental Health (NIMH)|National Institute on Drug Abuse (NIDA)","Female","Child, Adult, Older Adult","","1200","NIH","Observational","Time Perspective: Prospective","HIVNET/HPTN 055","null","null","null","October 30, 2002","null","May 14, 2010","R.K. Khan Hospital, Chatsworth, South Africa|Durban, South Africa|Medical Research Council, Hlabisa, South Africa|Hlabisa, South Africa|Kilimanjaro Christian Med Ctr, Moshi, Tanzania|Moshi, Tanzania|Chililabombwe, Zambia|Chilenje Clinic, Lusaka, Sambia, Lusaka, Zambia|Kamwala Clinic, Lusaka, Zambia|Lusaka, Zambia","","https://ClinicalTrials.gov/show/NCT00048282"
864,"NCT00398684","Nevirapine Plus Zidovudine to Prevent Perinatal HIV in Thailand",,"Completed","No Results Available","HIV Infections|Pregnancy","Drug: Single dose nevirapine to the mother and to the child|Drug: Single dose nevirapine to the mother and placebo to the child|Drug: Single dose placebo to the mother and to the child","Definitive HIV infection in infants as assessed by positive HIV DNA PCR on two peripheral blood samples|Tolerance of nevirapine, in particular rashes.","Institut de Recherche pour le Developpement|Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)","Female","Child, Adult, Older Adult","Phase 3","1792","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","PHPT-2; R01-HD39615; ANRS 1208","January 2001","null","June 2004","November 14, 2006","null","May 7, 2008","Phpt - Ird 174, Chiang Mai, Thailand","","https://ClinicalTrials.gov/show/NCT00398684"
865,"NCT00021775","HIV Prevention Preparedness Study in Russia, China, and India",,"Completed","No Results Available","HIV Infections","","","National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Mental Health (NIMH)","All","14 Years and older   (Child, Adult, Older Adult)","","2000","NIH","Observational","","HPTN 033|10611","April 2002","null","February 2004","August 31, 2001","null","January 3, 2014","Guangxi Ctrs. for Disease Control & Prevention and for HIV/AIDS Prevention & Control CRS, Nanning, Guangxi, China|Xinjiang Uygar Autonomous Region Ctr. for Disease Control & Prevention, HPTN Project Office, Urumqi, Xinjiang, China|St. Petersburg Univ. Biomedical Ctr., St. Petersburg, Russian Federation","","https://ClinicalTrials.gov/show/NCT00021775"
866,"NCT00237315","Longitudinal Study of Urea Cycle Disorders",,"Recruiting","No Results Available","Brain Diseases, Metabolic, Inborn|Amino Acid Metabolism, Inborn Errors|Urea Cycle Disorders","","Prevalence of specific morbid indicators of disease severity|Relationship between various biomarkers and disease severity and progression|Safety and efficacy of currently used and new UCD therapies","Andrea Gropman|National Center for Research Resources (NCRR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Rare Diseases Clinical Research Network|Children's Research Institute","All","Child, Adult, Older Adult","","1100","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN 5101|U54RR019453|U54HD061221","February 2006","July 2019","December 2019","October 12, 2005","null","December 21, 2018","University of California, Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital Boston (UCDC New England Center), Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Case Western Medical College, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|University of Heidelberg, Heidelberg, Germany|University Children's Hospital, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT00237315"
867,"NCT03196323","Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)",,"Recruiting","No Results Available","Rett Syndrome","","RettBE 1.0 Score|RettBe 2.0 Score|RettBe 3.0 Score","University of South Florida|National Institutes of Health (NIH)|National Center for Advancing Translational Science (NCATS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS)","Female","3 Years to 18 Years   (Child, Adult)","","400","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RTT5214","June 1, 2017","March 2019","March 2019","June 22, 2017","null","July 30, 2018","University of South Florida, Tampa, Florida, United States","","https://ClinicalTrials.gov/show/NCT03196323"
868,"NCT00474942","Natural History of Apparent Mineralocorticoid Excess Syndrome",,"Completed","No Results Available","Apparent Mineralocorticoid Excess Syndrome","","","Icahn School of Medicine at Mount Sinai|Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","130","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","GCO 04-0474|U54HD064382|RDCRN 5601","April 2007","November 2013","November 2013","May 17, 2007","null","December 11, 2015","Mount Sinai School of Medicine, New York, New York, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Sao Paulo, Sao Paulo, Brazil|University of Lyon, Lyon, France","","https://ClinicalTrials.gov/show/NCT00474942"
869,"NCT00345605","Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder",,"Completed","Has Results","Argininosuccinic Aciduria|Amino Acid Metabolism, Inborn Errors|Urea Cycle Disorders","Drug: Sodium Phenylbutyrate|Drug: Arginine","Measures of Liver Function: AST and ALT|Measures of Liver Function: PT and PTT|Measures of Liver Function: Coagulation Factors|Measures of Liver Function: INR|Argininosuccinic Acid Levels|Arginine Levels|Urea Production Rate","Brendan Lee|Office of Rare Diseases (ORD)|Rare Diseases Clinical Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Baylor College of Medicine","All","5 Years and older   (Child, Adult, Older Adult)","Phase 2","12","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","RDCRN 5102|U54HD061221","February 2008","May 2011","November 2012","June 28, 2006","November 5, 2014","January 31, 2018","Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00345605"
870,"NCT00505375","Intravenous CTLA4-lg Treatment in Recent Onset Type 1 Diabetes Mellitus",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: CTLA-4 Ig|Other: Placebo","Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 2 Year Visit","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|American Diabetes Association","All","6 Years to 45 Years   (Child, Adult)","Phase 2","112","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CTLA (IND)","February 2008","May 2012","May 2012","July 23, 2007","August 16, 2016","August 16, 2016","Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|The Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Southwestern Medical School, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00505375"
871,"NCT00397917","Oral Cleft Prevention Program",,"Completed","No Results Available","Cleft Lip|Cleft Palate","Drug: Folic acid: 4 mg versus 0.4 mg per day","Recurrence of cleft lip and palate","University of Iowa|National Institute of Dental and Craniofacial Research (NIDCR)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|RTI International|University of Sao Paulo","Female","16 Years to 45 Years   (Child, Adult)","Phase 3","4000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NIDCR-17958|U01DE017958","November 2006","May 2012","July 2013","November 10, 2006","null","March 31, 2017","University of Iowa, Iowa City, Iowa, United States","","https://ClinicalTrials.gov/show/NCT00397917"
872,"NCT00279305","Rituximab in New Onset Type 1 Diabetes",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: Anti-CD20 (rituximab)|Drug: Placebo Comparator","Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Diabetes Association|Juvenile Diabetes Research Foundation","All","8 Years to 45 Years   (Child, Adult)","Phase 2","87","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ritux (IND) (completed)","August 2005","April 2009","November 2009","January 19, 2006","August 18, 2016","November 2, 2016","Childrens Hospital of Los Angeles, Los Angeles, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|Joslin, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|San Raffaele Hospital, Milan, Italy","","https://ClinicalTrials.gov/show/NCT00279305"
873,"NCT01892982","Improving Preterm Outcomes by Safeguarding Maternal Mental Health",,"Completed","No Results Available","Depression|Child Development","Behavioral: Problem Solving Education tailored to NICU","Incidence of major depressive episode and depressive symptom trajectories|General Functioning|Caregiver burden, mastery and social support|Adherence to recommended NICU follow-up care|Parent-child interaction|Socio-emotional functioning|Cognitive functioning","Boston Medical Center|Tufts Medical Center|Beth Israel Deaconess Medical Center|Brigham and Women's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 64 Years   (Child, Adult)","Not Applicable","325","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","H-31407|R01HD072069","June 2013","May 25, 2018","July 31, 2018","July 8, 2013","null","August 28, 2018","Tufts Medical Center, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT01892982"
874,"NCT00105352","Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Procedure: Mixed Meal Tolerance Test|Procedure: Glucagon Stimulation Test","Stimulated C-peptide response derived from the 2-hour MMTT and the glucagon stimulation test (GST)|Time to peak C-peptide on MMTT, and the peak and AUC values from each test|Co-efficient of reproducibility of the MMTT, and the GST, provided from the duplicate tests within the same individuals","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|National Center for Research Resources (NCRR)","All","8 Years to 35 Years   (Child, Adult)","Not Applicable","120","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","MMTTGST (IND) (completed)","November 2004","null","November 2005","March 14, 2005","null","June 2, 2016","Children's Hospital Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|University of Florida, Gainesville,, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Riley Hospital for Children, Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center/ Children's Hospital Boston, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Naomi Berrie Diabetes Center, Columbia University, New York, New York, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|University of Texas Medical Center at Dallas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia|University of Toronto, Toronto, Ontario, Canada|University of Turku, Turku, Finland|Vita-Salute San Raffaele University, Milan, Italy|University of Bristol, Bristol, United Kingdom","","https://ClinicalTrials.gov/show/NCT00105352"
875,"NCT00100178","New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial",,"Completed","Has Results","Diabetes Mellitus, Type 1","Drug: Mycophenolate mofeteil (MMF)|Drug: Daclizumab (DZB)|Drug: Placebo control for Mycophenolate mofeteil (MMF)|Drug: Placebo control for Daclizumab (DZB)","Mean Stimulated C-peptide Area Under the Curve","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Juvenile Diabetes Research Foundation|National Center for Research Resources (NCRR)","All","8 Years to 45 Years   (Child, Adult)","Phase 2","126","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)","MMFDZB (IND) (completed)","May 2004","April 2008","April 2008","December 24, 2004","August 16, 2016","August 16, 2016","Childrens Hospital Los Angeles, Los Angeles, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|Indiana University, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Benaroya Research Institute, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00100178"
876,"NCT00489034","Engaging Care for HIV-infected Adolescent Females.",,"Completed","No Results Available","HIV Infection","Behavioral: Quantitative Interview|Behavioral: Ethnographic Interview|Behavioral: Gender Interview","Engagement in Care among Index Participants|Medication Adherence|Sexual Risk Behaviors|Substance Use","University of North Carolina, Chapel Hill|National Institute of Mental Health (NIMH)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)","Female","13 Years to 23 Years   (Child, Adult)","","178","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","ATN 009|1R01DA014706-01","July 2003","December 2010","December 2010","June 21, 2007","null","March 6, 2017","Universtiy of Southern California, Los Angeles, California, United States|University of Miami, School of Medicine, Miami, Florida, United States|Stroger Hospital of Cook County, Chicago, Illinois, United States|Tulane Medical Center, New Orleans, Louisiana, United States|Montefiore Medical Center, Bronx, New York, United States","","https://ClinicalTrials.gov/show/NCT00489034"
877,"NCT02167022","Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy",,"Recruiting","No Results Available","Cerebral Palsy","Other: Physical and occupational therapy","Change in Gross Motor Function Measure-66 (GMFM-66)|Change in Pediatric Evaluation of Disability Inventory-Functional Skills (PEDI-FS)","University of Arizona|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Tucson Medical Center|Phoenix Children's Hospital|United Cerebral Palsy-Central Arizona|Nemours Children's Hospital","All","12 Months to 36 Months   (Child)","Not Applicable","110","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","1401195212|1R01HD079498-01","November 2014","October 2019","October 2019","June 18, 2014","null","March 13, 2019","Phoenix Children's Hospital, Phoenix, Arizona, United States|United Cerebral Palsy-Central Arizona, Phoenix, Arizona, United States|Tucson Medical Center, Tucson, Arizona, United States|Nemours Children's Hospital, Orlando, Florida, United States","","https://ClinicalTrials.gov/show/NCT02167022"
878,"NCT00947700","Early Connections, Early Detection and Intervention in Infants at Risk for Autism",,"Completed","No Results Available","Autism Spectrum Disorder","Behavioral: Assessment, Monitoring & Intervention","Autism Symptoms|Mullen Receptive Language Scale|Communication and Symbolic Behavior Scale|Parent Child Interaction|Parent quality of life","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Environmental Health Sciences (NIEHS)|Autism Speaks|Washington State Department of Social and Health Services|Autism Science Foundation","All","5 Months to 12 Months   (Child)","Not Applicable","100","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Other","32400|P50HD055782|P30ES007033","January 2008","June 2013","June 2013","July 28, 2009","null","April 20, 2017","Center on Human Development and Disabilities, University of Washington, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00947700"
879,"NCT01854151","Promoting Safe Use of Pediatric Liquid Medications",,"Recruiting","No Results Available","Medication Errors","Other: New Labeling/Dosing Strategy","Medication dosing accuracy","New York University School of Medicine|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Emory University|Northwestern University|Stanford University","All","up to 8 Years   (Child)","Not Applicable","800","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","11-01122|1R01HD070864-01A1","July 2012","December 2019","December 2019","May 15, 2013","null","December 25, 2018","Stanford University School of Medicine, Stanford, California, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|New York University School of Medicine, New York, New York, United States","","https://ClinicalTrials.gov/show/NCT01854151"
880,"NCT02556996","Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children",,"Completed","No Results Available","Diarrhea","Biological: ETEC/rCTB vaccine|Other: Placebo","Time to first event of diarrhea due to vaccine-preventable ETEC (VP-ETEC) as defined below, and no other copathogen.|Time to first event of diarrhea due to ST-only ETEC expressing a vaccine-shared CF (ST-VCF-ETEC) as defined below, and no other copathogen..|All events of diarrhea irrespective of etiology|IgG seroconversion|IgA seroconversion|Number of solicited adverse events","U.S. Army Medical Research and Materiel Command|U.S. Naval Medical Research Unit No. 3|Ministry of Health and Population, Egypt|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Vaccine Institute|Göteborg University","All","6 Months to 18 Months   (Child)","Phase 3","356","U.S. Fed|Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","HSRRB A-7965","October 1998","March 2001","April 2002","September 22, 2015","null","October 12, 2015","","","https://ClinicalTrials.gov/show/NCT02556996"
881,"NCT00279318","TEDDY - The Environmental Determinants of Diabetes in the Young",,"Active, not recruiting","No Results Available","Type 1 Diabetes Mellitus","","Appearance of one or more islet cell autoantibodies: GADA, IAA, or IA-2A confirmed at two consecutive visits.|Development of T1DM","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Environmental Health Sciences (NIEHS)|Juvenile Diabetes Research Foundation|Centers for Disease Control and Prevention","All","up to 4 Months   (Child)","","8668","NIH|Other|U.S. Fed","Observational","Observational Model: Cohort|Time Perspective: Prospective","DK095300; DK100238; DK106955|1UC4DK095300-01|1UC4DK100238-01|1UC4DK106955-01|1UC4DK112243-01|1UC4DK117483-01","September 2004","September 2025","September 2025","January 19, 2006","null","June 13, 2018","University of Colorado Health Sciences Center, Denver, Colorado, United States|Augusta University, Gainesville, Florida, United States|Augusta University, Atlanta, Georgia, United States|Augusta University, Augusta, Georgia, United States|Children's Hospital of Pittsburgh of UPMC (this site is only screening babies whose mother, father or full sibiling have type 1 diabetes), Pittsburgh, Pennsylvania, United States|Pacific Northwest Diabetes Research Institute, Seattle, Washington, United States|Turku University Central Hospital, Turku, Finland|Diabetes Research Institute, Munich, Germany|Lund University, Malmo, Sweden","","https://ClinicalTrials.gov/show/NCT00279318"
882,"NCT02747706","Childhood Asthma Mentoring Program for Parents","CAMPP","Unknown status","No Results Available","Asthma","Behavioral: Parent-to-parent mentoring","Number of hospital admissions|Number of emergency department visits","InquisitHealth, Inc.|National Institutes of Health (NIH)|Montefiore Medical Center|University of North Carolina, Chapel Hill|Washington University School of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 12 Years   (Child)","Not Applicable","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Asthma23|4R44HD081830","April 2016","September 2017","March 2018","April 22, 2016","null","April 22, 2016","InquisitHealth, River Edge, New Jersey, United States","","https://ClinicalTrials.gov/show/NCT02747706"
883,"NCT00566488","Parathyroid and Thymus Transplantation in DiGeorge #931",,"Active, not recruiting","No Results Available","DiGeorge Syndrome|Hypoparathyroidism|Complete DiGeorge Syndrome","Biological: Thymus/Parathyroid Transplantation","Efficacy parameter: use of calcium/calcitriol at 1 year post-transplantation.|Efficacy parameters: ionized calcium|Efficacy parameters: CD3 count|Efficacy parameters: CD4 count|Efficacy parameters: CD8 count|Efficacy parameters: naive CD4 count|Efficacy parameters: naive CD8 count|Efficacy parameters: proliferative response to phytohemagglutinin|Efficacy parameters: proliferative response to tetanus toxoid|Efficacy parameters: spectra typing at 1 year post transplantation","M. Louise Markert|Food and Drug Administration (FDA)|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University","All","up to 24 Months   (Child)","Phase 1","25","Other|U.S. Fed|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00016482|R01AI047040|5K12HD043494-09|R01AI054843|FDA-FD-R-002606|2R01AI047040-11A2|R56 Bridge R01AI4704011A1|3R56AI047040-11A1S1|#931","January 2005","August 2007","June 2027","December 3, 2007","null","May 7, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00566488"
884,"NCT03758521","Natural History Study of Patients With Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency",,"Recruiting","No Results Available","Succinic Semialdehyde Dehydrogenase Deficiency","Device: Transcranial magnetic stimulation (TMS)|Device: Magnetic resonance imaging (MRI)|Device: Electroencephalogram (EEG)|Procedure: Bio-specimen Collection","Clinical Severity Score|Biochemical - GABA measurement|Biochemical - GHB measurement|Quantification of GABA related signals on the MRI spectroscopy","Boston Children’s Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Washington State University|University of South Florida|University Hospital Heidelberg","All","Child, Adult, Older Adult","","55","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00029917|1R01HD091142-01A1","January 15, 2019","December 2024","December 2024","November 29, 2018","null","February 15, 2019","Boston Children's Hospital, Boston, Massachusetts, United States|University Children's Hospital, Heidelberg, Germany","","https://ClinicalTrials.gov/show/NCT03758521"
885,"NCT02856984","Zika in Infants and Pregnancy (ZIP)",,"Recruiting","No Results Available","Zika Virus Disease (Disorder)","","Incidence of congenital malformations for ZIKV infected participants|Incidence of adverse fetal outcomes for ZIKV infected participants|Incidence of congenital malformations for ZIKV symptomatic participants|Incidence of adverse fetal outcomes for ZIKV symptomatic participants","RTI International|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Environmental Health Sciences (NIEHS)|Oswaldo Cruz Foundation","Female","15 Years and older   (Child, Adult, Older Adult)","","10000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","GN ZIKA","June 2016","June 2020","June 2020","August 5, 2016","null","June 6, 2018","Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz/MS; Rue Waldemar Falcao, Salvador, Bahia, Brazil|Departamento de Medicina Tropical da Universidade Federal de Pernambuco-UFPE, Recife, PE, Brazil|Instituto Fernandes Figueira - FIOCRUZ, Rio de Janeiro, RJ, Brazil|Ribeirão Preto Medical School, University of São Paulo, Av. Bandeirantes, 3900 - Monte Alegre, Ribeirão Preto, SP, Brazil|Universidad de Antioquia, Medellín, Colombia|Fundación para la Alimentación y Nutrición de Centro América y Panamá (INCAP), Guatemala, Guatemala|MINSA Central, Managua, Nicaragua|Universidad Peruana, Lima, Peru|University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico|University of Puerto Rico - Recinto de Río Piedras, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT02856984"
886,"NCT01561612","Promotion of Breastfeeding Intervention Trial","PROBIT","Completed","No Results Available","Effect of Breastfeeding on Maternal and Child Health Outcomes","Behavioral: Breastfeeding promotion and support","Gastrointestinal tract infection|Maternal adiposity|Child adiposity|asthma|cognition|dental caries|child behavior|vision|lung function|IGF-1|child height|adiponectin|Apo A1|glucose|insulin|Apo B|Child blood pressure|Maternal blood pressure|Child metabolic syndrome|Child growth|Respiratory tract infections|Atopic Eczema|Atopy|Eating Attitudes","Harvard Pilgrim Health Care|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Canadian Institutes of Health Research (CIHR)|European Union EarlyNutrition program|University of Bristol","All","Child, Adult, Older Adult","Not Applicable","17046","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","190250|R01HD050758|FOOD-DT-2005-007036|G0600705|K24HD069408|MOP-53155","June 1996","December 1998","null","March 23, 2012","null","October 10, 2013","Maternal and Child Health Center, Minsk, Belarus","","https://ClinicalTrials.gov/show/NCT01561612"
887,"NCT02055248","Study on Moebius Syndrome and Congenital Facial Weakness Disorders",,"Recruiting","No Results Available","Brain Disorders|Birth Defects|Craniofacial Differences","","Characterize the phenotype of Moebius syndrome and other congenital facial weakness disorders to determine the prevalence of associated malformations and inform subsequent genetic studies.|Obtain imaging studies to explore cranial nerve structure and associated brain/brainstem and white matter tract anomalies and associate with the neurocognitive and behavioral phenotype of the patients.","National Human Genome Research Institute (NHGRI)|National Eye Institute (NEI)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Icahn School of Medicine at Mount Sinai|Boston Children’s Hospital|National Institutes of Health Clinical Center (CC)","All","2 Years to 80 Years   (Child, Adult, Older Adult)","","700","NIH|Other","Observational","Time Perspective: Retrospective","140055|14-HG-0055","February 4, 2014","December 31, 2022","December 31, 2022","February 5, 2014","null","April 4, 2019","National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States","","https://ClinicalTrials.gov/show/NCT02055248"
888,"NCT01894126","Mobile Phone Messaging to Improve Women's and Children's Health (Mobile WACh) in Kenya","Mobile WACh","Completed","No Results Available","Maternal Health|Neonatal Health|Family Planning","Behavioral: Two-way SMS Dialogue|Behavioral: One-way SMS Messaging","Contraceptive uptake|Facility Delivery|Exclusive Breastfeeding|ANC attendance|Infant Immunizations|Maternal mortality|Infant mortality","University of Washington|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Nairobi|Kenyatta National Hospital","Female","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","300","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","K12HD001264-14UNGER|K12HD001264-14","July 2013","July 2015","null","July 9, 2013","null","November 9, 2016","Mathare North Health Centre, Nairobi, Kenya","","https://ClinicalTrials.gov/show/NCT01894126"
889,"NCT03464266","The Kampala Women's Bone Study",,"Recruiting","No Results Available","Bone Demineralization|Hypoestrogenism|Subclinical Kidney Injury|Bone Microarchitecture","Combination Product: FTC/TDF and DMPA|Drug: FTC/TDF|Drug: DMPA|Other: Neither DMPA nor FTC/TDF","The investigators will assess whether young women using TDF-based PrEP and DMPA concurrently attain lower peak bone mass over a 24-month relative to women using either agent singly or neither agent.|The investigators will assess whether young women using TDF-based PrEP and DMPA concurrently have evidence of disrupted microarchitecture, relative to women using either agent singly or neither agent.|The investigators will investigate whether young women concurrently using TDF-based PrEP and DMPA experience higher rates of bone turnover.|The investigators will investigate whether young women concurrently using TDF-based PrEP and DMPA experience higher rates of subclinical kidney injury.|The investigators will investigate whether young women concurrently using TDF-based PrEP and DMPA experience higher rates of hypoestrogenism.|Using mediation analysis, the investigators will identify the degree to which the pathways through subclinical kidney injury and hypoestrogenism account for changes in bone density among women concurrently using TDF-based PrEP and DMPA","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Makerere University|MU-JHU CARE|Columbia University|Icahn School of Medicine at Mount Sinai","Female","16 Years to 25 Years   (Child, Adult)","Phase 4","500","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","STUDY00001451|R01HD089843","May 15, 2018","August 2021","August 2021","March 14, 2018","null","December 19, 2018","Infectious Disease Institute, Kampala, Uganda","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03464266/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03464266"
890,"NCT02332265","Evaluation of the Effects of a Structural Economic and Food Security Intervention on HIV Vulnerability in Rural Malawi","SAGE4Health","Completed","No Results Available","HIV","Other: Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)","Change in economic status|Change in food security|Change in HIV vulnerability|Change in dietary diversity|Change in household perceptions of poverty|Change in household access to services|Change in sustainable agriculture practices|Change in personal health|Change in acute and chronic illness|Change in childbirth experiences|Change in family planning|Change in self-reported STD infections|Change in perceived HIV/AIDS stigma|Change in self-reported male circumcision prevalence and attitudes|Change in gender power attitudes|Change in community cohesion","University of Wisconsin, Milwaukee|CARE Malawi|University of Pennsylvania|University of Malawi|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","1901","Other|NIH","Observational","","144-PRJ51ZT|R01HD055868","February 2009","April 2012","April 2012","January 6, 2015","null","January 6, 2015","CARE International-Malawi, Lilongwe, Malawi","","https://ClinicalTrials.gov/show/NCT02332265"
891,"NCT01220531","Thymus Transplantation Safety-Efficacy",,"Available","No Results Available","Complete DiGeorge Anomaly|DiGeorge Syndrome|DiGeorge Anomaly|Complete DiGeorge Syndrome","Biological: Thymus Tissue for Transplantation|Procedure: Blood Draw|Drug: Rabbit anti-thymocyte globulin|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Methylprednisolone or Prednisolone|Drug: Basiliximab|Drug: Mycophenolate mofetil","","M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University","All","Child, Adult, Older Adult","","null","Other|NIH|Industry","Expanded Access":Intermediate-size Population|Treatment IND/Protocol","","Pro00025966|2R01AI047040-11A2|5K12HD043494-09","null","null","null","October 14, 2010","null","January 16, 2019","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT01220531"
892,"NCT00209235","Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments",,"Recruiting","No Results Available","Pseudohypoparathyroidism Type 1A|Albright Hereditary Osteodystrophy","Behavioral: Neurocognitive and psychosocial testing","PHP1a: Effect of GH on height, growth velocity, final height in children. Effect on weight, BMI, lipids, self-esteem in all ages.|Cognitive and behavioral function in Albright hereditary osteodystrophy","Connecticut Children's Medical Center|Johns Hopkins University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|UConn Health","All","2 Months to 89 Years   (Child, Adult, Older Adult)","Not Applicable","600","Other|NIH","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","16-110|R21HD078864","January 2003","October 2019","December 2025","September 21, 2005","null","January 31, 2019","Connecticut Children's Medical Center, Hartford, Connecticut, United States","","https://ClinicalTrials.gov/show/NCT00209235"
893,"NCT00579709","Thymus Transplantation With Immunosuppression","884","Active, not recruiting","No Results Available","DiGeorge Syndrome|DiGeorge Anomaly|Complete DiGeorge Anomaly|Complete DiGeorge Syndrome","Biological: Thymus Tissue for Transplantation","Safety & tolerability of Thymoglobulin and cyclosporine followed by thymus transplantation: Survival at 1 year post-transplantation.|Use of additional post transplant immunosuppression after that listed in the protocol.|Allograft biopsy used to evaluate graft rejection|CD3 count|Thymopoiesis|CD4 count|CD8 count|naive CD4 count|naive CD8 count","M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University","All","Child, Adult, Older Adult","Phase 1","15","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00013734|R01AI047040|R01AI054843|3R56AI047040-11A1S1|R56 Bridge R01AI4704011A1|2R01AI047040-11A2|5K12HD043494-09|#884","July 2002","December 2006","June 2027","December 24, 2007","null","July 12, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00579709"
894,"NCT00579527","Phase I/II Thymus Transplantation With Immunosuppression #950","#950","Active, not recruiting","No Results Available","DiGeorge Anomaly|Complete DiGeorge Anomaly|Complete Atypical DiGeorge Anomaly|Complete DiGeorge Syndrome|Complete Atypical DiGeorge Syndrome","Biological: Thymus Tissue for Transplantation|Other: Thymus Tissue and Parental Parathyroid Transplantation|Procedure: Blood Draw|Drug: Rabbit anti-thymocyte globulin|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Methylprednisolone or Prednisolone|Drug: Daclizumab|Drug: Mycophenolate mofetil","Safety/toxicity of 3 immunosuppression regimens in subjects undergoing thymus transplantation. Assessment will be survival at 1 year; incidence of fatal, severe, moderate, and disseminated infections; and, incidence of Grade 3 and 4 toxicities.|Thymopoiesis: assessment will be done by evaluating thymus graft biopsy tissue post transplantation|Development of T cell numbers and function post thymus transplantation using the 3 regimens tested.|Efficacy of parental parathyroid transplantation. Number of subjects who are off both calcium and calcitriol supplementation. The time at which calcium supplementation needs to be resumed post parathyroid transplant will also be recorded.","M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University","All","Child, Adult, Older Adult","Phase 1|Phase 2","28","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00011583|2R01AI047040-11A2|R56 Bridge R01AI4704011A1|5K12HD043494-09|R01AI047040|R01AI054843|#950","March 2006","December 2011","June 2027","December 24, 2007","null","July 12, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00579527"
895,"NCT00576836","Thymus Transplantation Dose in DiGeorge #932",,"Active, not recruiting","No Results Available","DiGeorge Anomaly|DiGeorge Syndrome|Complete DiGeorge Anomaly|Complete DiGeorge Syndrome","Biological: Thymus Tissue for Transplantation|Other: Parathyroid Tissue for Transplantation","Regression analyses used to correlate dose to immunologic parameters: T cell proliferative response; naïve T cells; and T cell variability.|Thymus transplantation efficacy: survival is recorded. Immune reconstitution efficacy: T cell phenotypic and functional parameters are evaluated. This is evaluated in descriptive fashion.|Parental parathyroid transplantation efficacy: number of subjects who are off calcium and calcitriol supplementation. The time that calcium supplementation needs to be resumed is recorded.|Safety. Particular attention on oligoclonal T cell development; pulmonary complications; infections; and autoimmune diseases. Dose is correlated with number of subjects who get rashes lasting >1 week with development of wheezing or oxygen requirement.|Correlations between dose and other immune parameters and factors which might affect outcome including HLA matching and thymus donor heart defect. Evaluate whether HLA-DR matching results in increased total CD4 T cell numbers.","M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University","All","Child, Adult, Older Adult","Phase 2","28","Other|NIH|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00016144 #932|FDA-FD-R-002606|2R01AI047040-11A2|R56 Bridge R01AI4704011A1|5K12HD043494-09|R01AI054843|R01AI047040|3R56AI047040-11A1S1","February 2006","August 2010","June 2027","December 19, 2007","null","May 4, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00576836"
896,"NCT00576407","Thymus Transplantation in DiGeorge Syndrome #668",,"Active, not recruiting","No Results Available","DiGeorge Syndrome|Complete Typical DiGeorge Anomaly","Biological: Thymus Tissue for Transplantation","Survival rate at one year post-transplantation.|T cell proliferative response to tetanus toxoid","M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University","All","Child, Adult, Older Adult","Phase 2","26","Other|NIH|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Pro00009955|2R01AI047040-11A2|R56 Bridge R01AI4704011A1|5K12HD043494-09|R01AI047040|3R56AI047040-11A1S1|R01AI054843|#668","November 2001","March 2008","June 2027","December 19, 2007","null","August 28, 2018","Duke University Medical Center, Durham, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT00576407"
897,"NCT00529399","Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects",,"Completed","Has Results","Type 1 Diabetes Mellitus","Drug: GAD-Alum|Drug: GAD-Alum and Aluminum hydroxide|Drug: Aluminum hydroxide","The Primary Outcome is the Area Under the Stimulated C-peptide Curve (AUC) at the One Year Visit","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association|Juvenile Diabetes Research Foundation","All","3 Years to 45 Years   (Child, Adult)","Phase 2","145","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GAD65 (IND)","February 2009","May 2012","May 2012","September 14, 2007","December 7, 2016","December 7, 2016","Childrens Hospital of Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of California-San Francisco, San Francisco, California, United States|Barbara Davis Center for Childhood Diabetes/University of Colorado Health Sciences Center, Aurora, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami/ Miller School of Medicine, Miami, Florida, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|University of Texas/Southwestern Medical School, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00529399"
898,"NCT00419562","Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Diabetes Mellitus, Type 1","Drug: Oral Insulin","Effect of treatment with oral insulin versus placebo in individuals in the primary stratum ( ICA+ confirmed or GAD65 and ICA512 positive on the same sample with confirmation of at least one of these autoantibodies).|Secondary analyses will be done to assess the effects of oral insulin versus placebo in other categories of subjects defined using different combinations of autoantibodies and metabolic status.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Allergy and Infectious Diseases (NIAID)|National Center for Research Resources (NCRR)|American Diabetes Association|Juvenile Diabetes Research Foundation","All","3 Years to 45 Years   (Child, Adult)","Phase 3","400","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Oral Insulin (IND)","February 2007","December 2016","June 2017","January 8, 2007","null","March 28, 2017","University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|Walter and Eliza Hall Institute, Parkville, Victoria, Australia|The Hospital for Sick Children, Toronto, Ontario, Canada|University of Turku, Turku, Finland|San Raffaele Hospital, Milan, Italy|University of Bristol, Bristol, United Kingdom","","https://ClinicalTrials.gov/show/NCT00419562"
899,"NCT01030861","Teplizumab for Prevention of Type 1 Diabetes In Relatives ""At-Risk""",,"Active, not recruiting","No Results Available","Autoantibody Positive|Non-diabetic Relatives at Risk for Type 1 Diabetes|High Risk|Impaired Glucose Tolerance","Drug: Teplizumab","Criteria are met for diabetes onset as defined by the American Diabetes Association (ADA) based on glucose testing or the presence of unequivocal hyperglycemia with acute metabolic decompensation.|effects on teplizumab based on age, gender, race/ethnicity,weight, BMI, immunologic, genetic , demographic, and lifestyle factors.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association","All","8 Years to 45 Years   (Child, Adult)","Phase 2","71","NIH|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TrialNet - tep (IND)|UC4DK106993","August 2010","January 2019","January 2019","December 14, 2009","null","July 9, 2018","University of California in San Francisco, San Francisco, California, United States|University of California-San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center for Childhood Diabetes/ University of Colorado, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Indiana University, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|The Children's Mercy Hospital, Kansas City, Missouri, United States|Columbia University, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Texas, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Benaroya Research Institute, Seattle, Washington, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Forschergruppe Diabetes, Munich, Germany","","https://ClinicalTrials.gov/show/NCT01030861"
900,"NCT00005129","Bogalusa Heart Study",,"Active, not recruiting","No Results Available","Atherosclerosis|Cardiovascular Diseases|Heart Diseases|Coronary Disease|Hypertension","","","Tulane University|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Environmental Health Sciences (NIEHS)","All","Child, Adult, Older Adult","","12000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","908|1R01AG041200|1R01HD069587-01A1|1R01ES021724-01|2R01AG016592-12A1|R01HL121230","June 1972","November 2023","November 2023","May 26, 2000","null","April 27, 2018","Tulane University, New Orleans, Louisiana, United States","","https://ClinicalTrials.gov/show/NCT00005129"
901,"NCT02461446","Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations",,"Active, not recruiting","No Results Available","PTEN|ASD|Autism|Macrocephaly|PTEN Hamartoma Tumor Syndrome","","Change in verbal abilities at 12 months|Change in communication ability at 12 months|Change in verbal abilities at 24 months|Change in visual perception at 12 months|Change in working memory at 12 months|Change in processing speed at 12 months|Change in working memory at 24 months|Change in processing speed at 24 months|Change in visual perception at 24 months|Change in communication ability at 24 months","Boston Children’s Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 21 Years   (Child, Adult)","","140","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00013150|1U54NS092090-01","May 2015","December 2019","December 2019","June 3, 2015","null","March 14, 2019","University of California at Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Stanford, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02461446"
902,"NCT02249962","Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART","S4","Recruiting","No Results Available","HIV|Infant Exposure to Efavirenz","","Proportion of participants with failure on Option B+ first-line treatment|Pharmacokinetic: progesterone level in women using contraceptive implant|Micronutrient assessment|Maternal CD4 count|HIV RNA level measurement|PHQ-9 evaluation|Laboratory serum markers|Pregnancy outcome assessment|HIV antibody testing- infant|Infant neuro-development assessment: Bayley score|Family planning use and proportion of women with subsequent pregnancy by 36 months|ART Adherence: pill-count","University of North Carolina, Chapel Hill|Ministry of Health and Population, Malawi|University of North Carolina|Lighthouse Trust|Baylor College of Medicine|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","16 Years to 50 Years   (Child, Adult)","","8600","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","14-1633|R01HD080485","May 2015","April 2019","April 2019","September 26, 2014","null","April 26, 2018","UNC Project Malawi, Lilongwe, Malawi","","https://ClinicalTrials.gov/show/NCT02249962"
903,"NCT00004984","The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)",,"Completed","No Results Available","Diabetes Mellitus, Type 1","Drug: Crystallized human recombinant insulin","","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Minority Health and Health Disparities (NIMHD)|Office of Research on Women's Health (ORWH)","All","3 Years to 45 Years   (Child, Adult)","Phase 3","null","NIH","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","DPT-1 (completed)|DK60782|DK60916|DK60987|DK61010|DK61029|DK61030|DK61034|DK61035|DK61036|DK61037|DK61038|DK61040|DK61041|DK61042|DK61058|DK61055","February 1994","null","June 2003","March 14, 2000","null","January 15, 2010","Childrens Hospital of Los Angeles, Division of Endocrinology, Los Angeles, California, United States|University of California-San Francisco, Milberry Union East RM 405, 500 Parnassus Ave Box 0136, San Francisco, California, United States|Stanford University, Stanford, California, United States|University of Colorado Barbara Davis Center for Childhood Diabetes, Denver, Colorado, United States|University of Florida Diabetes Research Center, Gainesville, Florida, United States|DPT-1 Operations Coordinating Center, Miami, Florida, United States|University of Miami School of Medicine, Jackson Medical Tower, Miami, Florida, United States|Indiana University, James Whitcomb Riley Hospital for Children, 702 Barnhill Dr, Ste 5960, Indianapolis, Indiana, United States|Joslin Diabetes Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave, New York, New York, United States|Children's Hospital of Pittsburgh, Dept/Pediatric Endocrinology, 3705 5th Ave, Pittsburgh, Pennsylvania, United States|University of Texas, Children's Medical Center, 6300 Harry Hines Ste 1200, Dallas, Texas, United States|Virginia Mason Research Center, 1201 Ninth Avenue, Seattle, Washington, United States|Hospital for Sick Children, Division of Endocrinology, 555 University Ave, Rm 5110, Toronto, Ontario, Canada","","https://ClinicalTrials.gov/show/NCT00004984"
904,"NCT01778634","Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants","AZIPIII","Active, not recruiting","Has Results","Ureaplasma Infections","Drug: Azithromycin|Drug: Placebo","Number of Participants With Survival And Transfer From NICU With Microbiological Eradication of Ureaplasma|Number of Participants Who Survived Until 36 Wks Postmenstrual Age That Were Diagnosed With Physiologic Defined Bronchopulmonary Dysplasia (BPD) at 36 Weeks Post Menstrual Age|Number of Participants With Death or Neurodevelopmental Impairment|Number of Participants With Pulmonary Impairment|Number of Participants Who Died|Duration of Positive Pressure Support|Duration of Oxygen Supplementation|Number of Participants Who Experienced Air Leaks|Number of Participants Who Received Postnatal Steroids|Number of Participants Who Received Non-Study Antibiotics|Pharmacokinetics (PK)/Pharmacodynamics (PD) Modelling of Time Course of Azithromycin Plasma Concentrations","University of Maryland|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Mercy Medical Center|Johns Hopkins University|University of Virginia|University of Alabama at Birmingham|Christiana Care Health Services","All","up to 72 Hours   (Child)","Phase 2","121","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HP-00054998|R01HD067126","July 2013","December 2016","December 2019","January 29, 2013","May 17, 2018","June 15, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Christiana Care Health Services, Newark, Delaware, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|University of Virginia, Charlottesville, Virginia, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01778634/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT01778634/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT01778634"
905,"NCT01040897","Addressing Health Literacy and Numeracy to Prevent Childhood Obesity","GreenLight","Completed","No Results Available","Obesity Prevention","Behavioral: Health Communication and Obesity Prevention|Behavioral: Injury Prevention Arm","Percent of children overweight or obese (BMI ≥ 85th%) at 2 years of life|BMI z score|Change in Weight/Length z-score over time|Parental report of infant eating and physical activity behaviors|Parental assessment of physician communication|Parental self-efficacy|Physician knowledge and satisfaction","Vanderbilt University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Miami|University of North Carolina, Chapel Hill|New York University|Stanford University|Duke University|Vanderbilt University Medical Center","All","6 Weeks to 12 Weeks   (Child)","Not Applicable","865","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1R01HD059794-01","April 28, 2010","October 1, 2014","October 1, 2014","December 30, 2009","null","August 21, 2018","Vanderbilt University Medical Center, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT01040897"
906,"NCT03626857","MiACLR: Michigan Initiative for Anterior Cruciate Ligament Rehabilitation","MiACLR","Recruiting","No Results Available","Anterior Cruciate Ligament Injury","Device: Neuromuscular Electrical Stimulation (NMES)|Other: Eccentric Exercise (ECC)|Device: Neuromuscular Electrical Stimulation (NMES) placebo|Other: Eccentric Exercise (ECC) placebo","Change from baseline to 6 months isokinetic quadriceps strength index|Change from baseline to 18 months isokinetic quadriceps strength index|T1 rho relaxation time symmetry scores for knee joint cartilage|T2 relaxation time symmetry scores for knee joint cartilage|Knee Flexion Angle at 6 months|Knee Flexion Angle at 18 months|Knee Flexion Moment at 6 months|Knee Flexion Moment at 18 months","University of Michigan|NIH - National Institutes of Child Health and Human Development|University of Connecticut|University of Delaware|University of North Carolina, Chapel Hill","All","14 Years to 40 Years   (Child, Adult)","Not Applicable","208","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","HUM00144992","February 22, 2019","September 30, 2023","September 30, 2023","August 13, 2018","null","February 28, 2019","MedSport, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States","","https://ClinicalTrials.gov/show/NCT03626857"
907,"NCT01542528","Integrated Brain, Body and Social Intervention for Attention Deficit Hyperactivity Disorder (ADHD)","IBBS","Completed","Has Results","Attention Deficit Hyperactivity Disorder (ADHD)","Behavioral: IBBS","Improvement in ADHD Severity From Baseline to End of Intervention|Overall Improvement","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Hamden Public Schools, Connecticut|C8Sciences|BeCaid China|Peking University|Capital Medical University|Beijing Sport University","All","5 Years to 10 Years   (Child)","Not Applicable","117","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","11100009142|R01HD070821","March 2012","July 2016","July 2016","March 2, 2012","September 25, 2017","January 17, 2018","Hamden Public Schools, Hamden, Connecticut, United States|Department of Psychiatry, Yale University, New Haven, Connecticut, United States|Yale Child Study Center, New Haven, Connecticut, United States|Capital Medical University, Beijing, Beijing, China|Peking University, Beijing, Beijing, China","","https://ClinicalTrials.gov/show/NCT01542528"
908,"NCT00395161","The CRISIS Prevention Study","CRISIS","Terminated","Has Results","Sepsis","Drug: Metoclopramide|Drug: Zinc|Dietary Supplement: Glutamine|Drug: Selenium|Other: saline|Other: sterile water|Other: selenium|Dietary Supplement: whey-protein","The Primary Endpoint of This Study is the Median Time Between Admission to the PICU and Occurrence of Nosocomial Infection or Clinical Sepsis in PICU Patients Who Have Endotracheal Tubes, Central Venous Catheters, or Urinary Catheters.|Rate of Nosocomial Infection or Clinical Sepsis Per 100 Study Days|Antibiotic-free Days|Incidence of Prolonged Lymphopenia (Absolute Lymphocyte Count Less Than or Equal to 1,000/mm³ for > or Equal to 7 Days)|All-cause 28-day Mortality Rate.","Michael Dean|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Seattle Children's Hospital|Children's Hospital Los Angeles|Arkansas Children's Hospital Research Institute|Children's Hospital of Michigan|University of Pittsburgh|Children's Research Institute|University of California, Los Angeles|Harborview Injury Prevention and Research Center|University of Utah","All","12 Months to 17 Years   (Child)","Phase 3","293","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","U01HD049934","April 2007","November 2009","November 2009","November 2, 2006","April 18, 2013","April 18, 2013","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Childrens Hospital of Los Angeles, Los Angeles, California, United States|University of California Los Angeles Medical Center, Los Angeles, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Michigan, Detroit, Michigan, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Seattle Children's Hospital, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT00395161"
909,"NCT02740153","PCORI Urea Cycle Disorder Study",,"Active, not recruiting","No Results Available","Urea Cycle Disorders","Other: No Intervention Given","Survival|Neurocognitive Function|Patient Reported Quality of Life|Caretaker Decision Making|Medical Provider Decision Making|Dissemination of Information (Aim 3)","Children's Research Institute|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Advancing Translational Science (NCATS)|Patient-Centered Outcomes Research Institute|The George Washington University Milken Institute School of Public Health (GWU)|The National Urea Cycle Disorders Foundation (NUCDF)|Studies of Pediatric Liver Transplantation (SPLIT)","All","up to 18 Years   (Child, Adult)","","321","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","7282","March 4, 2016","June 10, 2019","June 10, 2020","April 15, 2016","null","April 1, 2019","Childrens Research Institute, Washington, District of Columbia, United States","","https://ClinicalTrials.gov/show/NCT02740153"
910,"NCT00179777","TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk",,"Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Dietary Supplement: hydrolysed infant formula|Dietary Supplement: nonhydrolysed infant formula","Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age.|Diabetes associated islet antibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12 and 18 months of age, and annually from age 2 to 10 years","Children's Hospital of Eastern Ontario|US Congress|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Canadian Institutes of Health Research (CIHR)|Juvenile Diabetes Research Foundation|European Foundation for the Study of Diabetes|European Community (EC)|Mead Johnson Nutrition|Diabetes Research Foundation, Finland|Academy of Finland|Dutch Diabetes Research Foundation","All","up to 7 Days   (Child)","Not Applicable","2032","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MCT-49395|U01HD040364|U01HD042444","March 2002","March 2017","September 2017","September 16, 2005","null","July 14, 2017","University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Robarts Research Institute, London, Canada|3rd Faculty of Medicine, Charles University, University Hospital Vinohrady, Prague, Czechia|Tartu University Children's Hospital, Tartu, Estonia|University of Helsinki, Helsinki, Finland|Kinderkrankenhaus auf der Bult, Hannover, Germany|Semmelweis Medical University, Budapest, Hungary|St. Michele Hospital, Cagliari, Sardinia, Italy|University Campus Bio-Medico of Rome, Rome, Italy|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Sophia Children's Hospital, Rotterdam, Netherlands|Medical University of Wroclaw, Wroclaw, Poland|Hospital de Cruces, Barakaldo, Vizcaya, Spain|Hospital Clinico San Carlos, Madrid, Spain|University of Linkoping, Linkoping, Sweden|University Children's Hospital, Zurich, Switzerland","","https://ClinicalTrials.gov/show/NCT00179777"
911,"NCT03885232","Presumptively Initiating Vaccines and Optimizing Talk With Motivational Interviewing (PIVOT With MI)",,"Not yet recruiting","No Results Available","Preventive Health Services (PREV HEALTH SERV)","Behavioral: Experimental: PIVOT with MI|Other: Active Comparator: Control","Child's Immunization Status|Parent Visit Experience Survey|Change in Provider Perception of Vaccine Discussion - Pre- and Post-Surveys","University of Colorado, Denver|National Institutes of Health (NIH)|Seattle Children's Hospital|University of Missouri, Kansas City|Children's Mercy Hospital Kansas City|Portland State University|University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","up to 2 Months   (Child)","Not Applicable","600","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research","17-1274|1R01HD093628-01A1","September 1, 2019","August 31, 2022","July 31, 2023","March 21, 2019","null","March 21, 2019","","","https://ClinicalTrials.gov/show/NCT03885232"
912,"NCT03655223","Early Check: Expanded Screening in Newborns",,"Enrolling by invitation","No Results Available","Spinal Muscular Atrophy|Fragile X Syndrome|Fragile X - Premutation","Diagnostic Test: Confirmatory Testing","Incidence Rates: Number of newborns who screen positive comparative to the whole sample|Impact of Screening: Semi-structured parent interviews.","RTI International|University of North Carolina, Chapel Hill|The John Merck Fund|Duke University|Wake Forest University|North Carolina Department of Health and Human Services|National Center for Advancing Translational Science (NCATS)|Cure SMA|The National Fragile X Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Asuragen, Inc.","All","up to 28 Days   (Child)","","400000","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","18-0009|U01TR001792-01|HHSN27500003","October 15, 2018","June 30, 2021","December 2022","August 31, 2018","null","December 13, 2018","RTI International, Research Triangle Park, North Carolina, United States","","https://ClinicalTrials.gov/show/NCT03655223"
913,"NCT03321734","Intermittent Hypoxia and Caffeine in Infants Born Preterm","ICAF","Recruiting","No Results Available","Intermittent Hypoxia","Drug: Caffeine|Drug: Placebos","Compare the extent of IH exposure, from randomization through 42 weeks + 6 days PMA (within each gestational week and overall), in infants randomized to extended caffeine treatment to infants assigned to receive placebo.|Compare changes in a panel of inflammation-related cytokines and chemokines, from enrollment to the target age of 38 weeks + 0 days PMA, in infants randomized to extended caffeine treatment to infants assigned to receive placebo.|Compare changes in quantitative MRI structural, microstructural from enrollment to 43-46 weeks PMA, in infants randomized to extended caffeine treatment to infants assigned to receive placebo.|Association between Salivary Caffeine concentration and IH outcomes|Determine whether caffeine effects on changes in inflammatory or MRI biomarkers from baseline to follow-up are mediated by caffeine-related reduced IH.","Children's Research Institute|Boston University|Beth Israel Medical Center|University of Massachusetts, Worcester|American SIDS Institute|Walter Reed National Military Medical Center|Dartmouth-Hitchcock Medical Center|Children's Hospital of Philadelphia|Johns Hopkins All Children's Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","32 Weeks to 36 Weeks   (Child)","Phase 2","220","Other|U.S. Fed|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","R01HD089289|1R01HD089289-01A1","January 18, 2019","May 2022","May 2022","October 26, 2017","null","March 4, 2019","Children's National Medical Center/Children's Research Institute, Washington, District of Columbia, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Massachusetss, Worcester, Massachusetts, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT03321734/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03321734"
914,"NCT02023658","Systems Analysis and Improvement to Optimize pMTCT",,"Completed","No Results Available","HIV","Other: pMTCT systems analysis and improvement","Uptake of HIV counseling and testing at first antenatal care visit|Uptake of CD4 testing at antenatal care|Use of appropriate ARVs in pregnancy for prophylaxis or initiation of ART during pregnancy|Infant HIV determination","University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Network of AIDS Researchers of Eastern and Southern Africa|Centro de Investigacao Operacional da Beira|Health Alliance International|Eduardo Mondlane University","Female","Child, Adult, Older Adult","Not Applicable","36","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","44167-EG|R01HD075057","January 2014","March 2015","March 2015","December 30, 2013","null","January 26, 2017","Ministry of Health, Bouake, Côte D'Ivoire|Ministry of Health, Nairobi, Kenya|Ministry of Health, Beira, Sofala, Mozambique","","https://ClinicalTrials.gov/show/NCT02023658"
915,"NCT01883193","Women First: Preconception Maternal Nutrition","WF","Active, not recruiting","No Results Available","Maternal Malnutrition|Growth Failure|Mortality|Morbidity|Stunting","Dietary Supplement: Comprehensive Maternal Nutrition Intervention","Neonatal linear growth|Length-for-age Z-scores|Estimate fetal growth|Mean birth weight|Incidence of low birth weight (LBW) infants|Perinatal Mortality|Incidence of severe neonatal and infant infectious disease|Epigenome (Maternal)|Epigenome (Infant)|Deep phenotyping of maternal metabolic and nutritional status|Microbiome (maternal)|Microbiome (infant)|Composition of breast milk|Neurodevelopment assessment","University of Colorado, Denver|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Instituto de Nutricion de Centroamerica y Panama (INCAP)|Kinshasa School of Public Health|Jawaharlal Nehru Medical College|Aga Khan University|RTI International","Female","16 Years to 35 Years   (Child, Adult)","Not Applicable","7374","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-1672|OPP1055867|U10HD076474-01","August 2013","October 2019","October 2019","June 21, 2013","null","October 16, 2018","Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|INCAP, Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belgaum, India|Aga Khan University, Karachi, Pakistan","","https://ClinicalTrials.gov/show/NCT01883193"
916,"NCT03019367","Premature Infants Receiving Milking or Delayed Cord Clamping: PREMOD2","PREMOD2","Recruiting","No Results Available","Intraventricular Haemorrhage Neonatal|Death; Neonatal","Procedure: Umbilical cord milking UCM|Procedure: Delayed cord clamping DCC","Incidence of severe IVH or death|All Grade IVH|Severe IVH (Grade 3 or 4)|Hemoglobin/Hematocrit at 4 hours|Incidence of Severe IVH or death in infants <28 weeks gestation|Delivery room interventions|Blood pressures in the first 24 hours of life","Sharp HealthCare|Sharp Mary Birch Hospital for Women & Newborns|Loma Linda University|University of Pittsburgh|Providence Hospital|University of Alabama at Birmingham|University of Alberta|University College Cork|University of Ulm|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Christiana Care Health Services|Sharp Grossmont Hospital","All","23 Weeks to 33 Weeks   (Child)","Not Applicable","1200","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PREMOD2|1R01HD088646-01A1","June 6, 2017","December 31, 2022","December 2024","January 12, 2017","null","April 16, 2019","University of Alabama, Birmingham, Alabama, United States|Loma Linda Medical Center, Loma Linda, California, United States|Sharp Grossmont Hospital, San Diego, California, United States|Sharp Mary Birch Hospital for Women and Newborns, San Diego, California, United States|Christiana Care, Newark, Delaware, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Magee-Womens Hospital, Pittsburgh, Pennsylvania, United States|Governors of University of Alberta, Edmonton, Alberta, Canada|University of ULM, Ulm, Baden-Wurttemberg, Germany|Cork University Maternity Hospital, Cork, Ireland","","https://ClinicalTrials.gov/show/NCT03019367"
917,"NCT02050204","Evaluating the Health Benefits of Workplace Policies and Practices - Phase II","WFHS","Completed","No Results Available","Focus of Study: Work Conditions","Behavioral: Intervention","Change in total sleep time|change in wake after sleep onset|change in cardiometabolic risk score|change in sleep insufficiency|change in insomnia symptoms","Harvard School of Public Health|National Institute on Aging (NIA)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Heart, Lung, and Blood Institute (NHLBI)|Office of Behavioral and Social Sciences Research (OBSSR)|National Institute for Occupational Safety and Health (NIOSH/CDC)","All","Child, Adult, Older Adult","Not Applicable","2753","Other|NIH|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Other","P16633|U01AG027669|U01HD051218|U01HD051256|U01HD051276|U01HD051217|R01HL107240|U01OH008788|U01HD059773","September 2009","December 2012","December 2012","January 30, 2014","null","December 15, 2017","Harvard School of Public Health, Cambridge, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02050204"
918,"NCT00488462","Non-Pneumatic Anti-Shock Garment for Obstetrical Hemorrhage: Zambia and Zimbabwe","NASG","Completed","No Results Available","Hypovolemic Shock|Hemorrhage","Device: non-pneumatic anti-shock garment","Frequency of mortalities and frequency of severe morbidities combined as extreme adverse outcomes|Mean amount of blood loss in mL , frequency of emergency hysterectomy, time to recovery from shock.","University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Bill and Melinda Gates Foundation|University of Zambia|University of Zimbabwe|World Health Organization","Female","15 Years and older   (Child, Adult, Older Adult)","Not Applicable","887","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1R01HD053129-01A1|5R01HD053129-03","October 2007","May 2012","May 2012","June 20, 2007","null","January 21, 2015","Kitwe Central Hospital, Kitwe, Copperbelt, Zambia|Ndola Central Hospital, Ndola, Copperbelt, Zambia|University Teaching Hospital (UTH), Lusaka, Zambia|Harare Hospital, Harare, Zimbabwe|Parienyatwa Group of Hospitals, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT00488462"
919,"NCT01209754","EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)","EMBRACE","Recruiting","No Results Available","Pregnancy Related","","Pregnancy and delivery outcomes comparison|Major malformations comparison|Infant growth parameters comparison|HIV drug resistance mutations comparison","Microbicide Trials Network|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health (NIH)|Gilead Sciences|CONRAD","All","Child, Adult, Older Adult","","950","Other|NIH|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","MTN-016|3UM1AI068633|10737","October 2009","November 2020","November 2020","September 27, 2010","null","February 25, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Wits Reproductive Health Institute (WRHI), Johannesburg, Gauteng, South Africa|CAPRISA-The Aurum Institute, Johannesburg, Guateng, South Africa|CAPRISA eThekwini, Durban, KwaZulu Natal, South Africa|Perinatal HIV Research Unit (PHRU), Johannesburg, Soweto, South Africa|South African MRC HIV CTU Med Research Council; Botha's Hill Clinical Research Site, Durban, South Africa|South African MRC HIV CTU Med Research Council; Isipingo, Durban, South Africa|South African MRC HIV CTU Med Research Council; Overport, Durban, South Africa|South African MRC HIV CTU Med Research Council; R.K. Khan Hospital, Durban, South Africa|South African MRC HIV CTU Med Research Council; Tongaat, Durban, South Africa|South African MRC HIV CTU Med Research Council; Umkomaas, Durban, South Africa|South African MRC HIV CTU Med Research Council; Verulam, Durban, South Africa|Makerere University-Johns Hopkins University Collaboration, Kampala, Uganda|UZ-UCSF HIV Prevention Trials Unit, Chitungwiza, Seke South, Zimbabwe|UZ-UCSF HIV Prevention Trials Unit, Harare, Spilhaus, Zimbabwe|UZ-UCSF HIV Prevention Trials Unit, Chitungwiza, Zengeza, Zimbabwe","","https://ClinicalTrials.gov/show/NCT01209754"
920,"NCT02994355","HIV Testing at Family Planning Clinics in Mombasa County, Kenya",,"Active, not recruiting","No Results Available","HIV","Other: Systems Analysis and Improvement Approach","Change in proportion of eligible (not known HIV+) new FP clients who are tested for HIV at baseline and after intervention|Change in proportion of new FP clients who are counseled about HIV testing at baseline and after intervention|Change in proportion of new FP clients who are counseled about HIV testing at baseline, after intervention, and after year of minimal support","University of Washington|National Institutes of Health (NIH)|University of Nairobi|Kenyatta National Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Ministry of Health, Mombasa County","All","Child, Adult, Older Adult","Not Applicable","24","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","STUDY00001851|1K24HD088229-01","June 1, 2018","January 2019","January 2020","December 15, 2016","null","October 15, 2018","Alfarooq, Mombasa, Kenya|Jocham, Mombasa, Kenya|Junda Dispensary, Mombasa, Kenya|Junda, Mombasa, Kenya|Kongowea, Mombasa, Kenya|Magongo, Mombasa, Kenya|Marimani, Mombasa, Kenya|Mbuta, Mombasa, Kenya|Mikindani, Mombasa, Kenya|Mlaleo, Mombasa, Kenya|Mrima, Mombasa, Kenya|Mvita, Mombasa, Kenya|Mwakirunge, Mombasa, Kenya|Mwangaza, Mombasa, Kenya|Pandya, Mombasa, Kenya|Roadside, Mombasa, Kenya|ShikaAdabu, Mombasa, Kenya|Shukurani, Mombasa, Kenya|Singawa, Mombasa, Kenya|St. Thomas, Mombasa, Kenya|Tudor, Mombasa, Kenya|Waweni, Mombasa, Kenya|Wema, Mombasa, Kenya|Ziwa la ngombe, Mombasa, Kenya","","https://ClinicalTrials.gov/show/NCT02994355"
921,"NCT02738281","Natural History of Rett Syndrome & Related Disorders",,"Recruiting","No Results Available","Rett Syndrome|MECP2 Duplication dIsorder|RTT-related Conditions","","Clinical longitudinal assessments in Rett syndrome (RTT) as measured by mean growth over 5 years.|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as measured by mean change in head circumference over 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as measured by mean number of stereotypic movements at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as the percent of subjects with reported epilepsy at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as the percent of subjects with reported scoliosis at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as the percent of subjects with MECP2 mutations at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as reported by the mean Clinical Severity Scale (CSS) at 5 years|Clinical and neurobehavioral longitudinal assessments in Rett syndrome (RTT) as measured by the mean Motor Behavioral Assessment (MBA) at 5 years|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: mean growth rate over 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: mean change in head circumference 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: mean number of stereotypic movements in a 24 hour period at 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: percent of subjects reporting scoliosis 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: percent of subjects surviving at 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: the mean CSS score at 5 years with subjects having MECP2 duplication syndrome|Clinical and neurobehavioral longitudinal assessments in MECP2 duplication syndrome: the mean MAB score at 5 years with subjects having MECP2 duplication syndrome|Quality of Life Measures in RTT|Quality of Life Measures in MECP2 duplication syndrome|Quality of Life Measures in RTT-related disorders.|Quality of Life Measures in RTT-related disorders","University of Alabama at Birmingham|National Institutes of Health (NIH)|National Center for Advancing Translational Science (NCATS)|Rare Diseases Clinical Research Network|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS)","All","Child, Adult, Older Adult","","1200","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN 5211","November 2015","July 2020","December 2020","April 14, 2016","null","April 12, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|UCSF Benioff Children's Hospital of Oakland, Oakland, California, United States|University of California San Diego, San Diego, California, United States|University of Colorado Denver, Denver, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Washington University School of Medicine and St. Louis Children's Hospital, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02738281"
922,"NCT02705677","Biobanking of Rett Syndrome and Related Disorders",,"Recruiting","No Results Available","Rett Syndrome|MECP2 Duplication|CDKL5|FOXG1 Disorders","","X-chromosome inactivation in Rett syndrome (RTT)|Bdnf polymorphisms in RTT|Inflammation markers in MECP2 duplication syndrome|Biobanking of blood for Rett syndrome (RTT), MECP2 duplication syndrome, FOXG1, CDKL5, and MECP2 mutations not producing RTT|Breakpoints and gene content of MECP2 and FOXG1 duplications","University of Alabama at Birmingham|National Institutes of Health (NIH)|National Center for Advancing Translational Science (NCATS)|Office of Rare Diseases (ORD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute of Neurological Disorders and Stroke (NINDS)","All","Child, Adult, Older Adult","","1200","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN # 5213|U54HD061222","September 1, 2017","July 2019","December 2019","March 10, 2016","null","April 20, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hospital of Oakland, Oakland, California, United States|University of California San Diego, San Diego, California, United States|University of Colorado Denver, Denver, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Gillette Children's Specialty Healthcare, Minneapolis, Minnesota, United States|Washington University School of Medicine and St. Louis Children's Hospital, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02705677"
923,"NCT02461420","Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome",,"Active, not recruiting","No Results Available","Phelan-McDermid Syndrome|Autism Spectrum Disorder|Intellectual Disability","","Change in global cognitive ability at 12 months|Change in adaptive behavior at 12 months|Change in language abilities at 12 months|Change in motor functioning at 12 months|Change in autism symptoms at 12 months|Change in global cognitive ability at 24 months|Change in adaptive behavior at 24 months|Change is language abilities at 24 months|Change in motor functioning at 24 months|Change in autism symptoms at 24 months","Boston Children’s Hospital|National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health (NIH)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Phelan-McDermid Syndrome Foundation","All","3 Years to 21 Years   (Child, Adult)","","105","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","P00013300|1U54NS092090","May 2015","December 2019","December 2019","June 3, 2015","null","March 14, 2019","Stanford University, Stanford, California, United States|Rush University Medical Center, Chicago, Illinois, United States|National Institutes of Health, Bethesda, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|University of Texas Southwestern, Dallas, Texas, United States","","https://ClinicalTrials.gov/show/NCT02461420"
924,"NCT02461459","Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)",,"Active, not recruiting","No Results Available","Tuberous Sclerosis|Autism Disorder|Intellectual Disability","","Change in ADOS-2 at 12 months|Change in SBIS-5 at 12 months|Change in Fractional anisotropy (FA) at 12 months|Change in ADOS-2 at 24 months|Change in SBIS-5 at 24 months|Change in radial diffusivity (RD) at 12 months|Change in fractional anisotropy (FA) at 24 months|Change in axial diffusivity (AD) at 12 months|Change in mean diffusivity (MD) of cerebellar fascicles at 12 months|Change in radial diffusivity (RD) at 24 months|Change in axial diffusivity (AD) at 24 months|Change in mean diffusivity (MD) of cerebellar fascicles at 24 months","Boston Children’s Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Tuberous Sclerosis Alliance|National Center for Advancing Translational Science (NCATS)|Office of Rare Diseases (ORD)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","3 Years to 21 Years   (Child, Adult)","","105","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","IRB-P00013585|1U54NS092090","May 2015","December 2019","December 2019","June 3, 2015","null","March 14, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California at Los Angeles, Los Angeles, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|University of Texas at Houston, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT02461459"
925,"NCT01210040","Long-term Iron Supplements and Malaria Risk in Early Pregnancy: a Randomized Controlled Trial","PALUFER","Completed","No Results Available","Malaria","Dietary Supplement: Folic Acid|Dietary Supplement: Folic Acid and Iron","Prevalence of peripheral parasitaemia at first antenatal clinic visit (13-16 weeks gestation)|a) In the pregnant cohort: Prevalence of iron deficiency at first antenatal visit|a) In the pregnant cohort: Prevalence of anaemia at first antenatal clinic visit|a) In the pregnant cohort: Incidence of clinical malaria during the first and subsequent trimesters|a) In the pregnant cohort: Incidence of adverse pregnancy outcomes|a) In the pregnant cohort: Mean birth weight and prevalence of low birth weight (<2500g)|a) In the pregnant cohort: Mean gestational age at delivery|a) In the pregnant cohort: Prevalence of placental malaria|a) In the non-pregnant cohort: Prevalence of peripheral parasitaemia during the first rainy season after at least six months of supplementation|a) In the non-pregnant cohort: Incidence of clinical malaria|a) In the non-pregnant cohort: Incidence of gastrointestinal adverse events|a) In the non-pregnant cohort: Prevalence of iron deficiency after at least 18 months supplementation|a) In the non-pregnant cohort: Prevalence of anaemia after at least 18 months supplementation|a) In the non-pregnant cohort: Adherence to supplementation|a) In the non-pregnant cohort: Acceptability of weekly supplementation|In the non-pregnant cohort: Prevalence of bacterial vaginosis at end assessment|a) In the non-pregnant cohort: Prevalence of bacterial vaginosis at end assessment|a) In the non-pregnant cohort: Prevalence of bacterial vaginosis at first antenatal visit|a) In the non-pregnant cohort: Prevalence of iron deficiency at key study visits|a) In the non-pregnant cohort: Prevalence of peripheral parasitaemia at end assessment","Liverpool School of Tropical Medicine|Institute of Tropical Medicine, Belgium|University of Manchester|Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest|Centre Muraz|National Institutes of Health (NIH)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 24 Years   (Child, Adult)","Not Applicable","1959","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","10.55|1U01HD061234-01A1","April 2011","November 2013","January 2014","September 28, 2010","null","March 19, 2014","Institute de Recherche en Sciences de la Sante, Direction Regionale de l'Ouest (IRSS-DRO) - / Centre Muraz, Bobo-Dioulasso 01, Burkina Faso","","https://ClinicalTrials.gov/show/NCT01210040"
926,"NCT02215200","ATG-GCSF in New Onset Type 1 Diabetes","ATG-GCSF","Active, not recruiting","No Results Available","Diabetes Mellitus, Type 1","Drug: Anti-Thymocyte Globulin (ATG)|Drug: Granulocyte colony stimulating factor (GCSF)|Drug: Placebo (for ATG)|Drug: Placebo (for GCSF)","Measure of area under the stimulated C-peptide curve over the first 2 hours of a mixed meal glucose tolerance test conducted at the one-year visit.","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Center for Research Resources (NCRR)|Juvenile Diabetes Research Foundation|American Diabetes Association|Sanofi|The Leona M. and Harry B. Helmsley Charitable Trust|Amgen","All","12 Years to 45 Years   (Child, Adult)","Phase 2","84","NIH|Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ATG-GCSF (IND)|Type 1 Diabetes TrialNet|TN19|UC4DK106993|UC4DK117009","December 2014","August 2017","October 2018","August 13, 2014","null","December 26, 2017","University of California - San Francisco, San Francisco, California, United States|Stanford University, Stanford, California, United States|Barbara Davis Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|University of South Florida Diabetes Center, Tampa, Florida, United States|Indiana University-Riley Hospital for Children, Indianapolis, Indiana, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University-Naomi Berrie Diabetes Center, New York, New York, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt Eskind Diabetes Clinic, Nashville, Tennessee, United States|Benaroya Research Institute, Seattle, Washington, United States","","https://ClinicalTrials.gov/show/NCT02215200"
927,"NCT03177512","LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men",,"Recruiting","No Results Available","HIV|Sexually Transmitted Diseases|Risk Reduction|Pre-Exposure Prophylaxis","Behavioral: LYNX Mobile App","Acceptability|Feasibility|Frequency of app use|Duration of app use|Analysis of mobile application data showing what parts were used in order to assess what app content and functionalities are most and least utilized.|Number of HIV/STI home testing kits, condoms and lube requested|Preliminary efficacy: HIV testing frequency|Preliminary efficacy: STI testing frequency|PrEP interest and uptake as measured by self report|Sexual and drug use behaviors, as measured via questionnaire|Utilization of health care, by self-report via questionnaires and interviews|Information, Motivation, Behavior (IMB) model constructs for HIV/STI testing|Information, Motivation, Behavior (IMB) model constructs for PrEP uptake","Public Health Foundation Enterprises, Inc.|Cook County Health & Hospitals System|Duke University|Emory University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|San Francisco Department of Public Health|University of California, San Francisco|University of North Carolina, Chapel Hill|University of South Florida","Male","15 Years to 24 Years   (Child, Adult)","Not Applicable","60","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17-21876|U19HD089881","October 25, 2018","June 2019","June 2019","June 6, 2017","null","October 31, 2018","University of South Florida, Department of Pediatrics, Tampa, Florida, United States|The CORE Center, Cook County Health and Hospitals System, Chicago, Illinois, United States","","https://ClinicalTrials.gov/show/NCT03177512"
928,"NCT03715335","Adolescent Sexually Transmitted Infection Screening in the Emergency Department","STI","Not yet recruiting","No Results Available","Gonorrhea|Chlamydia","Other: Targeted STI Screening|Other: Universally Offered STI Screening","GC/CT testing rates|Positive GC/CT Rates by Risk Strata|Appropriate Treatment of Positive GC/CT Infections|GC/CT Detection Rates","Children's Hospital Medical Center, Cincinnati|Medstar Health Research Institute|Nationwide Children's Hospital|Children's Research Institute|Children's Hospital of Philadelphia|Ann & Robert H Lurie Children's Hospital of Chicago|Children's Hospital and Health System Foundation, Wisconsin|Texas Children's Hospital|Children's Hospital Colorado|University of Cincinnati|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","15 Years to 21 Years   (Child, Adult)","Not Applicable","70000","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Screening","CIN001-STI Screening|1R01HD094213-01A1","September 2019","June 2022","June 2023","October 23, 2018","null","October 24, 2018","","","https://ClinicalTrials.gov/show/NCT03715335"
929,"NCT03320512","P3 (Prepared, Protected, emPowered)","P3","Not yet recruiting","No Results Available","Sexually Transmitted Diseases|Safe Sex|Adherence, Medication","Behavioral: P3|Behavioral: P3+|Behavioral: Control","Change in PrEP adherence from Baseline to Month 6|Long-term adherence durability|Self-reported retention in PrEP clinical care|PrEP persistence|Sexual Risk Behaviors|Sexually Transmitted Infections (STI) Incidence","University of North Carolina, Chapel Hill|Emory University|Duke University|Children's Hospital of Philadelphia|The Fenway Institute|Children's Hospital at Montefiore|Texas Children's Hospital|Ruth M. Rothstein CORE Center|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Male","16 Years to 24 Years   (Child, Adult)","Not Applicable","240","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","17-1951|5U19HD089881-02","April 2019","April 30, 2020","April 30, 2020","October 25, 2017","null","March 7, 2019","","","https://ClinicalTrials.gov/show/NCT03320512"
930,"NCT02991807","RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome",,"Recruiting","No Results Available","PTEN Gene Mutation|PTEN Hamartoma Tumor Syndrome","Drug: RAD001|Drug: Placebo","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Change in Working Memory at 6 Months|Change in Processing Speed at 3 Months|Change in Processing Speed at 6 Months|Change in Fine Motor Skills at 3 Months|Change in Fine Motor Skills at 6 Months|Change in Attention at 3 Months|Change in Attention at 6 Months|Change in Impulsivity at 3 Months|Change in Impulsivity at 6 Months|Change in Global Cognitive Ability at 6 Months|Change in Motor Functioning at 3 Months|Change in Motor Functioning at 6 Months|Change in Communication Ability at 3 Months|Change in Communication Ability at 6 Months","Boston Children’s Hospital|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)|Office of Rare Diseases (ORD)|National Center for Advancing Translational Science (NCATS)|Novartis Pharmaceuticals|PTEN Research|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","5 Years to 45 Years   (Child, Adult)","Phase 1|Phase 2","40","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB-P00020332|1U54NS092090","June 12, 2017","June 2019","June 2019","December 14, 2016","null","November 16, 2018","Stanford University, Palo Alto, California, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Cleveland Clinic, Cleveland, Ohio, United States","","https://ClinicalTrials.gov/show/NCT02991807"
931,"NCT01824940","SHINE Sanitation, Hygiene, Infant Nutrition Efficacy Project","SHINE","Completed","No Results Available","Growth; Stunting, Nutritional|Anemia","Behavioral: Standard care|Other: WASH|Dietary Supplement: Infant and young child feeding|Other: WASH and Nutrition","Infant length at 18 months|Infant hemoglobin at 18 months|Infant environmental enteric dysfunction|Infant weight, mid-upper arm circumference and head circumference|To describe the Program Impact Pathways (PIP) linking implementation of each randomized intervention (WASH and IYCF) with length and hemoglobin concentrations|Exclusive breastfeeding|To evaluate the effect of the IYCF intervention on uptake of improved infant feeding practices by maternal/infant HIV status|To evaluate the effect of the WASH intervention on the 5 key behaviors it promotes by maternal/infant HIV status|Relative contributions of diarrhea vs EED|To measure the strength of association between other potential causes of stunting and anemia (other than poor WASH or IYCF) with linear growth and hemoglobin|Infant diarrhea prevalence, incidence and severity|Child neurodevelopment|Prevalence of mycotoxin exposure among mothers and infants|MAternal and infant microbiota|Infant rotavirus vaccine and polio vaccine immunogenicity|Adverse birth outcomes: miscarriage, still birth, small for gestational age, preterm delivery, neonatal death|Bioimpedance analysis, skinfold thicknesses and leg length measurement|Observational study of WASH and non-WASH infants|Assess metabolic pathways of pathogenesis of stunting|Friendship Bench for treatment of depression: a pilot study","Johns Hopkins Bloomberg School of Public Health|Ministry of Health and Child Care, Zimbabwe|Zvitambo|Cornell University|University of London|Bill and Melinda Gates Foundation|Department for International Development, United Kingdom|Wellcome Trust|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","15 Years to 49 Years   (Child, Adult)","Not Applicable","5280","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00004205|R01HD060338","November 2012","July 2017","July 31, 2017","April 5, 2013","null","July 26, 2018","Zvitambo, Harare, Zimbabwe","","https://ClinicalTrials.gov/show/NCT01824940"
932,"NCT02831296","Prospective Evaluation of Infants With Spinal Muscular Atrophy:","SPOTSMA","Recruiting","No Results Available","Spinal Muscular Atrophy","","Time to death and/or full time invasive ventilation or need for > 16 hours/day of bilevel respiratory support|Maximum Ulnar CMAP Amplitude|CHOP-INTEND|WHO Motor Milestones|Hammersmith Functional Motor Scale - Expanded|Hammersmith Infant Neurological Exam (HINE)|Body composition|Bone density|Need for tube feeding|Caregiver Questionnaire total score and subscores","Massachusetts General Hospital|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Utah|University of Massachusetts, Worcester|ARUP Laboratories|Newborn Screening Translational Research Network|American College of Medical Genetics and Genomics|Children's Hospital Medical Center, Cincinnati","All","Child, Adult, Older Adult","","200","Other|NIH","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2015P001934|R01HD069045","February 2016","March 2022","null","July 13, 2016","null","March 6, 2019","Massachusetts General Hospital, Boston, Massachusetts, United States","","https://ClinicalTrials.gov/show/NCT02831296"
933,"NCT01418014","Adolescent Master Protocol","AMP","Active, not recruiting","No Results Available","HIV/AIDS","","Abnormal growth|Delayed sexual maturation|Abnormal bone mineral density|Dyslipidemia|Cardiac abnormalities|Hearing dysfunction|Language dysfunction|Neurodevelopmental abnormalities|Substance Use|Sexual Activity|Pregnancy|Sexually Transmitted Infection|Mitochondrial dysfunction|Lactic acidosis|Renal abnormalities","Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute of Neurological Disorders and Stroke (NINDS)|Tulane University School of Medicine|National Institute of Dental and Craniofacial Research (NIDCR)|NIH Office of AIDS Research (OAR)","All","7 Years and older   (Child, Adult, Older Adult)","","678","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HD052102 - PH200|PH200","March 2007","July 2020","July 2020","August 16, 2011","null","September 10, 2018","University of California San Diego, La Jolla, California, United States|University of Colorado Denver Health Sciences Center, Aurora, Colorado, United States|Children's Diagnostic and Treatment Center, Fort Lauderdale, Florida, United States|University of Miami, Miami, Florida, United States|Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Rutgers - New Jersey Medical School, Newark, New Jersey, United States|Bronx Lebanon Hospital Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|San Juan Research Hospital, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT01418014"
934,"NCT01310023","Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women","SMARTT","Recruiting","No Results Available","Antiretroviral Toxicity","","Lactic acidosis|Neurologic abnormalities|Neurodevelopmental abnormalities|Abnormal growth and metabolic function|Cardiac abnormalities|Hearing dysfunction|Language dysfunction|Drug Use and Sexual Activity|Abnormal organ function|Death due to unknown medical condition|Maternal substance use during pregnancy","Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institute on Drug Abuse (NIDA)|National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Mental Health (NIMH)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute on Deafness and Other Communication Disorders (NIDCD)|National Institute on Alcohol Abuse and Alcoholism (NIAAA)|National Institute of Neurological Disorders and Stroke (NINDS)|Tulane University School of Medicine|National Institute of Dental and Craniofacial Research (NIDCR)|NIH Office of AIDS Research (OAR)","All","Child, Adult, Older Adult","","3400","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","HD052102 - PH100|PH100","March 2007","July 2020","July 2020","March 7, 2011","null","September 10, 2018","University of Alabama, Birmingham, Alabama, United States|University of California San Diego, La Jolla, California, United States|University of Southern California, Los Angeles, California, United States|University of Colorado Denver Health Sciences Center, Aurora, Colorado, United States|Children's Diagnostic & Treatment Center, Fort Lauderdale, Florida, United States|University of Florida Health Science Center, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|University of Illinois, Chicago, Chicago, Illinois, United States|Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Maryland, United States|Rutgers - New Jersey Medical School, Newark, New Jersey, United States|Bronx Lebanon Hospital Center, Bronx, New York, United States|Jacobi Medical Center, Bronx, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|New York University School of Medicine, New York, New York, United States|SUNY Stony Brook, Stony Brook, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|University of Puerto Rico Medical Center, San Juan, Puerto Rico|San Juan Research Hospital, San Juan, Puerto Rico","","https://ClinicalTrials.gov/show/NCT01310023"
935,"NCT01235546","Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection","C/SOAP","Completed","Has Results","Endometritis|Wound Infection|Abscess|Surgical Site Infection","Drug: Azithromycin and standard of care|Drug: Placebo and standard of care","Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)","Alan Tita|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|University of Texas|University of North Carolina|Mission Hospital|Ochsner Health System|The University of Texas Health Science Center, Houston|Columbia University|University of Utah|University of Mississippi Medical Center|University of Alabama at Birmingham","Female","14 Years and older   (Child, Adult, Older Adult)","Not Applicable","2013","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","F090323006|NIH 1R01HD064729-01A1","May 2011","December 2015","December 2015","November 5, 2010","July 28, 2017","July 28, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Columbia University, New York, New York, United States|Mission Hospital, Asheville, North Carolina, United States|University of North Carolina, Chapel Hill, North Carolina, United States|University of Texas Medical Branch, Galveston, Texas, United States|University of Texas Health Science Center at Houston, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States","","https://ClinicalTrials.gov/show/NCT01235546"
936,"NCT01180387","Reproductive Medicine Network Biologic Specimen Repository",,"Completed","No Results Available","Infertility","","Proportion of subject who accepted participation","Yale University|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Penn State University|University of Colorado, Denver|University of Michigan|University of Pennsylvania|University of Texas|University of Vermont|Wayne State University","All","Child, Adult, Older Adult","","1640","Other|NIH","Observational","Time Perspective: Prospective","RMN-Repository|5U10HD055925","September 2010","November 2014","January 2015","August 12, 2010","null","March 4, 2015","University of Alabama Birmingham, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|University of Connecticut, Storrs, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Hackensack University, Hackensack, New Jersey, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Pennsylvania State University College of Medicine, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont, Burlington, Vermont, United States|Virginia Commonwealth University, School of Medicine, Richmond, Virginia, United States","","https://ClinicalTrials.gov/show/NCT01180387"
937,"NCT03388398","Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe",,"Enrolling by invitation","No Results Available","HIV Infections","","Vertical transmission of HIV infection|HIV-free survival among infants exposed to HIV|Retention of mothers in antiretroviral therapy services (ART) services after weaning|Time between weaning and discontinuation of antiretroviral therapy services (ART) among mothers who did not continue ART after weaning|Heterogeneity of the impact of Option B+ on HIV-free survival among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilities|Heterogeneity of the impact of Option B+ on mother-to-child transmission of HIV (MTCT) among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilities|Cost-effectiveness of Option B+ compared to the standard of care before Option A|Cost-effectiveness of Option B+ compared to Option A|Variability in health facility accesibility|Variability in health facility quality of available services|Variability in health facility appropriateness of available services","University of California, Berkeley|Centre for Sexual Health and HIV/AIDS Research Zimbabwe (CeSHHAR Zimbabwe)|Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Liverpool School of Tropical Medicine|Ministry of Health and Child Welfare, Zimbabwe|Elizabeth Glaser Pediatric AIDS Foundation|Children's Investment Fund Foundation","All","16 Years and older   (Child, Adult, Older Adult)","","30642","Other|NIH","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","1R01HD080492-01","January 2012","July 2018","January 2019","January 3, 2018","null","August 27, 2018","","","https://ClinicalTrials.gov/show/NCT03388398"
938,"NCT03077308","Rare Diseases Clinical Research Network: Neurophysiological Correlates",,"Recruiting","No Results Available","Rett Syndrome, Preserved Speech Variant|Mecp2 Duplication Syndrome|Rett-related Disorders","Procedure: Auditory and Visual Event-related Potentials and EEG","Auditory Event-related potentials|Visual Event-related potentials|EEG","University of Alabama at Birmingham|Children's Hospital of Philadelphia|University of Colorado, Denver|Boston Children’s Hospital|Vanderbilt University|University of Rochester|University of South Florida|International Rett Syndrome Foundation Rettsyndrome.org|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","2 Years to 65 Years   (Child, Adult, Older Adult)","","250","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN 5212","January 2, 2017","July 31, 2019","July 31, 2019","March 10, 2017","null","April 20, 2018","University of Colorado Denver, Denver, Colorado, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Rochester, Rochester, New York, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States","","https://ClinicalTrials.gov/show/NCT03077308"
939,"NCT02993796","Krabbe Disease Global Patient Registry",,"Recruiting","No Results Available","Krabbe Disease","","Overall Survival","State University of New York at Buffalo|Rare Diseases Clinical Research Network|National Center for Advancing Translational Science (NCATS)|National Institute of Neurological Disorders and Stroke (NINDS)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Lysosomal Disease Network|Hunter's Hope Foundation|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","60","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN6726|U54NS065768|R-21 HD087818-01","September 2014","July 2019","August 2019","December 15, 2016","null","April 5, 2019","State University of New York at Buffalo, Buffalo, New York, United States","","https://ClinicalTrials.gov/show/NCT02993796"
940,"NCT00299312","Genetic and Physical Characteristics of Rett Syndrome",,"Completed","No Results Available","Rett Syndrome|MECP2 Duplication Disorder|Rett-related Disorder","","Genetic and Physical Characteristics of Rett Syndrome|Genetic and Physical Characteristics of Rett syndrome","University of Alabama at Birmingham|Rare Diseases Clinical Research Network|Greenwood Genetic Center|Baylor College of Medicine|Boston Children’s Hospital|University of Rochester|Children's Hospital of Philadelphia|University of Colorado, Denver|Rush University Medical Center|Children's Hospital & Research Center Oakland|University of California, San Diego|Vanderbilt University|University of South Florida|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","All","Child, Adult, Older Adult","","10","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","RDCRN 5201|U54HD061222|ARP 5201","March 2006","October 2015","October 2015","March 6, 2006","null","March 16, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|Children's Hospital of Oakland, Oakland, California, United States|University of California San Diego, San Diego, California, United States|University of Colorado Denver, Denver, Colorado, United States|Rush University Medical Center, Chicago, Illinois, United States|Children's Hospital Boston, Boston, Massachusetts, United States|University of Rochester, Rochester, New York, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Greenwood Genetic Center, Greenwood, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States","","https://ClinicalTrials.gov/show/NCT00299312"
